# GENERAL

- Welcoming words .................................................................................................................. IV
- About EAN ................................................................................................................................. IV
- Board and committees .............................................................................................................. V
- EAN membership information ................................................................................................ VI
- Education information ............................................................................................................. VII
- Resident and research section (EAN-RRFS) ............................................................................ VIII
- Congress Grants ...................................................................................................................... IX
- Appreciation and Thanks ......................................................................................................... X
- Continuing Medical Education (CME Information) ............................................................... XI
- Instructions for speakers and poster presenter ...................................................................... XII
- Information from A-Z .............................................................................................................. XII
- Floor plans ............................................................................................................................... XVI
- Business meetings .................................................................................................................. XVIII
- Poster sessions overview ...................................................................................................... XXI
- Official networking programme ............................................................................................. XXV
- Timetable ................................................................................................................................ XXVIII

# SCIENTIFIC PROGRAMME

### Saturday, 28 May, 2016

- Educational Sessions .......................................................... 37, 54
- Focused Workshops ......................................................... 37
- Special Sessions ......................................................... 39
- Symposia .............................................................................. 40
- Teaching Courses .......................................................... 44
- Oral Sessions ........................................................................ 48
- Poster Sessions ...................................................................... 59

### Sunday, 29 May, 2016

- Educational Sessions ......................................................... 59, 66, 69
- Focused Workshops ......................................................... 61
- Special Sessions .......................................................... 62
- Plenary Symposium .......................................................... 64
- Teaching Courses .......................................................... 67
- Tournament basic .......................................................... 72
- Oral Sessions ........................................................................ 72
- Poster Sessions ...................................................................... 108

### Monday, 30 May, 2016

- Educational Sessions ......................................................... 79, 82
- Focused Workshops ......................................................... 80
- Special Sessions .......................................................... 81, 82, 83
- Symposia .............................................................................. 82
- Teaching Courses .......................................................... 85
- Tournament clinical .......................................................... 87
- Oral Sessions ........................................................................ 87
- Poster Sessions ...................................................................... 155

### Tuesday, 31 May, 2016

- Symposia .............................................................................. 93
- Educational Sessions ......................................................... 93
- Special Sessions .......................................................... 94
- Plenary Symposium .......................................................... 96
- Teaching Courses .......................................................... 96

# COMPANY SPONSORED PROGRAMMES

- Exhibitors ................................................................................................................................. 104
- Satellite Symposia .................................................................................................................... 108
- Forum Programmes ............................................................................................................... 221
- Speaker Index ............................................................................................................................ 129
DEAR COLLEAGUES,

On behalf of the European Academy of Neurology and the Danish Society of Neurology, we are pleased to invite you to the 2nd Congress of the European Academy of Neurology (EAN) taking place in Copenhagen from May 28 - 31, 2016. The first highly successful meeting of the EAN in Berlin left us with valuable experiences that have been used to optimize our second annual meeting. You will meet innovations in the teaching courses and the programme outline. EAN has instituted three named lectures (Romberg, Golgi and Brown-Séquard), which will be presented for the first time during the presidential symposium. The congress will certainly also cover all the well-established formats for scientific exchange. The Copenhagen Bella Congress Center has outstanding facilities for lectures, small group teaching courses, exhibition and for scientific exchange, but also enough space for meeting colleagues and making new friends.

Denmark is renowned for the Little Mermaid, Hans Christian Andersen, Niels Bohr and Danish design. Today however, the “New Nordic Cuisine” as well as TV series like “Borgen” and “The Bridge” have taken over as “Danish Trademarks”. Landing at Copenhagen airport, you will have a wonderful view of “The Bridge” and on the ground again, you may visit “Borgen”, the Danish Parliament. In between is the newly modernised Bella Center, the venue of EAN 2016, with easy and fast transfer to both the city centre and the airport. The coastal area of southern Sweden – with the important cities of Malmö and Lund – is developing into one metropolitan area with Copenhagen, and thousands of citizens of both nationalities commute over the bridge every day. Copenhagen is one of the most vivid cities in northern Europe.

At the EAN congress 2016 you will interact with your European network, you will be absorbed in Academia, and you will be thrilled by Neurology.

Welcome to Copenhagen 2016!

Sincerely yours,

Günther Deuschl
President of the European Academy of Neurology

Mads Ravnborg
President of the Danish Neurological Society

ABOUT EAN

The European Academy of Neurology (EAN) has been founded on the initiative of the European Neurological Society (ENS) and the European Federation of Neurological Societies (EFNS), who both consider it essential to have one joint professional and scientific Neurology organisation in Europe. EAN shall provide the essential infrastructure together with the organisational framework for the support and development of neurological education and research in Europe.

The Aim of EAN (European Academy of Neurology) is Excellence in Neurology in Europe

EAN is a non-profit organisation and identifies itself with the following five values:

• Professionalism. EAN will strive to reach the highest scientific standards and to deliver unbiased information in its research and educational activities.
• High ethical standards. EAN will apply high ethical standards in all its activities within science, education, liaison, and administration, complying with applicable regulations and codes of ethics.
• Involvement. EAN will strive to involve its members and collaborators in the organisation of research, education and liaison activities.
• Independence. EAN will operate as a professional and scientific organisation, independent from the political or commercial interests of external companies or organisations.
• Transparency. EAN will provide transparency in the organisation of all its scientific and administrative activities.

The EAN is an organisation of:

• 47 European national neurological societies
• 800 individual members
• 9 corresponding member societies

The EAN consists of:

• an Assembly of Delegates of institutional and individual delegates
• elected officers
• 4 committees (+2 sub-committees)
• 31 Scientific Panels
BOARD

PRESIDENT
Günther Deuschl, GERMANY

VICE PRESIDENT
Franz Fazekas, AUSTRIA

SECRETARY GENERAL
Didier Leys, FRANCE

TREASURER
Marianne de Visser, THE NETHERLANDS

CHAIR SCIENTIFIC COMMITTEE
Antonio Federico, ITALY

CHAIR LIAISON COMMITTEE
David Vodusek, SLOVENIA

CHAIR EDUCATION COMMITTEE
Hannah Cock, UK

CHAIR PROGRAMME COMMITTEE
Paul A.J.M. Boon, BELGIUM

MEMBER AT LARGE
Per Soelberg Sørensen, DENMARK

PROGRAMME COMMITTEE

CHAIR: Paul A.J.M. Boon, BELGIUM

CO-CHAIR: Mads Henrik Ravnborg, DENMARK

Ljiljana Beslač-Bumbaširević, SERBIA
Valeria Caso, ITALY
Hannah Cock, UK (CHAIR EDUCATION COMMITTEE)
Marianne Dieterich, GERMANY
Antonio Federico, ITALY (CHAIR SCIENTIFIC COMMITTEE)
Theodor Landis, SWITZERLAND (CHAIR TEACHING COURSE SUB-COMMITTEE)
Philip Scheltens, THE NETHERLANDS
Aksel Siva, TURKEY
Riccardo Soffietti, ITALY
Guido Stoll, GERMANY
Joaquim Ferreira, PORTUGAL (MDS-ES REPRESENTATIVE)

LOCAL ORGANISING COMMITTEE

CHAIR: Mads Henrik Ravnborg

Karen Aegidius
Lars Bendtsen
Marie Bruun
Jakob Christensen
Jesper Erdal
Daniel Kondziella
Hanne Krarup Christensen
Christina Rostrup Kruse
Per Soelberg Sørensen
Gunhild Waldemar

TEACHING COURSE SUB-COMMITTEE

CHAIR: Theodor Landis, SWITZERLAND

Anish Bahra, UK
Gilles Edan, FRANCE
Oleg Levin, RUSSIAN FEDERATION
Erich Schmutzhard, AUSTRIA
Claudia Sommer, GERMANY
Marie José D. Vidalhlet, FRANCE
Viktoria Papp, DENMARK (REPRESENTATIVE RRFS)
EAN MEMBERSHIP INFORMATION

Become an EAN individual member and benefit from the following:

- reduced membership fee at the annual congresses
- active and passive voting rights at the Assembly of Delegates of the EAN
- possibility to participate in EAN Committees and Scientific Panels
- free online access to the online learning platform eBrain
- free online access to the European Journal of Neurology
- free online access to the guidelines
- access to educational grants (if applicable)
- right to purchase the European Journal of Neurology (EJN) at a reduced rate
- membership certificate
- monthly mailshots of the EAN electronic newsletter Neuropenews
- one free Teaching Course at EAN annual congresses
- free access to VIP (catering) area at EAN annual congresses
- free access to selected congress webcasts on the website after the congress
- NEW: AAN shared Membership:
  - If you are an AAN Member, you are eligible of a 10% discount off your EAN Individual Membership fee. In reverse, all EAN members receive a 10% discount when applying for AAN membership

Corresponding Individual Member:
- Neurologists who are nationals of and practice in countries other than EAN member countries and/or Health Professionals
- and/or Scientists of other specialities or professions related to Neurology

Undergraduate Student:
Undergraduate medical students can become individual members. They need to explain their special interest in neurology and the purpose why they request membership.

Retired Member:
Neurologists who are retired from their professional work but like to keep in touch and benefit from the various EAN membership highlights.

FELLOW OF THE EAN (FEAN)
The title ‘Fellow of the EAN’ acknowledges a limited number of neurologists who are full individual members and who deserve a special recognition of the EAN because of
- a scientific achievement that places them within the European leaders in their field, or
- significant and continuing service in a leadership position for of a European or World society for neurology or neurological subspecialty society, or
- a service for neurological patients that is considered exceptional

Fellow of the EAN is a title honouring special service to neurology and the Society.

Please apply by sending your application form and CV (in English) to the EAN Head Office: membership@ean.org

Forms can be downloaded online or be sent to upon request.

INDIVIDUAL MEMBERSHIP CATEGORIES:

Full Individual Member:
Neurologists who are nationals of any EAN member country; and/or neurologists practicing in any EAN member country including neurologists in training.

Resident and Research Fellow (RRF):
Physicians in training can become individual members of the EAN via the EAN Resident and Research Fellow Section at a reduced fee. Residency has to be proven annually by a signed confirmation of the physician in charge of the residency programme.
EDUCATION INFORMATION

CLINICAL FELLOWSHIP 2017
APPLICATION DEADLINE: OCTOBER 31, 2016

The purpose of this award is to provide a well-defined observational clinical practice, service structure or technical experience to support training. The grant is to support a visit of six weeks duration.

Each grant is amounting to € 1,500.-/month (plus travel expenses of up to € 300.-)

A list of approved hosting departments (and details for interested hosts of how to apply) is available on www.eaneurology.org

Candidates from all EAN member (and associate member) countries are eligible to apply. Applicants must be current residents with a minimum of 2 – 8 years training in neurology, or have obtained their board certificate/completed training within the last 3 years at the time of application; be fluent in English or the local language (host department).

Awardees from previous years (applies also to former D-D programme) are no more qualified.

All application documents must be submitted by October 31 2016 by email to Ms. Magda Dohnalová: E-MAIL: dohnalova@ean.org

Application is open between 1 August and 31 October 2016.

EAN RESEARCH FELLOWSHIP 2017
APPLICATION DEADLINE: AUGUST 31, 2016

In 2017, the EAN will offer up to 8 research experience or training fellowships. The research work must be carried out at a European academic neurological department outside the country of residence. The purpose is to support training and experience for European Neurologists in any area of basic or clinical or applied research in neuroscience. All applications should demonstrate experience/training of clear value to the home department/individual beyond that available in their own countries/institutions. Successful applicants will be awarded € 2,000.- per month. Research training fellowship: Expected to be of 12 months duration, to lead either to completion of a higher degree, a grant application or peer-reviewed publication. Research experience fellowship: Expected to be of at least 6 months duration for individuals who might otherwise not have the opportunity to gain high quality research experience, more experienced clinicians/researchers requiring training in a specific research methodology or technique not currently available in their own country and of clear value to home department will also be considered. Candidates from EAN member countries and affiliated to a European academic neurological department with a minimum of 2 years neurology training, up to a maximum of 5 years beyond their final degree (PhD, MD, or equivalent) at the time of application are eligible to apply. Applicapants and hosts are expected to have consulted and worked together on any application to maximise the likelihood of success. All application documents must be submitted by August 31, 2016 by email to Ms. Magda Dohnalová: E-MAIL: dohnalova@ean.org

APPLICATION DEADLINE: AUGUST 31, 2016

EAN SPRING SCHOOL 2017
MAY 11-14, 2017
APPLICATION DEADLINE: JANUARY 31, 2017

Preliminary Programme:
1. Multiple sclerosis
2. Inflammatory neuropathies
3. Stroke

Participants can prepare their own cases for presentation and discussion, including video if appropriate and the patient has consented. Contributions to the optimal organisation of neurological care, neurological services and postgraduate education throughout Europe will be presented.

Location:
Hotel Bezděz
Lazensky Vrch 216
471 63 Staré Splavy
Czech Republic

This site is situated in North Bohemia, about 90 km from Prague, on the shore of the romantic Macha Lake. A half-day trip to Prague is planned. All applicants must be neurologists in training (not yet completed residency/ clinical speciality training) who will have had at least 2 years of clinical experience by the time of the course, and who are able to attend the full course. Participants nominated for attendance by their national neurological societies will be prioritised, but individual applications are also welcome up to the full capacity. Where oversubscribed, the selection process will take into account geographical and gender balance, and unsuccessful applications in previous years. Awardees from previous years are no more qualified. Accommodation, tuition, board and programme are sponsored by the EAN. Participants pay only for their travel. All participants will receive a manuscript CD-ROM and a certificate after having finished the course. All application documents must be submitted by January 31, 2017 by email to Ms. Magda Dohnalová: E-MAIL: dohnalova@ean.org

Applications open between 1 October 2016 and 31 January 2017
CME ARTICLES

Each month a CME article is published in the European Journal of Neurology and on the EAN website. Answer 5 article-related questions correctly and receive a certificate recommending one hour of CME.

Please register on the EAN website for free-of-charge access to all e-learning features and the online version of the European Journal of Neurology.

EBRAIN

ebrain represents the world's largest, most comprehensive web-based training resource in clinical neuroscience designed to support training and continuous professional development for clinical neuroscience trainees, consultants and non-specialists. It is free-of-charge for EAN members. For log-in data, please contact education@ean.org.

The multimedia-rich, engaging materials are designed to enhance traditional learning, support existing teaching methods and provide a valuable reference point that is accessible anytime, anywhere.

The online training content comprises approximately 20 modules of e-learning, with each of the 550+ individual lessons taking around 20 minutes to complete.

www.ebrainJNC.com

GUIDELINE PAPERS

Included in the EJoN, the Handbook as well as FREE OF CHARGE access for EAN members via the Guidetive Reference Center the EAN website.

EAN REGIONAL TEACHING COURSES (RTC)

EAN RTCs are specially designed for the purpose to bring neurological standards directly to those countries that are seeking EAN support in education and to avoid that our colleagues in training have to travel to expensive congresses. In the past, these courses were in the Eastern European Regions as well as in Sub-Saharan Africa. RTCs provide basic teaching in neurology and thus also establish friendly relations with the colleagues still in training or wishing to expand their knowledge.

The 3-day courses are organised by the local host together with the EAN Teaching Course sub-committee. Plenary sessions in the morning are followed small tuitional groups in the afternoon. Each day is dedicated to one topic plus various themes on the third day. The exam quiz as well as certificates will be made available to all participants.

RESIDENT AND RESEARCH FELLOW SECTION

Residents and research fellows section of the European Academy of Neurology (EAN-RRFS) represents the junior generation of neurologists within EAN. Our members are physicians currently working as a resident in Neurology, research fellow, PhD student or neurologist with not more than 3 years of practice after completion of the residence training. Application for membership should be sent to rrfs@ean.org, further information is provided on the EAN homepage. The aims of RRFS are to support neurology trainees in their clinical training or research, to promote network between European junior neurologists and different generations of neurologists. Our program during the 2nd Congress of the European Academy of Neurology in Copenhagen 2016:

THE RRFS BOOTH will welcome you during the whole congress. Here, you can receive information on how to become an RRFS member and regarding the benefits of the membership.

RRFS HOSPITAL VISIT (max. 100 participants) on Sunday, 29 May 2016 will be organised in co-operation with the Danish Young Neurologist Society. We are going to meet 18.00-18.15 in front of the registration desk. We will visit the Rigshospital - University Hospital followed by a get-together. Registration is available via facebook or by contacting rrfs@ean.org or at the RRFS booth at the congress.

RRFS ASSEMBLY on Monday, 30 May 2016 in Room B4M2 at 16.45-18.15.

RRFS SPECIAL SESSION on Tuesday 31 May 2016, 8.30-10.00 in Hall B5.2. The discussed topic is “Prospects for young neurologists in 3 corners of Europe.” See Page XXVI

RRFS LOTTERY on Tuesday 31 May 2016, 10.00-10.30 at the RRFS Booth.

PHOTO CONTEST, upload your best picture of the congress to RRFS facebook profile until 01 July 2016.

EAN NETWORKING EVENT on Monday 30 May 2016, at 20.00 we meet in front of the conference center and will travel together to the networking event of the EAN at the renowned Paper Island Street Food market.
CONGRESS GRANTS

BUSSARIES
The 2nd Congress of the EAN offered up to 320 bursaries consisting of free registration to the congress and up to four nights hotel accommodation. In addition, free admission to three half-day teaching courses was offered. Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) who are working in Europe and whose abstract has been accepted. It was also possible for colleagues in training from Algeria, Egypt, Jordan, Kyrgyzstan, Lebanon, Libya, Morocco, Palestine, Tunisia and Syria as well as from sub-Saharan countries belonging to the HINARI Group A list of countries as established by WHO (www.who.int/hinari/eligibility/en/) to apply for bursaries. Bursary recipients were selected on the basis of abstract evaluation by the Programme Committee. The prize is not transferable and will not be paid off in cash. The bursaries were co-sponsored by an educational grant from MDS-ES and Lundbeckfonden.

INVESTIGATOR AWARD
All free presentations (oral presentations, posters) selected for presentation at the 2nd EAN Congress 2016 will automatically take part in the selection of an Investigator Award. The award for the 20 best presentations will be a registration to the 3rd EAN Congress in Amsterdam, The Netherlands, a diploma and the winners will be announced in the European Journal of Neurology and the EAN newsletter. These presentations will also be filmed and displayed on the EAN website if the presenters agree. The award will be given to the first author who needs to be the person to present the work at the congress. The EAN Scientific Panels together with the Scientific Committee and the Programme Committee will be responsible for the evaluation process before as well as during the congress.

TOURNAMENT FOR NEUROLOGISTS IN TRAINING
A tournament for neurologists in training will take place. The tournament will be carried out in two groups, one on clinical related research, and one on basic neurological science. Eligible were PhD (neurology) students, residents of neurology or certified clinical neurologists (with no more than 3 years practice since completing training) working in Europe and whose abstract has been accepted. Selection of candidates: The EAN Programme Committee was selected 6 candidates for each tournament group on the basis of the contents of the abstracts submitted. The clinical subjects must be received from authors who work in Europe and thus carry out their projects in Europe. For the basic science session, clinical relevance will be weighted.

Financial support: Candidates selected for the tournament have received a bursary consisting of free registration to the Congress, up to four nights hotel accommodation, and a travel grant.

Presentation: Each selected candidate is allotted 10 minutes for presentation of his/her paper plus five minutes for discussion with the jury.

Jury: Members of the Programme, the Scientific and the Teaching Course Committees.

Evaluation: Candidates will be judged not only on the scientific value of the work presented, but also on the quality of the oral presentation and the way the candidate responds to the questions of the jury.

Prize: The winner of each group will receive a prize consisting of: Free registration at the 3rd EAN Congress in Amsterdam 2017, up to four nights hotel accommodation as well as a travel grant. The prize is not transferable and will not be paid off in cash.

Two runner-up prizes in each, the clinical and basic tournament will be awarded. They will consist of a certificate and a free registration to the 3rd EAN Congress in Amsterdam 2017.
APPRECIATION AND THANKS
We would like to thank the reviewers of the submitted abstracts for their invaluable help and assistance:

A
Federica Agosta, ITALY
Corrado Angelini, ITALY
Heather Angus-Leppan, UK
Pasquale Annunziata, ITALY
Fabio Antonacci, ITALY
Isabelle Arnulf, FRANCE
Ethem Murat Arsova, TURKEY
Nadine Attal, FRANCE

B
Peter Balicza, HUNGARY
Frederik Barkhof, THE NETHERLANDS
Mads Barloese, DENMARK
Rui Barreto, PORTUGAL
Hansjörg Bäzner, GERMANY
Peter Berlit, GERMANY
Kailash Bhatia, UK
Michela Bisciglia, BELGIUM
Paul A. J. M. Boon, BELGIUM
Geir Brathen, NORWAY
Jean Marc Burgunder, SWITZERLAND

C
Stefano Cappa, ITALY
Valeria Caso, ITALY
Abhijit Chaudhuri, UK
Pawel Chochol, POLAND
Hanne Krarup Christensen, DENMARK
Pamela Correia, INDIA
Giorgio Cruccu, ITALY
Anna Czlonkowska, POLAND

D
Gunther Deuschl, GERMANY
Marianne Dieterich, GERMANY
Volker Dietz, GERMANY
Raffaele Dubbioso, ITALY
Andriy Dubenko, UKRAINE
Francois Ducray, FRANCE
Karolina Dziezyc, POLAND

E
Edvard Ehler, CZECH REPUBLIC
Stefan Evers, GERMANY

F
Franz Fazekas, AUSTRIA
Antonio Federico, ITALY
Óscar Fernández, SPAIN
Joaquim Ferreira, PORTUGAL
Massimo Filippi, ITALY
Alessandro Filla, ITALY
Gereon Fink, GERMANY
Katharina Fink, SWEDEN
Ana Catarina Fonseca, PORTUGAL

G
Christopher Gardner-Thorpe, UK
Orsi Györfi, HUNGARY

H
Maija Haanpää, FINLAND
Orla Hardiman, IRLAND
Raimund Helbok, GERMANY
Max Hilz, GERMANY
Henry Houlden, UK
Helle Hvilsted Nielsen, DENMARK

I
Isabel Illa, SPAIN
Alejandro Iranzo, SPAIN

K
Ludwig Kappos, SWITZERLAND
Peter Kennedy, UK
Lisa Klingelhofer, GERMANY
Matthias Koepf, UK
Anneli Kolk, ESTONIA
Daniel Kandziella, DENMARK
Christian Krarup, DENMARK
Nikola Kresojevic, SERBIA

L
Lieven Lagae, BELGIUM
Hans Lassmann, GERMANY
Pavel Leahu, MOLDOVA
Letizia Leocani, ITALY
Maurizio Leone, ITALY
Vitalie Lisnic, MOLDOVA
Albert Ludolph, GERMANY

M
Michelangelo Mancuso, ITALY
Monica Margoni, ITALY
Luca Massaccesi, ITALY
Antonija Mišmaš, CROATIA
Monica Moarcas, UK
Tiziana Mongini, ITALY
Elena Moro, FRANCE
Kirsten Müller-Vahl, GERMANY
Lucia Muntean, GERMANY

N
Eduardo Nobile-Orazio, ITALY
Lino Nobili, ITALY

O
Stefan Oberndorfer, AUSTRIA
David Oliver, UK
Józef Opara, POLAND

P
Massimo Pandolfo, BELGIUM
Eleftherios Papathanasiou, CYPRUS
Viktoria Papp, UK
Giovanni Pellegrino, ITALY
Marja Perovska, FYRO MACEDONIA
Fabienne Perren, SWITZERLAND
Gordon Plant, UK
Werner Poewe, AUSTRIA
Maura Pugliatti, ITALY

R
Martin Rakusa, SLOVENIA
Dorota Religa, SWEDEN
Maria Assunta Rocca, ITALY
Andrea Rossetti, ITALY
Uros Rot, SLOVENIA
Philippe Ryvlin, SWITZERLAND

S
Anna Sauerbier, UK
Philip Scheltingens, THE NETHERLANDS
Reinhold Schmidt, AUSTRIA
Erich Schmutzhard, AUSTRIA
Benedikt Schoser, GERMANY
Stefan Schwab, GERMANY
Barry Seemungal, UK
Johann Sellner, AUSTRIA
Vincenzo Silani, ITALY
Aksel Siva, TURKEY
Riccardo Soffietti, ITALY
Sandro Sorbi, ITALY
Israel Steiner, ISRAEL
Maria Stoyanova, BULGARIA
Dominik Straumann, SWITZERLAND
Walter Struhal, AUSTRIA

T
Pravin Thomas, UK
Maarten Titulaer, THE NETHERLANDS

U
Bjarne Udd, FINLAND

V
Josep Valls-Sole, SPAIN
Sanja Vodopić, CROATIA
David B. Vodušek, SLOVENIA

Z
Panagiotis Zis, UK
CONTINUING MEDICAL EDUCATION
(CME INFORMATION)

PURPOSE
The purpose of the 2nd EAN Congress is to offer a forum for clinical and basic discussion on a variety of neurological topics including presentations of current research and available treatments.

LEARNING OBJECTIVES
Through Plenary Symposia, Main Symposia, Focused Workshops, Teaching Courses, Case-based facilitated workshops, Hands-on courses, controversy sessions, interactive sessions and special sessions, participants will be better able to:
1. Describe the pathophysiology and neurobiology of neurological diseases
2. Discuss the diagnostic approaches and tool available for neurological diseases
3. Discuss the pharmacological and non-pharmacological treatment options available for neurological diseases

TARGET AUDIENCE
The target audience includes clinicians, researchers, post-doc fellows, medical residents, students and other healthcare professionals with an interest in the current research and diagnosis and treatment of neurological diseases. Kindly note that in the description of some courses the target audience is separately disclosed.

FINANCIAL DISCLOSURE INFORMATION
It is the policy of the European Academy of Neurology to ensure objectivity, independence and balance in all congress activities. All participants are required to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the activity. Financial disclosure information will be provided on the presentations and/or abstracts.

EACCME ACCREDITATION STATEMENT
EACCME Event code: 13595
The 2nd Congress of the European Academy of Neurology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): http://www.uems.net.
The Congress of the European Academy of Neurology (Saturday, Sunday, Monday, Tuesday) is designated for a maximum of 24 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. These points are accepted by several national societies, and thus may be claimed in these countries.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be in the Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
The Danish Medical Association is accepting the EACCME CME accreditation.

EACCME CREDITS
Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.
EACCME credits are automatically accepted by the Austrian Chamber of Physicians.

ATTENDANCE TRACKING REPORT
If you need a report of your attendance in sessions, please approach the information desk located at the exhibition entrance area, in order to scan your badge and record your attendance. Only participants who have recorded their attendance receive a report, tracking their daily attendance at the congress, which will be sent from the secretariat on request.
INSTRUCTIONS FOR SPEAKERS
AND POSTER PRESENTERS

SPEAKERS’ SERVICE CENTRE
All speakers are requested to hand in their presentations (PowerPoint only) via a USB compatible memory stick at the Speakers’ Service Centre (SSC) at least three hours before the beginning of the session. The SSC is located outside of the exhibition area close to the entrance.

Speakers will have the opportunity to check their presentations on PCs available in the SSC.

The Speakers’ Service Centre is supported by Bial Group.

POSTERS
All posters will be presented as e-posters only.

Within the Poster area (located in the exhibition area) there are poster screens (30 screens, 25 computer stations) available throughout the whole congress, where presenters and audience are invited to interact with each other. You will be able to contact poster presenters and meet with them at any time at one of the poster screens to discuss his/her work.

In addition there will be poster sessions, taking place Saturday to Monday from 12.30 – 13.15 and 13.30 – 14.15. Please see page XXIII or Interactive Programme Planner (IPP) for details and exact presentation times.

Poster with discussion
All poster sessions will be discussed with a chairperson. In such poster sessions (45 minutes) up to 15 presentations are scheduled at the dedicated poster screens. A chairperson will be present and discuss each presentation with the presenter and the audience. Each presenter will have 2 minutes presentation time and approximately 1 minute of discussion. Please make sure that you are present at your poster screen during your session.

The poster stations are supported by Bial Group.

POSTER DESK
Technicians will be available throughout the congress in the poster area.

INFORMATION FROM A TO Z

ABSTRACTS
All accepted abstracts will be published as a supplement to the European Journal of Neurology. There will be no printed book available, but a USB drive can be picked up at the Genzyme booth in the Exhibition Area. You will receive a voucher together with your badge. The abstracts can also be found online on www.eaneurology.org/copenhagen2016 and www.europeanjournalofneurology.com.

You can create your personal abstract book by using the Interactive Programme Planner (IPP).

APP
The congress app “EAN 2016” is available for download free of charge on Google Play and iTunes.

The congress app is supported by Hoffmann-LaRoche AG.

ATM/CASH MACHINE
An ATM cash machine is located at the Bella Sky, Tower 1 close to the reception. VISA and MasterCard are accepted.

ATTENDANCE TRACKING REPORT
See page XI.

BADGES
Access to all scientific events will only be possible with your personal badge, which you will receive at the self-print stations if your registration is fully paid. Therefore, please print the page which contains the barcode and take it along with you to the conference. All participants are requested to wear their name badge throughout the congress.

Full and Corresponding Individual Members of the EAN will receive special badges providing them with exclusive access to the VIP member area.

For replacement of a lost badge EUR 30 will be charged.

BUSINESS CENTRE
There is a business centre located at the main entrance of the Bella Center (entrance west).

Opening times:
Saturday, 28 May 2016: 08.00 – 17.00 h
Sunday, 29 May 2016: 08.00 – 17.00 h
Monday, 30 May 2016: 08.00 – 17.00 h
Tuesday, 31 May 2016: 08.00 – 16.00 h
CARING FOR THE ENVIRONMENT

**Green print** - The print materials of this congress have been printed on paper that is PEFC approved. The PEFC is an organisation that certifies paper manufacturers who keep to sustainable forest management criteria.

**Reducing print** - The book of abstracts is published on a USB drive. The printed programme is available only for participants who ordered it in advance at the material Pick-up. The complete programme can also be found online in the Interactive Programme Planner (IPP).

**Recycling** - As part of our efforts we try to produce less waste. We will recycle plastic, glass, cans and paper.

**Offset your Carbon Footprint** - You can contribute to our ecological efforts by offsetting the Carbon Footprint of your travels to Copenhagen. A Carbon Offset represents a reduction in emissions somewhere else. You can learn more and offset your carbon footprint at: www.carbonfund.org. We are doing our best and there is still much to learn. We will be happy to hear your ideas; please do not hesitate to write to us at headoffice@ean.org.

CERTIFICATE OF ATTENDANCE

Certificates of attendance (not indicating CME credits) are available from Monday morning, 30 May 2016. They can be printed at the self-print stations in the registration area, using the barcode printed on your name badge. Changes of certificates due to incorrect submission of names and/or email addresses will be charged EUR 10.

CHILDREN AT EAN CONGRESS 2016

There is no childcare facility available at the congress. Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the pharma codex. Thank you for your understanding.

CLOAKROOM

A cloakroom is available at the main entrance of the Bella Center (Entrance West) and is open during the secretariat opening hours. The cloakroom service is free of charge.

CME CERTIFICATE

You will receive an email with your personal login details for the online evaluation form during the evening of the last day of the congress (Tuesday, 31 May 2016). After completing the congress evaluation form you can download the certificate indicating the CME credits at home. If you need a tracking report for your national body to receive accreditation, please see page XI.

CONGRESS SECRETARIAT AND REGISTRATION

The registration desk at the congress venue is open during the following hours:

- **Friday,** 27 May 2016: 16.00 – 19.00 h (badge/congress bag pick-up for pre-registered delegates only)
- **Saturday,** 28 May 2016: 07.30 – 20.30 h
- **Sunday,** 29 May 2016: 08.00 – 19.00 h
- **Monday,** 30 May 2016: 08.00 – 19.00 h
- **Tuesday,** 31 May 2016: 07.30 – 17.00 h

All documents included in the registration package (congress bag, personal name badge) will be handed over to the registered participants. Onsite registration will be accepted, but receipt of all congress documents cannot be guaranteed.

The secretariat can be reached at +45 91 608 588 (from Thursday, 26 May onwards)

CONGRESS VENUE

Bella Center Copenhagen
Bella Center A/S
Center Boulevard 5
2300 Copenhagen
Denmark

www.bellacenter.dk

The 2nd Congress of the European Academy of Neurology takes place at the Bella Center. The Bella Center is located in the heart of Ørestad with its own Metro station. Bella Center Copenhagen is just 6 kilometers away from Copenhagen Airport and 8 kilometers away from Copenhagen city centre.

CURRENCY

The official currency of the 2nd EAN Congress in Copenhagen is Euro (€). However, the local currency is Danish Krone (DKK). Please keep in mind that credit cards (Visa, Mastercard, American Express) will be charged only in Euro.

EAN BOOTH

Location: in front of the exhibition hall

Opening hours:
- **Saturday,** 28 May 2016: 10.00 – 17.00 h
- **Sunday,** 29 May 2016: 10.00 – 17.00 h
- **Monday,** 30 May 2016: 10.00 – 17.00 h
- **Tuesday,** 31 May 2016: 09.30 – 13.30 h

EXHIBITION

An extensive exhibition will be held concurrently with the congress.

Exhibition opening hours are:
- **Saturday,** 28 May 2016: 10.00 – 17.00 h
- **Sunday,** 29 May 2016: 10.00 – 17.00 h
- **Monday,** 30 May 2016: 10.00 – 17.00 h
- **Tuesday,** 31 May 2016: 09.30 – 13.30 h
Accompanying children over the age of 1 year are not allowed to access the exhibition area due to the Pharma Codex. Thank you for your understanding. The exhibition floor plan can be found on page 105.

HOTEL AND TRAVEL
Official Housing/Travel Agency
Congrex Travel Ltd.
PHONE: +45 91 60 87 69
E-MAIL: hotel.ean@congrex.com

Congrex Travel is present at the Congress Secretariat. Staff can assist you with your hotel and flight bookings.

INSURANCE & LIABILITY
The Congress organisers and PCO cannot accept liability for personal accidents or loss of or damage to private property of participants, either during or indirectly arising from the 2nd Congress of the European Academy of Neurology. It is recommended that all participants are covered by personal travel insurance for their trip.

INTERNET CORNER
An Internet Corner is located in the exhibition area and is available to all congress participants during the opening hours of the exhibition. In this area also Wi-Fi (see page XV) is available. The Internet Corner is supported by Bial Group.

INTERACTIVE PROGRAMME PLANNER (IPP)
Please use the IPP in order to create your personal programme and abstract book. All invited lectures, oral sessions and poster presentations will be available in the IPP. By logging in you will be able to save and edit your personal programme. It is available for desktop, laptop and as smartphone app. Contents are sorted by topic and prerequisites and can be searched through standard web search functions. Once you have created your personal programme, you can export it to different calendar formats, or download it as a book of abstracts. The IPP will be available before and during the congress. iPad Stations will be placed on different locations throughout the congress venue. The congress app including the IPP will be displayed on the iPads. The iPad Stations are supported by Bial Group.

LANGUAGE
The official language of the congress is English. No simultaneous translation will be provided.

LOST & FOUND
Please apply to the congress secretariat.

LUNCH AND COFFEE BREAKS
Light lunch and coffee is included in the registration fee and will be served in the exhibition area as per the times indicated in the timetable.

MAIL/MESSAGES
A message board is available close to the congress secretariat in the registration area.

MEDICAL ASSISTANCE
Please apply to the congress secretariat.

MINI-PROGRAMME
The mini-programme gives you an overview of the scientific programme at a glance.

MOBILE PHONES
Please note that mobile phones must be switched off during all sessions.

NETWORKING
Opening (See page XXV)
Challenges for women in neurology (see page XXVI)
Networking event on Monday “Meet the speakers” (see page XXVII)
Resident and Research Fellow Section Activities (see page VIII)

POSTER SESSIONS
Please see page XXI

PRESS CONFERENCE AND PRESS ROOM
A media room with wireless internet access is available to registered journalists. The Press Room is located in room B4 M5. The press conference will be held on Monday, 30 May 2016 from 10.30 to 11.30 in meeting room 5 (first floor, Bella Center).

QUALITY CONTROL/ EVALUATION
In order to guarantee the quality of the upcoming congresses, and to get CME certification, we have to carry out congress evaluations. Each teaching course participant should fill in an electronic TC evaluation directly after the TC. The general evaluation of the congress will be done online. On Tuesday, 31 May all participants will receive a username and password per email during the evening. We kindly ask you to participate to receive your certificate. Please take time to complete the electronic evaluation forms provided for each session you attend. The forms are available in the EAN Congress app and on the Congress website. Your input is essential for planning future EAN congresses.

SCIENTIFIC REPLAY LOUNGE
The Scientific Replay Lounge is located in the exhibition area and will be available for the comfort of participants, providing a place to see webcasts of selected previous sessions, relax and meet with colleagues. The Scientific Replay Lounge is supported by SANOFI GENZYME Europe B.V.
SESSIONS
Please make sure to be in session halls on time as all sessions will begin as per schedule.

SYMPOSIA:
Symposia are scheduled in the morning of each congress day and will last 2 hours each. Lecturers will give general information on the main topics of the congress. Special insight will be covered in Teaching courses and Focused workshops.

TEACHING COURSES:
If you wish to participate, tickets may still be purchased at the Secretariat for a fee of €40/€25, availability permitting. TCs are held on each congress day in the afternoon and last for 3 hours (plus 1/2 hour coffee break). They are interactive with ample opportunity for participants to ask questions. All TCs are aimed primarily at a post-graduate audience.

There are 3 levels of TCs:
Level 1 (Introductory): Aimed primarily at neurologists in training, or those wishing to refresh/update their basic knowledge in the field. Level 1 may also be suitable for undergraduates or general trainees with a particular interest.

Level 2 (standard): Assumes familiarity with basic clinical knowledge and practice, aimed at specialist trainees or practitioners wishing to update and further develop their knowledge in the field.

Level 3 (advanced): Aimed at specialist trainees or practitioners with a particular interest in that field, covering the latest advances of particular interest to a specialist audience.

Participants will receive a manuscript/summary of the lectures as well as a certificate of attendance. TCs are not included in the registration fee, but have to be booked in addition.

HANDS-ON COURSES:
These Hands-on teaching courses (HoC) are for a limited number of participants only, with some built-in work in smaller groups who attend parallel by rotating to each presenter of the course. Live demonstrations with screening machines are the core of these courses.

For a limited number of participants only. Participation is not included in the registration fee.

CASE-BASED FACILITATED WORKSHOPS:
The case-based workshops are to support knowledge and practice in clinical diagnosis and management in a format, which requires the attendees to actively participate, with opportunities for direct discussion/contact with leading experts to discuss pre-prepared cases.

For a limited number of participants only. Participation is not included in the registration fee.

INTERACTIVE SESSIONS:
These sessions are open for all participants. Through an interactive voting system, the opinions of colleagues will be collected.

FOCUSED WORKSHOPS
Focused workshops (FWs) will be held in the late morning and last for 1.5 hours. They will cover narrow topics and will aim to promote discussion around new ideas, evidence or theories. Ample time for discussion will be provided.

SPECIAL SESSIONS:
Special Sessions (SPS) cover topics of special interest.

“How to improve your chances”:
This new format shall allow to share and improve knowledge on: “how to best write an academic paper”; “how to plan and organize a clinical or scientific study”; “how to apply for a grant”, “how to get a paper accepted” etc... and shall thus “improve your chances”.

These sessions are open for all participants and primarily aim at a post-graduate audience.

SMOKING POLICY
Smoking is prohibited at all times in the meeting halls, exhibit halls and restrooms. Your compliance is appreciated.

SPEAKERS’ SERVICE CENTRE (SSC)
See page XII.

TRAVEL
See “Hotel and Travel”

VIP LOUNGE
EAN Full and Corresponding individual members and FEANs have the possibility to enjoy their lunch in a separated VIP Area. The VIP Area is located on the right side next to the exit of the exhibition area and is open during the exhibition opening hours. Coffee and lunch will be available during the official coffee and lunch breaks.

WI-FI
Wi-Fi will be available free of charge in the session rooms and the exhibition area.

Network name: sanofigenzyme@EAN2016
Password: see the voucher in your bag or visit the Genzyme Booth #A10

The Wi-Fi is supported by SANOFI GENZYME 🌟
(in chronological order, as per date of printing)
Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area.

<table>
<thead>
<tr>
<th>GROUP/COMMITTEE</th>
<th>DAY, TIME</th>
<th>BELLY CENTER/SKY HOTEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>European Affairs Sub-committee</td>
<td>Saturday, 28 May 08:30 - 10:00</td>
<td>Room 18a</td>
</tr>
<tr>
<td>Education Committee</td>
<td>Sunday, 29 May 09:00 - 11:00</td>
<td>Room 21</td>
</tr>
<tr>
<td>Quality Assurance Sub-Committee</td>
<td>Sunday, 29 May 11:15 - 12:45</td>
<td>Room 21</td>
</tr>
<tr>
<td>Scientific Committee</td>
<td>Sunday, 29 May 12:45 - 14:45</td>
<td>Room B4 M7</td>
</tr>
<tr>
<td>TF Sub-saharan Africa</td>
<td>Sunday, 29 May 13:30 - 15:30</td>
<td>Room 21</td>
</tr>
<tr>
<td>European Journal of Neurology – Editorial Board</td>
<td>Sunday, 29 May 13:30 - 14:30</td>
<td>Room 16</td>
</tr>
<tr>
<td>EAN/WFN Meeting</td>
<td>Sunday, 29 May 15:00 - 16:00</td>
<td>Room 16</td>
</tr>
<tr>
<td>Meeting with Wiley</td>
<td>Sunday, 29 May 16:30 - 17:30</td>
<td>Room 21</td>
</tr>
<tr>
<td>Liaison Committee</td>
<td>Monday, 30 May 09:00 - 10:30</td>
<td>Room 16</td>
</tr>
<tr>
<td>E-communication Board</td>
<td>Monday, 30 May 10:30 - 12:00</td>
<td>Room 16</td>
</tr>
<tr>
<td>Panel Chairs Meeting</td>
<td>Monday, 30 May 12:30 - 14:30</td>
<td>Hall B4 M1</td>
</tr>
<tr>
<td>Industrial Relations Board</td>
<td>Monday, 30 May 15:00 - 16:30</td>
<td>Room 5</td>
</tr>
<tr>
<td>Corresponding Institutional Member Societies</td>
<td>Monday, 30 May 15:00 - 16:30</td>
<td>Room 16</td>
</tr>
<tr>
<td>Guideline Production Group</td>
<td>Tuesday, 31 May 09:00 - 10:30</td>
<td>Room 16</td>
</tr>
<tr>
<td>Teaching Course Committee</td>
<td>Tuesday, 31 May 10:30 - 12:00</td>
<td>Room 16</td>
</tr>
<tr>
<td>Programme Committee</td>
<td>Tuesday, 31 May 12:45 - 14:15</td>
<td>Room 16</td>
</tr>
</tbody>
</table>
(in chronological order, as per date of printing)
Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area.

<table>
<thead>
<tr>
<th>SCIENTIFIC PANEL</th>
<th>DAY, TIME</th>
<th>ROOM #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Panel Higher cortical functions</td>
<td>Saturday, 28 May 10.30 - 12.00</td>
<td>Room 16</td>
</tr>
<tr>
<td>Scientific Panel Neuroimaging</td>
<td>Saturday, 28 May 16.00 - 17.00</td>
<td>Room 16</td>
</tr>
<tr>
<td>Scientific Panel Neuroimmunology</td>
<td>Sunday, 29 May 9.00 - 10.30</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel Neuro-ophthalmology and -otology</td>
<td>Sunday, 29 May 10.30 - 11.30</td>
<td>Room 60/61</td>
</tr>
<tr>
<td>Scientific Panel Neurorehabilitation</td>
<td>Sunday, 29 May 11.00 - 13.00</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel Autonomic nervous system disorders</td>
<td>Sunday, 29 May 11.30-12.30</td>
<td>Room 62/63</td>
</tr>
<tr>
<td>Scientific Panel Multiple sclerosis</td>
<td>Sunday, 29 May 12.00 - 13.00</td>
<td>Hall B5M2</td>
</tr>
<tr>
<td>Scientific Panel Clinical neurophysiology</td>
<td>Sunday, 29 May 12.00 - 13.00</td>
<td>Room 60/61</td>
</tr>
<tr>
<td>Scientific Panel Stroke</td>
<td>Sunday, 29 May 13.00 - 14.00</td>
<td>Room 62/63</td>
</tr>
<tr>
<td>Scientific Panel Coma and chronic disorders of consciousness</td>
<td>Sunday, 29 May 13.30 - 14.30</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel Neuroepidemiology</td>
<td>Sunday, 29 May 14.30 - 16.00</td>
<td>Room 60/61</td>
</tr>
<tr>
<td>Scientific Panel Neurogenetics</td>
<td>Sunday, 29 May 14.30 - 16.00</td>
<td>Room 62/63</td>
</tr>
<tr>
<td>Scientific Panel ALS and frontotemporal dementia</td>
<td>Sunday, 29 May 16.00 - 19.00</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel General neurology</td>
<td>Sunday, 29 May 17.00 - 18.30</td>
<td>Room 62/63</td>
</tr>
<tr>
<td>Scientific Panel Sleep-wake disorders</td>
<td>Sunday, 29 May 17.00 - 19.00</td>
<td>Room 60/61</td>
</tr>
</tbody>
</table>
(in chronological order, as per date of printing)
Additional meetings reserved after the date of printing will be announced on the Message screen in the registration area.

<table>
<thead>
<tr>
<th>GROUP/COMMITTEE</th>
<th>DAY, TIME</th>
<th>BELLY CENTER/SKY HOTEL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific Panel Translational neurology</td>
<td>Sunday, 29 May 17.00 - 19.00</td>
<td>Room 5</td>
</tr>
<tr>
<td>Scientific Panel Palliative care</td>
<td>Monday, 30 May 08.00 - 09.00</td>
<td>Room 22</td>
</tr>
<tr>
<td>Scientific Panel Muscle disorders</td>
<td>Monday, 30 May 08.00 - 09.30</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel Neurosonology</td>
<td>Monday, 30 May 08.00 - 09.30</td>
<td>Room 21</td>
</tr>
<tr>
<td>Rare Neurological Diseases Task Force</td>
<td>Monday, 30 May 09.30 - 11.00</td>
<td>Room 22</td>
</tr>
<tr>
<td>Scientific Panel Child neurology</td>
<td>Monday, 30 May 09.30 - 10.30</td>
<td>Room 60</td>
</tr>
<tr>
<td>Scientific Panel Neuropathies</td>
<td>Monday, 30 May 10.30 - 12.00</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel Neuro-oncology</td>
<td>Monday, 30 May 11.00 - 12.00</td>
<td>Room 22</td>
</tr>
<tr>
<td>Scientific Panel Epilepsy</td>
<td>Monday, 30 May 11.30 - 12.30</td>
<td>Room 61</td>
</tr>
<tr>
<td>Scientific Panel Pain</td>
<td>Monday, 30 May 11.30 - 12.30</td>
<td>Room 60</td>
</tr>
<tr>
<td>Scientific Panel Dementia and cognitive disorders</td>
<td>Monday, 30 May 14.30 - 16.00</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>Scientific Panel Neurotoxicology</td>
<td>Monday, 30 May 15.00 - 16.00</td>
<td>Room 22</td>
</tr>
<tr>
<td>Scientific Panel Neurotraumatology</td>
<td>Monday, 30 May 15.00 - 16.00</td>
<td>Room 21</td>
</tr>
<tr>
<td>Scientific Panel Infectious diseases</td>
<td>Monday, 30 May 15.00 - 16.30</td>
<td>Room 61</td>
</tr>
<tr>
<td>Scientific Panel Neurocritical care</td>
<td>Monday, 30 May 16.00 - 17.30</td>
<td>Room 69/70</td>
</tr>
<tr>
<td>YESNA Meeting</td>
<td>Monday, 30 May 16.30 - 18.30</td>
<td>Room 22</td>
</tr>
<tr>
<td>Scientific Panel Headache</td>
<td>Monday, 30 May 17.00 - 18.30</td>
<td>Room 16</td>
</tr>
</tbody>
</table>
**SATURDAY, 28 MAY 2016 12.30–13.15**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 1 (Screen A2)</td>
<td>P11001 - P11013</td>
<td>Pasquale Calabrese, ITALY</td>
</tr>
<tr>
<td>Autonomic nervous system 1 (Screen B1)</td>
<td>P11014 - P11022</td>
<td>Astrid Terkelsen, DENMARK</td>
</tr>
<tr>
<td>Cerebrovascular diseases 1 (Screen G1)</td>
<td>P11023 - P11038</td>
<td>Anna Czlonkowska, POLAND</td>
</tr>
<tr>
<td>Cerebrovascular diseases 2 (Screen G3)</td>
<td>P11037 - P11049</td>
<td>Adam Kobayashi, POLAND</td>
</tr>
<tr>
<td>Cerebrovascular diseases 3 (Screen G4)</td>
<td>P11050 - P11065</td>
<td>Zuzana Gdovinova, SLOVAKIA</td>
</tr>
<tr>
<td>Child neurology/developmental neurology (Screen H1)</td>
<td>P11066 - P11080</td>
<td>Vittoria Papp, DENMARK</td>
</tr>
<tr>
<td>Clinical neurophysiology 1 (Screen H2)</td>
<td>P11081 - P11092</td>
<td>Einar Wilder-Smith, SINGAPORE</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 1 (Screen A3)</td>
<td>P11093 - P11105</td>
<td>Rita Formisano, ITALY</td>
</tr>
<tr>
<td>Critical care (Screen F4)</td>
<td>P11106 - P11116</td>
<td>Raimund Helbok, AUSTRIA</td>
</tr>
<tr>
<td>Epilepsy 1 (Screen B2)</td>
<td>P11117 - P11128</td>
<td>Jakob Christensen, DENMARK</td>
</tr>
<tr>
<td>Epilepsy 2 (Screen B3)</td>
<td>P11129 - P11141</td>
<td>Alla Guekht, RUSSIAN FEDERATION</td>
</tr>
<tr>
<td>Headache and pain 1 (Screen C1)</td>
<td>P11142 - P11155</td>
<td>Henriette Kilt, DENMARK</td>
</tr>
<tr>
<td>Movement disorders 1 (Screen E4)</td>
<td>P11156 - P11168</td>
<td>Kristian Winge, DENMARK</td>
</tr>
<tr>
<td>MS and related disorders 1 (Screen F1)</td>
<td>P11169 - P11181</td>
<td>Oluf Andersen, SWEDEN (TBC)</td>
</tr>
<tr>
<td>MS and related disorders 2 (Screen F2)</td>
<td>P11182 - P11194</td>
<td>Ludwig Kappos, SWITZERLAND</td>
</tr>
<tr>
<td>MS and related disorders 3 (Screen F3)</td>
<td>P11195 - P11208</td>
<td>Krzysztof Selmaj, POLAND</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 1 (Screen B4)</td>
<td>P11209 - P11220</td>
<td>Tiziana Mongini, ITALY</td>
</tr>
<tr>
<td>Neuro-oncology 1 (Screen C4)</td>
<td>P11221 - P11233</td>
<td>Stefan Oberndorfer, AUSTRIA</td>
</tr>
<tr>
<td>Neurorehabilitation 1 (Screen G2)</td>
<td>P11234 - P11245</td>
<td>Józef Opara, POLAND</td>
</tr>
<tr>
<td>Peripheral nerve disorders 1 (Screen D2)</td>
<td>P11246 - P11258</td>
<td>Michaela Auer-Grumbach, AUSTRIA</td>
</tr>
<tr>
<td>Sleep disorders 1 (Screen E1)</td>
<td>P11259 - P11273</td>
<td>Isabelle Arnulf, FRANCE</td>
</tr>
<tr>
<td>Spinal cord and root disorders (Screen E2)</td>
<td>P11274 - P11286</td>
<td>Josef Bednarik, CZECH REPUBLIC (TBC)</td>
</tr>
</tbody>
</table>

**SATURDAY, 28 MAY 2016 13.30 – 14.15**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 2 (Screen A2)</td>
<td>P12001 - P12013</td>
<td>Dorota Religa, SWEDEN</td>
</tr>
<tr>
<td>Autonomic nervous system 2 (Screen B1)</td>
<td>P12014 - P12023</td>
<td>Josef Zeithofer, AUSTRIA (TBC)</td>
</tr>
<tr>
<td>Cerebrovascular diseases 4 (Screen G1)</td>
<td>P12024 - P12037</td>
<td>Christine Kremer, SWEDEN</td>
</tr>
<tr>
<td>Cerebrovascular diseases 5 (Screen G3)</td>
<td>P12038 - P12051</td>
<td>Urs Fischer, SWITZERLAND</td>
</tr>
<tr>
<td>Clinical neurophysiology 2 (Screen H2)</td>
<td>P12052 - P12062</td>
<td>Martin Rakusa, SLOVENIA</td>
</tr>
<tr>
<td>Epilepsy 3 (Screen B2)</td>
<td>P12063 - P12075</td>
<td>Philippe Ryvlin, SWITZERLAND</td>
</tr>
<tr>
<td>Headache and pain 2 (Screen C1)</td>
<td>P12076 - P12089</td>
<td>Troels Staehlin Jensen, DENMARK (TBC)</td>
</tr>
<tr>
<td>Movement disorders 2 (Screen E4)</td>
<td>P12090 - P12102</td>
<td>Christer Nilsson, SWEDEN</td>
</tr>
<tr>
<td>Movement disorders 3 (Screen E3)</td>
<td>P12103 - P12113</td>
<td>Espen Dietrichs, NORWAY</td>
</tr>
<tr>
<td>MS and related disorders 4 (Screen F1)</td>
<td>P12114 - P12126</td>
<td>Gordon Plant, UNITED KINGDOM</td>
</tr>
<tr>
<td>MS and related disorders 5 (Screen F2)</td>
<td>P12127 - P12139</td>
<td>Hans Lassmann, AUSTRIA</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 2 (Screen B4)</td>
<td>P12140 - P12151</td>
<td>Abhijit Chaudhuri, UNITED KINGDOM</td>
</tr>
<tr>
<td>Neuroimaging 1 (Screen A3)</td>
<td>P12152 - P12165</td>
<td>Frederik Barkhof, THE NETHERLANDS</td>
</tr>
<tr>
<td>Neurological manifestations of systemic diseases 1 (Screen B3)</td>
<td>P12166 - P12175</td>
<td>Daniel Kondziella, DENMARK</td>
</tr>
<tr>
<td>Peripheral nerve disorders 2 (Screen D2)</td>
<td>P12176 - P12187</td>
<td>Jonathan Baets, BELGIUM</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and poster stations in the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).
TOPIC (SCREEN NR) | POSTER NUMBERS | CHAIRS
---|---|---
**SUNDAY, 29 MAY 2016 12.30–13.15**
Ageing and dementia 3 (Screen A2) | P21001 - P21013 | Sandro Sorbi, ITALY
Cerebrovascular diseases 6 (Screen G4) | P21014 - P21027 | Didier Leys, FRANCE
Cerebrovascular diseases 7 (Screen G3) | P21028 - P21042 | Caroline Renner, GERMANY
Cognitive neurology/neuropsychology 2 (Screen A3) | P21043 - P21055 | Thomas Bak, UNITED KINGDOM (TBC)
Epilepsy 4 (Screen B2) | P21056 - P21068 | Leone Ridsdale, UNITED KINGDOM
Headache and pain 3 (Screen C1) | P21069 - P21082 | Mads Barloese, DENMARK
Motor neurone diseases 1 (Screen C2) | P21083 - P21095 | Vincenzo Donadio, ITALY (TBC)
Movement disorders 4 (Screen E4) | P21096 - P21108 | Joaquim Ferreira, PORTUGAL
MS and related disorders 6 (Screen F1) | P21109 - P21121 | Bruno Stankoff, AUSTRIA
MS and related disorders 7 (Screen F2) | P21122 - P21133 | Xavier Montalban, SPAIN
MS and related disorders 8 (Screen F3) | P21134 - P21147 | Tjalf Ziemssen, GERMANY
Muscle and neuromuscular junction disease 3 (Screen B4) | P21148 - P21159 | Edina Varga, HUNGARY
Neuroepidemiology 1 (Screen C3) | P21160 - P21167 | Maura Pugliatti, ITALY
Neurogenetics 1 (Screen F4) | P21168 - P21181 | Péter Balicza, HUNGARY
Neuroimmunology 1 (Screen H2) | P21182 - P21196 | Pasquale Annunziata, ITALY
Neuro-oncology 2 (Screen C4) | P21197 - P21209 | Maria Mallia, MALTA (TBC)
Neuro-ophthalmology/ neuro-otology 1 (Screen H1) | P21210 - P21221 | Katharina Feil, GERMANY (TBC)
Neurorehabilitation 2 (Screen G2) | P21222 - P21234 | Michaela Bisciglio, BELGIUM
Neurotoxicology/occupational neurology (Screen G1) | P21235 - P21247 | Maurizio Leone, ITALY
Peripheral nerve disorders 3 (Screen D2) | P21248 - P21260 | Frouke Nijhuis, THE NETHERLANDS
Sleep disorders 2 (Screen E1) | P21261 - P21274 | Ulf Kallweit, SWITZERLAND

**SUNDAY, 29 MAY 2016 13.30–14.15**
Ageing and dementia 4 (Screen A2) | P22001 - P22013 | Jonathan Schott, UK
Cerebrovascular diseases 8 (Screen G4) | P22014 - P22027 | Volker Dietz, SWITZERLAND
Cerebrovascular diseases 9 (Screen G3) | P22028 - P22042 | Uta Meyding-Lamadé, GERMANY
Epilepsy 5 (Screen B2) | P22043 - P22055 | Gert Braathen, NORWAY
Headache and pain 4 (Screen C1) | P22056 - P22069 | Kathrin Doppler, GERMANY
Motor neurone diseases 2 (Screen C2) | P22070 - P22082 | David Oliver, UNITED KINGDOM
Movement disorders 5 (Screen E4) | P22083 - P22095 | Lisa Klingelhofer, GERMANY
MS and related disorders 9 (Screen F1) | P22096 - P22108 | Nicola De Stefano, ITALY
MS and related disorders 10 (Screen F2) | P22109 - P22121 | Celia Oreja-Guevara, SPAIN
Muscle and neuromuscular junction disease 4 (Screen B4) | P22122 - P22134 | Miguel Pinto, PORTUGAL (TBC)
Neuroepidemiology 2 (Screen C3) | P22135 - P22142 | Alexander Tiskaridze, GEORGIA
Neurogenetics 2 (Screen F4) | P22143 - P22156 | Karolina Dziezyc, POLAND
Neuroimaging 2 (Screen A3) | P22157 - P22172 | Luigi Ferrari Strambi, ITALY
Neuroimmunology 2 (Screen H2) | P22173 - P22186 | Maarten Titulaer, THE NETHERLANDS
Neurological manifestations of systemic diseases 2 (Screen B3) | P22187 - P22196 | Peter Berlit, GERMANY
Neuro-ophthalmology/ neuro-otology 2 (Screen H1) | P22197 - P22208 | Dominik Straumann, SWITZERLAND
Peripheral nerve disorders 4 (Screen D2) | P22209 - P22221 | Davide Pareyson, ITALY

All posters will be available throughout the congress on the poster screens and poster stations in the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).
Poster presenters are requested to be at their poster screen at the beginning of the sessions.

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MONDAY, 30 MAY 2016</strong></td>
<td><strong>12.30–13.15</strong></td>
<td></td>
</tr>
<tr>
<td>Ageing and dementia 5 (Screen A2)</td>
<td>P31001 - P31012</td>
<td>Stefano Cappa, ITALY</td>
</tr>
<tr>
<td>Cerebrovascular diseases 10 (Screen G4)</td>
<td>P31013 - P31026</td>
<td>Fabienne Perren, SWITZERLAND</td>
</tr>
<tr>
<td>Cerebrovascular diseases 11 (Screen G3)</td>
<td>P31027 - P31041</td>
<td>Ana Subic, SLOVENIA (TBC)</td>
</tr>
<tr>
<td>Cognitive neurology/neuropsychology 3 (Screen A3)</td>
<td>P31042 - P31054</td>
<td>Laszlo Csiba, HUNGARY</td>
</tr>
<tr>
<td>Epilepsy 6 (Screen B2)</td>
<td>P31055 - P31067</td>
<td>Hermann Stefan, GERMANY</td>
</tr>
<tr>
<td>Headache and pain 5 (Screen C1)</td>
<td>P31068 - P31081</td>
<td>Panagiotis Zis, UNITED KINGDOM</td>
</tr>
<tr>
<td>Infection and AIDS 1 (Screen F3)</td>
<td>P31082 - P31093</td>
<td>Leo Visser, THE NETHERLANDS</td>
</tr>
<tr>
<td>Motor neurone diseases 3 (Screen C2)</td>
<td>P31094 - P31106</td>
<td>Josef Finsterer, AUSTRIA</td>
</tr>
<tr>
<td>Movement disorders 6 (Screen E4)</td>
<td>P31107 - P31119</td>
<td>Antonella Macerollo, UNITED KINGDOM</td>
</tr>
<tr>
<td>Movement disorders 7 (Screen E3)</td>
<td>P31120 - P31132</td>
<td>Nabil Mohsen, LEBANON</td>
</tr>
<tr>
<td>MS and related disorders 11 (Screen F1)</td>
<td>P31133 - P31145</td>
<td>Ralf Gold, GERMANY</td>
</tr>
<tr>
<td>MS and related disorders 12 (Screen F2)</td>
<td>P31146 - P31159</td>
<td>Paolo Preziosa, ITALY</td>
</tr>
<tr>
<td>MS and related disorders 13 (Screen E2)</td>
<td>P31160 - P31172</td>
<td>Johann Sellner, AUSTRIA</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 5 (Screen B4)</td>
<td>P31173 - P31184</td>
<td>Benedikt Schoser, GERMANY</td>
</tr>
<tr>
<td>Neurogenetics 3 (Screen F4)</td>
<td>P31185 - P31197</td>
<td>David Lynch, UNITED KINGDOM</td>
</tr>
<tr>
<td>Neuroimmunology 3 (Screen H2)</td>
<td>P31198 - P31211</td>
<td>Frank Leyboldt, GERMANY</td>
</tr>
<tr>
<td>Neuro-oncology 3 (Screen C4)</td>
<td>P31212 - P31225</td>
<td>Anette Storstein, NORWAY</td>
</tr>
<tr>
<td>Neuro-ophthalmology/ neuro-otology 3 (Screen H1)</td>
<td>P31226 - P31236</td>
<td>Eleftherios Papathanasiou, CYPRUS</td>
</tr>
<tr>
<td>Neurorehabilitation 3 (Screen G2)</td>
<td>P31237 - P31247</td>
<td>Stefan Golazewski, AUSTRIA</td>
</tr>
<tr>
<td>Neurotraumatology (Screen G1)</td>
<td>P31248 - P31261</td>
<td>Edvard Ehler, CZECH REPUBLIC</td>
</tr>
<tr>
<td>Peripheral nerve disorders 5 (Screen D2)</td>
<td>P31262 - P31273</td>
<td>Henry Houlden, UNITED KINGDOM</td>
</tr>
<tr>
<td>Sleep disorders 3 (Screen E1)</td>
<td>P31274 - P32000</td>
<td>Maria Stamelou, GREECE</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and poster stations in the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).
**MONDAY, 30 MAY 2016**

<table>
<thead>
<tr>
<th>TOPIC (SCREEN NR)</th>
<th>POSTER NUMBERS</th>
<th>CHAIRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ageing and dementia 6 (Screen A2)</td>
<td>P32001 - P32011</td>
<td>Rik Ossenkoppele, THE NETHERLANDS</td>
</tr>
<tr>
<td>Cerebrovascular diseases 12 (Screen G4)</td>
<td>P32012 - P32025</td>
<td>Valeria Caso, ITALY</td>
</tr>
<tr>
<td>Cerebrovascular diseases 13 (Screen G3)</td>
<td>P32026 - P32040</td>
<td>Catarina Fonseca, PORTUGAL</td>
</tr>
<tr>
<td>Epilepsy 7 (Screen B2)</td>
<td>P32041 - P32053</td>
<td>Eugen Trinka, AUSTRIA (TBC)</td>
</tr>
<tr>
<td>Headache and pain 6 (Screen C1)</td>
<td>P32054 - P32066</td>
<td>Jera Kruja, ALBANIA</td>
</tr>
<tr>
<td>Headache and pain 7 (Screen C4)</td>
<td>P32067 - P32081</td>
<td>Jes Olesen, DENMARK</td>
</tr>
<tr>
<td>Infection and AIDS 2 (Screen F3)</td>
<td>P32082 - P32093</td>
<td>Johann Sellner, AUSTRIA</td>
</tr>
<tr>
<td>Motor neurone diseases 4 (Screen C2)</td>
<td>P32094 - P32105</td>
<td>Vincenzo Silani, ITALY</td>
</tr>
<tr>
<td>Movement disorders 8 (Screen E4)</td>
<td>P32106 - P32118</td>
<td>Evzen Ruzicka, CZECH REPUBLIC</td>
</tr>
<tr>
<td>Movement disorders 9 (Screen E3)</td>
<td>P32119 - P32131</td>
<td>Anna Sauerbier, UNITED KINGDOM</td>
</tr>
<tr>
<td>MS and related disorders 14 (Screen F1)</td>
<td>P32132 - P32144</td>
<td>Nicholas Gutowski, UNITED KINGDOM</td>
</tr>
<tr>
<td>MS and related disorders 15 (Screen F2)</td>
<td>P32145 - P32158</td>
<td>Óscar Fernández, SPAIN</td>
</tr>
<tr>
<td>Muscle and neuromuscular junction disease 6 (Screen B4)</td>
<td>P32159 - P32171</td>
<td>Klaus Toyka, GERMANY (TBC)</td>
</tr>
<tr>
<td>Neurogenetics 4 (Screen F4)</td>
<td>P32172 - P32184</td>
<td>Jochen Schafer, GERMANY</td>
</tr>
<tr>
<td>Neuroimaging 3 (Screen A3)</td>
<td>P32185 - P32198</td>
<td>Tim von Oertzen, AUSTRIA</td>
</tr>
<tr>
<td>Neuroimmunology 4 (Screen H2)</td>
<td>P32199 - P32211</td>
<td>Heinz Wiendl, GERMANY</td>
</tr>
<tr>
<td>Neurological manifestations of systemic diseases 3 (Screen B3)</td>
<td>P32212 - P32221</td>
<td>Eduardo Nobile-Orazio, ITALY</td>
</tr>
<tr>
<td>Neurology and arts; History of neurology; Ethics in neurology; Education in neurology (Screen E2)</td>
<td>P32222 - P32236</td>
<td>Jan Kuks, THE NETHERLANDS</td>
</tr>
<tr>
<td>Neuro-ophthalmology/ neuro-otology 4 (Screen H1)</td>
<td>P32237 - P32347</td>
<td>Christopher Kennard, UNITED KINGDOM</td>
</tr>
<tr>
<td>Peripheral nerve disorders 6 (Screen D2)</td>
<td>P33248 - P33259</td>
<td>Nazha Birouk, MOROCCO</td>
</tr>
</tbody>
</table>

All posters will be available throughout the congress on the poster screens and poster stations in front of the exhibition area. You can contact poster presenters via the Interactive Programme Planner (IPP).
EFNA PUBLIC AWARENESS DAY FOR: PATIENTS, CARERS, FAMILIES AND HEALTH PROFESSIONALS
Together under the Umbrella for Huntington’s disease
10:30 - 17:00

Location: DGI-byen, Tietgensgade 65, 1704 Copenhagen V, Denmark.

As part of the Together Under the Umbrella awareness campaign for brain disorders, the European Federation of Neurological Associations will organise an information day on Huntington’s Disease. The event, which will be organised to coincide with the EAN Annual Congress, is open to those living with Huntington’s disease, their families and friends, carers, health professionals or those with an interest in learning more. World-Leading, Huntington Disease Specialist, Prof. Bernhard Landwehrmeyer will be the keynote speaker on the day.

This free event will take place on Saturday, 28 May, 2016 from 10:30 – 17:00 (Registration and Breakfast from 09:30) at DGI-byen, Tietgensgade 65, 1704 Copenhagen V, Denmark.

Presentations will focus on:
• Current, best-practice approaches to treatment and management
• Latest research and studies in the field – hope for the future
• Patient and Carer personal stories
• National service and support structures
• Coping tips and strategies for Carers
• Mindfulness and Relaxation

A buffet breakfast and sandwich lunch will be provided on the day, and there will be time throughout to speak to other families, ask questions and pick up more information on HD.
CHALLENGES FOR WOMEN IN NEUROLOGY – EXPERIENCES FROM WESTERN AND EASTERN EUROPE

13:00-14:30 | HALL B4 M1

The aim of this event is to help identify and overcome the challenges that women may find during their academic and hospital career development in neurology. This event is mainly directed to female neurology residents and female neurologists at the beginning of their career.

You are invited to bring your lunch to this session.

Nazha Birouk,
RABAT, MOROCCO

Professors Nazha Birouk (MD, Prof) is President of the Moroccan Society of Neurology (2012-2016). She received her Professor’s Degree in Neurology at the Faculty of Medicine of Rabat in November 1997. Her training for neuromuscular disorders and neurophysiology was at the Hôpital de la Salpêtrière, Paris, France from 1994-1997. Her main fields of interest are Neuromuscular disorders - Hereditary neuropathies and myopathies; ENMG, Neurophysiology. She is involved in research projects in hereditary neuropathies, muscular dystrophies, and hereditary ataxia. She gave invited lectures in International and National Meetings: Themes: Peripheral nerve disorders: hereditary neuropathies; Inflammatory neuropathies; Muscle disorders; ENMG; Neuropathic Pain. She was Secretary General of the Moroccan Society of Neurology from 1998 to 2004; Secretary General of the Moroccan Association against Myopathy: Since 2005 and was a Delegate Member of the EFNS for the Moroccan Society of Neurology; 2007-2013.

Elena Lebedeva,
JEKATERINBURG, RUSSIA

Elena Lebedeva (MD, PhD, DocMedSci) is associate professor of neurology of the Ural State Medical University, director of International Headache Center “Europe-Asia” in Yekaterinburg and consultant neurologist. She works 70% clinically and 30% in research. She has 5 PhD students. Her main areas of interest concern stroke, intracranial aneurysms and headache. She got Investigator Award from the EFNS in 2012. She is currently part of the EAN Scientific Panels on Stroke and Headache. She was organizer of two EFNS Regional Teaching courses in Yekaterinburg (2006, 2011), 9 annual conferences on actual topics of neurology and 15 Headache schools. She is married and has two sons.

Gunhild Waldemar,
COPENHAGEN, DENMARK

Gunhild Waldemar, MD DMSc, Honorary member of the EAN, is a professor of clinical neurology and coordinating professor at the Neuroscience Centre, Rigshospitalet, University of Copenhagen, Denmark. She established the multi-disciplinary memory clinic in her department in 1995, and later extended the clinic with a dementia research lab. In 2007 with a national info & education centre, funded by the Danish Ministry of Health. In 2010 the combined centre, now named, The Danish Dementia Research Centre, won the “Global Excellence in Health” award from the Capital Region of Denmark and University of Copenhagen. She has also chaired the Liaison Committee in the EFNS and was part of the task force merging the EFNS with the ENS, forming the EAN.

RRFS HOSPITAL VISIT
18:00 | REGISTRATION DESK

(max. 100 participants) on Sunday, 29 May 2016 will be organised in co-operation with the Danish Young Neurologist Society. We are going to meet at 18.00-18.15 in front of the registration desk. We will visit the Rigshospital - University Hospital followed by a get-together. Registration is available via facebook or by contacting rrfs@ean.org or at the RRFS booth at the congress.
NETWORKING RECEPTION AND “MEET THE SPEAKERS”

EAN will be happy to encourage speakers and participants likewise to come to the renowned Paper Island Street Food market and offer the possibility to mingle and encounter in a relaxed atmosphere.

Copenhagen Street Food offers 35 food and beverage counters/stalls that represent almost the entire globe in a culinary way.

Entry is free of charge, food and beverages have to be paid at one’s own expense. Come to the EAN Booth and win vouchers for food+drink at Paper Island Streetfood.

Location: Christiansholm - Papirøen Trangravsvej 14, Warehouse 7/8, 1436 København.

More information can be found here: http://copenhagenstreetfood.dk/en/

From 20.15-22.15 a shuttle boat Nyhavn-Paper Island-Nyhavn will be available every 15 minutes for all participants.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-10:00</td>
<td>MDS-ES European Basal Ganglia Club</td>
<td>FW1</td>
<td>08:30-10.00 Neurolgy across continents: WFNI/WHO</td>
<td>FW1</td>
<td>08:30-10.00 New concepts about speech and language processing in the brain</td>
<td>FW1</td>
<td>08:30-10.00 Genetic approaches in neuropathies</td>
<td>FW2</td>
<td>08:30-10.00 Abnormal movements in deep</td>
<td>FW4</td>
<td>08:30-10.00 Cost effective investigations of CNS infections</td>
<td>FW5</td>
<td>08:30-10.00 Front applications in Neurosurgery</td>
<td>SpS2</td>
</tr>
<tr>
<td>10:00-10:30</td>
<td>Coffee break @ exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>Sy1</td>
<td>10.30 - 12:30 MDS-ES/EAN: Update in Movement disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30-14:45</td>
<td>Lunch break @ exhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45-18:15</td>
<td>TC1</td>
<td>14:45-18:15 Acute management of stroke Level 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OS1</td>
<td>14:45-15:15 Movement disorders Level 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OS2</td>
<td>14:45-15:15 Movement disorders Level 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC1</td>
<td>14:45-18:15 Neuro-gastroenterological Emergencies Level 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC2</td>
<td>14:45-18:15 Neurogenetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC3</td>
<td>14:45-18:15 Neuro-oncology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TC4</td>
<td>14:45-18:15 Autonomic nervous system disorders &amp; Clinical neurophysiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OS1</td>
<td>14:45-18:15 Motor neuron disease Level 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OS2</td>
<td>14:45-18:15 Sleep disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30 – 21:00</td>
<td>19:30 – 21:00 Welcome Reception @ Centerhall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30-10:00</td>
<td>Zika/Arboviral Infections - Challenges in the Treatment of Viral Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30-11:45</td>
<td>Cognition and Cognitive Reserve: Consensus and Controversies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45-16:15</td>
<td>What's New in Neurology - Translating Evidence into Management</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:15-18:45</td>
<td>Satellite Symposia - Hands-on, Case-based, and Interactive Workshops</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30-20.00</td>
<td>Networking Events, Symposiums, and Satellite Symposia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sunday, 29 May**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-12.30</td>
<td>Presidential Exhibition</td>
</tr>
<tr>
<td>12.30-14.30</td>
<td>Symposium: New European Neurological Syndromes – Consensus and Controversies</td>
</tr>
<tr>
<td>14.45-18.15</td>
<td>Symposium: The Management of Motor Complications in PD?</td>
</tr>
<tr>
<td>18.30-20.00</td>
<td>Networking Events, Symposiums, and Satellite Symposia</td>
</tr>
</tbody>
</table>

**Tuesday, 31 May**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10.45</td>
<td>CbFW</td>
</tr>
<tr>
<td>10.45-12.30</td>
<td>CBFW</td>
</tr>
</tbody>
</table>

**Terms and Abbreviations**
- **HALL**: Hall
- **PS**: Poster Session
- **OS**: Oral Session
- **TC**: Teaching Course
- **Sy**: Symposium
- **IS**: Interactive Session
- **SpS**: Special Session
- **HOC**: Hands-on course
- **NE**: Networking Events
- **CbfW**: Case-based facilitated Workshops
- **hands-on course:** Hands-on course
- **Poster Session:** Poster Session
<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>M0</td>
<td>IS3</td>
<td>MDS-ES/EAN: Paroxysmal and acute movement disorders</td>
</tr>
<tr>
<td></td>
<td>M1</td>
<td>FW13</td>
<td>Sleep and Cognition</td>
</tr>
<tr>
<td></td>
<td>M2</td>
<td>SpS6</td>
<td>ILAE-CEA/EAN: Hot topics in Epilepsy</td>
</tr>
<tr>
<td></td>
<td>M3</td>
<td>FW14</td>
<td>Gut microbiota, immunology and neurological diseases</td>
</tr>
<tr>
<td></td>
<td>M4</td>
<td>FW15</td>
<td>Exome sequencing goes bedside: new genes in neurological disorders</td>
</tr>
<tr>
<td></td>
<td>M5</td>
<td>FW16</td>
<td>Syndromes of central visual and vestibular disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FW17</td>
<td>ALS and FTD: two converging diseases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CbfW4</td>
<td>Management of multiple sclerosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HoC4</td>
<td>Neurophysiology III Non-invasive brain stimulation</td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td>PS2</td>
<td>Neuroimaging of dementia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SaS</td>
<td>1. Ever Neuropharma: Integrating acute and rehabilitation strategies in stroke therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2. Novartis: The real MS: outcomes and evidence in the real-world</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3. Sanofi Genzyme: Tales of the unexpected: elementary clues to diagnosing muscular diseases</td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td>Sy6</td>
<td>ESO-EAN: Acute Stroke: New Opportunities and challenges for neurologists</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sy5</td>
<td>New perspectives in the treatment of neuromuscular diseases: therapies on the horizon</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TC13</td>
<td>Diagnostic and therapeutical approach to muscle syndromes Level 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SpS11</td>
<td>History of neurology</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TC14</td>
<td>Pain in central neurological conditions: Level 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TC15</td>
<td>Clinical presentations of metabolic disorders: Level 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TC16</td>
<td>Interventions in neurocritical care: Level 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TC17</td>
<td>Update on epilepsy in children – new trends in diagnosis and treatment: Level 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EHF/EAN Topical Symposium CGRP antibodies: A new class of migraine specific preventive medication</td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td>Care of the person with ALS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tournament</td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td>OS</td>
<td>Cerebrovascular diseases 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Muscle and neuromuscular junction diseases (cont.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Movement disorders 3 (cont.) (cont.) (cont.) (cont.)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Headache and pain 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Resident and Research Fellow Assembly</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cognitive neurology/neuropsychology 2</td>
</tr>
</tbody>
</table>

**Note:** The above schedule is subject to change and may be updated closer to the event date. Always check the official programme for the latest information.
<table>
<thead>
<tr>
<th>Hall</th>
<th>Time</th>
<th>Event Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HALL B1</td>
<td>08:00-10:00</td>
<td>Understanding functional connectivity using MRI</td>
<td>Visiting exhibition and poster area</td>
</tr>
<tr>
<td>HALL B2</td>
<td>08:00-10:00</td>
<td>New diagnostic developments in Epilepsy</td>
<td>Visiting exhibition and poster area</td>
</tr>
<tr>
<td>HALL B3</td>
<td>08:00-10:00</td>
<td>Untangling inflammatory and degenerative aspects of multiple sclerosis</td>
<td>Visiting exhibition and poster area</td>
</tr>
<tr>
<td>M1</td>
<td>08:30-10:00</td>
<td>European reference network</td>
<td></td>
</tr>
<tr>
<td>M2</td>
<td>08:30-10:00</td>
<td>Shared decision making (SDM) in neurology</td>
<td></td>
</tr>
<tr>
<td>B4.M2</td>
<td>08:00-10:30</td>
<td>Coffee break @ exhibition</td>
<td></td>
</tr>
<tr>
<td>B5.M1</td>
<td>09:30-13.30</td>
<td>Exhibition</td>
<td></td>
</tr>
<tr>
<td>B5.M2</td>
<td>10:30-12:30</td>
<td>Highlights and Breaking News</td>
<td></td>
</tr>
<tr>
<td>B5.M1</td>
<td>10:30-12:30</td>
<td>Overflow</td>
<td></td>
</tr>
<tr>
<td>B5.M2</td>
<td>12:00-13:00</td>
<td>Lunch break @ exhibition</td>
<td></td>
</tr>
<tr>
<td>HALL B3</td>
<td>13:00-16:30</td>
<td>Life after stroke Level 2</td>
<td></td>
</tr>
<tr>
<td>HALL C</td>
<td>13:00-16:30</td>
<td>Challenges in newly diagnosed epilepsy Level 1</td>
<td></td>
</tr>
<tr>
<td>M3</td>
<td>13:00-16:30</td>
<td>Current trends in neurology II Level 1</td>
<td></td>
</tr>
<tr>
<td>M4</td>
<td>13:00-16:30</td>
<td>Preventing delayed neurological deficits in neurocritical care – Old foes, new concepts Level 2-3</td>
<td></td>
</tr>
<tr>
<td>M5</td>
<td>13:00-16:30</td>
<td>Developing an EAN guideline Level 1</td>
<td></td>
</tr>
<tr>
<td>M2</td>
<td>13:00-16:30</td>
<td>Current treatments in neurology II Level 1</td>
<td></td>
</tr>
<tr>
<td>M4</td>
<td>14:30-15:00</td>
<td>Coffee break @ exhibition</td>
<td></td>
</tr>
</tbody>
</table>
SAVE THE DATE

ESNCH 2017

22nd MEETING of the EUROPEAN SOCIETY of NEUROSONOLOGY and CEREBRAL HEMODYNAMICS

19–21 May 2017
www.neurosonology2017.de

THE CONFERENCE OF ULTRASOUND IN NEUROLOGY

- discover the latest technologies
- present and discuss your research
- talk to the specialists
- improve your practical skills
- take the ESNCH exam

SEE YOU IN BERLIN
CONCISE, PEER-REVIEWED, OPEN-ACCESS, OPINION based ARTICLES & VIDEOS from KEY OPINION LEADERS, ACCESS and DOWNLOAD FREE

www.touchNEUROLOGY.com
CASE-BASED FACILITATED WORKSHOP 1: EEG IN PATIENTS WITH ACUTE CONSCIOUSNESS IMPAIRMENT
08:30 - 10:00 | HALL B4.M1

CHAIRPERSON:
Andrea Rossetti, LAUSANNE, SWITZERLAND

Use of the new ACNS nomenclature
Erik Westhall, LUND, SWEDEN

Advanced EEG monitoring
Nicolas Gaspard, BRUSSELS, BELGIUM

Spiky EEG: to treat or not to treat?
Andrea Rossetti, LAUSANNE, SWITZERLAND

Dr Westhall will familiarise the audience with some examples of EEG patterns to be described with the ACNS nomenclature. Dr Gaspard will focus on indications and values of video-EEG monitoring. Dr Rossetti will highlight some differentials regarding sharply contoured EEG patterns and treatment implications. The audience will interactively work in 3 groups of about 20 persons on vignettes with clinical and EEG data. Each speaker will discuss 4-5 vignettes; speakers will rotate among groups every 30 minutes.

INTERACTIVE SESSION 1: COST EFFECTIVE INVESTIGATIONS OF CNS INFECTIONS
08:30 - 10:00 | HALL M5

CHAIRPERSON:
Israel Steiner, PETACH TIKVA, ISREAL

Neuroimaging
Uta Meyding-Lamade, FRANKFURT A.M., GERMANY

Microbiology
Peter Kennedy, GLASGOW, UK

Molecular biology
Israel Steiner, PETACH TIKVA, ISREAL

Biopsy/Histology
Hans Lassmann, VIENNA, AUSTRIA

CNS infections are an important clinical challenge. Early diagnosis enables to provide specific therapy that will reduce mortality, cut down neurological sequels and improve prognosis. Besides history and systemic and neurological examination, laboratory tests are an important tool that may enable to reduce differential diagnosis and establish correct diagnosis. This interactive session will cover a spectrum of challenging neurological cases and provide knowledge how to cost-effectively employ laboratory tests (on fluids and CSF) and auxiliary examinations (imaging, tissue biopsy) to provide prompt diagnosis.

Participants are encouraged to actively engage with immediate feedback to support learning (voting system)

FOCUSED WORKSHOP 1: ADVANCED IMAGING METHODS FOR THE ASSESSMENT OF MS PATHOGENESIS AND TREATMENT
08:30 - 10:00 | HALL B

CHAIRPERSON:
Bruno Stankoff, PARIS, FRANCE

Insight into the pathogenesis of multiple sclerosis using metabolic imaging
Olga Ciccarelli, LONDON, UK

The promise of ultra high field MRI in multiple sclerosis
Frederik Barkhof, AMSTERDAM, NETHERLANDS

Assessing tissue damage and repair in multiple sclerosis by positron emission tomography
Bruno Stankoff, PARIS, FRANCE

Target Audience:
Clinical academicians, Students/Residents/Trainees

Scientific Content:
Lecture 1 will discuss insights gained from metabolic imaging studies in MS patients, including raised sodium concentrations in the brain, increased glutamate levels in acute lesions and normal-appearing white matter, reduced GABA levels in the grey matter, and neuronal mitochondrial dysfunction.

Lecture 2 will describe the (challenges and) opportunities of ultra-high filed MRI (7T) for human in vivo imaging, including how improved spatial resolution can be used for better cortical lesion detection, and how new contrast mechanisms provide novel diagnostic and pathogenetic disease insights

Lecture 3 will describe how molecular imaging by PET and various radiotracers will contribute to the quantitative assessment of the major pathophysiological mechanisms of MS: demyelination and remyelination in the white matter, neuronal damage in the grey matter, microglial activation in the CNS. Methodological issues related to this technology will be presented.
FOCUSED WORKSHOP 2: GENETIC APPROACHES IN NEUROPATHIES
08:30 - 10:00 | HALL M1

CHAIRPERSON:
Davide Pareyson, MILAN, ITALY

Genotype-phenotype correlations in hereditary neuropathies
Michaela Auer-Grumbach, GRAZ, AUSTRIA

Whole-exome sequencing in patients with inherited neuropathies: outcome and challenges
Jonathan Baets, ANTWERP, BELGIUM

New opportunities of therapy in genetic neuropathies
Davide Pareyson, MILAN, ITALY

Target Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

Scientific Content: The definition of quality is care that is effective, safe and that provides a positive experience for patients. Quality of health care is a key concern in patients with long term neurological disorders. In this workshop, using examples of three common and chronic neurological conditions, the speakers will discuss measures to optimise care standards and quality of life in patients with epilepsy, multiple sclerosis and Parkinson’s disease. The presentations will aim to provide a standardised approach in assessing the performance and impact of clinical services in the care quality of these patients.

The learning objective of the workshop is to empower professionals to recognise the key elements of care pathways that can meet patients’ needs better and to challenge poor practices.

FOCUSED WORKSHOP 3: ADDRESSING QUALITY OF CARE FOR NEUROLOGICAL PATIENTS
08:30 - 10:00 | HALL M2

CHAIRPERSON:
Abhijit Chaudhuri, ROMFORD, UK

Optimising quality of care in epilepsy
Elinor Ben-Menachem, GOTHENBORG, SWEDEN

Quality standards of multiple sclerosis service
Abhijit Chaudhuri, ROMFORD, UK

Health related quality of life in Parkinson’s disease
Bastiaan R. Bloem, NIJMEGEN, THE NETHERLANDS
Marjam Faber, NIJMEGEN, THE NETHERLANDS

Target Audience: Clinical academicians, Practitioners, Students/Residents/Trainees, Non-physician Health Professionals

Scientific Content: The definition of quality is care that is effective, safe and that provides a positive experience for patients. Quality of health care is a key concern in patients with long term neurological disorders. In this workshop, using examples of three common and chronic neurological conditions, the speakers will discuss measures to optimise care standards and quality of life in patients with epilepsy, multiple sclerosis and Parkinson’s disease. The presentations will aim to provide a standardised approach in assessing the performance and impact of clinical services in the care quality of these patients.

The learning objective of the workshop is to empower professionals to recognise the key elements of care pathways that can meet patients’ needs better and to challenge poor practices.

FOCUSED WORKSHOP 4: FRONTIER APPLICATIONS IN NEUROSONOLOGY
08:30 - 10:00 | HALL B4.M2

CHAIRPERSON:
David Russell, OSLO, NORWAY

Magnetic resonance guided focused ultrasound for neurological disorders
Ilana Schlesinger, HAIFA, ISRAEL

Ultrasound on the earth and in the orbit
Zsolt Garami, HOUSTON, USA

The unstable carotid artery plaque
David Russell, OSLO, NORWAY

Target Audience: Basic Scientists, Clinical academicians, Non-physician Health Professionals

Scientific Content: During the last years revolutionary developments could be experienced in the field of neurosonology. New imaging and hemodynamic methods enriched the treasure of neurosonology and opened new diagnostic avenues. Besides, the neurosonology became one of the efficient tools of therapy in cerebrovascular and other neurological diseases. The focused workshop will discuss the advantages and problems of these new methods.
FOCUSED WORKSHOP 5: ABNORMAL MOVEMENTS IN SLEEP  
08:30 - 10:00 | HALL M4

CHAIRPERSON:
Ramin Khatami, BARMELWEID, SWITZERLAND

Regulation of motor control during sleep
Pierre-Hervé Luppi, LYON, FRANCE

Simple motor movements
Alejandro Iranzo, BARCELONA, SPAIN

Complex motor movements
Ramin Khatami, BARMELWEID, SWITZERLAND

Target Audience: (Basic Scientists), Clinical academicians, Practitioners, Students/Residents/Trainees

Scientific Content: Patients with complex motor movements present with a spectrum of semi-purposeful or non-purposeful movements arising from NREM- or REM-sleep. These movements typically last for minutes, and occur at sleep stages transitions or consolidated sleep stages. Movements are involuntary and characterized by repetitive stereotyped simple movements or irregular, unpredictable complex behaviours that occur as single event or clusters of episodes. Movements may include violent behaviour leading to self-injuries or unwarranted physical harm on others. Apart from injuries these movements can cause daytime symptoms such as excessive daytime sleepiness by disrupting sleep continuity or sleep quality. Complex motor movement of the adult population can result from various etiologically different conditions, including parasomnias, epilepsy, and psychiatric diseases. They frequently share common triggers such as sleep deprivation, fever or certain medications. This workshop will introduce the most common complex movements arising from NREM ad REM-sleep and related disorders including arousal disorders and rapid eye movement behavior disorders (RBD), nocturnal frontal lobe epilepsy (NFLE), or dissociative states and factitious disorders.

FOCUSED WORKSHOP 6: NEW CONCEPTS ABOUT LANGUAGE PROCESSING IN THE BRAIN  
08:30 - 10:00 | HALL M0

CHAIRPERSON:
Cornelius Weiller, FREIBURG, GERMANY

The dual-loop model and aphasia
Cornelius Weiller, FREIBURG, GERMANY

The impact of bilingualism on cognitive functions across the lifespan and in brain diseases
Thomas Bak, EDINBURGH, UK

The writing brain
Jean-Francois Démonet, LAUSANNE, SWITZERLAND

Target Audience: Basic Scientists, Clinical academicians, Practitioners, Students/Residents/Trainees, Non-physician Health Professionals

Scientific Content: The dual loop model provides a domain general frame work of brain organisation. Its application to stroke patients may help in better understanding the fuzzy link of aphasia syndromes and brain lesions as well as recovery from aphasia. Bilingualism is associated with better cognitive performance in younger and older adults, also in people who have acquired their second language later in life and without reaching a perfect command of it. Writing offers an interesting framework between language and motor output. Many conditions, from Parkinson’s disease to developmental dyslexia, are interesting models to understand more how abstract orthography representations are transformed into motor output.

SPECIAL SESSION 1: MDS-ES EUROPEAN BASAL GANGLIA CLUB  
08:30 - 10:30 | HALL A

CHAIRPERSONS:
Kailash Bhatia, LONDON, UK
Angelo Antonini, PADUA, ITALY

Video Case Presentations
Various presenters

Consciousness, Emotions and Basal Ganglia
Yves Agid, PARIS, FRANCE

Scientific Content: Every year the European Basal Ganglia Club features a prominent speaker to present a C. David Marsden Award lecture. During the 2nd congress of the European Academy of Neurology, it is an honor to have Prof. Yves Agid give a lecture on “Consciousness, Emotions and Basal Ganglia”. The lecture will be preceded by the presentation of video case studies. Presenters of the video case studies will have been chosen through an application and selection process in partnership with the European Editor of the Movement Disorders – Clinical Practice Journal, providing Young Neurologists presenting their cases with a chance to see their work become published.
SYMPOSIUM 1: MDS-ES/EAN: UPDATE IN MOVEMENT DISORDERS
10:30 - 12:30 | HALL A

CHAIRPERSONS:
Joaquim Ferreira, LISBON, PORTUGAL
K. Ray Chaudhuri, LONDON, UK

Essential tremor
Günther Deuschl, KIEL, GERMANY

Non-motor symptoms in Parkinson’s disease
K. Ray Chaudhuri, LONDON, UK

Dystonia
Espen Dietrichs, OSLO, NORWAY

PSP/MSA
Maria Stamelou, ATHENS, GREECE

Scientific content: This symposium is dedicated to major recent developments in the field of movement disorders. Essential tremor definition is currently revised. Non-motor symptoms are becoming continuously more important for early diagnosis of PD and treatment. Major progress of the genetics and diagnosis of dystonias have been made and exciting new insights into the course and the causes of progressive supranuclear palsy and multiple system atrophies have been made.

SYMPOSIUM 2: NEUROSTIMULATION, WHAT CAN BE ACHIEVED IN...
10:30 - 12:30 | HALL B

CHAIRPERSONS:
Paul Boon, GHENT, BELGIUM
Sandra Boccard, OXFORD, UK

...Movement disorders
Marie Vidailhet, PARIS, FRANCE

...Epilepsy
Paul Boon, GHENT, BELGIUM

...Chronic pain
Sandra Boccard, OXFORD, UK

Scientific content: This symposium will provide an overview of the current status of deep brain stimulation in the most prevalent neurological disorders in which it has been applied. Besides providing information on mechanism of action, indication, efficacy, safety, quality of life outcomes and practical procedures, a prospect for the future of these neuromodulation applications will be provided. The target audience is practicing neurologists who treat patients with difficult to treat Parkinson disease, epilepsy and pain.

SPECIAL SESSION 2: MUSIC AND NEUROLOGY - NEUROLOGICAL DISORDERS OF FAMOUS COMPOSERS
08:30 - 10:00 | HALL B5.M1

CHAIRPERSON:
Tomislav Breitenfeld, ZAGREB, CROATIA

Subarachnoid haemorrhage as a likely cause of Mendelssohn’s death
Hansjörg Bäzner, STUTTGART, GERMANY

Mozart’s possible neurological disorders
Christopher Gardner Thorpe, EXETER, UK

Stroke in famous composers
Tomislav Breitenfeld, ZAGREB, CROATIA

Wagner’s migraine and Gershwin’s uncinate seizures
Vlasta Vukovic-Cvetkovic, GLOSTRUP, DENMARK

Scientific content: This special session will present a series of biopatho-graphies and short portraits of famous composers describing their biography, talent, creation and medical history. All presented famous composers suffered from different neurological disorders. Presentations will explain influence of those disorders on composer’s creativity. Audience will be allowed (and animated) to comment and discuss the interaction between neurological disorders and composer’s ability to create art. While trying to explain the complex relationship between neurological disorders and creativity through pathographies of famous composers, the organisers intend to present a new, really interesting and “something else from other topics” session. “We believe that it will turn into a memorable gathering of people who share the same passion, genuine love and enthusiasm for both, neurology and music. After all, Copenhagen with its glorious musical, cultural and medical history seems to be an ideal site for a special session „Neurological disorders of famous composers.”

SPECIAL SESSION 7: NEUROLOGY ACROSS CONTINENTS: WFN/WHO
09:00 - 10:00 | HALL C

CHAIRPERSON:
Raad Shakir, LONDON, UK

The new WHO Neurology Atlas
Raad Shakir, LONDON, UK

Education Programmes of the WFN
Steven Lewis, CHICAGO, USA

The WFN teaching centres.
Wolfgang Grisold, VIENNA, AUSTRIA

Scientific content: This session will provide an overview of the current status of deep brain stimulation in the most prevalent neurological disorders in which it has been applied. Besides providing information on mechanism of action, indication, efficacy, safety, quality of life outcomes and practical procedures, a prospect for the future of these neuromodulation applications will be provided. The target audience is practicing neurologists who treat patients with difficult to treat Parkinson disease, epilepsy and pain.
SYMPOSIUM 3: THE CHANGING LANDSCAPE OF COMA TREATMENT
10:30 - 12:30 | HALL C

CHAIRPERSONS:
Steven Laureys, LIÈGE, BELGIUM
Daniel Kondziella, COPENHAGEN, DENMARK

Amantadine, benefit-risk balance in severe brain injury
Joe Giacino, CHARLESTOWN, USA

Deep brain stimulation in the minimally conscious state: which targets?
Jean Jacques Lemaire, CLERMONT-FERRAND, FRANCE

Modulating the anterior forebrain mesocircuit in disorders of consciousness
Nicholas Schiff, NEW YORK, USA

Transcranial direct current stimulation: a promising new avenue
Steven Laureys, LIÈGE, BELGIUM

Scientific content: The past years have provided an unprecedented collection of discoveries that bear upon our scientific understanding of recovery of consciousness following severe brain damage. Highlighted among these findings are unique demonstrations that patients with little or no behavioral evidence of conscious awareness (e.g., minimally conscious and unresponsive wakefulness/vegetative states) may retain critical cognitive capacities and the first scientific demonstrations that some patients, with severely injured brains and longstanding conditions of limited behavioral responsiveness, may nonetheless harbor latent capacities for recovery – either spontaneously or related to pharmacological interventions (e.g., amantadine) or electrical stimulation (e.g., deep brain stimulation and transcranial direct current stimulation).

SYMPOSIUM 4: EVOLVING CONCEPTS IN THE MANAGEMENT OF GLIOMAS
10:30 - 12:30 | HALL M1

CHAIRPERSONS:
Riccardo Soffietti, TURIN, ITALY
Michael Weller, ZÜRICH, SWITZERLAND

How to integrate molecular markers of prognostic significance in the new WHO classification?
Johan Kros, ROTTERDAM, THE NETHERLANDS

Will new forms of immunotherapy improve the outcome of glioblastomas?
Michael Weller, ZÜRICH, SWITZERLAND

From chemotherapy to targeted therapy in low grade gliomas
Riccardo Soffietti, TURIN, ITALY

New developments in neuroimaging to monitor response and toxicity following antiangiogenic agents
Wolfgang Wick, HEIDELBERG, GERMANY

Scientific content: The aim of the symposium is to provide an update on the recent advances in terms of molecular diagnosis and treatment modalities of both high and low grade gliomas. Overall, these advances have led to new concepts of management of these tumors. The target audience is represented either by general neurologists, who are involved in the diagnostic and follow-up phases of management of brain tumors or more specifically neurologists with interest in the whole management of gliomas.
ISNI
13th International Congress of Neuroimmunology
1st GSNI Course
Global Schools of Neuroimmunology
ESNI - ASNI - APSNI

26 - 29 September 2016  Jerusalem, Israel
TEACHING COURSE 1: 
ACUTE MANAGEMENT OF STROKE – LEVEL 2
14:45 - 18:15 | HALL A

CHAIRPERSON:
Robert Mikulik, BRNO, CZECH REPUBLIC

Acute Ischemic Stroke - what you should do in the first 4.5 hours
Dejana Jovanovic, BELGRADE, SERBIA

What you should do in the first 6-12 hours
Urs Fischer, BERN, SWITZERLAND

What you should do in the first 24-48 hours
Bart van der Worp, UTRECHT, THE NETHERLAND

What you should do in the first days
Robert Mikulik, BRNO, CZECH REPUBLIC

Recanalisation strategies in acute stroke aim to establish revascularization. Endovascular techniques have shown benefit up to 8 h after stroke onset in the proximal anterior circulation, in addition to rtPA compared to rt-PA alone. In selected patients with malignant anterior circulation infarct, decompressive surgery reduces mortality. This teaching course is divided into four different time frames in order to cover the main decision-making processes in acute stroke, starting from the onset of stroke, how to decrease DNT to perform intravenous thrombolysis, provide an overview on thrombectomy, to the selection of patients for hemicraniectomy and when to start early secondary prevention.

PAEDiatric movement disorders is a relatively new and exciting field of Child Neurology. In this session, the faculty will provide clear descriptions of the diagnosis and management of various movement disorders in children, with emphasis on their clinical features. They will concentrate on selected important conditions chosen because of their clinical relevance, potential benefit of treatment or because they cover a relatively new or poorly understood area. The session is supplemented by videos.

TEACHING COURSE 2: 
MDS-ES/EAN: ABNORMAL MOVEMENT DISORDERS IN CHILDREN (DIAGNOSIS AND MANAGEMENT) – LEVEL 1
14:45 - 18:15 | HALL B4.M2

CHAIRPERSON:
Emilio Fernandez-Alvarez, BARCELONA, SPAIN

Normal and abnormal cerebral movements in babies and young children
Emilio Fernandez-Alvarez, BARCELONA, SPAIN

Primary dystonias: from childhood to adulthood
Nardo Nardocci, MILAN, ITALY

Clinical features of genetic and metabolic disorders from childhood to adulthood
Emmanuel Roze, PARIS, FRANCE

Cerebral Palsy
Jean-Pierre Lin, LONDON, UK

Visual loss
Gordon Plant, LONDON, UK

Diplopia
Konrad Weber, ZURICH, SWITZERLAND

Spontaneous nystagmus
Michael Strupp, MUNICH, GERMANY

Pupillary deficits
Aki Kawasaki, LAUSANNE, SWITZERLAND

The course will review the diagnosis and management of common Neuro-Ophthalmological emergencies. The discussion will centre around three syndromic presentations, Acute Monocular Visual Loss, Acute Bilateral Visual Loss and Acute Ophthalmoplegia. Consideration will also be given to situations when the presence of nystagmus or pupillary abnormalities can give important clues in the acute setting. After attending the course the trainees can expect to have a clearer understanding of the how the Neuro-Ophthalmic aspects of history taking and examination can be employed in the emergency setting to better manage patients.

TEACHING COURSE 4: 
TESTING FOR AUTO-ANTIBODIES IN NEUROLOGICAL DISORDERS – LEVEL 2
14:45 - 18:15 | HALL M1

CHAIRPERSONS:
Johann Sellner, SALZBURG, AUSTRIA
Maarten J. Titulaer, ROTTERDAM, THE NETHERLANDS

Neuropathies and myasthenic syndromes
Jan J.G.M. Verschuuren, LEIDEN, THE NETHERLANDS
Myelopathic and rhombencephalitic syndromes
Johann Sellner, SALZBURG, AUSTRIA

Epilepsy and status epilepticus in autoimmune encephalitis
Maarten J. Titulaer, ROTTERDAM, THE NETHERLANDS

Psychosis, movement disorders or rapid progressive dementia and autoimmune encephalitis
Josep O. Dalmau, BARCELONA, SPAIN

This teaching course will provide practical guidance to the emerging field of auto-antibodies in different neurological disorders. In recent years the number of autoantibodies against targets in the central as well as the peripheral nervous system has expanded. The knowledge of the underlying pathogenesis helps to understand the clinical features and course of the disease, and defines the treatment options. The speakers will discuss which patients should be tested (and re-tested) for autoantibodies, which panel of antibodies to consider, which assay to use and whether antibody titers are relevant for treatment decisions. Furthermore, the current state of therapeutic options, as well as new treatments that are being developed, will be covered.

TEACHING COURSE 5:
PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENTS IN ALZHEIMER’S DISEASE – LEVEL 2
14:45 - 18:15 | HALL M4

CHAIRPERSON:
Bruno Dubois, PARIS, FRANCE

Ethical limitations and considerations on prodromal Alzheimer’s disease diagnosis and treatment
Giovanni Frisoni, BRESCIA, ITALY

Prevention strategies
Philip Scheltens, AMSTERDAM, NETHERLANDS

Development of novel pharmacological treatment in Alzheimer’s disease: an update
Jakub Hort, PRAGUE, CZECH REPUBLIC

The preclinical state of AD: is it a new target for intervention?
Bruno Dubois, PARIS, FRANCE

The course is dedicated to pharmacological and non-pharmacological intervention. The course provides an update on new approaches in the treatment of the patients with AD given the lack of efficacy of the current valuable therapies. The move to early phase of the disease, including the prodromal stage, is important to consider together with ethical considerations, which need to be addressed.

TEACHING COURSE 6:
EXPERIMENTAL STUDY DESIGNS IN NEUROLOGICAL DISORDERS – LEVEL 2
14:45 - 18:15 | HALL M5

CHAIRPERSON:
Maura Pugliatti, FERRARA, ITALY

The methodological bases of clinical trial designs
Ettore Beghi, MILAN, ITALY

Clinical trials: practical examples – stroke
Georgios Tsivgoulis, ATHENS, GREECE

Meta-analysis in clinical trials
Tony Marson, LIVERPOOL, UK

Writing your protocol for clinical studies in Neurology
Maura Pugliatti, FERRARA, ITALY

This TC on Experimental Study Designs (ESD) is part of an educational programme on Neuroepidemiology aimed to improve knowledge about study methodology, as fundamental basis for good scientific research, and started in 2014 with an introductory course on descriptive epidemiology. Analytical Study Designs (e.g. ESD) imply ‘comparison’ across groups differing for an ‘exposure’ assigned by the investigator: the highest hierarchical methodology to investigate association between exposures and outcomes. Among ESD are randomized clinical trials (RCTs). The TC will include lectures on clinical trials (methodological bases, examples with stroke, use of meta-analysis), and a practical session for developing a research protocol.
Save the date! 2017

ANNUAL MEETING OF THE
THE CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS

New Orleans Ernest N. Morial Convention Center
May 24 - 27
New Orleans, Louisiana
MSCARE.ORG/2017
JOIN US IN VIENNA

Mechanisms, Clinical Strategies, and Promising Treatments of Neurodegenerative Diseases

AD/PD™ 2017
The 13th International Conference on Alzheimer's & Parkinson's Diseases
March 29 - April 2, 2017 | Vienna, Austria

ORGANIZING COMMITTEE
Abraham Fisher, Israel, President
Roger M. Nitsch, Switzerland, Executive Organizer
Manfred Windisch, Austria, Executive Organizer

adpd2017.kenes.com
ORAL SESSION:
AUTONOMIC NERVOUS SYSTEM DISORDERS AND CLINICAL NEUROPHYSIOLOGY
14:45-16:15 | HALL B5. M2
CHAIRPERSONS:
Max Hilz, ERLANGEN, GERMANY
Walter Struhal, LINZ, AUSTRIA

O 1101
14:45
Intravascular electroencephalography: a pilot study in patients undergoing neuro-interventional surgery
V. Keereman, P. van Mierlo, L. Defreyne, P.A. Boon | GHENT, BELGIUM

O 1102
15:00
Fatigue of forearm extensor muscles induced by repetitive peripheral magnetic stimulation in healthy subjects
C. Cabib | BARCELONA, SPAIN, 2GUADALAJARA, MEXICO, 3LISBON, PORTUGAL, 4CORUÑA, SPAIN

O 1103
15:15
De-synchronization does not contribute to intra-cortical inhibition and facilitation: a paired-pulse paradigm combined with triple stimulation study
L. Caranzano, M.A. Stephan, F. Herrmann, D. Benninger | LAUSANNE, SWITZERLAND

O 1104
15:30
Autonomic dysfunction in Wilson’s disease: a comprehensive evaluation
K. Li, C. Lindauer, R. Haase, H. Reichmann, U. Reuner, T. Ziemssen | DRESDEN, GERMANY

O 1105
15:45
The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy
J. Castro, B. Miranda, I. Castro, M. Carvalho, I. Conceição | LISBON, PORTUGAL

O 1106
16:00
Combined CV and sudomotor autonomic testing to differentiate multiple system atrophy from Parkinson’s disease

ORAL SESSION:
EPILEPSY 1
14:45-16:15 | HALL M0
CHAIRPERSONS:
Reetta Kalviainen, KUOPIO, FINLAND
Tim von Oertzen, LINZ, AUSTRIA

O 1107
14:45
Localizing value of electrical source imaging as compared to SEEG: which patients are the best candidates?
C. Abdallah | LIEGE, BELGIUM
E. Beghi | MILAN, ITALY
F. Herrmann | ROCHESTER, USA
L. Koessler | LIEGE, BELGIUM
A. Leal | ROCHESTER, USA

O 1108
15:00
Long-term prognosis of epilepsy and drug-resistance
E. Beghi | MILAN, ITALY
G. Giussani | ROCHESTER, USA
V. Canelli | LONDON, UK
E. Bianchi | ROCHESTER, USA
G. Erba | ROCHESTER, USA

O 1109
15:15
Cognitive problems among children exposed to antiepileptic drugs: preliminary data
L. S. Elkjaer | AARHUS, DENMARK
B.H. Bech | T.M. Laursen, J. Christensen | AARHUS, DENMARK

O 1110
15:30
MiR - 155: a biomarker with a dual role in epilepsy?

O 1111
15:45
Predicting outcome of epilepsy after meningioma resection

O 1112
16:00
Long-term, observational study evaluating the impact of VNS therapy on SUDEP in drug resistant epilepsy patients
P. Ryvlin | LAUSANNE, SWITZERLAND
D. Hesdorffer | NEW YORK, USA
M. Sperling | NEW YORK, USA
E. So | ROCHESTER, USA
D. Friedman | NEW YORK, USA
M. Bunker | HOUSTON, USA
ORAL SESSION: MOVEMENT DISORDERS 1
14:45-15:45 | HALL C
CHAIRPERSONS:
Joaquim Ferreira, LISBON, PORTUGAL (TBC)
Kailash Bhatia, LONDON, UK

O 1113 Abstract cancelled

O 1114 14:45
Clinical and genetic heterogeneity of paroxysmal dyskinesias

O 1115 15:00
Predicting incident impulse control disorder behaviour in Parkinson’s disease patients using a clinical-genetic model
J. Kraemmer1, K. Smith1, D. Weintraub2, M. Nalls3, F. Cormier-Dequaire1, V. Guillemot1, I. Moszer1, A. Brice1, A. Singleton1, J.-C. Corvol1  I 1PARIS, FRANCE, 2PHILADELPHIA, 3BETHESDA, USA

O 1116 15:15
Long-term effect of Epoetin alfa on clinical and biochemical markers in Friedreich Ataxia
F. Sacca1, G. Puorro1, A. Marsili1, A. Antenora1, C. Pane1, C. Casali2, C. Marcatulli2, G. Defazio3, D. Liuzzi3, C. Tatillo1, D.M. Cambriglia1, G. Schiano Di Cola1, L. Giuliani1, V. Guardasole1, A. Saltano1, A. Ruvolo1, A. de Rosa1, A. Cittadini1, G. de Michele1, A. Filla1  I 1NAPLES, 2ROME, 3BARI, ITALY

O 1117 15:30
Guided focused ultrasound thalamotomy for tremor
I. Schlesinger, A. Eran, A. Sinai, I. Erikh, M. Nassar, D. Goldsher, M. Zaanor  I HAIFA, ISRAEL

O 1118 Abstract cancelled

ORAL SESSION: MS AND RELATED DISORDERS 1
14:45-16:15 | HALL B
CHAIRPERSONS:
Mads Ravnborg, COPENHAGEN, DENMARK
Per Soelberg Sørensen, COPENHAGEN, DENMARK

O 1119 14:45
Dysregulation of energy metabolism in multiple sclerosis measured in-vivo with diffusion-weighted spectroscopy
B. Bodini1, F. Branzoli1, E. Poirion1, D. Garcia-Lorenzo1, E. Maillart1, J. Socha1, G. Ber1, C. Lubetzki1, I. Ronen2, S. Sehericy1, B. Stankoff1  I 1PARIS, FRANCE, 2LEIDEN, NETHERLANDS

O 1120 15:00
Cross-modal plasticity among sensory networks in neuromyelitis optica spectrum disorders
M.A. Rocca1, F. Savoldi1, P. Valsasina1, A. D’ambrosio2, M. Radaelli1, P. Prezios1, G. Comi1, A. Falini1, M. Filippi1  I 1MILAN, 2NAPLES, ITALY

O 1121 15:15
Age and disability drive cognitive impairment in multiple sclerosis independent of disease subtype: insights from an Italian multicentre study
L. Ruano1, E. Portaccio2, B. Goretti2, C. Niccolai2, F. Patti3, S. Cilia4, P. Gallo5, P. Grossi6, A. Ghezzi6, M. Roscio6, F. Mattioli7, C. Stampatori7, M. Trojano8, R.G. Viterbo8, M.P. Amato9  I 1PORTO, PORTUGAL, 2FLORENCE, 3CATANIA, 4CATANIA, 5PADUA, 6GALLARATE, 7BRESCIA, 8BARI, 9ITALY

O 1122 15:30
Longitudinal changes in structural cortical networks after clinically isolated syndrome

O 1123 15:45
Systematic review of ganglion cell layer changes measured by optical coherence tomography in multiple sclerosis and optic neuritis
J. Britze1, J.L. Frederiksen2  I 1COPENHAGEN, 2GLOSTRUP, DENMARK

O 1124 16:00
Cerebellar contribution to motor and cognitive impairment in multiple sclerosis patients: an MRI sub-regional structural analysis
A. D’ambrosio1, M.A. Rocca, E. Pagani, G.C. Riccitelli, B. Colombo, M. Rodegher, A. Falini, G. Comi, M. Filippi1  I 1MILAN, ITALY
ORAL SESSION: NEUROEPIDEMIOLOGY
14:45-16:15 | HALL B5.M1
CHAIRPERSONS:
David Gaist, ODENSE, DENMARK
Vitalie Lisnic, CHISINAU, MOLDAVIA

O 1125 14:45
The burden of neurological diseases in Hungary. The initial database of the NEOUROHUN-2004–2017 project
D. Bereczki, A. Ajtay, F. Oberfrank | BUDAPEST, HUNGARY

O 1126 15:00
Diagnosing hereditary neuropathies in the clinic with next-generation sequencing technology, the Norwegian experience
H. Høyer1, Ø.L. Busk1, Ø.L. Holla1, L. Strand1, C.F. Skjelbred1, M.B. Russell2, G.J. Braathen1 | 1SKIEN, 2SAN FRANCISCO, USA

O 1127 15:15
Temporal trends in transthyretin familial amyloid polyneuropathy survival over the last 100 years
M. Ines1, T. Coelho2, I. Conceicao1, P. Saramago3, M. Carvalho1, J. Costa1 | 1LISBON, 2PORTO, 3YORK, UK

O 1128 15:30
Epidemiology of Listeria monocytogenes meningitis in the Netherlands, 1985-2014
M. Koopmans, M. Bijlsma, M. Brouwer, A. van der Ende, D. van de Beek | AMSTERDAM, NETHERLANDS

O 1129 15:45
Seasonal changes in the incidence of transient global amnesia
N. Lev, O. Keret, I. Steiner | PETACH TIKVA, ISRAEL

O 1130 16:00
Epidemiologic aspects of the Charcot-Marie-Tooth diagnosis in Denmark: a nationwide study
S. Vaeth, M. Vaeth, H. Andersen, R. Christensen, U.B. Jensen | AARHUS, DENMARK

ORAL SESSION: NEUROGENETICS
14:45-16:15 | HALL B4.M1
CHAIRPERSONS:
Jörgen Nielsen, COPENHAGEN, DENMARK
Jean-Marc Burgunder, BERN, SWITZERLAND

O 1131 14:45
Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: cross-sectional and preliminary longitudinal data in a cohort of 13 patients
A. Castellano1, N. Papinutto2, G. Brugnara1, G. Scigliuolo1, A. Falini2, R. Henry3, D. Pareyson1, L. Politi1, F. Salsano1 | 1MILAN, ITALY, 2SAN FRANCISCO, USA

O 1132 15:00
Variants in four genes on chromosome 12 is associated with intermediate Charcot-Marie-Tooth disease
G.J. Braathen1, H. Høyer1, Ø.L. Busk1, K. Tveten1, C.F. Skjelbred1, M.B. Russell2 | 1MILAN, ITALY, 2ROCHESTER, USA, 3LONDON, UK

O 1133 15:15
Low cancer prevalence in polyglutamine expansion diseases
G. Coarelli1, A. Diallo1, F. Calvas1, P. Charles1, C. Tosi Marelli2, C. Ewenczyk1, C. Tranchant3, M. Tchikviladzé1, M.-L. Monin1, B. Carlander2, M. Anheim3, F. Mochel1, A. Brice1, S. Tezenas Du Montcel1, S. Humbert1, A. Dürr1 | 1PARIS, 2MONTPELLIER, 3STRASBOURG, 4GRENOBLE, FRANCE

O 1134 15:30
An SPG2/PLP1 mutation mimicking multiple sclerosis in a family identified through targeted next generation sequencing
A. Rubegni1, A. Tessa1, C. Battisti1, E. Storti1, A. Cerase2, A. Malandrini1, F.M. Santorelli1, A. Federico1 | 1pisa, 2sienna, italy

O 1135 15:45
Idebenone is effective and well tolerated in Leber’s Hereditary Optic Neuropathy (LHON): results of a 3-year Expanded Access Program (EAP)
T. Klopstock1, G. Metz2, C. Gallenmüller1, B. Livonius-Freifrau von Eyb2, F. Lob1, T. Meier2, C. Catarino2 | 1MUNICH, GERMANY, 2LIESTAL, SWITZERLAND

O 1136 16:00
Patients carrying a loss-of-function mutation in ABCA7 exhibit a classical late-onset Alzheimer’s disease phenotype
T. van Den Bossche1, K. Sleegers1, S. Engleborghs1, A. Sieben1, A. de Roeck1, M. Vandenbulcke1, R. Vandenberghe2, J.-J. Martin2, P.P. de Deyn1, P. Cras1, C. van Broeckhoven1 | 1ANTWERP, 2LEUVEN, BELGIUM
ORAL SESSION: CEREBROVASCULAR DISEASES 1
16:30-18:15 | HALL C
CHAIRPERSONS:
Tove Henriksen, HELLERUP, DENMARK
Daniel Strbian, HELSINKI, FINLAND

O 1201 16:30
Physicians are more certain when prescribing thrombolysis to MRI-examined stroke patients
C.K. Hansen, A. Christensen, I. Havsteen, H.K. Christensen | COPENHAGEN, DENMARK

O 1202 16:45
Mortality and use of psychotropic medication in stroke patients: a population-wide register-based study
P.J. Jenum¹, A.O. Baandrup², H.K. Iversen³, R. Ibsen⁴, J. Kjellberg⁵ | ¹GLOSTRUP - COPENHAGEN, ²ROSKILDE, ³GLOSTRUP, ⁴AARHUS, ⁵COPENHAGEN, DENMARK

O 1203 17:00
Non-infectious complications of acute stroke and their impact on hospital mortality in an urban Polish stroke unit: changes from 1995 to 2013
M. Karlinski, J. Bembenek, A. Baranowska, I. Kurkowska-Jastrzebska, A. Członkowska | WARSAW, POLAND

O 1204 17:15
Does the proportion of single-chain rtPA influence outcomes in patients with cerebral ischemia?
D. Leys¹, I. Sibon², J.-L. Mas³, T. Moulin⁴, M. Giroud⁵, R. Bordet⁶, D. Vivien⁷ | ¹LILLE, ²BORDEAUX, ³PARIS, ⁴BESANÇON, ⁵DIJON, ⁶CAEN, FRANCE

O 1205 17:30
Early start of NOAC after an acute cerebrovascular event: risk of intracranial hemorrhage and recurrent events
D. Seiffge, C. Traenka, A. Polymeris, L. Hert, R. Sutter, N. Peters, P. Lyver, L. Bonati, S. Engelter, G.M. de Marchis | BASEL, SWITZERLAND

O 1206 17:45
The rs12041331G alleles are associated with aspirin response in ischemic stroke patients in China
Y. Xu, X. Zhang, Y. Shao | NANJING, CHINA

O 1207 18:00
Endovascular therapy versus medical care alone for ischemic stroke: a systematic review and meta-analysis of 10 RCTs

ORAL SESSION: MOTOR NEURONE DISEASE
16:30-18:15 | HALL B4.M1
CHAIRPERSONS:
Federica Agosta, MILAN, ITALY
Orla Hardiman, DUBLIN, IRELAND

O 1208 16:30
Long-term survival of 3000 transthyretin familial amyloid polyneuropathy patients over 100 years
M. Inesi¹, T. Coelho², I. Conceicao², P. Saramago³, M. Carvalho¹, J. Costa¹ | ¹LISBON, ²PORTO, PORTUGAL, ³YORK, UK

O 1209 16:45
GDAP1 mutations in Spain: a nationwide study
R. Sivera¹, M. Frasquet Carrera¹, T. Garcia Sobrino², J. Pardo³, R. Fernandez Torron⁴, A. Lopez de Munain Arregui⁵, C. Marquez Infante⁶, R. Rojas-Garcia⁷, S. Segovia⁷, A. Nascimento⁸, C. Cortez⁸, M. Garcia⁸, S.I. Pascual Pascual⁹, A. Guerrero Sola⁹, C. Casasnovas¹⁰, J. Esteban Pérez¹, J. Vázquez-Costa¹, M. Barreiro¹, M.J. Chumillas¹, C. Diaz¹, F. Palau¹, J.J. Vilchez¹, C. Espinós¹, T. Sevilla¹ | ¹VALENCIA, ²SANTIAGO DE COMPOSTELA, ³SANTIAGO, ⁴SAN SEBASTIÁN, ⁵SAN SEBASTIÁN, ⁶SEVILLE, ⁷BARCELONA, ⁸MADRID, ⁹ALICANTE, SPAIN

O 1210 17:00
Structural and functional MRI signatures of ALS patients with C9orf72 hexanucleotide repeat expansion
F. Agosta¹, P.M. Ferraro¹, N. Riva¹, T. Domi¹, M. Copetti², C. Lunetta¹, M. Ferrarí³, G. Comi³, P. Carrera³, A. Falini³, A. Quattrini¹, M. Filippi¹ | ¹MILAN, ²SAN GIOVANNI ROTONDO, ITALY

O 1211 17:15
The utility of multimodal imaging in the diagnosis of ALS
P.M. Ferraro¹, F. Agosta¹, N. Riva¹, M. Copetti², Y. Falzone³, A. Chiò³, G. Soraru³, G. Comi³, A. Falini³, M. Filippi¹ | ²SAN GIOVANNI ROTONDO, ³TURIN, ⁴PADUA, ITALY

O 1212 17:30
Deconstructing caregiver burden in amyotrophic lateral sclerosis – adding a qualitative perspective
M. Galvin, T. Burke, B. Corr, G. Madden, I. Mays, R. McQuillan, V. Timonen, A. Staines, O. Hardiman | DUBLIN, IRELAND

O 1213 17:45
The CANALS study: a randomized, double-blind, placebo-controlled, multicentre study to assess the safety and efficacy on spasticity symptoms of a cannabis sativa extract in motor neuron disease Patients
N. Riva¹, G. Morali¹, G. Soraru³, C. Lunetta¹, M. Clerici¹, Y. Falzone¹, K. Marinou¹, E. Maestri¹, R. Fazio¹, M. Comola¹, G. Comi³ | ¹MILAN, ²PADUA, ITALY

O 1214 18:00
Neurofilament light chain protein as a biomarker in ALS differential diagnoses
D. Primdahl, K. Svenstrup, K. Winge, N. Heegaard, K. Hansen | COPENHAGEN, DENMARK
ORAL SESSION: SLEEP DISORDERS
16:30-18:00 | HALL B5.M2
CHAIRPERSONS:
Poul Jennum, COPENHAGEN, DENMARK
Pierre Maquet, LIEGE, BELGIUM (TBC)

O 1215 16:30
Sleep transitions in hypocretin deficient narcolepsy
M.H. Hansen1, B. Kornum2, P.J. Jennum3 1GLOSTRUP, 2COPENHAGEN, 3GLOSTRUP - COPENHAGEN, DENMARK

O 1216 16:45
Hypocretin-reactive CD4+ T-cells in narcoleptic patients
D. Latorre1, E. Armentani1, U. Kallweit2, M. Manconi3, R. Khatami4, C. Bassetti2, F. Sallusto1 1BELLINZONA, 2BERNE, SWITZERLAND, 3LUGANO, ITALY, 4BARMELWEID, SWITZERLAND

O 1217 17:00
Alzheimer’s disease cerebrospinal-fluid biomarkers are altered in untreated but normal in continuous positive airway pressure treated obstructive sleep apnea patients
C. Liguori, N.B. Mercuri, F. Izzi, G. Sancesario, A. Romigi, A. Cordella, F. Placidi 1ROME, ITALY

O 1218 Abstract cancelled

O 1219 17:15
White matter lesion burden and sleep disordered breathing in acute stroke
A. Seiler1, M. Camilo1, S. Ott1, S. Miano2, R. Wiest1, C. Bassetti1 1BERNE, SWITZERLAND

O 1220 17:30
The comparison of cerebral hemodynamics between patients with obstructive sleep apnea syndrome (OSA) and periodic limb movement disorder (PLMD) during sleep
Z. Zhang, M. Schneider, M. Laures, M. Qi, R. Khatami 1BARMELWEID, SWITZERLAND

O 1221 17:45
Does vitamin D play a role in restless legs syndrome/Willis Ekbom disease?
A. Stefani, T. Mitterling, G. Weiss, B. Högl 1INNSBRUCK, AUSTRIA

ORAL SESSION: EPILEPSY 2
16:45-18:15 | HALL M0
CHAIRPERSONS:
Jukka Peltola, TAMPERE, FINLAND
Elinor Ben-Menachem, GOTHENBURG, SWEDEN (TBC)

O 1222 16:45
Efficacy and tolerability of lacosamide monotherapy in patients with newly diagnosed epilepsy: A randomized double-blind trial versus controlled-release carbamazepine
M. Baulac1, F. Rosenow2, M. Toledo3, K. Terada4, T. Li5, M. de Backer6, K.J. Werhahn7, M. Brock8 1PARIS, FRANCE, 2FRANKFURT AM MAIN, GERMANY, 3BARCELONA, SPAIN, 4SHIZUOKA, JAPAN, 5RALEIGH, USA, 6BRUSSELS, BELGIUM, 7MONHEIM AM RHEIN, GERMANY

O 1223 Abstract cancelled

O 1224 17:05
Verbal learning and memory outcome in selective amygdalohippocampectomy versus temporal lobe resection in 108 patients with hippocampal sclerosis
M.T. Foged1, K. Vinter1, L. Kristensen1, M.H. Litman1, N. Breinegaard1, V. Olesen1, T.W. Kjær1, F.F. Madsen1, The Danish Epilepsy Surgery Group1, O.B. Paulson1, L.H. Pinborg1 1COPENHAGEN, 2ROSKILDE, DENMARK

O 1225 17:25
Exposure-response analysis of adjunctive everolimus therapy in patients with refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)
J. French1, J. Lawson2, Z. Yapıcı3, T. Polster4, R. Nabbout5, P. Curatolo6, P. de Vries7, N. Berkowitz8, M. Voi8, S. Peyra9, A. Vaury9, D.N. Franz10 1NEW YORK, INDIA, 2RANDWICK, AUSTRALIA, 3ISTANBUL, TURKEY, 4BIELEFELD, GERMANY, 5PARIS, FRANCE, 6ROME, ITALY, 7CAPE TOWN, SOUTH AFRICA, 8NEW JERSEY, USA, 9RUEIL-MALMAISON, FRANCE, 10OHIO, USA

O 1226 17:45
Sleep-related hypermotor seizures arising outside the frontal lobe: a review of 44 surgically treated cases

O 1227 18:00
Diagnostic accuracy of Salzburg criteria for nonconvulsive status epilepticus
M. Leitinger1, E. Trinka1, E. Gardella2, A. Rohracher2, G. Kaliss2, E. Gerama3, J. Höfler1, A.H. Lindberg-Larsen3, G. Zimmermann1, G. Kuchukhidze1, J. Dobsberger4, P.B. Langthaler5, S. Beniczky7 1SALZBURG, AUSTRIA, 2DIANALUND, 3AARHUS, DENMARK
ORAL SESSION:
MS AND RELATED DISORDERS 2
16:45-18:15 | HALL B
CHAIRPERSONS:
Ludwig Kappos, BASEL, SWITZERLAND (TBC)
Xavier Montalban, BARCELONA, SPAIN

O 1228
16:45
Efficacy and Safety of Tocilizumab for the Treatment of Refractory Neuromyelitis Optica
L. Moiola1, G. Dalla Costa1, F. Sangalli1, M. Romeo1, M. Radaelli1, M. Falcini2, M. Capobianco3, S. Malucchi3, G. Comi1, V. Martinelli1 I 1MILAN, 2PRATO 3ORBASSANO, ITALY

O 1229
17:00
Efficacy of ocrelizumab in patients with primary progressive MS with and without T1 gadolinium-enhancing lesions at baseline in a Phase III, placebo-controlled trial
J. Wolinsky1, D. Arnold2, A. Bar-or3, J. de Seze3, G. Giovannoni4, B. Hemmer5, K. Rammohan6, A. Sauter7, D. Masterman8, P. Fontoura9, P. Chin9, X. Montalban10 I 1HOUSTON, USA, 2MONTREAL, CANADA, 3STRASBOURG, FRANCE, 4LONDON, UK, 5MUNICH, GERMANY, 6MIAMI, USA, 7BASEL, SWITZERLAND, 8SOUTH SAN FRANCISCO, USA, 9BARCELONA, SPAIN

O 1230
17:15
Myelin lipids attenuate Th17-cell during autoimmune demyelination
M. Mycko1, B. Sliwinska1, M. Cichalewska1, H. Cwiklinska1, C.S. Raine2, K.W. Selmaj1 I 1LODZ, POLAND, 2BRONX, USA

O 1231
17:30
Anoctamin 2 identified as an autoimmune target in multiple sclerosis
B. Ayoglu, N. Mitsios, I. Kockum, T. Olsson, P. Nilsson I STOCKHOLM, SWEDEN

O 1232
17:45
Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies
A. Traboulsee1, D. Arnold2, A. Bar-or3, G. Comi3, H.-P. Hartung4, L. Kappos5, F. Lublin6, K. Selma7, G. Klingelschmitt8, D. Masterman9, P. Fontoura10, P. Chin11, H. Garren9, S. Hauser11 I 1VANCOUVER, 2MONTREAL, CANADA, 3MILAN, ITALY, 4DUSSERDORF, GERMANY, 5BASEL, SWITZERLAND, 6NEW YORK, USA, 7LODZ, POLAND, 8SOUTH SAN FRANCISCO, 9SAN FRANCISCO, USA

O 1233
18:00
Neural correlates of motor fatigue and fatigability in multiple sclerosis: a functional MRI study
O. Svolgaard, K.W. Andersen, C. Bauer, K. Madsen, M. Blinkenberg, F. Selleberg, H.R. Siebner I COPENHAGEN, DENMARK

ORAL SESSION:
NEURO-ONCOLOGY
16:45-18:15 | HALL B5.M1
CHAIRPERSONS:
Michael Weller, ZURICH, SWITZERLAND
Riccardo Soffietti, MILAN, ITALY

O 1234
16:45
IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas
A. Darli1, J. Deverdun1, C. Gozé2, F. Castani3, S. Zouaoui1, V. Rigau4, M. Fabbro5, Y. Yordanova6, E. Le Bars7, L. Bauchet7, N. Menjot de Champfleur7, H. Duffau1 I 1MONTPELLIER, FRANCE, 2PARIS, FRANCE

O 1235
17:00
GLITRAD: A national multidisciplinary group dedicated to brainstem gliomas (BSG) in adults

O 1236
17:15
Dural metastases in 14 patients with systemic cancer: an exploratory retrospective study
M. Acker1, M. Loyoddin, B. Horvath-Mechtler, A. Grisold, B. Surboeck, W. Grisold I VIENNA, AUSTRIA

O 1237
17:30
Clinical characteristics and outcome of neurosarcoidosis: a meta-analysis
D. Fritz, D. van de Beek, M. Brouwer I AMSTERDAM, NETHERLANDS

O 1238
17:45
Risk for prescription of psychotropic drugs among partners of glioma patients: a nationwide registry study

O 1239
18:00
MEK inhibitor-related rhabdomyolysis
S. Koeppen, B. Schilling, L. Zimmer, D. Schadendorf I Essen, Germany
HOW TO IMPROVE YOUR CHANCES 1: EUROPEAN JOURNAL OF NEUROLOGY SESSION: "HOW TO WRITE AND PUBLISH ACADEMIC PAPERS?"

16:45-18:15 | HALL M3

CHAIRPERSON:
Anthony Schapira, LONDON, UK

Writing a paper and increasing its chances of publication
Anthony Schapira, LONDON, UK

Writing for publication - the publisher’s perspective
Silvana Losito, OXFORD, UK

Authorship issues and fraud in scientific publishing
Pertti Saloheimo, ESPOO, FINLAND

In this course the speakers will address the following points:

1. How to set about planning a paper for publication
2. Maximizing your chances of success
3. What not to do when trying to publish
4. What is the publisher’s perspective on the publication process?
5. How can you ensure that your paper has the greatest impact?
6. The ICMJE criteria for authorship and challenges in defining authorship
7. Plagiarism and other types of fraud in science publication
WHEN DO I NEED TO REQUEST AN MRI FOR THIS MS PATIENT?

DO YOU AGREE WITH THEIR DEFINITION OF AGGRESSIVE MS?

PERMANENT OR REVERSIBLE?

NeuroCompass
Where experts are talking MS

JOIN US

www.neuro-compass.education

- HOT TOPICS - PRACTICE POINTS - DIAGNOSIS
- IMMUNOPATHOLOGY - MS IMAGING - MEASURING DISEASE ACTIVITY
- TREATMENT SAFETY MONITORING

This educational resource has been developed independently with educational funding support from Biogen International GmbH.
© Adelphi Communications Ltd 2016
POSTER SESSION
AGEING AND DEMENTIA 1
12:30-13:15 | SCREEN A2
CHAIRPERSONS:
Pasquale Calabrese, BASEL, SWITZERLAND

P 11001  "I think I caught Alzheimer’s disease in the surgery"

P 11002  Abstract cancelled

P 11003  Abstract cancelled

P 11004  The latent cognitive impairment – an unrecognized disorder
Y. Balash, A.D. Korczyn, T. Gurevich I TEL AVIV, ISRAEL

P 11005  Cases of posterior cortical atrophy with and without amyloid pathology: is there any difference?

P 11006  Infectious dementias. Experience of the Memory center of Rabat.
M. Benabdellili, N. Essahli, M. Rahmani, S. Aïdi, M. El Alaoui Faris I RABAT, MOROCCO

P 11007  Heterogeneous clinical manifestation of familial Creutzfeldt-Jakob disease with D178N mutation
F. Caisberger, J. Kuchynka, Z. Pavelka, R. Herzig, M. Valis I HRADEC KRALOVE, CZECH REPUBLIC

P 11008  Multimodal imaging to distinguish in-vivo early onset Alzheimer’s disease from behavioral variant of frontotemporal dementia

P 11009  Abstract cancelled

P 11010  Modelling trajectories of brain damage in progressive supranuclear palsy: a longitudinal multimodal MRI study
F. Caso, F. Agosta, M. Ječmenička Lukić, I. Petrović, P. Valsasina, P.M. Ferrari, A. Meani, M. Copetti, V.S. Kostic, M. Filippi I MILAN, SAN GIOVANNI ROTONDO, ITALY, BELGRADE, SERBIA

P 11011  Different profiles of emotion recognition in amnestic MCI patients: the utility of early screening in patients with focal medial temporal lobe dysfunction.
C. Cerami, A. Dodich, S. Torre, G. Lettieri, S. Iannaccone, D. Perani, S.F. Cappa I MILAN, ITALY

P 11012  The supportive role of FDG-PET imaging in the differential diagnosis of primary progressive aphasias: a voxel-based FDG-PET study at the single-subject level

P 11013  Anosognosia for memory impairment in Mild Cognitive Impairment is not predictive for dementia and Alzheimer’s disease
I. Cova, G. Grande, V. Cucumo, R. Ghiretti, L. Maggiore, D. Galimberti, E. Scarpini, S. Pomati, C. Mariani I MILAN, ITALY

POSTER SESSION
AUTONOMIC NERVOUS SYSTEM DISORDERS 1
12:30-13:15 | SCREEN B1
CHAIRPERSON
Astrid Terkelsen, AARHUS, DENMARK (TBC)

P 11014  Autonomic disturbances in carpal tunnel syndrome
N. Belova, N. Suponeva, M.A. Piradov, V.V. Gnezditsky, A. Shabalina, D. Yusupova, D. Lagoda I MOSCOW, RUSSIAN FEDERATION

P 11015  Iatrogenic Harlequin syndrome due to central venous catheterization
V. Carvalho, C. Cunha, J. Martins I MATOSINHOS, PORTUGAL

P 11016  Autonomic dysfunction in multiple sclerosis correlates with EDSS and disease duration
L. Crnokić, A. Junaković, M. Krbot Skoric, M. Lovrić, I. Adamec, M. Habek I ZAGREB, CROATIA

P 11017  Dysautonomia is widely present in clinically isolated syndrome and correlates with brainstem lesions
L. Crnokić, I. Adamec, A. Junaković, B. Malojcic, S. Butkovic Soldo, M. Habek I ZAGREB, OSLOJEC, CROATIA
SATURDAY, 28 MAY
12:30 - 13:15

**POSTER SESSIONS**

**CEREBROVASCULAR DISEASES 1**
12:30-13:15 | SCREEN G1

**Chairperson:** Anna Czlonkowska, WARSAW, POLAND

---

**P 11018** Fingolimod-initiation reduces cardiovagal buffer capacity in response to baroreflex loading in multiple sclerosis patients  

**P 11019** Autonomic neuropathy associated with anti-Gad antibodies  
E. Fileccia, R. Liguori, A. Incensi, R. Rinaldi, R. D'angelo, M.P. Giannoccaro, V. Donadio | BOLOGNA, ITALY

**P 11020** Hemodynamic response to air-conducted sound stimulus is mediated via vestibulosympathetic reflex  
L. Crnošija, A. Pavelić, M. Krbot Skoric, I. Adamec, M. Habek | ZAGREB, CROATIA

**P 11021** Autonomic function tests for Dysreflexia in Spinal Cord Injuries  

**P 11022** Abstract cancelled

---

**POSTER SESSIONS**

**CEREBROVASCULAR DISEASES 1**
12:30-13:15 | SCREEN G1

**Chairperson:** Anna Czlonkowska, WARSAW, POLAND

---

**P 11023** Cardiac hemodynamic measurements and short-term outcome in patients with acute ischemic stroke  
A. Acewicz, H. Dudek, J. Siebert, D. Ryglewicz | WARSAW, GDANSK, POLAND

**P 11024** Right posterior portal watershed infarct in a right handed patient presentin with global aphasia: a case of crossed aphasia  

**P 11025** Gerstmann’s syndrome with atypical MRI findings: a case report  
A. Çetiz, H. Akgun, Z. Özkân, S. Tosdemir, S. Demirkaya | ANKARA, TURKEY

**P 11026** Feasibility study of the implementation of a strokes Registry in Grande-Terre and Marie Galante in Guadeloupe, F.W.I.  
C. Alecu, L. Place, F. Alecu, N. Deschamps, A. Lannuzel, J. Deloumeaux | POINTE À PITRE, FRANCE

---

**P 11027** Stroke thrombolysis in a tertiary care teaching hospital in Saudi Arabia  

**P 11028** Simultaneous ischemic stroke and acute myocardial infarct of cardioembolic etiology  
P. Alves, J. Pires, M. Menezes, D. Silva, A.C.G. Fonseca | LISBON, PORTUGAL

**P 11029** Lumbar puncture associated with corticotherapy as a predisposing factor of Cerebral Venous Thrombosis  
I. Ammon, C. Silva, M. Santos, A.P. Antunes, F. Falcão, L. Albuquerque | LISBON, PORTUGAL

**P 11030** Total cholesterol, high-density and low-density lipoprotein cholesterol in adult patients with acute ischemic or hemorrhagic stroke  
D. Arabadzhieva, A. Kaprelyan, I. Dimitrov, A. Tzoukeva, M. Boyadzhieva | VARNA, BULGARIA

**P 11031** The significance of Holter ECG in cryptogenic ischemic stroke  
Y. Arslan, B. Selbest Demirtaş, C. Ekmekçi, U. Sener, Y. Zorlu | IZMIR, TURKEY

**P 11032** Severity of the ischemic stroke and rheological disturbances in the blood  
M. Azhermacheva, V. Alifirova, N. Pugachenko, T. Valikova, P.D. Plotnikov Denis, O. Aliev, M.A. Nikitina, O. Izboldina | TOMSK, RUSSIAN FEDERATION

**P 11033** Stroke risk factors and survival of patients during 28 post-stroke days  
M. Azhermacheva, V. Alifirova, N. Pugachenko, T. Valikova, M.A. Nikitina, O. Izboldina, E. Stegmeier | TOMSK, RUSSIAN FEDERATION, BAAR-EBENHAUSEN, GERMANY

**P 11034** Thrombolysis for acute ischaemic stroke in Malta; the first 5 years  
D. Micallef, S. Azzopardi, A.P. Grima, J. Aquilina, M. Mallia | ANKARA, TURKEY

**P 11035** Spontaneous vertebral artery dissection associated with Poi-1, MTHFR C677T gene mutations and positive anti-Ro52 antibodies in a young woman  
R.S. Badea, I.C. Cernat, A. Craciunoiu | BUCHAREST, ROMANIA

**P 11036** Cannabis and cerebrovascular diseases  
S. Aïdi, M. Benabdeljlil, M. El Khalfi, M. Rahmani, M. El Aloufi Faris | RIYADH, SAUDI ARABIA
POSTER SESSION
CEREBROVASCULAR DISEASES 2
12:30-13:15 | SCREEN G3
CHAIRPERSON:
Adam Kobayashi, WARSAW, POLAND

P 11037 Risk profile in patients with ischemic stroke aged under 50
M. Cholakova | SOFIA, BULGARIA

P 11038 Posterior reversible encephalopathy syndrome and intracranial hypotension syndrome in puerperium
A. Costa, J. Meireles, M. Rodrigues, S. Fonseca, L. Fonseca, P. Abreu | PORTO, PORTUGAL

P 11039 Abstract cancelled

P 11040 The effect of prior antithrombotic therapy in acute stroke in patients with atrial fibrillation
P. Crnac, H. Budincevic, L. Friedrich | ZAGREB, CROATIA

P 11041 Risk of cancer after ischemic stroke
A. Ois Santiago, E. Cuadrado, A. Rodríguez-Campello, E. Giralt-Steinhauer, R.M. Vivanco-Hidalgo, J. Jiménez-Conde, A. Gomez, J. Roquer Gonzalez | BARCELONA, SPAIN

P 11042 Short-term outcome in symptomatic carotid occlusion

P 11043 Death and pneumonia incidence in relation to dysphagia severity
J. Zaborski, A. Czernuszenko | WARSAW, POLAND

P 11044 Does it matter whether saliva is aspirated or penetrates only?
J. Zaborski, A. Czernuszenko | WARSAW, POLAND

P 11045 Risk factors and primary stroke prevention in the population of Republic of Moldova
E. Daniela, N. Ciobanu, S. Groppa | CHISINAU, MOLDOVA

P 11046 Importance in diagnosis of troponin values in stroke
V. Delgado1, E. Sánchez2, J.A. Sánchez3, N. Segura4 | 1LA LÍNEA DE LA CONCEPCIÓN, 2ALGECIRAS, 3MÁLAGA, SPAIN

P 11047 Expression of TRPM2 ion channels with histopathological alterations following brain ischemia-reperfusion injury in rats
F. Balgetir, C. Demir, T. Kuloğlu, M. Gönen, E. Aytaç, S. Bulut | ELAZIG, TURKEY

Ischemic stroke as an isolated manifestation of temporal arteritis
L. Di Meglio, M. Yger, S. Alamowitch | PARIS, FRANCE

Prevention of stroke in Republic of Srpska
V. Djajić, S. Miljkovic, Z. Vujočić, D. Račić | BANJALUKA, BOSNIA AND HERZEGOVINA

POSTER SESSION
CEREBROVASCULAR DISEASES 3
12:30-13:15 | SCREEN G4
CHAIRPERSON:
Zuzana Gdovinova, KOSICE, SLOVAKIA

P 11050 Bilateral extracranial internal carotid artery dissection with haemodynamic symptoms treated by stenting

P 11051 Dynamical changes of hematological parameters in ischemic stroke patients after IV thrombolysis
M. Gafarova, M. Domashenko, M. Loskutnikov, M. Maximova, V. Shandalin, R. Konovalov, A. Shabalina | MOSCOW, RUSSIAN FEDERATION

P 11052 Did anything change in prevention of stroke in patients with atrial fibrillation (AF) after initiation therapy with direct oral anticoagulants?
Z. Gdovinova, N. Lesko, V. Han | KOSICE, SLOVAKIA

P 11053 Internal carotid artery pseudo-occlusion in acute stroke patients
P. Gelemer, S.H. Akpinar | NICOSIA, CYPRUS

P 11054 Safety and outcome of rTPA use in acute ischemic stroke in patients with active cancer: a case-control study

P 11055 Detection of paroxysmal atrial fibrillation by implantable loop recorder in cryptogenic stroke
D. Giobbe, A. Balducci, G. Paglia, M.L. Giobbe, C. Budano, G.L. Alunni, M. Giorgi | TURIN, ITALY

P 11056 Cryptogenic stroke, patent foramen ovale and high risk associated conditions: very low recurrence rate with percutaneous closure
D. Giobbe | TURIN, ITALY

P 11057 Abstract cancelled
P 11058  Malignant posterior reversible encephalopathy syndrome (PRES): a case report
N. Giraldo Restrepo1, L.V. Delgado González2, M. Torres2, O.E. Hernández Ortiz2, P. Urueña1  I CIUDAD REAL, SPAIN, 1MEDELLIN, COLOMBIA

P 11059  Correlation of cerebral autosomal dominant arteriopathy with subcortical infarcts and lekoencephalopathy syndrome (CADASIL) with retinal pathology
E. Giyazitdinova, B. Muinjonov, G. Rakhimbaeva, Y. Musaeva  I TASHKENT, UZBEKISTAN

P 11060  Neuropsychological abnormalities link with sensorimotor plasticity in cerebral autosomal dominant arteriopathy with subcortical infarcts and lekoencephalopathy (CADASIL) patients
E. Giyazitdinova, B. Muinjonov, G. Rakhimbaeva, Y. Musaeva  I TASHKENT, UZBEKISTAN

P 11061  Platelet receptor to von Willebrand factor in patients with different variant of ischemic stroke
V. Goldobin, E. Klocheva, O. Sirotkina, T. Vavilova  I ST. PETERSBURG, RUSSIAN FEDERATION

P 11062  Association of Posterior Reversible Encephalopathy Syndrome (PRES) and Transient apical ballooning syndrome (Tako-Tsubo): first case report of a man and review of literature
S. Grimaldi, E. Doche, C. Rey, E. Robinet, N. Laksiri, J. Pelletier  I TASHKENT, UZBEKISTAN

P 11063  Door-needle-times for CT versus MRI-examined stroke patients: a clinical randomized trial
C.K. Hansen, A. Christensen, I. Havsteen, H.K. Christensen  I COPENHAGEN, DENMARK

P 11064  Centralisation of acute stroke treatment is associated with improved quality of care and lower mortality

P 11065  Endothelial dysfunction in leukoaraiosis
M. Zupan, M. Šabović, M. Zaletel, K. Šurlan Popović, B. Zvan  I LJUBLJANA, SLOVENIA

P 11066  Sex differences in affective disorders in adult rats after infantile immune stimulation
I. Berkiks, A. Mesfioui, A. El Hessni  I KENITRA, MOROCCO

P 11067  Abstract cancelled

P 11068  Diagnosing neuronal ceroid lipofuscinosis with next-generation sequencing: a case report
G.J. Braathen, S. Slinde, Ø.L. Busk, K. Tveten, Ø.L. Holla, H.T. Hilmarsen, J.R. Helle  I SKIEN, NORWAY

P 11069  Long-term follow-up of two patients with cerebellar ataxia and CoenzymeQ10 deficiency due to mutations in ADCK3 gene.
V. Emmanuele1, C. Sobreira2, E. Barca1, S. Dimaroa, C.M. Quinzii1, M. Hirano1  I 1MESSINA, ITALY, 2SAO PAULO, BRAZIL, 1NEW YORK, USA

P 11070  Gross motor function of children with hereditary spastic paraplegia is related with knee flexion in swing: an instrumented gait analysis study
D. Gómez-Andrés1, I. Pulido-Valdeolivas1, J.A. Martín-Gonzalo1, J. López-Lozzi, S.I. Pascual Pascual1, E. Rausell1  I MADRID, 1SAN SEBASTIÁN DE LOS REYES, SPAIN

P 11071  Flexion movements during the gait cycle are less predictable in children with cerebral palsy: a new dimension in motor control
M. Zanini, D. Gómez-Andrés1, I. Pulido-Valdeolivas1, J.A. Martín-Gonzalo1, J. López-Lozzi, S.I. Pascual Pascual1, E. Rausell1  I MADRID, 1SAN SEBASTIÁN DE LOS REYES, SPAIN

P 11072  Abstract cancelled

P 11073  Abstract cancelled

P 11074  Focal-onset seizures in children: correlation between clinical presentation and EEG findings
M. Mazurkiewicz-Beldzińska, M. Szmuda, M. Zawadzka  I GDANSK, POLAND
Poster Session: Clinical Neurophysiology 1
12:30-13:15 | Screen H2
Chairperson: Einar Wilder-Smith, Singapore, Singapore

P11081 Neurophysiological stability at median and ulnar nerve entrapment sites after weekly paclitaxel chemotherapy
A. Bandla, S. Tan, R. Sundar, N. Thakor, E. Wilder-Smith | Singapore, Singapore

P11082 The importance of dense array EEG in detection of interictal epileptiform discharges and localization of epileptogenic foci
D. Ciocla, V. Chiosa, C. Munteanu, L. Mișina, A. Vataman, N. Gorincioi, S. Groppa | Chişinău, Moldova

P11083 How long should we record routine EEG to get relevant information?
H. Doudoux, L. Vercueil | Grenoble, France

P11084 Abstract cancelled

P11086 Goniometric measurement of joint angles: a simple tool for standardising muscular pre-contraction to elicit motor evoked potentials?
A. Giordano, M. Fichera, M. Pisa, F. Vitali, A. Nuara, G. Comi, L. Leocani | Milan, Italy

P11087 Optical Coherence Tomography, full-field Visual Evoked Potentials and multifocal Visual Evoked Potentials combined use to assess the visual system in multiple sclerosis.

P11089 The influence of brainstem and cognitive function on upper extremities function in early multiple sclerosis
M. Krbot Skoric, T. Gabelic, L. Crnošija, D. Petravić, B. Barun, I. Adamec, M. Habek | Zagreb, Croatia

P11090 The level of coherence with the largest number of events in the EEG is significantly lower in dementia
J. Kuchynka1, F. Caisberger1, Z. Pavelek1, O. Vysata1, A. Procházka2, M. Valis1 | 1Hradec Králové, 2Prague, Czech Republic

P11091 Typical communication EEG frequency is significantly lower in dementia
J. Kuchynka1, Z. Pavelek1, F. Caisberger1, O. Vysata1, A. Procházka1, M. Valis1 | 1Hradec Králové, 2Prague, Czech Republic

P11092 The efficacy of vitamin D replacement on pain, quality of life and nerve conduction velocities in the patients with chronic widespread pain
G. Akyuz, C. Sanal, I. Yagci, E. Giray, P. Kuru | Istanbul, Turkey

Poster Session: Experience of usage of antibodies to brain specific protein S100 (antiS100) and regular herbal medicines (based on Valeriana officinalis - Valeriana) in children with non-severe tics
O. Mukalova, A. Mukalau | Minsk, Belarus

Poster Session: Phenotypic variability in 4H leukodystrophy caused by POLR3A mutations
A. Potic, S. Pekic | Belgrade, Serbia

Poster Session: Prognostic factors in children with PRES and hematologic diseases
M. Romoli, N. Tambasco, E. Mastrodicasa, C. Salvatori, G. Mancini, M. Caniglia, P. Calabresi, A. Verrotti | Perugia, Italy

Poster Session: Case report: Ataxia-telangiectasia: cerebral abnormalities in a case of long survival
E. Zupanic, S. Sega Jazbec | Ljubljana, Slovenia

Abstract cancelled
POSTER SESSION
COGNITIVE NEUROLOGY/NEUROPSYCHOLOGY 1
12:30-13:15 | SCREEN A3
CHAIRPERSON:
Rita Formisano, ROME, ITALY

P 11093  The functional side of neurology in an ER

P 11094  Limb apraxia: neuropsychological and imaging study of two cases
D. Aquiar de Sousa1, S. Reimão1, G. Leal1, J. Almeida2, I. Pavão Martins1 | COIMBRA, PORTUGAL

P 11095  Loss of ownership feeling following a left hemisphere infarct

P 11096  Abstract cancelled

P 11097  Sex differences in cognitive behaviour and melatonin treatment in early neuroinflammation induced by LPS in Wistar rats
J. Berkiks, A. Mesfioui, Y. Bahbiti, A. El Hessni | KENITRA, MOROCCO

P 11098  Subjective spatial navigation complaints – a frequent symptom reported by patients with subjective cognitive decline, mild cognitive impairment and Alzheimer’s disease
J. Cerman1, R. Andel3, J. Laczó1, M. Vyhnálek1, Z. Nedelska1, I. Mokrisova1, K. Sheardova2, J. Hort1 | 1PRAGUE, 2BRNO, CZECH REPUBLIC, 3TAMPA, FLORIDA, USA

P 11099  Mild neurocognitive disorder related to epilepsy
I.D. Cuciureanu, T. Cuciureanu, A. Cuciureanu | IASI, ROMANIA

P 11100  Neuropsychological disorders in patients with obstructive sleep apnea
M. Dimitrova, K. Genov, A. Pavlov, K. Prinova, K. Kostov, L.D. Traykov | SOFIA, BULGARIA

P 11101  Abstract cancelled

P 11102  The role of pre-morbid intelligence in the Clock Drawing Test: studies with the Portuguese Irregular Word Reading Test

P 11103  The Clock Drawing Test as a cognitive screening instrument: development of Portuguese normative data for the Mini-mental State Examination + clock drawing combination
D. Duro, S. Freitas, M. Tábuas-Pereira, M.R. Simões, I. Santana | COIMBRA, PORTUGAL

P 11104  Selectively impaired visual processing in insomnia disorder patients
E. Giora, A. Galbiati, S. Marelli, M. Zucconi, L. Ferini Strambi | MILAN, ITALY

P 11105  The Italian validation of the QOLIBRI - Proxy Version

POSTER SESSION
CRITICAL CARE
12:30-13:15 | SCREEN F4
CHAIRPERSON:
Raimund Helbok, INNSBRUCK, AUSTRIA

P 11106  Reversible liver dysfunction associated with high dose ketamine in refractory status epilepticus
H.C. Chua | SINGAPORE, SINGAPORE

P 11107  Abstract cancelled

P 11108  Lesional Shapiro syndrome
P. Devic, F. Mauguière, A. Richard-Mornas, S. Ernesto, L. Peter-Derez, S. Rheims | ILYONS, FRANCE

P 11109  Objective and reliable diagnosis of delirium by quantitative EEG analyses: results from a large retrospective case–control study
R. Fleischmann, S. Tränkner, S. Schmidt, S. Schreiber, S. Brandt | BERLIN, GERMANY

P 11110  Levetiracetam vs. Phenytoin for Status Epilepticus: a prospective study
A. Gujjar, A. Al-Asmi, R. Nandhagopal, J. Pc, A. Obaidi, G. Ss, A. Al-Hashim, K. Al-Amrani | MUSCAT, OMAN

P 11111  Causes of admission, morbidity and mortality of multiple sclerosis patients at the ICU: a matched cohort study
A. Karamyan1, M. Dünser1, D. Wiebe2, G. Pilz1, P. Wipfler2, V. Chroust1, H.F. Novak1, E. Trinka1, J. Sellner1 | SALZBURG, AUSTRIA, 1PHILADELPHIA, USA
**POSTER SESSIONS**

**SATURDAY, 28 MAY**

**12:30 - 13:15**

---

**POSTER SESSION EPILEPSY 1**

**12:30 - 13:15 | SCREEN B2**

**CHAIRPERSON:** Jakob Christensen, AARHUS, DENMARK

- **P 11112** Optic nerve sheath sonography is a promising tool for assessment of raised intracranial pressure in stroke patients

- **P 11113** CONsciousness in NEurocritical Care cohort study using fMRI and EEG (CONNECTME)

- **P 11114** Abstract cancelled

- **P 11115** Documentation of brain death diagnostics in Upper Austria 2011–2013 – an audit

- **P 11116** Abstract cancelled

---

**POSTER SESSION EPILEPSY 2**

**12:30 - 13:15 | SCREEN B3**

**CHAIRPERSON:** Alla Guekht, MOSCOW, RUSSIAN FEDERATION

- **P 11117** Abstract cancelled

- **P 11118** Drug resistant epilepsy in adult Sudanese epilepsy patients: prevalence, patterns & characteristics
  - T. A-Hakam1, H.E.R. Mohamed2 I KHAMS MUSHAYT, SAUDI ARABIA, 2KHARTOUM, SUDAN

- **P 11119** Mobile phone based micro-personalised support groups in people with epilepsy
  - H. Angus-Leppan, A. Hasan I LONDON, UK

- **P 11120** Seizure triggers in focal and generalised epilepsies
  - A.A. Arbune, O. Tarta-Arsene, D. Craiul I BUCHAREST, ROMANIA

- **P 11121** Investigation of epilepsy by array CGH
  - A. Babameto Laku, Z. Ylli, D. Ylli, M. Rakacoll, J. Krupa I TIRANA, ALBANIA

- **P 11122** Midazolam and thiopental for the treatment of refractory status epilepticus: a retrospective comparison of efficacy and safety
  - F. Bellante, B. Legros, C. Depondt, J. Creteur, F. Taccone, N. Gaspard I BRUSSELS, BELGIUM

- **P 11123** Retrospective study on outcome of treatment of psychogenic non-epileptic seizures
  - S.A. Beniczky1, K. Noergaard2, N. Andersen Becser2 I 1ROSKILDE, 2GLOSTRUP, DENMARK

- **P 11124** Absence status epilepticus in adults: subtleness of its clinical features
  - F. Bernardo, R. Martins, A. Martins, A.N. Pinto I AMADORA, PORTUGAL

- **P 11125** First Seizure Clinic evaluation at University Hospital centre of Tours
  - J. Biberon, N. Limousin, B. de Toffol I TOULOUSE, FRANCE

- **P 11126** Responsive VNS Therapy: Long term results from two long-term, prospective, multi-center studies
  - P. Boon1, K. Eggleston1, P. Raman2, A. Jayewardene2, R.S. Fisher3 I 1GHENT, BELGIUM, 2TEXAS, 3STANFORD, USA

- **P 11127** Abstract cancelled

- **P 11128** Non-convulsive status epilepticus presenting with hiccups

---

**POSTER SESSIONS**

**COPENHAGEN, DENMARK, 28 – 31 MAY, 2016**

65
POSTER SESSIONS

SATURDAY, 28 MAY
12:30 - 13:15

P 11131 Unpredictable seizure-worsening induced by Levetiracetam monotherapy in a patient with focal cortical dysplasia type II

P 11132 Non-hyperammonaemic Valproate encephalopathy after 20 years of treatment
E. Galizia, J. Isaacs, H. Cock | LONDON, UK

P 11133 Nocturnal temporal lobe epilepsy: reappraisal of a rare syndrome

P 11134 Altered brain connectivity in patients with long QT syndrome – a link between heart and brain?
A. Gonzalez, I.T. Dahl, P.G. Larsson, K.H. Haugaard, T. Edvardsen, D. Aurlien | OSLO, STAVANGER, NORWAY

P 11135 Attitude towards people with epilepsy in Moscow
A. Guekht, O. Danilenko, A. Lebedeva, I. Kaimovskiy, M. Mizinova, M. Grishkina, A. Gersamiya, R. Akzhigitov | MOSCOW, RUSSIAN FEDERATION

P 11136 The Danish Epilepsy Surgery Programme aligns with international standards
E. Holm, M.T. Foged, J. Brennum, L.H. Pinborg, The Danish Epilepsy Surgery Group | COPENHAGEN, DENMARK

P 11137 De novo truncating mutation in SCN1A as a cause of epilepsy with febrile seizures plus (FS+) A. Jaimes, M. Machio, M. Oses, R. Guerrero-Lopez, B.G. Giraldez, J.M. Serratosa | MADRID, SPAIN

P 11138 Abstract cancelled

P 11139 Affective disorders in patients with epilepsy
T. Kapustina, A. Kotsiubinskiy, N. Sivakova, L. Lipatova | ST. PETERSBURG, RUSSIAN FEDERATION

P 11140 Enalapril but not losartan protects development of pentylenetetrazole induced kindling in rats: role of BDNF
J. Katyal, H. Kumar, D. Joshi, Y.K. Gupta | NEW DELHI, INDIA

P 11141 The diagnostic accuracy of dynamic susceptibility contrast-enhanced perfusion MRI in temporal lobe epilepsy
G. Witkowski, H. Sienkiewicz-Jarosz, M. Restel, R. Rola, G. Makowicz, D. Ryglewicz | WARSAW, POLAND

POSTER SESSION
HEADACHE AND PAIN 1
12:30-13:15 | SCREEN C1

CHAIRPERSON:
Henriette Klit, AARHUS, DENMARK

P 11142 EMA401, a novel angiotensin II type 2 receptor antagonist for treatment of peripheral neuropathic pain: design of two phase II studies
S. Pandhi, F. von Raison, A. Shah, G. Flesch, F. Callegari | BASEL, SWITZERLAND, EAST HANOVER, USA

P 11143 A case of Stroke-Like Migraine Attacks after Radiation Therapy (SMART)-syndrome: a rare but important differential diagnosis of migraine and stroke V. Haller, D. Dashti, N. Peters | BASEL, LIESTAL, SWITZERLAND

P 11144 Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, semi-randomized, placebo-controlled crossover study
A.S. Petersen, M. Barloese, N. Lund, R. Jensen | Glostrup, Denmark

P 11145 Prolonged migraine attack: acute and preventive response to anaesthetic nerve blockade in 41 patients

P 11146 Changes in topographical pressure pain sensitivity maps over the head after onabotulinumtoxin-A therapy in chronic migraine
M. Ruiz Piñero, J. Barón, A. Juanatey, L. Blanco, A.L. Guerrero, M. Palacios-Ceña, P. Madeleine, C. Fernández-de-Las-Peñas | VALLADOLID, MADRID, SPAIN, AALBORG, DENMARK

P 11147 Systematic literature review of health state utility values in patients with migraine
P. Desai, A. Ahuja, G. Pietri, S. Sapra | THOUSAND OAKS, USA, CHANDIGARH, INDIA, LONDON, UK

P 11148 TV publicity: one of the causes of medication-overuse headache?
G. Socoliuc, G. Mihalescu, B. Alexandra-Doina, C. Boetu, I. Buraga | BUCHAREST, ROMANIA

P 11149 Headache characteristics in cerebral venous thrombosis: an analysis of 55 patients

COPENHAGEN, DENMARK, 28 – 31 MAY, 2016

66
### POSTER SESSIONS

**COPENHAGEN, DENMARK, 28 – 31 MAY, 2016**

**POSTER SESSIONS**

**SATURDAY, 28 MAY**

**12:30 – 13:15 | SCREEN E4**

**Chairperson:** Kristian Winge, COPENHAGEN, DENMARK

**POSTER SESSIONS**

**MOVEMENT DISORDERS 1**

**12:30 – 13:15 | SCREEN E4**

**Chairperson:** Kristian Winge, COPENHAGEN, DENMARK

---

**P 11150** Remote limited headaches associated with Varicella Zoster Virus  
K. Takagi, K. Yamazaki, R. Hishida, S. Nojima, H. Kobayashi  
INASHIKI-GUN, NAGOYA, JAPAN

**P 11151** Abstract cancelled

**P 11152** Abstract cancelled

**P 11153** Prevalence of migraineous infarction  
T.S. Tsypushkina, N.M. Gurary, M.G. Toporkova, E.R. Lebedeva, J. Olesen  
YEKATERINBURG, RUSSIAN FEDERATION, GLOSTRUP, DENMARK

**P 11154** CO2 laser-evoked potentials: working population normative values  
D. Petravić, K.I. Tudor, M. Krbot Skoric, V. Ižgum  
ZAGREB, CROATIA

**P 11155** Acute post-traumatic headache  
I. Vyshlova, S. Karpov, A. Starodubcev, I. Azoidis, A. Karpov  
STAVROPOL, RUSSIAN FEDERATION

---

**P 11156** Evaluation of impulse control disorders and related behaviours in patients with idiopathic Parkinson’s disease  
A. Acarer, A. Bayramov, S. Ciftci, Z. Colakoglu  
IZMIR, TURKEY

**P 11157** White matter connectome in patients with genetic dystonia  
SAN GIOVANNI ROTONDO, ITALY, BELGRADE, SERBIA

**P 11158** Features of pain perception during periods of motor fluctuations in Parkinson’s disease  
O. Alenicova, S. Likhachev  
MINSK, BELARUS

**P 11159** Constant-current stimulation in Parkinson’s disease patients  
P. Amami, M. Mascia, L.M. Romito, A. Albanese  
CAGLIARI, ITALY

**P 11160** Rest and postural parkinsonian tremors are based on a common mechanism: an analysis of motor unit firing synchrony and patterns  
O. Agapaki, C. Christakos, D. Anastasopoulos  
IoANNINA, GREECE

---

**P 11161** Ventilatory disturbance in early Parkinson’s disease: a prospective study  
G. Baille, T. Peres, D. Devos, L. Defebvre, C. Moreau  
LILLE, FRANCE

**P 11162** Decreased coenzyme Q10 levels in multiple system atrophy cerebellum  
E. Barca, G. Klenner, G. Tang, S. Tadesse, C.-Y. Lin, E. Masliah, S.-H. Kuo, C.M. Quinzii  
NEW YORK, NEUROLOGY, USA

**P 11163** Accuracy of deep brain stimulation electrodes placement using frameless system – Nexframe®  
J. Borden, D. Krauhluk, M. Nevrly, P. Otruba, M. Vaverka  
MONDOV, CZECH REPUBLIC

**P 11164** The anatomical basis of genetic dystonia: a multimodal MRI study  
SAN GIOVANNI ROTONDO, ITALY, BELGRADE, SERBIA

**P 11165** Conjugal Parkinson’s disease – real or chance?  
B. Balint, R. Erro  
LONDON, UK, VERONA, ITALY

**P 11166** The role of transcranial sonography in diagnosis of progressive supranuclear palsy and multiple system atrophy  
K. Blazina, V. Miletic, M. Relja  
ZAGREB, CROATIA

**P 11167** Neurophysiological features of balance control in patients with Parkinson’s disease by posturographic analysis  
R. Bogdanov, S. Borisova, P. Patmanova, D. Napalkov  
MOSCOW, RUSSIAN FEDERATION

**P 11168** Progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with glycine receptor antibodies as first manifestation of Hodgkin’s lymphoma: a case report  
L. Borellini, S. Lanfranconi, I. Trezzi, G. Franco, A. Di Fonzo, S. Bonato, N. Bresolin  
MILAN, ITALY
P 11169  Longitudinal assessment of cervical cord atrophy across MS clinical phenotypes: a multicenter study
M. Aboulwafa1, M.A. Rocca1, P. Valsasina1, F. Barkhof3, H. Vrenken3, A. Rovira4, X. Montalban4, H. Kearney5, O. Ciccarelli5, L. Matthews 6, J.A. Palace6, A. Gallo2, A. Bisecco2, A. Gass7, P. Eisele7, C. Lukas8, B. Bellenberg 8, G. Comi1, M. Filippi1  I 1MILAN, 2NAPLES, ITALY, 3AMSTERDAM, NETHERLANDS, 4BARCELONA, SPAIN, 5LONDON, 6OXFORD, UK, 7MANNHEIM, 8BOCHUM, GERMANY

P 11170  Sudomotor dysfunction in clinically isolated syndrome
I. Adamec, L. Crnošija, M. Lovrić, A. Junaković, M. Krbot Skoric, M. Habek  I ZAGREB, CROATIA

P 11171  Abstract cancelled

P 11173  Endocan, novel potential biomarker for multiple sclerosis?

P 11174  Comparative evaluation of clinical and epidemiological characteristics of multiple sclerosis in Kazakhstan
K. Almakanova1, A. Siva2, A. Zhussupova1  I ASTANA, KAZAKHSTAN, 1ASTANA, TURKEY

P 11175  CSF markers of inflammation and neurodegeneration in two Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS) families with diverging genotype and phenotype
O. Andersen1, C. Sunda1, H. Zetterberg1, V.D. Karrenbauer2  I 1GOTHENBURG, 2STOCKHOLM, SWEDEN, 3GOTHENBURG, NORWAY

P 11176  Fatigue, depression and memory impairment in multiple sclerosis
L. Ben Aljia, K. Anissa, D. Rabiaa, N. Salma, B.A. Sofian, B.A. Leila  I SOUSSE, TUNISIA

P 11177  Real life efficacy and tolerability of Teriflunomide: a multicentre study
P. Annovazzi1, G. Mallucci2, M. Lo Re3, S. Miate4, R. Cavarretta1, L. Mioila1, R. Bergamaschi2, A. Bertolotto3, P. Perini1, M. Raveris5, G. Comi5, A. Ghezzi6  I GALLARATE (VA), 1PAVIA, 2ORBASSANO (TO), 3PADOVA, 4MILAN, ITALY

P 11178  T2 and Gd+ lesion conversion to chronic T1 black holes is correlated with worse outcomes in patients with RRMS in the ADVANCE Study
D. Arnold1, X. You2, D. Gasparotto2, C. Castrillo-Viguer2, B. Werneburg2, D. Fiore2  I MONTREAL, CANADA, 1CAMBRIDGE, USA

P 11179  Comparative study of neuromyelitis optica and multiple sclerosis patients by optical coherence tomography

P 11180  Neuropsychological assessment of patients with neuromyelitis optica spectrum disorders (NMOSD)

P 11181  How does fampridine change gait kinematics to improve walking speed in primary progressive multiple sclerosis?

P 11182  Antibodies to myelin lipids in multiple sclerosis
M. Ivanova, M. Zakharova  I MOSCOW, RUSSIAN FEDERATION

P 11183  Is there a relation between development of disease disability and cervical spinal cord lesion load in the early disease course of Multiple Sclerosis?
N. Kale, B. Kara, R. Simsekoglu, N. Karagoz Sakalli, A. Soysal  I ISTANBUL, TURKEY

P 11184  Early treatment with teriflunomide reduces the risk of advancing to EDSS ≥6 and EDSS ≥7 over the long term
L. Kappos1, M.S. Freedman1, G. Comi1, A. Miller1, K. Thangavelu3, P. Truffinet4, F. Lublin1, G. Comi1  I GALLARATE (VA), 1PAVIA, 2ORBASSANO (TO), 3PADOVA, 4MILAN, ITALY, 5NEW YORK, 6CAMBRIDGE, USA, 7CHILLY-MAZARIN, FRANCE
P 11185  Clinical outcomes in patients with faster advancing MS treated with teriflunomide in TEMSO and TOWER
L. Kappos1, K. Thangavelu5, S. Cavalier5, P. Truffinet2, G. Comi3, A. Miller4  I 1BASEL, SWITZERLAND, 2CHILLY-MAZARIN, FRANCE, 3MILAN, ITALY, 4NEW YORK, 5CAMBRIDGE, USA

P 11186  Abstract cancelled

P 11187  Is active herpes simplex virus a predictor of interferon-beta flu-like syndrome occurrence?
D. Kasatkin, N. Spirin, M. Gris' I YAROSLAVL, RUSSIAN FEDERATION

P 11188  Comparison of the efficacy and retention of Natalizumab vs. Fingolimod in Cypriot patients with Relapsing Remitting Multiple Sclerosis.
E. Kiolou, E. Leonidou, E. Gaglia, M. Pantzaris I NICOSIA, CYPRUS

P 11189  Abstract cancelled

P 11190  Similarities and Differences in Properties of Glatiramer Acetate (Copaxone®, Teva) versus Polimunol (Synthom) using Standard and Emerging Technologies
A. Komlosh1, T. Hasson1, K. Wells-Knecht1, T. Wells-Knecht1, R. Krispin1, G. Papir1, H. Cooperman1, S. Bakshi1, S. Kolitz1, B. Weiner1, B. Zeskind1, D. Ladkani2, P. Loupe3, V. Weinstein1, I. Grossman1, M. Hayden1  I 1NETANYA, 2PETAH TIKVA, ISRAEL, 3WEST CHESTER PA, 4CAMBRIDGE MA, 5OVERLAND PARK KS, USA

P 11191  Helminths are not associated with increased Multiple Sclerosis risk
A. Koskderelioglu, M. Gedizlioglu, I. Afsar, B. Pektas IIZMIR, TURKEY

P 11192  Open-label Phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS
R. Kuhel2, G. Deol-Bhullar1, M. Garas1, P. Chin3, S. Hauser3, X. Montalban4 I 1BASEL, SWITZERLAND, 2SOUTH SAN FRANCISCO, 3SAN FRANCISCO, USA, 4BARCELONA, SPAIN

P 11193  Executive functions and complex attention deficits in patients with relapsing-remitting multiple sclerosis
T. Kunchev, M. Petrova, M. Raycheva, L.D. Traykov I SOFIA, BULGARIA

P 11194  Abstract cancelled

P 11195  Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) β-1a-controlled OPERA I and OPERA II studies
K. Selmaj1, D. Arnold2, A. Bar-or3, G. Comi4, H.-P. Hartung5, S. Hauser4, F. Lublin6, A. Traboulsee7, N. Mairon8, P. Chin9, P. Fontoura9, H. Garren9, G. Klingelschmitt10, D. Masterman9, L. Kappos6  I 1LODZ, POLAND, 2MONTREAL, 3VANCOUVER, CANADA, 4MILAN, ITALY, 5DÜSSELDORF, GERMANY, 6BASEL, SWITZERLAND, 7SOUTH SAN FRANCISCO, 8SAN FRANCISCO, USA

P 11196  Integrated rehabilitation paradigm for managing some disabling multiple sclerosis-related impairments
N. Shalaby, H. Shehata, A. Elmazny I CAIRO, EGYPT

P 11197  Pharmacokinetics, pharmacodynamics, safety, and tolerability of a novel anti-IL-6 receptor recycling antibody SA237: first in-human phase 1 single- and multiple-dose studies
Y. Shimada1, Y. Munakata2, M. Inoo3, R. Hanada1, A. Yamada1, R. Takubo1, M. Shiramoto4 I 1TOKYO, 2SENDAI, 3UTAZU, 4FUKUOKA, JAPAN

P 11198  More rapid multiple sclerosis progression in North African second generation immigrants to France: comparison between French Caucasians, North Africans in Tunisia and immigrants to France
Y. Sidhom1, E. Maillart 2, S. Tezenas Du Montcel2, Y. Nadjar2, I. Kacem1, R. Gouider1, C. Lubetzki2, C. Papeix2 I 1PARIS, FRANCE

P 11199  Abstract cancelled

P 11200  Demyelination after anti TNFα therapy: An emerging trend? Report of two cases from South East England
S. Harikrishnan, J. Sivaqanasasundaram, N. Moran, I. Redmond I CANTERBURY, UK

P 11201  Demyelinating neurological disease after treatment with etanercept: description of 2 cases
S. Skalska, V. Sladkova, Z. Matejcikova, J. Dolakova, T. Srvinova, J. Mares, P. Kanovsky I OLOMOUC, CZECH REPUBLIC

P 11202  Immunogenicity with repeated dosing of ocrelizumab in patients with relapsing MS
A. Songi, P. Hendricks1, S. Chung3, Q. Wang3, P. Chin2, H. Garren2  I 1SOUTH SAN FRANCISCO, USA, 2BASEL, SWITZERLAND
SATURDAY, 28 MAY
12:30 – 13:15

**POSTER SESSIONS**

**MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 1**
12:30-13:15 | SCREEN B4

**Chairperson:**
Tiziana Mongini, Turin, Italy (TBC)

**Abstract cancelled**

**P 11209**

**Study design of an assessment protocol for central and peripheral fatigue in myotonic dystrophy type 1 DM1**
S. Boldanzi, M. Bottari, C. Simoncini, G. Ricci, G. Siciliano 1, Pisa, Italy

**P 11210**

**Anosognosic vs. non-anosognosic behaviour in adult-onset myotonic dystrophy type 1: clinical and management relevance**
S. Boldanzi, F. Bevilacqua, R. Lorio, C. Simoncini, A. Petrucci, G. Massimetti, G. Ricci, C. Angelini, G. Siciliano 1, Pisa, Italy

**Oculopharyngeal muscular dystrophy (OPMD): long-term follow-up in 19 patients**
S. Bortolani, P. Ponzalino, N. Ragusa, L. Chiado Piat, E. Vittonatto, S. Boschi, L. Vercelli, L. Pinessi, T. Mongini 1, Turin, Italy

**Lymphoma-associated inflammatory myopathy: a case report**
R. Brusa, E. Mauri, L. Villa, S. Brajkovic, I. Faravelli, F. Tiberio, A. Govoni, F. Magri, M. Sciacco, M.G. Moggio, G.P. Comi 1, Milan, Italy

**Visceral leishmaniasis in a myasthenia gravis patient: a diagnostic and therapeutic challenge**
A. Camacho, A. Hernandez, N. Giraldo, J.J. Bravo, A. Parralo, S. Carrasco García de León 1, Ciudad Real, Spain

**Evidence-based survival prediction in patients with sporadic inclusion body myositis (sIBM)**
G. Capkun 1, S. Ghosh 1, T. Obadia 1, H. Sharma, B. Amzal 1, Hyderabad, India, Paris, France

**Systematic review and meta-analyses of the prevalence of sporadic inclusion body myositis (sIBM)**
A. Callan 1, G. Capkun 1, V. Vasanthaprasad 1, S. Ghosh 1, M. Needham 1, Dublin, Ireland, Basel, Switzerland, Hyderabad, India, Perth, Australia

**Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1**
P. Cecchi 1, S. Boldanzi 1, S. Fabbri, I. Pesaresi, C. Simoncini, C. Angelini, U. Bonuccelli, M. Cosottini, G. Siciliano 1, Pisa, Lido Venice, Italy

**Abstract cancelled**

**P 11208**

**Anti–MOG antibody positivity in a case of chronic relapsing inflammatory optic neuritis**
D. Tzanetakos, E. Andreoudou, M.E. Evangelopoulos, M. Anagnostouli, G. Koutsis, K. Kilidireas 1, Athens, Greece

**Bone marrow mesenchymal stem cells intrathecal transplantation in patients with progressive multiple sclerosis – 1-year follow-up**
M. Swiderek-Matysiak 1, J. Wątkiiewicz 2, A. Habich 1, I. Selmaj 1, W. Maksymowicz 2, K. Selmaj 1, Lodz, Olsztyn, Poland

**Multiple Sclerosis (MS) in Iceland 1900–2000: Survival and mortality up to the Year 2011 in a total population**
S. Sveinbjornsdottir 1, H. Magnusson 2, J. Benedict 2 1, London, UK, Reykjavik, Iceland

**Attention and Processing Speed Performance in Multiple Sclerosis is mostly related to thalamic and cerebellar volume**
S. Stamenova 1, A. Bisecco 2, G. Caiazzo 2, A. D’ambrosio 2, R. Sacco 2, S. Bonavita 2, R. Docimo 2, L. Lavorgna 2, M. Cirillo 2, P.F. Esposito 2, G. Tedeschi 2, A. Gallo 2 1, Sofia, Bulgaria

**P 11203**

**Persistent MRI lesion activity and brain volume loss as predictors of long-term disability progression under treatment in relapsing–remitting multiple sclerosis**
M.P. Sormani 1, L. Kappos 3, D. Piani-Meier 2, D. Haring 2, D. Tomic 2, N. de Stefano 3 1, Genoa, Italy, Basel, Switzerland, SIENA, Italy

**P 11204**

**Attention and Processing Speed Performance in Multiple Sclerosis is mostly related to thalamic and cerebellar volume**
S. Stamenova 1, A. Bisecco 2, G. Caiazzo 2, A. D’ambrosio 2, R. Sacco 2, S. Bonavita 2, R. Docimo 2, L. Lavorgna 2, M. Cirillo 2, P.F. Esposito 2, G. Tedeschi 2, A. Gallo 2 1, Sofia, Bulgaria

**P 11205**

**Multiple Sclerosis (MS) in Iceland 1900–2000: Survival and mortality up to the Year 2011 in a total population**
S. Sveinbjornsdottir 1, H. Magnusson 2, J. Benedict 2 1, London, UK, Reykjavik, Iceland

**Bone marrow mesenchymal stem cells intrathecal transplantation in patients with progressive multiple sclerosis – 1-year follow-up**
M. Swiderek-Matysiak 1, J. Wątkiiewicz 2, A. Habich 1, I. Selmaj 1, W. Maksymowicz 2, K. Selmaj 1, Lodz, Olsztyn, Poland

**Abstract cancelled**

**P 11207**

**Relationship between neuropsychological impairment and grey and white matter changes in adult-onset myotonic dystrophy type 1**
P. Cecchi 1, S. Baldanzi 1, S. Fabbri 1, I. Pesaresi, C. Simoncini, C. Angelini 1, U. Bonuccelli, M. Cosottini 1, G. Siciliano 1, Pisa, Lido Venice, Italy
P 11218  A case of dropped head syndrome caused by focal myositis  
J. Cho  I GYEONGG-DO, GOYANG-SI, KOREA, REPUBLIC OF

P 11219  The significance of thymectomy: a retrospective study comparing thymectomy with conservative treatment for myasthenia gravis  
I. Dejanović, D. Lavrnic, S. Knezevic-Apostolski, S. Apostolski  I BELGRADE, SERBIA

P 11220  Mutations causing myofibrillar myopathies in the Polish population  
J.P. Fichno, A. Potulska-Chromik, A. Macias, A. Kaminska, C. Zekanowski, A. Maruszak  I WARSAW, POLAND

P 11221  Autoimmune encephalitis in a patient with benign pancreatic neoplasia  
A. Addis, A.L. Rassu, E. Sechi, R. Piredda, L. Agranò, C. Fois, D.G. Corda, G. Sechi  I SASSARI, ITALY

P 11222  Diffuse large B-cell Lymphoma of the central nervous system in mycophenolate mofetil treated patients with lupus nephritis  
D. Aksoy1, P. Gelener3, S. Usar Incırlı 2  I 1LEFKOSA, 2NICOSIA, 3MERSIN, TURKEY

P 11223  Neurological paraneoplastic syndromes with positive antineuronal antibodies: clinical and laboratory characterization  
J.N. Alves  I BRAGA, PORTUGAL

P 11224  Evaluation of intraoperative photodynamic therapy with Photolon in patients with glioblastoma  
A. Barouski, A. Fedulov, I. Sakovich, T. Trukhachova, S. Shliakhtsin  I MINSK, BELARUS

P 11225  Infiltrating melanotic schwannoma of the cervical spinal cord: case report, radiology and pathology  
S. Caerels1, A. Boogers1, T. D’hoore1, M.-A. van Caillie1, K. Ramboer1, N. Libbrecht1, P. Vanacker2  I BRUGES, 1ANTWERP, BELGIUM

P 11226  Accuracy of magnetic resonance imaging in pre-operative diagnosis of brain tumours: concordance with histopathology and interobserver reliability  
S. Caerels1, A. Boogers1, T. D’hoore1, M.-A. van Caillie1, K. Ramboer1, N. Libbrecht1, P. Vanacker2  I BRUGES, 1ANTWERP, BELGIUM

P 11227  Rare primary tumour of the neurohypophysis: pitucytoma  
E. Cengiz1, S. Demir2, C. Kafadar3, E. Togrol4  I 1IZMIR, 2ISTANBUL, TURKEY

P 11228  Lhermitte-Duclos disease: a clinical and neuroradiological diagnosis: a case report  
T. Croese1, R. Messina1, S. Guerrieri1, V. Martinelli2, A. Castellano1, G. Comi1, A. Falini1, B. Colombo1  I MILAN, 1ALME, 2VENAFRO, ITALY

P 11229  Age-histopathology related patterns of primary Central Nervous System (CNS) tumours in Albania  
P. Djamandi, G. Brace, G. Kaloshi  I TIRANA, ALBANIA

P 11230  Medical risk factors in the development of brain tumours in Albania  
P. Djamandi, G. Brace, G. Kaloshi  I TIRANA, ALBANIA

P 11231  Incidence patterns of primary Central Nervous System Tumours (CNS) in Albania  
P. Djamandi, G. Brace, G. Kaloshi  I TIRANA, ALBANIA

P 11232  Treatment efficacy of patients with neuroepithelial brain tumours under local intraoperative chemotherapy  
V. Dmitry, A. Fedulov  I MINSK, BELARUS

P 11233  The spectrum of neurological presentations of intravascular lymphoma: from recurrent stroke to severe peripheral neuropathy  

P 11234  Behavioural therapy for enhancing physical activity in Parkinson’s disease – preliminary results  
J. Opara1, D. Grzybowska-Ganszczyk2, A. Malecki2  I TARNOWSKIE GÓRY, 1KATOWICE, POLAND

P 11235  Predictor for positive response to an implanted drop foot stimulator post stroke  
M.M. Pinter1, O. Schuhfried2  I KREMS, 1VIENNA, AUSTRIA
POSTER SESSIONS

SATURDAY, 28 MAY
12:30 - 13:15

P 11236  
A new liquid formulation of abobotulinumtoxinA (Dysport®) significantly improves disease-specific quality of life (CDIP-58) and pain in cervical dystonia: a double-blind and open-label study
M. Simonetta-Moreau1, S. Vohanka2, J. Ilkowski4, M. Magalhães5, T. Kovács6, P. Picaut2, M. Volteau2, W. Poewe1
1TOULOUSE CEDEX, 2PARIS, FRANCE, 3BRNO, CZECH REPUBLIC, 4POZNAN, POLAND, 5PORTO, PORTUGAL, 6BUDAPEST, HUNGARY, 7INNSBRUCK, AUSTRIA

P 11237  
Abstract cancelled

P 11238  
Abstract cancelled

P 11239  
Enhancement of cortical excitability and motor function in stroke patients after combined repetitive transcranial and peripheral magnetic stimulation
S. Kuznetsova, V. Kuznetsov, N. Skachkova
1KIEV, UKRAINE

P 11240  
Efficacy of low-frequency rTMS on motor recovery after-stroke
O. Sorato Bezerra1, C. Babis Magoulas1, A.L. Schuh Teixeira Da Rosa2, L. Primo de Carvalho Alves2
1LONDON, UK, 2PORTO ALEGRE, BRAZIL

P 11241  
A study of lobar atrophy and white matter tract damage in pediatric patients with traumatic brain injury
L. Storelli1, M.A. Rocca1, E. Molteni2, E. Pagani1, G. Boffa1, M. Copetti1, S. Galbiati2, F. Arrigoni1, M. Recla2, A. Bardoni1, S. Strazzer2, M. Filippi1
1MILAN, 2BOSISIO PARINI, 3SAN GIOVANNI ROTONDO, ITALY

P 11242  
Neurogenic lower urinary tract dysfunction in acute stroke
K.I. Tudor1, D. Petrvaci1, M. Botică1, D. Mahovic Lakusic1, B. Ribarić1
1ZAGREB, CROATIA

P 11243  
Innovations in the rehabilitation of patients with spinal cord injury
S. Turuspeková1, D. Mitrokhin1, A. Ostapenko1, E. Kudabaeva1, B. Gaziz1, A. Seydanova1, Z. Kalezov1, L. Abdullahova1, I. Almaty1
1STAVROPOL, RUSSIAN FEDERATION

P 11244  
Clinical assessment of dysphagia in neurodegeneration (CADDN): reliability and validity
A. Vogel1, N. Rommel2, C. Sauer2, M. Synofzik2
1MELBOURNE, AUSTRALIA, 2TÜBINGEN, GERMANY

P 11245  
Video game-based speech rehabilitation for reducing dysarthria severity in adults with degenerative ataxia
A. Vogel1, J. Skarratt1, J. Castles1, M. Synofzik2
1MELBOURNE, AUSTRALIA, 2TÜBINGEN, GERMANY

POSTER SESSION
PERIPHERAL NERVE DISORDERS 1
12:30-13:15 | SCREEN D2

CHAIRPERSON
Michaela Auer-Grumbach, GRAZ, AUSTRIA

P 11246  
POEMS syndrome – case descriptions from a center of Neuromuscular disorders
1COIMBRA, PORTUGAL

P 11247  
Ectopic Nav1.8 channels on motor axons aggravate the toxicity of prolonged repetitive activity in a mouse model of CMT1B
S. Alvarez Herrero1, M.R. Rosberg1, D. Klein2, R. Martini2, S.R. Levinson3, M. Moldovan1, C. Krarup1
1COPENHAGEN, DENMARK, 2WÜRZBURG, GERMANY, 3DENVER, USA

P 11248  
Dynamic science internationalization in the field of polyneuritis and polyradiculoneuritis
D. Arabadzhieva, A. Kaprelyan, I. Dimitrov, B. Ivanov
1VARNA, BULGARIA

P 11249  
Chronic immune sensory polyradiculapthy (CISP): two cases
R. Araújo, S. Batista, J. Parra, L.J.M.P. Negrão, A. Matos
1COIMBRA, PORTUGAL

P 11250  
Dopaminergic medicines are alternative drugs for medicament-resistant facial nerve neuropathy: EMG study.
A. Azimov, R. Sadykov, G. Rakhimbaeva, O. Azizova, S. Dadajonov, R. Ismoilov
1TASHKENT, UZBEKISTAN

P 11251  
Immunological aspects of the nervous system in patients with postoperative hypothyroidism and autoimmune thyroiditis
S. Karpov, G. Balaeva, G. Saneeva, I. Azoidis, I. Prochorenko
1STAVROPOL, RUSSIAN FEDERATION

P 11252  
Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculopathy: Is it really effective? Our experience
C. Baetu1, I. Buraga1, G. Giurea Neacsu2, V. Lungu2, A.M. Enachi1, G. Mihaiescu1
1BUCHAREST, 2RM VALCEA, ROMANIA

P 11253  
The evaluation of small fibers in asymptomatic patients with Val30Met mutation
C. Bekircan-Kurt, F.G. Yildiz, H.N. Gunes, S. Erdem-Ozdamar, E. Tan
1ANKARA, TURKEY
<table>
<thead>
<tr>
<th>Abstract ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 11255</td>
<td>Spastic paraplegia and mutilating sensory neuropathy caused by mutation in FAM134B gene</td>
<td>S. Majid, S. Bohlega, D. Monies, S. Hagas, A. Al Qahtani, B. Meyer</td>
<td>RIYADH, SAUDI ARABIA</td>
</tr>
<tr>
<td>P 11256</td>
<td>A tropical polyneuropathy in a European country</td>
<td>M. Branco, L. Ruano, R. Taipa, M. Melo Pires, V.T. Cruz, M. Lopes</td>
<td>SANTA MARIA DA FEIRA, PORTO, PORTUGAL</td>
</tr>
<tr>
<td>P 11257</td>
<td>Non-systemic vasculitic neuropathy manifested as transient multiple mononeuropathy</td>
<td>J. Castelo, R. Taipa, M. Melo Pires, C. Santos</td>
<td>SANTA MARIA DA FEIRA, PORTO, PORTUGAL</td>
</tr>
<tr>
<td>P 11258</td>
<td>Distal sensory polyneuropathy with orthostatic syncopes: Transthyretin-related amyloid polyneuropathy</td>
<td>W. Heide, L. Langfeldt, M. Trauscheid</td>
<td>CELLE, GERMANY</td>
</tr>
<tr>
<td>P 11259</td>
<td>Evolution of sleep-disordered breathing following acute ischemic stroke and TIA and its impact on neurological outcome at 3 months (SAS Care Study)</td>
<td>S. Ott, F. Fanfulla, S. Miano, T. Horvath, A. Seiler, A.-K. Brill, C. Bernasconi, C. Cereda, P. Young, L. Nobili, M. Manconi, C. Bassetti</td>
<td>BERNE, PRAGUE, CZECH REPUBLIC, KOSICE, SLOVAKIA</td>
</tr>
<tr>
<td>P 11260</td>
<td>Polysomnographic findings in craniopharyngioma patients: a controlled study</td>
<td>L. Pickering, M. Klose, U. Feldt-Rasmussen, P. Jennum</td>
<td>GLOSTRUP, COPENHAGEN, DENMARK</td>
</tr>
<tr>
<td>P 11261</td>
<td>Polysomnographic predictors of mortality in stroke patients</td>
<td>L. Ponsaing, H.K. Iversen, P. Jennum</td>
<td>GLOSTRUP, COPENHAGEN, DENMARK</td>
</tr>
<tr>
<td>P 11262</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 11263</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 11264</td>
<td>Vagus nerve stimulation-induced catathrenia</td>
<td>M. Santos, T. Teodoro, R. Peralta, C. Bentes</td>
<td>LISBON, PORTUGAL</td>
</tr>
<tr>
<td>P 11265</td>
<td>Driving simulation as a clinical tool to assess fitness-to-drive in sleepy patients</td>
<td>D. Schreier, C. Banks, J. Mathis</td>
<td>BERNE, SWITZERLAND, LONDON, UK</td>
</tr>
<tr>
<td>P 11268</td>
<td>Influence of high altitude on periodic leg movements during sleep in individuals with restless legs syndrome and healthy controls: a pilot study</td>
<td>A. Stefani, A. Heidbreder, H. Hackner, M. Burtscher, B. Högl</td>
<td>INNSBRUCK, AUSTRIA</td>
</tr>
<tr>
<td>P 11269</td>
<td>Evaluating the effect of night-shift working on sleep and attention of nurse professionals</td>
<td>G.H. Tomasi, A.B. Tomasi, M.D. Soldatelli, J. Lin</td>
<td>PORTO, ALEGRE, TUBARAO, BRAZIL</td>
</tr>
<tr>
<td>P 11270</td>
<td>Is HPV (human papilloma virus) vaccine associated with later onset of narcolepsy type 1?</td>
<td>E.W. Torstensen, L. Schoubo Brinth, J. Mehlsen, P.J. Jennum</td>
<td>GLOSTRUP, FREDERIKSBERG, DENMARK</td>
</tr>
<tr>
<td>P 11271</td>
<td>The degree of anxiety and depression in patients with insomnia versus patients with obstructive sleep apnea syndrome</td>
<td>V. Vovc, A. Lupusor, I. Moldovanu, I. CHISINAU, MOLDOVA</td>
<td></td>
</tr>
<tr>
<td>P 11272</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 11273</td>
<td>REM sleep behaviour screening questionnaire (RBDSQ): validation study</td>
<td>B. Ziso, A. Larner</td>
<td>LIVERPOOL, UK</td>
</tr>
</tbody>
</table>
POSTER SESSION
SPINAL CORD AND ROOT DISORDERS
12:30 - 13:15 | SCREEN E2
CHAIRPERSON:
Josef Bednarik, BRNO-BOHUNICE, CZECH REPUBLIC (TBC)

P 11274  Longitudinal extensive transverse myelitis: a rare complication of Varicella-Zoster virus reactivation in an immunocompetent individual
S. Abbas, J. El Helou, H. Hilal, G. Eid, G. Saliba | BEIRUT, LEBANON

P 11275  Epidemiology and imaging characteristics of degenerative cervical cord compression

P 11276  Acute inflammatory myelitis: 8-year retrospective study
L. Braz, C. Andrade, M.J. Sá, J. Guimaraes | PORTO, PORTUGAL

P 11277  Spinal dural arteriovenous Fistulas - diagnosis, endovascular treatment and outcome
A. Ciobotaru, O. Rusu, A.C. Mergeani, C. Coclitu, F. Antochi, O. Bajenaru, B. Dorobat, A. Dimitriade | BUCHAREST, ROMANIA

P 11278  Abstract cancelled

P 11279  Longitudinally extensive transverse myelitis in neuromyelitis optica and Sjögren’s syndrome: a case report

P 11280  Single vertebral manipulative therapy (Kitchener’s Technique): a new technique for treatment of acute and subacute spinal root compression
N. Kitchener | CAIRO, EGYPT

P 11281  Use of electromyography to evaluate recovery in patients with chronic and complete spinal cord injury who received combined therapy: Neurorehabilitation and autologous neural stem cell implant
M.T. Moviglia Brandalino, G.A. Moviglia, G. Albanese, S. Piccone | CIUDAD AUTONOMA DE BUENOS AIRES, ARGENTINA

P 11282  Bilateral involvement in three patients with Hirayama disease
K. Okamoto, M. Amari, M. Takatama | MAEBASHI, JAPAN

P 11283  Are patients receiving spinal surgery at higher risk for multiple-drug resistant urinary infections?
M. Ricco | TRENTO, TRENTO, PIACENZA, ITALY

P 11284  Hirayama disease: a not so rare neither so idiopathic non-progressive, juvenile spinal muscular atrophy of the upper limbs
M. Ricco, S. Cattani | TRENTO, PARMA, ITALY

P 11285  Electromyography and muscle biopsy of paraspinal muscles in adolescent idiopathic scoliosis
I. Štětkářová, J. Zamecník, V. Bocek, P. Vasko, K. Břabec, M. Krbeč | PRAGUE, CZECH REPUBLIC

P 11286  Going to the root of the problem: Horner syndrome caused by T1-T2 disc herniation
M. Tóbuas-Pereira, J. Parra, C. Januário | COIMBRA, PORTUGAL
POSTER SESSION
AGEING AND DEMENTIA 2
13:30-14:15 | SCREEN A2
CHAIRPERSON:
Dorota Religa, STOCKHOLM, SWEDEN

P 12001 Cognitive impairment as a predictor of functional decline after hospitalisation, DECOFIRH STUDY
A. de Albóniga-Chindurza, C. Anciones, F. Acebrón, C. Guirao, D. Ibáñez, P. Roiz, P. Pérez, G. García-Ribas I MADRID, SPAIN

P 12002 Pathological gambling: an uncommon onset of frontotemporal dementia
F. de Marchi, G. Tondo, M. Sacchetti, E. Terazzi, R. Cantello I NOVARA, ITALY

P 12003 Real-world Alzheimer’s disease drug treatment – 18-month results from an observational study in three European countries (GERAS)
C. Reed1, J. Lebrec2, G. Dell’agnello1 I WINDLESHAM, UK, 1BAD HOMBURG, GERMANY, 2SESTO FIORENTINO, ITALY

P 12004 Family C9ORF72 mutation revealed by a severe catatonia syndrome
A. Dormeuil, Y. Chen, S. Bombois I LILLE, FRANCE

P 12005 Alzheimer’s disease with or without the co-occurrence of other neurodegenerative diseases: Distinct clinical and neuropathological phenotypes? A preliminary survey
B. Dufournet, A. Maues de Paula, M. Ceccaldi I MARSEILLES, FRANCE

P 12006 Deviant driving measures of healthy controls, MCI and AD patients in simulated driving

P 12007 Midlife coffee drinking and dementia-related brain changes on MRI up to 28 years later
M. Eskelinén1, G. Spulber1, T. Ngandu2, M. Kivipelto3, H. Soininen1, A. Solomon1 I 1KUOPIO, 2HELSINKI, FINLAND, 3STOCKHOLM, SWEDEN

P 12008 Effect of moderate–high intensity aerobic exercise on cortical beta-amyloid accumulation measured with 11C-PIB-PET in patients with mild Alzheimer’s disease
K.S. Frederiksen1, K. Madsen1, B.B. Andersen1, N. Beyer1, E. Garde1, P. Hegh2, G. Waldemar1, S.G. Hasselbalch1, J. Law1 1COPENHAGEN, 2ROSILDE, DENMARK

P 12009 Effect of moderate-to-high intensity aerobic exercise on hippocampus and cortical regions in patients with mild Alzheimer’s disease
K.S. Frederiksen1, C.T. Larsen1, A.N. Christensen1, S. Hasselbalch1, P. Hegh2, L. Wermuth1, A. Lolk1, B.B. Andersen1, H.R. Siebner1, G. Waldemar1, E. Garde1 1COPENHAGEN, 2ROSILDE, DENMARK

P 12010 Appraisal of the utility of the AIT appropriate use criteria of the amyloid-PET
M. Boccardi1, D. Altomare1, U. Guarra1, M. Pievani1, E. Albanese1, C. Festari1, L. Antelmi2, P. Pasqualetti3, C. Muscio1, F. Nobili1, A. Padovani1, G. Frisoni1 I 1BRESCIA, 2ROME, 3GENOA, ITALY

P 12011 The incremental diagnostic value of 18F-Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the INDIA-FBP study
D. Altomare1, M. Boccardi1, C. Ferrari1, C. Festari1, L. Antelmi2, A. Tarallo1, P. Pasqualetti2, C. Muscio1, U. Guarra1, B. Paghera1, A. Padovani1, G. Frisoni1 I 1BRESCIA, 2ROME, ITALY, 3GENEA, SWITZERLAND

POSTER SESSION
AUTONOMIC NERVOUS SYSTEM 2
13:30-14:15 | SCREEN B1
CHAIRPERSON:
Josef Zeitlhofer, VIENNA, AUSTRIA (TBC)

P 12012 Primary progressive aphasia as presentation of frontotemporal lobar degeneration due to novel GRN g.1642_1645delTGAG mutation
D. Galimberti1, S. Cioffi1, C. Fenoglio1, M. Serpente1, M. Hagen2, A. Oblak3, F. Rodriguez-Porcel1, E. Oldoni1, M. Arcaro1, E. Scarpini1, B. Ghetto1, A. Espay2 I 1MILAN, ITALY, 2CINCINNATI, 3INDIANAPOLIS, USA

P 12013 Abstract cancelled

P 12014 The correlation of response between the Valsalva maneuver and head-up tilt table test
J.-J. Lee I DAEGU, KOREA, REPUBLIC OF

P 12015 Jasmine stimulation mitigates sympathetic and augments parasympathetic cardiovascular modulation in patients with a history of moderate or severe traumatic brain injury
M. Liu1, R. Wang2, F. Canavesi1, C. de Rojas Leal1, K. Höfl1, T. Hummel1, M. Hilz1 I 1ERLANGEN, 2NUREMBERG, GERMANY

P 12016 Abstract cancelled
POSTER SESSIONS

SATURDAY, 28 MAY
13:30 - 14:15

P 12017  Cardiovascular autonomic involvement in Holmes-Adie-Ross spectrum

P 12018  Abstract cancelled

P 12019  Fatigue in multiple sclerosis associates with autonomic dysfunction
O. Tolson, J. Guadagno, J. Newton  I NEWCASTLE, UK

P 12020  Cardiac autonomic modulation changes within one hour after Fingolimod-initiation
R. Wang1, C. de Rojas Leal1, M. Liu1, F. Canavese1, K. Hösl2, D.-H. Lee1, R. Linker1, M. Hilz1  I ERLANGEN, 2NUREMBERG, GERMANY

P 12021  Neurological manifestations revealing a cerebral lymphoma
N. Yenqui, I. Ben Abdelaziz, B. Ayadi, E. Farhat, M. Zouari, F. Hentati  I TUNIS, TUNISIA

P 12022  The disparity of patient-reported symptoms of autonomic dysfunction and objective autonomic nervous system testing in multiple sclerosis
I. Zadro1, L. Crnošija1, B. Barun1, A. Junaković1, I. Lušić2, I. Adamec1, M. Habeck1  I ZAGREB, -SPLIT, CROATIA

P 12023  The influence of arousals, periodic leg movements, detected by EMG and 3D-videosomnography and heart-rate variability on non-restorative sleep
J. Zeitlhofer, H. Garn, B. Kohn, P. Hauschild, R. Stepansky, A. Stefanić, M. Boeck, M. Kemethofer, D. Grossegger, S. Seidel, G. Kloesch  I VIENNA, AUSTRIA

POSTER SESSION CEREBROVASCULAR DISEASES 4
13:30-14:15 | SCREEN G1

CHAIRPERSON:
Christine Kremer, MALMO, SWEDEN

P 12024  Association between mycoplasma pneumonia and increased risk of ischemic stroke: a case report
S. Benghanem, C. Rosso, A. Leger, J. Haroche, Y. Samson  I PARIS, FRANCE

P 12025  Balint’s syndrome after cardiac catheterisation: an unusual presentation of stroke
F. Bernardo, Á. Timóteo, A.N. Pinto  I AMADORA, PORTUGAL

P 12026  CADASIL frequency in patients with leukoencephalopathy
J. Buczek, B. Blazejewksa-Hyżorek, K. Gramza, A. Cudna, I. Kurkowska-Jastrzebska  I WARSAW, POLAND

P 12027  Football: passion, indifference or vascular risk?
C. Borbinha, J.P. Marto, L. Conceição, L. Alves, S.L. Calado, M. Viana-Baptista  I LISBON, PORTUGAL

P 12028  Abstract cancelled

P 12029  Syndrome of the trephined: a case report related to atmospheric pressure changes

P 12030  Ventricular myxoma as a cause of vertebrobasilar stroke
J.J. Bravo, M.J. Corrales Arroyo, N. Giraldo, A. Parralo, S. Carrasco García de León  I CIUDAD REAL, SPAIN

P 12031  Uric acid in acute ischemic stroke prognosis
F. H. Cabrera Naranjo1, M. Sosa Henriquez2, P. Saavedra Santana1, A. Gonzalez Hernandez2, Ó. Fabre Pi1  I 1LAS PALMAS DE GC, 2LAS PALMAS, SPAIN

P 12032  Syncope and neurological signs: double trouble?
E. Campos Costa, E. Guevara, M. Rodrigues  I ALMADA, PORTUGAL

P 12033  Headache associated with acute stroke is less frequent in patients treated with intravenous recombinant tissue-type plasminogen activator treatment

P 12034  Reversible posterior leukoencephalopathy syndrome (RPLS) associated to therapy with sunitinib: first Italian case report and review of the literature
M. Cavalli, L. Saraceno, G. Bosco, G. Meola  I MILAN, ITALY

P 12035  Abstract cancelled

P 12036  Abstract cancelled

P 12037  Risk factors for stroke-related pain and its variants in acute period ischemic stroke
T. Cherenko, O. Markulan L Sokolova  I KIEV, UKRAINE
**POSTER SESSION**  
**CEREBROVASCULAR DISEASES 5**  
**13:30-14:15 | SCREEN G3**  
**CHAIRPERSON:** Urs Fischer, Bern, Switzerland

**P 12038** Ischaemic stroke as presenting manifestation of a paraneoplastic granulomatous vasculitis  
A. Ekmen, C. Rosso, F. Baroynet Chauvet, S. Crozier, A. Léger, D. Leclercq, Y. Samson | Paris, France

**P 12039** Clinical and prognostic impact of radiological parenchymal abnormalities associated with cerebral venous thrombosis  

**P 12040** Brain vascular lesions, gait and balance  

**P 12041** Abstract cancelled

**P 12042** Spinal epidural haematoma during apixaban treatment  

**P 12043** Transient ischemic attack mimics in older patients with convexity subarachnoid hemorrhage: an early feature of cerebral amyloid angiopathy  
S. Evain, B. Guillon, S. de Gaalon, P. Derkinderen, M. Sevin | Nantes, France

**P 12044** How good is primary prevention of patients with known atrial fibrillation and a first-ever stroke  
Ó. Fabre Pi, A. Gonzalez Hernandez, F. H. Cabrera Naranjo, Y. Miranda Bacallado, M. Viana-Baptista | Las Palmas de Gran Canaria, Spain

**P 12045** HTRA1 expression in HTRA1 gene mutation carriers  
P. Formichi, A. Fasano, S. Bianchi, M. T. Dotti, A. Federico | Sienna, Italy

**P 12046** Cerebral venous sinus thrombosis complicated with venous infarction with hemorrhagic transformation, sub-arachnoid hemorrhage and subdural hematoma – are NOAC safe?  
A. Félix, A. Andre, H. Nzwalo | Faro, Portugal

**P 12047** A case of posterior reversible encephalopathy syndrome with isolated pons involvement in a patient with Turner syndrome  
M. Ferrara, M. P. Di Viesti, M. V. Inchingola, M. R. Latino, M. T. Popolizio, M. Leone | San Giovanni Rotondo (FG), Italy

**P 12048** Does antiplatelet therapy during bridging thrombolysis increase rates of intracerebral hemorrhage in stroke patients?  

**P 12049** Simultaneous acute both sided major trunk pulmonary artery embolism and ischemic stroke of left hemisphere. Successful multidisciplinary therapeutic collaboration  

**P 12050** Bilateral middle cerebellar peduncles ischemia due to large vessel arteritis  
A. Franco, S. Reimão, L. Neto, J. M. M. C. Ferro, T. Pinho E Melo | Lisbon, Portugal

**P 12051** Do patients with stroke and newly diagnosed atrial fibrillation have benefit from prior treatment with acetylsalicylic acid?  
I. Friedrich, P. Crnac, H. Budincevic | Zagreb, Croatia

**POSTER SESSION**  
**CLINICAL NEUROPHYSIOLOGY 2**  
**13:30-14:15 | SCREEN H2**  
**CHAIRPERSON:** Martin Rakusa, Maribor, Slovenia

**P 12052** The N100 potential in pattern reversal VEP: incidence and consequences for P100 interpretation  
W. H. Mess, N. Bauer, D. Hilkman, J. Reulen | Maastricht, Netherlands

**P 12053** The burst-suppression EEG pattern in comatose children is reactive to photic stimulation  
D. Nita, M. Moldovan, R. Sharma, S. Avramescu, H. Otsubo, C. Hahn | Toronto, Canada, Copenhagen, Denmark
CORTICOSPINAL RESERVE AND DISABILITY PREDICT EFFICACY OF REPEATED TRANSCRANIAL STIMULATION ON WALKING ABILITIES IN PEOPLE WITH PROGRESSIVE MULTIPLE SCLEROSIS UNDERGOING REHABILITATION

A. Nuara1, R. Chieffo1, M. Fichera1, F. Esposito1, F.G. Martinelli Boneschi1, M. Radaelli1, A. Zangen2, M. Comola1, G. Comi1, L. Leocani1 1MILAN, ITALY, 2BEER-SHEVA, ISRAEL

P 12055  Motor Unit Number index (MUNIX) of six muscles: normal values and effects of age and gender

T.A. Omer, G. Mullins, O. Hardiman 1DUBLIN, IRELAND

P 12056  The number of events in the EEG is significantly lower in dementia

Z. Pavelek1, J. Kuchynka1, F. Casberger1, O. Vyšata1, A. Procházková1, M. Valíščik1 1HRADEC KRÁLOVÉ, 2PRAGUE, CZECH REPUBLIC

P 12057  Intraoperative neurophysiological monitoring in transpedicle fixation at lumbosacral level

M. Podgurskaia1, V. Lebedev, D. Ivanova, O. Vinogradov, E. Plastunenko, A. Tishuk, D. Epifanov1 1MOSCOW, RUSSIAN FEDERATION

P 12058  Proposal for electrodiagnostic evaluation of patients with suspected ulnar neuropathy at the elbow

G. Omejec, S. Podnar 1LJUBLJANA, SLOVENIA

P 12059  Wide prefrontal and sensory-motor network involvement in the preparation of the choice in comparison to the simple reaching

M. Rakusa1, P. Busan2, P.P. Battaglini3, B. Koritnik2, J. Zidar2 1MARIBOR, 2LJUBLJANA, SLOVENIA, 3TRIESTE, ITALY

P 12060  Repeater F-waves in ALS

D. Veletsista, C. Papapavlou, E. Chroni 1PATRAS, GREECE

P 12061  Asymmetric sensory nerve action potential amplitudes as an early hint for diagnosing Lewis-Sumner Syndrome

M.I. Yan, H.N. Günes, B. Gökcê Çokal, C.S. Demircan, S. Keskin Guler, C. Ataç Uçar, T. Yöldas 1ANKARA, TURKEY

P 12062  Searching for electroencephalographic markers for use in long-term brain monitoring

J. Zibrandtsen1, P. Kidmose2, M. Otto2, J. Ibsen2, T. Kjaer1 1ROSKILDE, 2AARHUS, DENMARK

POSTER SESSION

EPILEPSY 3

13:30-14:15 | SCREEN B2

CHAIRPERSON: Phillippe Ryvlin, LAUSANNE, SWITZERLAND

P 12063  The influence of antiepileptic drugs in the lipid profile in patients with vascular epilepsy

I.-R. Carcalici1, A. Lazaroae, G. Cioca, C. Roman-Filip 1SIBIU, ROMANIA

P 12064  Continuous thetaburst stimulation for the treatment of refractory epilepsy: a case report

S. Carrette1, D. Klooster2, L. Nollet1, R. Duprat1, W. Stajansens1, P. van Mierlo1, A. van Dycke2, E. Carrette1, R. Roedt1, A. Meurs1, C. Baeken1, K. Vonck1, P.A. Boon1 1GHENT, 2BRUGES, BELGIUM, 3HEEZE, NETHERLANDS

P 12065  Abstract cancelled

P 12066  Prognostic factor of Status epilepticus patients in Korea

S.-H. Chae, J. Han, M.-K. Kim, J.W. Cho 1YANGSAN, KOREA, REPUBLIC OF

P 12067  Serotonin receptors in genetic generalized epilepsies


P 12068  Fear of the dentist, a new form of reflex epilepsy?

R. de Jong, T. Schreuder 1HEERLEN, NETHERLANDS

P 12069  Perampanel in the clinical practice. Data after one year of treatment

M. de Toledo1, I. Garamendi Ruiz2, M.E. Garcia-Garcia1, V. Bertol1, J.A. Mauri Llerda1, A.B. Gago-Veiga1, A. Marinas Alejo3, I. Garcia Morales1, V. Garayoa Iriogeny2, V. Garcia Morales1, M.J. Garcia Gomara1, M. Agündez Sarasola1, S. Santos Lasoasa1, C. Arcos Sánchez1, I. Escolza Cortina1, E. Rueda1, M. Gómez Equilaz1, I. Aranzabal Alustiza2, J.A. Olivan Usieto1, L. Diaz de Cerio Julian1, J.C. Gómez Esteban2 1MADRID, 2BARACALDO, 3SARAGOSSA, SPAIN

P 12061  Asymmetric sensory nerve action potential amplitudes as an early hint for diagnosing Lewis-Sumner Syndrome

M. de Toledo1, I. Garamendi Ruiz2, M.E. Garcia-Garcia1, V. Bertol1, J.A. Mauri Llerda1, A.B. Gago-Veiga1, A. Marinas Alejo3, I. Garcia Morales1, V. Garayoa Iriogeny2, V. Garcia Morales1, M.J. Garcia Gomara1, M. Agündez Sarasola1, S. Santos Lasoasa1, C. Arcos Sánchez1, I. Escolza Cortina1, E. Rueda1, M. Gómez Equilaz1, I. Aranzabal Alustiza2, J.A. Olivan Usieto1, L. Diaz de Cerio Julian1, J.C. Gómez Esteban2 1MADRID, 2BARACALDO, 3SARAGOSSA, SPAIN
POSTER SESSIONS

SATURDAY, 28 MAY

13:30 - 14:15

POSTER SESSION HEADACHE AND PAIN 2
13:30 - 14:15 | SCREEN C1

CHAIRPERSON:
Troels Staehlin Jensen, AARHUS, DENMARK

P 12070  An epileptic patient presented with atypical perivascular space
S. Demir, E. Togrol, C. Kafadar, M.F. Özdağ | ISTANBUL, TURKEY

P 12071  Differences between mesial and neocortical magnetic resonance imaging negative temporal lobe epilepsy
I. Doležalová | BRNO, CZECH REPUBLIC

P 12072  Adult onset continuous partial epilepsy and acute unilateral hemispheric involvement. What is the diagnosis?
C. Duwicquet, C. Mouthon Reigner, J. Biberon, B. de Toffol, N. Limousin | TOURS, FRANCE

P 12073  Abstract cancelled

P 12074 Transient amnesic syndromes. The challenge to explain forgetfulness
T. Liano Sanchez, M.E. Garcia Garcia, B. Parejo Carbonell, B. Abarrategui, D. Toledo Alfocea, I. Garcia Morales | MADRID, SPAIN

P 12075  The relationship between frequency of seizures, number of antiepileptic medications with anxiety, depression and quality of life (QoL) issues
G. Zemgulyte, G. Jurkeviciene, K. Lauckaite | KAUNAS, LITHUANIA

P 12076  Intercital cortex excitability in transcranial magnetic stimulation of migraine and chronic tension type headache
J.H. Han¹, D.E. Kim¹, S.W. Han¹, J.J. Joo² | SEOUL, KOREA, REPUBLIC OF; GUMI, KOREA, REPUBLIC OF

P 12077  Management of headaches and sleep disturbances in patients with consequences of traumatic brain injury
I. Iakubenko, T. Litovchenko, O. Zavalna, L. Shevchenko | KHARKIV, UKRAINE

P 12078  Paroxysmal hemicrania evolving to cluster headache: a resistant case
L.E. Inan, C. Ataç-Uçar, H.A. Unal-Artik, S. Akin-Takmaz | ANKARA, TURKEY

P 12079  Treatment of status migrainosus with local anesthetics
L.E. Inan, H.A. Unal-Artik, C. Ataç-Uçar, N. Inan | ANKARA, TURKEY

P 12080  Personality traits in fibromyalgia patients with paresthetic complaints
O. Balbaloglu¹, N. Tanik¹, M. Alpayci², H. Ak¹, E. Karaahmet³, L.E. Inan¹ | YOZGAT, IVAN, İÇANAKKALE, TURKEY

P 12081  Botulinum toxin in chronic refractory migraine: is the effect of IncobotulinumtoxinA (XEOMIN®) sustained?
I.M. Ion¹, A. Le Floch¹, M.M. de Verdal¹, M.A. Lozza², M.P.E. Thouvenot¹, G. Castelnovo¹ | NÎMES, FRANCE; PAVIA, ITALY

P 12082  Depression and anxiety as comorbidities in migraine
J. Jesus Ribeiro, A.M. Novo, L. Sousa, S. Batista | COIMBRA, PORTUGAL

P 12083  Peripheral nerve blocks in the treatment of migraine in pregnancy and breastfeeding: experience in a series of 23 patients

P 12084  Primary headache associated with sexual activity: clinical characteristics in a series of 17 cases

P 12085  Fibromyalgia is more prevalent in migraine with aura: a cross-sectional study
F. Khorvash | ISFAHAN, IRAN, ISLAMIC REPUBLIC OF

P 12086  Migraine and irritable bowel syndrome: an epidemiological study
M. Ghasemi, F. Khorvash, S. Mirzaei, S. Memar Montazerin, M. Khazaellî | ISFAHAN, IRAN, ISLAMIC REPUBLIC OF

P 12087  Vertebrogenic cervicalgia as a risk factor for pathological deformation of the main arteries of the brain and their neurological symptoms in young people
S. Khudayarova, G. Rakhmatullava, K. Khalimova | TASHKENT, UZBEKISTAN

P 12088  Microstructural and metabolic abnormalities on migraine
K. Sadokha, V. Kistsen, V. Evstigneev, R. Sakovich | MINSK, BELARUS
POSTER SESSIONS

SATURDAY, 28 MAY
13:30 - 14:15

P12089 Epidemiology of vertebrogenic pain syndromes
I. Vyshlova, I. Azoidis, S. Karpov | STAVROPOL, RUSSIAN FEDERATION

P12088 Abstract cancelled

P12089 Sleep in essential tremor patients: a polysomnographic study
O. Dogu, S. Ozal, H. Kaleagasi | MERSIN, TURKEY

P12100 The frequency of copper deficiency due to overtreatment in Wilson’s disease patients
K. Dziezyc, A. Sobanska, T. Litwin, M. Rakowicz, A. Czlonkowska | WARSAW, POLAND

P12101 Deviant driving measures and variability of Parkinson’s disease patients and healthy controls in simulated driving

P12102 Prevalence and characteristics of impulse control disorders in Parkinson’s disease

POSTER SESSION
MOVEMENT DISORDERS 2
13:30-14:15 | SCREEN E4
CHAIRPERSON
Christer Nilsson, LUND, SWEDEN

P12090 Validation of the University of Pennsylvania Smell Identification Test (UPSIT-40) in Greek Parkinson’s disease patients and healthy controls
E. Boura, T. Goiltzoglou, D. Tsilikakis, D. Karakostas, N. Grigoriadis | THESSALONIKI, GREECE

P12091 The effects of visual cues on gait in Parkinson’s disease patients with DBS

P12092 Quality of life in Parkinson’s disease: impact of non-motor symptoms
M. Calejo, A. Gonçalves, I. Moreira, N.M.D.S. Vila-Chã, J. Damasio, A. Bastos Lima, S. Cavaco, A. Mendes, J. Fernandes | PORTO, PORTUGAL

P12093 Longitudinal clinical and brain MRI changes in multiple system atrophy
F. Caso1, F. Agosta1, I. Nikolic2, M. Ječmenica Lukić2, I. Petrović2, I. Stanković2, M. Filippi1 | 1BELGRADE, SERBIA

P12094 Efficacy of safinamide on motor and non-motor symptoms in fluctuating Parkinson’s disease patients
C. Cattaneo1, E. Bonizzoni2, M. Sardina3
N. Grigoriadis | 1BRESSO (MILAN), 2MILAN, ITALY

P12095 Abstract cancelled

P12096 Tyrosine Hydroxylase variant associates with motor disability in de-novo Parkinson’s patients
J. Kraemmer, F. Cormier-Dequaire, V. Guillemot, F. Danjou, A. Brice, J-C. Corvol | PARIS, FRANCE

P12097 Late onset ophthalmoplegia and parkinsonism due to a novel POLG mutation
A. de Pue, P. Santens | GHENT, BELGIUM

P12098 Abstract cancelled

P12099 Sleep in essential tremor patients: a polysomnographic study
O. Dogu, S. Ozal, H. Kaleagasi | MERSIN, TURKEY

P12100 The frequency of copper deficiency due to overtreatment in Wilson’s disease patients
K. Dziezyc, A. Sobanska, T. Litwin, M. Rakowicz, A. Czlonkowska | WARSAW, POLAND

P12101 Deviant driving measures and variability of Parkinson’s disease patients and healthy controls in simulated driving

P12102 Prevalence and characteristics of impulse control disorders in Parkinson’s disease

POSTER SESSION
MOVEMENT DISORDERS 3
13:30-14:15 | SCREEN E3
CHAIRPERSON
Espen Dietrichs, OSLO, NORWAY

P12103 Glucocerebrosidase activity in a cohort of PD patients
I. Trezzi, V. Melzi, G. Franco, L. Borellini, E. Monfrini, A. Bordoni, N. Bresolin, G.P. Comi, A.B. Di Fonzo | MILAN, ITALY

P12104 Frequency of the dopamine dysregulation syndrome and risk factors for its development in Slovenian Parkinson’s disease patients
V. Šet, J. Šinkovec, Z. Pirtošek, M. Trošt | LJUBLJANA, SLOVENIA

P12105 Abstract cancelled
P 12106  Hemichorea due to hyperosmolar nonketotic hyperglycemia

P 12107  Email in a Movement Disorders clinic: answers one click away

P 12108  Sleep problems in dystonia patients and influence of deep brain stimulation
V. Vuletić I ZAGREB, CROATIA

P 12109  Abstract cancelled

P 12110  The efficacy of combination 123I-FP-CIT and 123I-MIBG in Parkinson syndrome

P 12111  Correlation between duration of Parkinson’s disease and development of non-motor symptoms in a Siberian region

P 12112  Sleep disturbances in Parkinson’s disease patients
L. Žonic, O. Sinanović I TUZLA, BOSNIA AND HERZEGOVINA

P 12113  A case of the levitating hand: rapid progression of neurodegenerative disorder?
E. Župančič, M. Jožef, L. Savšek, G. Grande I LJUBLJANA, CELJE, SLOVENIA

POSTER SESSION MS AND RELATED DISORDERS 4
13:30-14:15 | SCREEN F1

P 12114  A case of neuromyelitis optica with optic neuritis, extensive cerebral and spinal cord lesions, associated with anti-Ku antibodies and complicated with toxocariasis
R. S. Badea, I. C. Cernat, A. Craciunoiu I BUCHAREST, ROMANIA

P 12115  Quality of life does not predict conversion from CIS to definite MS: a five-year prospective study

P 12116  Effect of organisational features on patient satisfaction with care in Italian Multiple Sclerosis centres
E. Baldin1, K. Mattarozzi1, C. Zenesini1, G. Franchino1, A. Solaro2, M. P. Amato1, M. Leone2, G. L. Mandeli3, V. Martinelli4, G. Savettileri5, C. Solaro6, M. R. Tola7, R. D’ Alessandro1, Agorà Study Group1 BOLOGNA, MILAN, FLORENCE, SAN GIOVANNI ROTONDO, GENOA, PALERMO, FERRARA, ITALY

P 12117  Anti-KIR4.1 antibodies as a biomarker for Multiple Sclerosis: difficulties and preliminary data
A. Bertolotto, P. Valentino, M. Caldano, F. Marnetto I ORBASSANO, ITALY

P 12118  Abstract cancelled

P 12119  Clinical trial subjects with relapsing-remitting multiple sclerosis in Russia have more advanced disease and/or higher disease activity than those enrolled in broader international trials: demographic evaluation of the RUSTYS trial of natalizumab
A. Boyko1, E. Evdoshenko2, O. Vorobyeva1, V. Pukaite3 I MOSCOW, SAINT PETERSBURG, RUSSIAN FEDERATION, ZUG, SWITZERLAND

P 12120  Therapeutic plasma exchange treatment in an aggressive tumefactive multiple sclerosis patient
M. Yucel, A. Çetiz, O. Boyraz, O. Altay, S. Alay, S. Demirkaya I ANKARA, TURKEY

P 12121  Value of cerebrospinal fluid oligoclonal bands in current everyday practice: analysis of a CIS patients cohort
L. Braz, L. Carvalho, M. J. Sá, J. Guimaraes I PORTO, PORTUGAL
SATURDAY, 28 MAY
13:30 - 14:15

**P 12122** Progression of idiopathic optic neuritis to multiple sclerosis in a population of 93 patients from the North of Portugal
L. Braz, J. Máximo, C. Andrade, M.J. Sá, J. Guimaraes | PORTO, PORTUGAL

**P 12123** Repeated episodes of status epilepticus correspond with severity of multiple sclerosis and can also indicate double pathology
T. Brede, E. Kantorova, E. Kurca, K. Zeleneňák, L. Plank | MARTIN, SLOVAKIA

**P 12124** Zinc in multiple sclerosis – a systematic review and meta-analysis
M. Bredholt | GLOSTRUP, DENMARK

**P 12125** Clinical features of patients with relapsing inflammatory optic neuropathy
A. Çakar, H.I. Akçay, T. Gunduz, M. Kürtüncü, M. Eraksoy | İSTANBUL, TURKEY

**P 12126** Abstract cancelled

**POSTER SESSION MS AND RELATED DISORDERS 5**
13:30-14:15 | ROOM: SCREEN F2

CHAIRPERSON
Hans Lassmann, VIENNA, AUSTRIA

**P 12127** The risk of multiple sclerosis: a possible role of an interaction of the age of infections and a specific dietary factor at young age
K. J. Lauer¹, A. Wahl², M. Geilenkeuser³ | ¹GRIESHEIM, ²DARMSTADT, ³OBER-RAMSTADT, GERMANY

**P 12128** First dose effects of fingolimod: in depth electrocardiographic analysis confirms first dose observation is usually uneventful
V. Limrroth¹, W. Haverkamp², R. Dechend³, M. Lang³, J. Haas⁴, B. Wagner⁵, S. Richter⁶, H. Schieb⁷, G. Wendt⁸, T. Ziemssen⁹ | ¹COLOGNE, ²BERLIN, ³ULM, ⁴STUTTGART, ⁵NUREMBERG, ⁶DRESDEN, GERMANY

**P 12129** Treatment-naive patients who had highly active relapsing–remitting multiple sclerosis at baseline demonstrate persistent suppression of MRI activity and brain atrophy with alemtuzumab over 5 years
V. Limrroth¹, P. Vermersch², J. Lycke³, B. Singer⁴, S. Krieger⁵, D.H. Margolin⁶, K. Thangavelu⁶, A. Traboulsee⁷, On Behalf Of The Care-Ms I Investigators⁸ | ¹COLOGNE, GERMANY, ²ULLE, FRANCE, ³GOTHENBURG, SWEDEN, ⁴ST LOUIS, ⁵NEW YORK, ⁶CAMBRIDGE, USA, ⁷VANCOUVER, CANADA, ⁸COPENHAGEN, DENMARK

**P 12130** Are eyes with and without history of optic neuritis in multiple sclerosis aging differently?
J. Lizrova Preingererova, L. Sobisek, P. Kuthan, P. Diblik, E. Havrdova | PRAGUE, CZECH REPUBLIC

**P 12131** Nasal RNFL segment thickness correlates best with corpus callosum atrophy in multiple sclerosis

**P 12132** The plasma values of 8-OH-deoxyguanosine and neurofilaments correlate with clinical and radiological features of initial and relapsed demyelinating attacks
S. Ljubisavljevic, I. Stojanovic, S. Vojinovic, D. Stojanov | NICE, SERBIA

**P 12133** Improved probabilistic segmentation of white matter lesions in multiple sclerosis
E. Lommers, G. Delrue, G. Reuter, P. Calay, V. Delvaux, P. Maquet, C. Phillips | LIEGE, BELGIUM

**P 12134** Effect of fampridine on cognitive performance in patients with multiple sclerosis

**P 12135** Infusion-associated reactions decline from the first to the second course of alemtuzumab in relapsing–remitting multiple sclerosis patients previously treated with SC IFNB-1a: CARE-MS extension study
J. Lycke¹, B. Khatri², B. Sharrack³, V. Brinar⁴, T. Miller⁵, D.H. Margolin⁶, K. Thangavelu⁶, L. Mayer⁷ | ¹GOTHENBURG, SWEDEN, ²SHEFFIELD, UK, ³ZAGREB, CROATIA, ⁴MILWAUKEE, ⁵FORT COLLINS, ⁶CAMBRIDGE, ⁷ROUND ROCK, USA

**P 12136** Month of birth effect on the risk of multiple sclerosis in Denmark
M. Magyari, N.J. Koch-Henriksen | COPENHAGEN, DENMARK

**P 12137** The effects of smoking on clinical evolution of multiple sclerosis patients treated with first line DMTs
M.-S. Maier, Z. Bajko, A. Motataianu, L. Bărcuţean, S. Voidăzan, R. Bălaşa | TÂRGU MUREŞ, ROMANIA

**P 12138** Vitamin D metabolic pathway abnormalities and risk of multiple sclerosis in patients with clinically isolated syndromes
P 12139  Autologous mesenchymal stem cells transplantation impacts on neurological deficiency development in patients with relapsing-remitting multiple sclerosis
Y. Maskouskikh, A. Fedulov, A. Borisov, M. Andreeva  I MINSK, BELARUS

P 12140  Stress from myasthenic crisis triggers Takotsubo (broken heart) syndrome
J. Finsterer, C. Stollberger  I VIENNA, AUSTRIA

P 12141  Affection of the respiratory muscles in combined complex I and IV deficiency
J. Finsterer, H. Rauscha, L. Segal, G. Kovacs  I VIENNA, AUSTRIA

P 12142  Polymyositis in antisynthetase syndrome: a piece of the puzzle
T. Geraldes, I. Cordeiro, I. Cruz, M.D. Grunho, A.C. Ribeiro  I ALMADA, PORTUGAL

P 12143  Symptomatic Duchenne Muscular Dystrophy (DMD) in a female carrier of mutated dystrophin gene
N. Giraldo Restrepo, A. Hernandez, J.J. Bravo, A. Parralo, A. Camacho, S. Carrasco García de León  I CIUDAD REAL, SPAIN

P 12144  Statin-induced necrotizing autoimmune myopathy: a case report
E. Gozke, Z. Aktan, P. Doğan Ak, I. Kalyoncu Aslan, P. Oflazer  I ISTANBUL, TURKEY

P 12145  Pregnancy in anti-MuSK myasthenia gravis

P 12146  Abstract cancelled

P 12147  Abstract cancelled

P 12148  Myasthenia Gravis: clinical and epidemiological approaches (cohort of 40 cases)

P 12149  A prospective natural history study of inclusion body myositis: baseline characteristics
P. Houston1, P. Machado2, A. Genge3, I. Scholten4, L. Lowes5, D. Laurent6, D. Papanicolau7, M. Hanna8  I BASEL, SWITZERLAND, 1LONDON, UK, 2QUEBEC, CANADA, 3COLUMBUS, 4EAST HANOVER, USA

P 12150  Worsening of Myasthenia Gravis after administration of injectable long-acting risperidone for treatment of schizophrenia: a first case report
I. Ismail  I KUWAIT, KUWAIT

P 12151  A Case of Myasthenia Gravis Presenting With Bilateral Facial Weakness and Bulbar Signs Without Extraocular Muscle Involvement
K.D. Jo, W. Jang, M.K. Lee  I GANGNEUNG, KOREA, REPUBLIC OF

P 12152  The combined use of 3D T1- and T2-weighted sequences improves cervical cord lesion detection in patients with multiple sclerosis: a multicenter study at 3T
M. Aboulwafa1, M.A. Rocca1, P. Valsasina1, F. Camesasca1, M. Copetti2, A. Rovira4, X. Montalban4, H. Kearney5, O. Ciccarelli6, L. Matthews6, J.A. Palace6, A. Gallo6, A. Bisecco7, C. Lukas7, B. Beilenga7, G. Comi, M. Filippi  I MILAN, 1SAN GIOVANNI ROTTONDO, 2NAPLES, ITALY, 3BARCELONA, SPAIN, 4LONDON, 5OXFORD, UK, 6BOCHUM, GERMANY

P 12153  3D-imaging applying in MRI for assessment of the pathological dynamics in patients with multiple sclerosis after autologous mesenchymal stem cells transplantation
M. Andreeva  I MINSK, BELARUS

P 12154  Imaging of vertebral artery: differentiation of hypoplasia from stenosis.
A. Azimov, G. Rakhimbaeva  I TASHKENT, UZBEKISTAN

P 12155  Functional connectome architecture of Alzheimer’s disease, mild cognitive impairment and behavioral variant of frontotemporal dementia: a graph analysis study
P 12156 Radiological findings in Behçet disease
M. Chraa, N. Kissani I MARRAKECH, MOROCCO

P 12157 Abstract cancelled

P 12158 Significance of voxel-based morphometry in studying mild cognitive impairment.
A. Damulina, R. Konovalov, A. Kadukov I MOSCOW, RUSSIAN Federation

P 12159 Structural connectivity in multiple sclerosis and simulation of disconnection
E. de Meo, M.A. Rocca, E. Pagani, B. Colombo, M. Rodegher, P. Preziosa, G. Comi, A. Falini, M. Filippi I MILAN, ITALY

P 12160 A PRES case developing in a young patient with a diagnosis of nephrotic syndrome after using cyclosporine
S. Demir, B. Öztürk, E. Togrol, H. Tekeli I ISTANBUL, TURKEY

P 12161 Reproducibility of resting state connectivity in patients with stable multiple sclerosis
D. Pinter, C. Beckmann, M. Koini, E. Pirker, N. Filippini, A. Pichler, S. Fuchs, F. Fazekas, C. Enzinger I GRAZ, AUSTRIA, 1NIJMEGEN, NETHERLANDS, 2OXFORD, UK

P 12162 Dynamics of cerebral blood flow in patients with non-ischemic heart failure

P 12163 Delayed leukoencephalopathy following acute methadone intoxication
S. Fastré, O. Rocrelle, M.-C. Duray, M. Gille I OTTIGNIES-LOUVAIEN-LA-NEUVE, BELGIUM

M.A. Rocca, P. Valsasina, A. Colombi, F. Pirro, E. Pagani, E. de Meo, B. Colombo, P. Preziosa, M. Rodegher, G. Comi, A. Falini, M. Filippi I MILAN, ITALY

P 12165 Diffusional Kurtosis Imaging Study in bilateral Substantia Nigra and Red Nucleus of Parkinson's Disease
X. Ma, J. Guan, R. Wu, Z. Cao I SHANTOU, CHINA

P 12166 Limbic encephalitis with GABA receptor antibodies
A. Andre, M. Shamasna, C. Basilio, A. Félix, M. Milheiro, H. Nzawolo I FARO, PORTUGAL

P 12167 CNS involvement in familial amyloidotic polyneuropathy: what mechanisms?
J. Araújo, J.N. Alves, C. Machado, V. Mendes, J. Pereira, J. Pinho I BRAGA, PORTUGAL

P 12168 Diagnosis of a new mutation for Ehlers Danlos Syndrome type IV in a patient with a spontaneous spinal subarachnoid haemorrhage

P 12169 Subacute tetraparesis mimicking Guillain-Barré syndrome in two cases of acute intermittent porphyria
A.A. Arbune, A.M. Cobzaru, L. Tatu, C. Tiu, O.A. Bajenaru I BUCHAREST, ROMANIA

P 12170 Cerebrospinal fluid osmolality: determinants and correlation with plasma osmolality
G. Bellomo, M.B. Bardone, A. Mora, V. Castellina, E. Beltrami, E. Mairate, I. Crespi I NOVARA, ITALY

P 12171 Potassium channel antibodies in a patient with Sjögren syndrome, Hashimoto encephalitis and lung adenocarcinoma
R. Beyrouti, S. Mostoufizadeh, E. Penombre, A. Fickl, E. Schluck, A. La Porta, S. Courtois, E. Cohen I MILHOUSE, FRANCE

P 12172 Isolated myelitis in Behcet’s disease: report of seven cases
W. Bnouhanna, M. Rahmani, M. Benabdelljalil, S. Aïdi, M. El Alaoui Faris I RABAT, MOROCCO

P 12173 Neurosarcoïdosis: sometimes, the essential is invisible to the eye...
E. Campos Costa, A.P. Pereira, I.R. Marques, A.C. Ribeiro I ALMADA, PORTUGAL

P 12174 Bickerstaff’s brainstem encephalitis
H. Çavuş, S. Aydinlik, P. İşeri I KOCAELI, 12IMIT, TURKEY
P 12175 Neurological involvement in adult hemophagocytic lymphohistiocytosis as presenting manifestation of systemic lupus erythematosus
A. de Sousa, P. Brás, I. Botelho, M. Almeida, M. Manita
LISBON, PORTUGAL

POSTER SESSION
PERIPHERAL NERVE DISORDERS 2
13:30-14:15 | SCREEN D2
CHAIRPERSON:
Jonathan Baets, ANTWERP, BELGIUM

P 12176 Clinical significance of asymmetrical polyneuropathy on nerve conduction studies
S.D. Pandya, Y.-C. Chan
SINGAPORE, SINGAPORE

P 12177 Sustained muscle strength and quality of life in patients with CIDP and MMN switched from intravenous to subcutaneous immunoglobulin
I. Christiansen1, L.H. Markvardsen2
FREDERIKSBERG, AARHUS, DENMARK

P 12178 Improvement of hemoglobin level following switch from intravenous to subcutaneous administration of immunoglobulin in CIDP and MMN
I. Christiansen1, L.H. Markvardsen2
FREDERIKSBERG, AARHUS, DENMARK

P 12179 Efficacy of intravenous immunoglobulin for painful peripheral neuropathy in a patient with eosinophilic granulomatosis with polyangiitis and type II diabetes
E.M. D’adda, A. Cagnana, M. Gennuso, A. Prelle
CREMA, ITALY

P 12180 Abstract cancelled

P 12181 Usefulness of skin biopsy for the etiological diagnosis of small fiber neuropathy
V. Davy, F. Pico
VERSAILLES, FRANCE

P 12182 Genotypic and phenotypic presentation of TTR-FAP in turkey
H. Durmuş1, A. Çakar1, M.M. Atmaca1, Z. Matur1, U. Altunoglu1, M. Poda1, U.H. Ulas2, P. Oflazer1, F. Deymeer1, Y. Parman1
ISTANBUL, ANKARA, TURKEY

P 12183 Chronic inflammatory demyelinating polyradiculoneuropathy associated with an inflammatory disease of the central nervous system: a case report
J. El Mesbahy, N. Louhab, N. Kissani
MARRAKECH, MOROCCO

P 12184 Functioning and quality of life in patients with peripheral neuropathy associated with anti-MAG antibodies
Y.M. Falzone1, D. Martinelli1, N. Riva1, C. Brian1, E. Nobile-Orazio1, G. Lauria1, F. Giannini1, L. Benedetti1, P. Dacci1, A. Quattrini1, G. Comi1, R. Fazio1, A. Schenone1
MILAN, SIENNA, GENOA, ITALY

P 12185 Guillain–Barré syndrome following acute hepatitis E
D. Fitas, R. Lobato
VIANA DO CASTELO, PORTUGAL

P 12186 Epileptic seizures as a presentation of central nervous system involvement in TTR Val30Met–FAP
A. Franco, C. Bentes, M. de Carvalho, P. Pereira, J. Pimentel, I. Conceicao
LISBON, PORTUGAL

P 12187 Description of a family with autosomal dominant spastic paraparesis and peripheral neuropathy caused by a novel KIF1A mutation
M. Frasquet Carrera1, M. Barreiro1, R. Sivera2, J.F. Vázquez Costa1, C. Espinos1, Á. Álamo Arenas1, T. Sevilla1
VALENCIA, GANDIA, SPAIN
SUNDAY, 29 MAY 2016
SESSIONS
**HANDS-ON COURSE 1: NEUROSONOLOGY (VASCULAR)**

08:30 - 10:00 | HALL B5.M1

CHAIRPERSONS:
Natan Bornstein, TEL AVIV, ISRAEL
Laszlo Csiba, DEBRECEN, HUNGARY

Doppler evaluation of the carotid arteries
Natan Bornstein, TEL AVIV, ISRAEL

Duplex ultrasound evaluation of intracranial arteries – anterior circulation
Stephan Schreiber, BERLIN, GERMANY

Extra and intracranial sonographic assessment of the posterior circulation
Edoardo Vicenzini, ROME, ITALY

Neurosonology methods used in pharmaceutical trials
Laszlo Csiba, LASZLO CSIBA

This course will start with 4 short lectures (10 minutes each) about different aspects of methods, evaluation and assessment of neurosonology. These will be followed by hands-on demonstrations where the audience will be divided into two working-groups:

- Insonation of the extracranial and intracranial anterior circulation by Stephan Schreiber.
- Insonation of the extracranial and intracranial posterior circulation by Edoardo Vicenzini.

**HANDS-ON COURSE 6: NEURO-OOTOLOGY**

08:30 - 10:00 | HALL B4.M1

CHAIRPERSON:
Eleftherios Papathanasiou, NICOSIA, CYPRUS

Benign paroxysmal positional vertigo: provocation and liberation manoeuvres
Michael Leo Strupp, MUNICH, GERMANY

Vestibular evoked myogenic potentials
Eleftherios Papathanasiou, NICOSIA, CYPRUS
Dominik Straumann, ZURICH, SWITZERLAND

Video impulse test
Erich Schneider, SENFTENBERG, GERMANY
Konrad P. Weber, ZURICH, SWITZERLAND

Neuro-otological bedside tests
Adolfo Bronstein, LONDON, UK
Marianne Dieterich, MUNICH, GERMANY

This course encompasses the major bedside and auxiliary tests for evaluating patients with vestibular signs and symptoms. A room rotating scheme has been designed with four stations, spending twenty minutes at each, with practical demonstrations. The benign paroxysmal positional vertigo (BPPV) and neurootological bedside test stations will involve the neurootological clinical examination and the treatment of BPPV with the different manoeuvres for each separate canal BPPV. The vestibular evoked myogenic potential station will use a common evoked potential system available in all neurophysiological laboratories. The head impulse station will demonstrate head mounted video systems commercially available for eye movement documentation.

**CASE-BASED FACILITATED WORKSHOP 2: CLUSTER HEADACHE – A CLINICAL CHALLENGE?**

08:30 - 10:00 | HALL B4.M2

CHAIRPERSON:
Peter Goadsby, LONDON, UK

Diagnosis of cluster headache and other TACS
Peter Goadsby, LONDON, UK

Neurobiology of cluster headache
Mads Barloæs, GLOSTRUP, DENMARK

Pharmacological treatment strategies in cluster headache
Arne May, HAMBURG, GERMANY

Use of neuromodulation of cluster headache
Tim Jürgens, ROSTOCK, GERMANY

Cluster headache is one of the most painful disorders, severe enough to lead patients to suicidal thoughts. This primary headache, belonging to the trigeminal autonomic cephalalgias (TACs), is underdiagnosed and under- or mistreated. The diagnosis of other TACs (hemicrania continua, SUNCT...) may also be challenging, the more that their respective clinical presentations can overlap. The first purpose of this course is to provide a clear update on diagnosis and pathophysiology of cluster headache and other TACs, based on the most recent publications. The treatment strategies as well as the new non-pharmacological options like neurostimulation, will then be discussed using illustrative cases. We expect the audience to actively take part in the debate, especially by sharing personal experiences or issues with patients and their management.
INTERACTIVE SESSION 2: PITFALLS IN NEUROLOGICAL SLEEP MEDICINE
08:30 - 10:00 | HALL A

CHAIRPERSON: Isabelle Arnulf, PARIS, FRANCE

Pitfalls in diagnosis of hypersomnias
Isabelle Arnulf, PARIS, FRANCE

Pitfalls in diagnosis of parasomnias/epilepsy
Lino Nobili, MILANO, ITALY

Pitfalls in diagnosis of movement disorders asleep
Birgit Högl, INNSBRUCK, AUSTRIA

Patients referred to a neurologist may complain of falling abnormally asleep during daytime (10% of the population), as well as experiencing abnormal behaviours (4% of young adults, 8% of elderly), sensations or movements during the night (2-4%). Because the nocturnal world is invisible to the neurologist unless the patient is studied in a sleep lab, the interview of patients and their bed-sharers is essential to recognize restless leg syndrome from numerous sensory problems (including neuropathies), to differentiate apathy and fatigue from sleep apnoea, narcolepsy and idiopathic hypersomnia, and to differentiate sleepwalking and REM sleep behaviour disorder from epilepsy and psychiatric disorders. Clinical cases and video-clips will help clinicians to switch on lights when lost in the darkness of the night.

Participants are encouraged to actively engage with immediate feedback to support learning (voting system)

FOCUSED WORKSHOP 7: STEM CELL THERAPIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES
08:30 - 10:00 | HALL B

CHAIRPERSON: Antonio Uccelli, GENOVA, ITALY

Adult stem cells for the treatment of multiple sclerosis
Antonio Uccelli, GENOVA, ITALY

Stem cells in muscle diseases
Yvan Torrente, MILANO, ITALY

Cell transplantation for stroke
Sean I. Savitz, HOUSTON, USA

Target Audience: Basic scientists, clinical academicians, practitioners

Scientific Content: The workshop will focus on the most recent achievements in the field of adult stem cells and neurological diseases (focusing on multiple sclerosis, muscle diseases and stroke) encompassing the biological rationale arising from preclinical studies and current clinical translation at the bed side.

FOCUSED WORKSHOP 8: MDS-ES/EAN: TICS AND TOURETTE SYNDROME – CONSENSUS AND CONTROVERSIES
08:30 - 10:00 | HALL M1

CHAIRPERSON: Andrea Cavanna, BIRMINGHAM, UK

Challenges in diagnosing tics, Tourette’s and comorbidities
Kerstin von Plessen, BERGEN, NORWAY

Tics and Tourette Syndrome – Movement disorders or behavioural conditions?
Andrea Cavanna, BIRMINGHAM, UK

Treatment of tics and Tourette syndrome – cannabis, deep brain stimulation and beyond
Kirsten Müller-Vahl, HANNOVER, GERMANY

Target Audience: Clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

Scientific Content: Tics and Tourette Syndrome: Consensus and Controversies Educational Objectives Tourette syndrome and other tic disorders are amongst the most common hyperkinetic movement disorders, especially in school-age children, and pose significant challenges in terms of both diagnosis and treatment. This Focused Workshop provides a comprehensive educational package on the clinical assessment of motor and phonic tics, with particular attention to the differential diagnosis, which is often complicated by the presence of behavioural co-morbidities such as obsessive-compulsive disorder and attention-deficit/hyperactivity disorder. Therapeutic frontiers for tics include use of cannabinoids and deep brain stimulation for severe treatment-refractory cases and illustrate current and future pathways to improve patient’s health-related quality of life.
FOCUSED WORKSHOP 9: FOCAL DEMENTIAS  
08:30 - 10:00 | HALL M2

CHAIRPERSON:  
Jonathan M. Schott, LONDON, UK

The parietal lobes  
Jonathan M. Schott, LONDON, UK

The temporal lobes  
Stefano Cappa, MILAN, ITALY

The frontal lobes  
Rik Ossenkoppele, AMSTERDAM, THE NETHERLANDS

Target Audience:  
Clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

Scientific Content:  
The classical cortical dementia syndromes have predilection for certain brain regions with attendant fairly predictable patterns of cognitive impairment. This not only allows for them to be distinguished from one another and from normal ageing, but also informs the deficits encountered by patients, and how best these might be addressed. Identifying patterns of regional brain impairment is therefore a critical step in the evaluation of the cognitively impaired individual. In this focused workshop, we will use dementia syndromes associated with particular focal involvement to illustrate this approach, focussing on disorders that predominantly affect the parietal lobes, the temporal lobes, and the frontal lobes. Each speaker will provide a clinical overview of focal dementias affecting each of these three brain regions. Based on case histories, this will include aspects of the history, examination, and neuropsychology – illustrated with videos where possible – associated with involvement of different cortical areas, as well as a discussion of relevant investigations and the underlying pathology.

FOCUSED WORKSHOP 10: MDS-ES/EAN: BIOMARKERS FOR PARKINSON’S DISEASE  
08:30 - 10:00 | HALL M4

CHAIRPERSON:  
Werner Poewe, INNSBRUCK, AUSTRIA

The need for better biological markers for PD  
Werner Poewe, INNSBRUCK, AUSTRIA

Alpha-Synuclein: a new evidence?  
Wassilios Meissner, BORDEAUX, FRANCE

Imaging markers: MRI  
Umberto Sabatini, ROME, ITALY

Imaging markers: PET/SPECT  
Philippe Remy, CRETEIL, FRANCE

Target Audience:  
Basic scientists, clinical academicians, practitioners, students/residents/trainees

Scientific Content:  
The diagnostic accuracy and early diagnosis are major needs in current PD research. The focussed workshop will review the performance of current criteria to diagnose PD and the concept of preclinical and prodromal disease stages as well as state of current knowledge regarding diagnostic biomarkers. The role of alpha-synuclein in body fluids (particularly CSF and tissues accessible to biopsy) for PD diagnosis will be reviewed as well as current developments in MRI-based techniques to diagnose Parkinson’s disease and follow its progression.
FOCUSED WORKSHOP 12: IMPAIRED HAND FUNCTION AFTER STROKE AND PERIPHERAL NERVE INJURY: CONSEQUENCES FOR TREATMENT
08:30 - 10:00 | HALL M0

CHAIRPERSON
Volker Dietz, ZURICH, SWITZERLAND

Treatment of hand function after peripheral nerve injury
Josep Valls-Solé, BARCELONA, SPAIN

Normal and impaired neural coupling of cooperative hand movements
Volker Dietz, ZURICH, SWITZERLAND

Bilateral hand movement training after stroke: what is the benefit?
Caroline Renner, LEIPZIG, GERMANY

Target Audience: Clinical academicians, practitioners, students/residents/trainees, occupational therapists, rehabilitation experts

Scientific Content: The process from lesion repair to recovery and to functional rehabilitation of hand function after traumatic neurotmesis of ulnar or median nerves will be presented. Role and effects of peripheral nerve grafts. Focused training of hand function to promote nerve regeneration. In stroke patients with a severe hemiparesis constraint induced movement therapy (CIMT) will be contrasted with bimanual arm training. Significance of bimanual movements in the recovery of hand function after stroke. Task-specific neural coupling during cooperative hand movements involves ipsi- and contralateral pathways in movement control. Influence of unaffected hemisphere in the neural control of the paretic arm/hand during cooperative hand movements.

SPECIAL SESSION 3: NEW EUROPEAN NEUROLOGICAL GUIDELINES
08:30 - 10:00 | HALL M3

CHAIRPERSON
Antonio Federico, SIENA, ITALY

Neurostimulation in Neuropathic Pain
Giorgio Cruccu, ROME, ITALY

Diagnosis and management of tick borne encephalitis
Pille Taba, TARTU, ESTONIA

Pre-hospital stroke management
Adam Kobayashi, WARSAW, POLAND

Alcohol-withdrawal seizures
Geir Brathen, TRONDHEIM, NORWAY

Scientific Content: We will report the most relevant results of the European Neurologic Academy Guidelines produced during the past year: Neurostimulation in Neuropathic Pain (G Cruccu, Roma, and N. Attal , Boulogne-Billancourt) reviewing the 2007 EFNS guideline. The new recommendation is that given the weak evidence available so far, for future trials the authors encourage large scale multicentre studies of non-invasive and invasive neurostimulation. They also recommend high quality studies of predictive factors of the efficacy of these techniques.

Diagnosis and Management of Tick Borne Encephalitis (P Taba, Tartu, Estonia), reporting data obtained by a large analysis of the literature from 1979 to 2015.

Prehospital stroke management (A Kobayashi, Warsaw, Poland)

Alcohol-withdrawal seizures (G Brathen, Trondheim, Norway) presenting the preliminary results. Although important, the dosing and frequency of Thiamine treatment is virtually undocumented. Benzodiazepines but no other anticonvulsants reduced the seizure risk significantly compared to placebo. In three randomized controlled studies, phenytoin failed to prevent recurrent seizures. No recent evidence supports advice to people with epilepsy regarding safe levels or frequency of alcohol consumption.
SPECIAL SESSION 4: EFNA OPEN DIALOGUE: LET’S TALK ABOUT SEX, SLEEP AND STRESS

08:30 - 10:00 HALL B5, M2

CHAIRPERSONS:
Audrey Craven, EFNA PAST PRESIDENT
Viktoria Papp, RRFS PRESIDENT

Sleep: raising awareness of sleep disorders in neuroscientific and neurological communities
Wolfgang Oertel, MARBURG, GERMANY

Stress: addressing mental health in neurological disorders: experiences and findings from clinical practice in neuropsychiatry
Christian Schmidt-Kraepelin, DÜSSELDORF, GERMANY

Sex: communicating on sexual dysfunction as a symptom of neurological disorders
David B. Vodušek, LJUBLJANA, SLOVENIA

Scientific Content: This session will show that for many patients affected by neurological disorders, it is the ‘secondary symptoms’ which are often the most burdensome. Sleep Disorders, Mental Health Problems and Sexual Dysfunction are all common ‘secondary symptoms’ or co-morbidities for neurology patients. During this session, specialists in each area will impart:

- Knowledge of the science/latest research on the symptoms/co-morbidities of sexual dysfunction, sleep disorders and poor mental health/wellbeing in patients affected by neurological disorders
- Education on how sexual dysfunction, sleep disorders and poor mental health/wellbeing, as symptoms of a primary neurological disorder, can be managed and treated effectively
- Tools/skills to ensure that such symptoms/co-morbidities are included as part of the consultation and how patient concerns/preferences can be accurately elicited
in Europe to evaluate efficacy of novel surgical strategies for Parkinson’s disease such as subthalamic nucleus stimulation and its impact upon patients cognition and quality of life. In addition, during the last years, he has dedicated his investigations to the study of the asymptomatic individuals carrying PD-cause mutations in the LRRK2 gene.

Prof. Giacomo Rizzolatti, was born in Kiev, in the former Soviet Union. He studied at University of Padua where he graduated in Medicine and obtained the specialization in Neurology. He spent three years at the University of Pisa at the Institute of Physiology, directed at that time by Prof. Giuseppe Moruzzi. His subsequent academic career took place mostly at the University of Parma where he started as an Assistant in Human Physiology and became Professor of Human Physiology, which is still his present academic position. He spent one year in the Department of Psychology of the McMaster University, Hamilton, Ontario, Canada and one year, as a Visiting Professor, in the Department of Anatomy of the University of Pennsylvania, Philadelphia. Since the early nineties he has a close collaboration with the Department of Computer Science and Neuroscience of the University of Southern California, Los Angeles and with Ahmanson Lovelace Brain Mapping Center of UCLA, Los Angeles. He was President of the European Brain Behavior Society and Italian Society for Neuroscience. For several years he directed the European Training Program in Brain and Behaviour Research (ETP) sponsored by the European Science Foundation and for a short time he has been a member of the “European Medical Research Council”. At present he is a member of Scientific Committee of “Fondation Fyssen” and Associate Member of the Neuroscience Program directed by Gerald Edelman, San Diego. Among his major awards are the “Golgi Prize for Physiology”, “George Miller Award” of the Cognitive Neuroscience Society, the “Feltrinelli Prize for Medicine” of Accademia dei Lincei, and the Herlitzka Prize for Physiology, Accademia delle Scienze di Torino.

He received Honorary Degrees from the University Claude Bernard of Lyon, from the University of St. Petersburg, St. Petersburg, the Grawemeyer Prize for Psychology from the University of Louisville (USA) and the Prix J.-L. Signoret in Neuropsychologie from the IPSEN Fondation.
Prof. Thomas Brandt, studied medicine at the Universities of Cologne and Essen. His clinical training was under Richard Jung in Neurology and Clinical Neurophysiology in Freiburg. From 1976 to 1984 he was Director of the Neurological Clinic of the Alfried Krupp Hospital in Essen, and from 1984 to 2008 Chairman of Neurology and Director of the Department of Neurology of Munich University. He has held a Hertie Senior Research Professorship since 2008 and is also Chief Executive Director of the German Center for Vertigo and Balance Disorders of Munich University. Prof. Brandt was formerly President of the German Neurological Society, the German Society for Clinical Neurophysiology and Functional Imaging, the International Society for Posture and Gait Research, and the European Neurological Society. He is an honorary member of the German, British, and French Neurological Societies, a member of the Bavarian Academy of Sciences, and of the German Academy of Life Scientists, Leopoldina. Awards include the Srinivasan Gold Medal, the Betty and David Koetser Prize for Brain Research, the Bárány Gold Medal, the Doctor Robert Pfleger Award, the Hans Berger Prize, the Wilhelm Erb Medal, and the Federal Cross of Merit, Germany.

Major research fields: general neurology and management of dizzy patients, basic mechanisms of vertigo, balance and ocular motor disorders, locomotion, visual-vestibular interaction, motion perception, spatial orientation, and navigation. Applied methods are stance and gait analysis, eye movement recordings, other neurophysiological measures, as well as psychophysics, functional imaging with MRI and PET, and modeling sensorimotor control.
very important issues on imaging clues for diagnosis, in addition to the nearly always present cerebellar atrophy will be discussed and illustrated by clinical cases and their discussion. The diagnostic approach in dominant and recessive ataxias and genotype-phenotype correlations illustrated by cases in each group will be discussed. The learning objectives are:

a) becoming familiar with the growing genetic heterogeneity of cerebellar ataxias and
b) apprehension of strategies to choose genetic analysis to be performed insisting on important issues for treatment and genetic counseling.

TEACHING COURSE 7:
IATROGENIC LESIONS OF THE PERIPHERAL NERVOUS SYSTEM – LEVEL 2
14:45 - 18:15 | HALL A

CHAIRPERSON:
Peter Berlit, ESSEN, GERMANY

Drug-induced neuropathies
Hadi Manji, LONDON, UK

Radiation induced lesions of the peripheral nervous system
Peter Berlit, ESSEN, GERMANY

Perioperative neuropathies
Isabel Conceição, LISABON, PORTUGAL

Neuropathies caused by puncture, injection or tourniquets
Ivana Stetkarova, PRAGUE, CZECH REPUBLIC

Newer recognised drugs causing neuropathy include TNF alpha antagonists, bortezombib and linezolid. Radiation lesions of the peripheral nervous system may occur many years after radiotherapy for neoplastic disease. The main diagnostic difficulty is distinguishing radiation-induced nerve lesions from tumour recurrence. Perioperative neuropathies are mainly due to direct damage during surgery, i.e. sciatic nerve during hip surgery, accessory nerve at the posterior triangle of the neck. Nerve injuries may develop secondary to expanding hematomas and pseudoneurysms after angiography or puncture. Other causes are brakes, blasts, tourniquets or the dislocation of cement during vertebroplasty. Critical in all iatrogenic lesions of the peripheral nervous system is an early recognition and prompt diagnosis.
TEACHING COURSE 8: MDS-ES/EAN: MOTOR SYMPTOMS REFRACTORY TO L-DOPA IN PARKINSON’S DISEASE – LEVEL 1

14:45 - 18:15 | HALL B

CHAIRPERSON:
Evzen Ruzicka, PRAGUE, CZECH REPUBLIC

Dysarthria and Dysphagia
Evzen Ruzicka, PRAGUE, CZECH REPUBLIC

Postural instability
Bastiaan Bloem, NIJMEGEN, THE NETHERLANDS

Frozen gait
Joaquim Ferreira, LISBON, PORTUGAL

Non-motor symptoms/cognitive and behavioural symptoms
Jaime Kulisevsky, BARCELONA, SPAIN

A variety of motor and non-motor symptoms not related to the nigrostriatal dopaminergic deficit develop in the course of Parkinson’s disease (PD). Those dopa-unresponsive disorders may seriously interfere with life activities of patients in advanced stages of the disease. Postural instability and freezing of gait limit the patients’ ability to walk and increase the risk of falls. Cognitive and behavioral disorders do further decrease the quality of life of both patients and their families. In addition, the patients’ communication ability is limited due to unintelligible speech. Four lectures included in this course will demonstrate the clinical picture, basic pathophysiology and treatment strategies in specific subgroups of dopa-unresponsive PD symptoms. Possible pharmacological and non-pharmacological treatment approaches will be discussed.

TEACHING COURSE 9: OPTIMISING THE MANAGEMENT OF HEADACHE: ACUTE, PREVENTIVE AND NON-PHARMACOLOGICAL ASPECTS – LEVEL 2

14:45 - 18:15 | HALL M1

CHAIRPERSON:
Till Sprenger, WIESBADEN, GERMANY

How can we optimise the acute migraine treatment?
Messoud Ashina, COPENHAGEN, DENMARK

Advances and challenges in the preventive treatment of headache
Till Sprenger, WIESBADEN, GERMANY

Non-pharmacological treatment approaches 1:
Is there evidence in favour of using acupuncture and alternative medicine in headache management?
Lars Bendtsen, COPENHAGEN, DENMARK

Non-pharmacological treatment approaches 2:
Emerging neurostimulation techniques for the treatment of headache.
Tim Jürgens, ROSTOCK, GERMANY

Headache is one of the most frequent reasons for neurological consultations and many patients seek improved acute and preventive treatment of their attacks. Both of these fundamental aspects of headache treatment will be covered in this teaching course using an evidence-based approach. We will discuss medical as well as non-medical and neuromodulation approaches with the participants. Migraine will be the focus, but other primary headache syndromes will be covered, too. There is an evolving landscape of novel headache treatment approaches and we will discuss pros and cons of such approaches.

TEACHING COURSE 10: GENERALISED EPILEPSIES: GENETICS, DIAGNOSTICS AND TREATMENT – LEVEL 3

14:45 - 18:15 | HALL M2

CHAIRPERSON:
Reetta Kalviainen, KUOPIO, FINLAND

Pathophysiology of generalised epilepsies
Gilles van Luijtenaar, NIJMEGEN, THE NETHERLANDS

Absence epilepsies
Marina Nikanorova, DIANALUND, DENMARK

Juvenile myoclonus epilepsy
Matthias Koepp, LONDON, UK

Progressive myoclonus epilepsies
Reetta Kalviainen, KUOPIO, FINLAND

The purpose of this teaching course is to review the pathophysiology of most common forms of generalized epilepsies. We will also provide an update in the clinical, electroencephalographic, imaging and genetic findings of the specific syndromes as well as an update of the current therapy.
TEACHING COURSE 11: CURRENT TREATMENTS IN NEUROLOGY I – LEVEL 1

14:45 – 18:15 | HALL M3

CHAIRPERSON:
Eugen Trinka, SALZBURG, AUSTRIA

**Therapeutics in Amyotrophic Lateral Sclerosis**
Albert Ludolph, ULM, GERMANY

**Stroke in women**
Hanne Christensen, COPENHAGEN, DENMARK

**New therapeutic options for treating MS: benefits, limits and safety**
Ludwig Kappos, BASEL SWITZERLAND

**Current treatment of status epilepticus in adults**
Eugen Trinka, SALZBURG, AUSTRIA

This Teaching Course will focus on complex diseases and special situation of common diseases. Professor Albert Ludolph will talk on the therapeutics in Amyotrophic Lateral Sclerosis, Professor Hanne Krarup Christensen will cover a special issue in cerebrovascular disorders in Women. Professor Ludwig Kappos will present the latest therapeutic options for treating MS with the focus on risks and benefits. Professor Eugen Trinka will cover the current treatment options of Status Epilepticus in adults.

Sexual function and dysfunction – central and peripheral aspects of most important but coarsely neglected topic in medical education
Max J. Hilz, ERLANGEN, GERMANY

Differentiating autonomic dysfunction in movement disorders made easy
Jean-Michel Senard, TOULOUSE, FRANCE

Autonomic nervous system (ANS) disorders are common and increasingly recognized as relevant subspecialty. However, there are currently only very few neurologists specialized in this field and therefore teaching and mentoring is lacking. This teaching introduces autonomic dysfunction in general neurology by presenting common syndromes in everyday clinical practice. After the teaching course, you will be able to:
- Form a structured autonomic differential diagnosis in the most common autonomic syndromes based on a sound history and bed side tests.
- Address and manage autonomic uro-sexual dysfunction
- Establish a sound autonomic syndrome diagnosis in movements disorders

In addition, this teaching course should act as your door opener to the wide field of autonomic dysfunction in general neurology. Therefore, our lectures will also provide recommendations for additional training resources.

TEACHING COURSE 12: HOW TO ASSESS AUTONOMIC DYSFUNCTION IN GENERAL NEUROLOGY – LEVEL 1

14:45 – 18:15 | HALL M0

CHAIRPERSON:
Jean-Michel Senard, TOULOUSE, FRANCE

**Bedside testing of cardiovascular autonomic function made easy**
Walter Struhal, LINZ, AUSTRIA

**Neuro-urology – an important territory lost between specialties but readily assessed in neurology**
David B. Vodušek, LJUBLJANA, SLOVENIA
HANDS-ON COURSE 3: NEUROPHYSIOLOGY II - NERVE CONDUCTION STUDIES AND NERVE/MUSCLE ULTRASOUND
16:45 - 18:15 | HALL B5.M1

CHAIRPERSON:
Josep Valls-Solé, BARCELONA, SPAIN

Nerve conduction studies
Josep Valls-Solé, BARCELONA, SPAIN

Nerve echography
Luca Padua, ROME, ITALY

In this hands-on session, we will present methods and techniques on how to perform two paraclinical tests that help with the assessment of peripheral neuropathies. In the first part, Josep Valls-Sole will demonstrate motor and sensory nerve conduction studies, together with some cues on the use of them for the diagnosis of functional disorders in neuropathies. In the second part, Luca Padua will demonstrate the use of echography for nerve and muscle ultrasound to show the various structural alterations that may affect peripheral nerves or muscles. Both techniques are nowadays complementary to each other and useful for the neurologist with interest in the assessment of functional or structural disorders involving the peripheral nervous system.

This course is supported by NATUS MEDICAL Inc.

HOW TO IMPROVE YOUR CHANCES...
QUESTION-WRITING WORKSHOP
16:45 - 18:15 | HALL B4.M2

CHAIRPERSONS:
Hannah Cock, LONDON, UK
Jan Kuks, GRONINGEN, THE NETHERLANDS

Hannah Cock and Jan Kuks, members of the EAN Education Committee will guide you through the difficult task on preparing questionnaires and SBAs which are of imminent importance for teachers and educators.
10th Congress of the EUROPEAN PAIN FEDERATION EFIC®

September 6-9, 2017 | Copenhagen, Denmark

PAIN IN EUROPE X
Bringing Pain Relief to All Patients
32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

And

21st Annual Conference of Rehabilitation in MS

14 – 17 September 2016
London, United Kingdom

Follow us on #ECTRIMS2016

www.ectrims-congress.eu
COPENHAGEN, DENMARK, 28 – 31 MAY, 2016

SUNDAY, 29 MAY

14:45 - 16:15

ORAL SESSIONS

14:45-16:15 | HALL M5
CHAIRPERSONS:
Lieven Lagae, LEUVEN, BELGIUM
Morton Ingvar Lossius, BAERUM, NORWAY

O 2101
14:45
Tuberous sclerosis complex. Serbian referral centre experience
A. Kosac, N. Jovic, D. Karaklic I BELGRADE, SERBIA

O 2102
15:00
Repeated dramatic reversal of thiamine-responsive necrotising encephalopathy due to SLC19A3 mutations emphasises the importance of considering vitamin-responsive pathologies in acute neurology
D. Lewis-Smith1, A. Basu1, R. Hussain1, B. Patil2, V. Ramesh1, P. Chinnery3 I 1NEWCASTLE UPON TYNE, MIDDLESBROUGH, 2CAMBRIDGE, UK

O 2103
15:15
The genetic deficiency of folate cycle, and autistic spectrum: the relationship with immunodeficiency, demyelination and i/v immunoglobulin effectiveness
D. Maltsev I KIEV, UKRAINE

O 2104
15:30
Neurologic manifestations of congenital disorders of glycosylation: a clinical follow-up study of 18 patients
C. Melo1, A. Bandeira2, C. Garrido2, A. Falini3, M. Gonçalves-Rocha3, S. Figueiroa2, I. Carrilho2, M. Santos2, D. Quelhas2, E. Martins2 I 1VILA NOVA DE FAMALICÃO, 2PORTO, 3BRAGA, PORTUGAL

O 2105
15:45
Differential contribution of cerebellar resting state functional connectivity abnormalities to cognitive impairment in pediatric and adult patients with multiple sclerosis
M. A. Rocca1, P. Valsasina1, L. Vacchi1, A. Ghezzi1, P. Veggiotti1, R. Capra1, M.P. Amato1, A. Fiorino2, L. Pippola2, M.C. Pera3, G. Comi1, A. Falini1, M. Filippi1 I 1MILAN, 2GALLARATE, 3FLORENCE, 5FLORENCE, 6SAN GIOVANNI ROTONDO, ITALY

O 2106
16:00
M. Santos1, R. Sousa1, J. Coelho1, F. Durão2, R. Machado2, S. Quintas1, T. Moreno2, A. Levy2, T. Santos2 I 1AMADORA/LISBON, 2LISBON, PORTUGAL

TOURNAMENT BASIC

14:45 - 16:15 | HALL B4.M1
CHAIRPERSONS:
Hannah Cock, LONDON, UK
Wolfgang Oertel, MARBURG, GERMANY

T 101
14:45
Cognitive correlates of the brain functional connectome abnormalities in pediatric patients with multiple sclerosis
E. de Meg1, M.A. Rocca1, L. Moiola1, A. Ghezzi2, P. Veggiotti3, R. Capra1, M.P. Amato1, L. Vacchi1, A. Fiorino2, L. Pippola2, M.C. Pera3, M. Copetti3, G. Comi1, A. Falini1, M. Filippi1 I 1MILAN, 2GALLARATE, 3PAVIA, 4BRESSA, 5FLORENCE, 6SAN GIOVANNI ROTONDO, ITALY

T 102
15:00
Zinc release and action at excitatory Schaeffer collateral-CA1 pyramidal cell synapses
A. Ekmen, A. Vergnano, P. Paoletti I PARIS, FRANCE

T 103
15:15
Modifications of gray matter volume in migraine patients over four years: a tensor-based morphometry study
R. Messina, M.A. Rocca, B. Colombo, E. Pagani, A. Falini, G. Comi, M. Filippi I MILAN, ITALY

T 104
15:30
Role of REM sleep and melanin concentrating hormone in the neuroprotective effect of sleep deprivation pre-ischemia preconditioning
M. Pace, A. Adamantidis, C. Bassetti I BERNE, SWITZERLAND

T 105
15:45
Bevacizumab: is the lower the better for glioblastoma patients?

T 106
16:00
Clinical characterisation of SORL1 mutation carriers in a European early-onset Alzheimer’s disease cohort
T. van Den Bossche1, J. Verheijen1, J. van der Zee1, S. Engelborghs1, R. Sanchez-Valle2, A. Lladó2, C. Graff3, H. Thonberg3, P. Pastor4, S. Ortega-Cubero5, M.A. Pastor5, L. Benussi6, R. Ghidoni6, G. Binetti6, J. Clarimon6, A. Lleó6, J. Forte6, A. de Mendonça7, M. Martins8, E. Gelpi9, P.P. de Deyn10, K. Sleegers11, C. van Broeckhoven12 I 1ANTWERP BELGIUM, 2BARCELONA, SPAIN, 3HUDDINGE, SWEDEN, 4PAMPLONA, 5MADRID, SPAIN, 6BRESSA, ITALY, 7LISBON, PORTUGAL.
ORAL SESSION: COGNITIVE NEUROLOGY/NEUROPSYCHOLOGY 1
14:45-16:15 | HALL B5.M2
CHAIRPERSONS:
Theodor Landis, LAUSANNE, SWITZERLAND
Lüder De Wee, VIENNA, AUSTRIA

O 2107 14:45
Insensitivity to reward characterises apathy but not depression in Parkinson’s disease
K. Muhammed1, M. Ben Yehuda2, D. Drew1, S. Manohar1, T. Chong2, D.G. Tofaris3, D.M. Bogdanovic1, D.G. Lennox1, M. Hu1, M. Husain1, 1OXFORD, UK, 2SYDNEY, AUSTRALIA

O 2109 15:15
Relevance of functional connectivity abnormalities to cognitive impairment in neuromyelitis optica spectrum disorder
M.A. Rocca1, P. Valsasina, F. Savoldi, G.C. Riccitelli, M. Radaelli, P. Presiosi, G. Comi, A. Falini, M. Filippi1 MILAN, ITALY

O 2110 15:30
The head turning sign in Alzheimer’s disease: its relationship with cognitive impairment and CSF biomarkers
M. Tábuas-Pereira, J. Durães, R. Araújo, S. Bernardino, D. Duro, B. Santiago, I. Santana COIMBRA, PORTUGAL

O 2111 15:45
Predictors and signatures of recovery from neglect in acute stroke
R. Umarova1, C. Kaller1, K. Nitschke1, S. Köppel1, L. Beume2, I. Mader1, C. Weiller2 1FRIEBURG, 2FRIEBURG, GERMANY

O 2113 16:00
Functional cognitive control load across multiple sclerosis phenotypes: a clinical-imaging evaluation
L. Vacchi, M.A. Rocca, A. Meani, M. Rodegher, V. Martinelli, G. Comi, A. Falini, M. Filippi MILAN, ITALY

ORAL SESSION: MS AND RELATED DISORDERS 3
14:45-16:15 | HALL C
CHAIRPERSONS:
Finn Sellebjerg, COPENHAGEN, DENMARK (TBC)
Giancarlo Comi, MILAN, ITALY

O 2113 14:45
Bipolar disorder, schizophrenia and psychoses in multiple sclerosis: a population-based, nationwide study in Denmark
A. Thormann, M. Magyari, N.J. Koch-Henriksen, B. Laursen, P.S. Sørensen COPENHAGEN, DENMARK

O 2114 15:00
Long-term effect of fingolimod on disability: a categorical trend analysis over 8 years
A. Reder1, J. Cohen2, D. Piani-Meier3, D. Tomic3, S. Ritter4, B. Cree5 1CHICAGO, 2CLEVELAND, USA, 3BASEL, SWITZERLAND, 4EAST HANOVER, 5SAN FRANCISCO, USA

O 2115 15:15
High doses of biotin in progressive multiple sclerosis: extension phase results of the MS-SPI trial
A. Tourbah1, C. Lebrun-Frenay2, G. Edan3, M. Clanet4, M. Clanet1, C. Lebrun-Frenay2, G. Edan3, M. Clanet4, M. Clanet1, 1RHEIMS, 2NICE, 3RENNES, 4TOULOUSE, 5PARIS, 6LYONS, 7STRASBOURG, 8NANCY, 9CLERMONT-FERRAND, 10CAEN, 11NANTES, 12DIJON, 13MONTPELLIER, 14BORDEAUX, 15MARSEILLES, FRANCE

O 2116 15:45
Spinal cord volume loss in multiple sclerosis patients: a 7-Year longitudinal study
C. Tsagkas1, M. Magon1, L. Gaetano1, S. Pezold1, Y. Naegelin1, M. Amann1, P. Cattin1, A. Falini1, M. Filippi MILAN, ITALY

O 2117 16:00
Human polyomavirus JC and BKV antibody response in patients with PML
O. Adams, M. André, H.-P. Hartung, C. Warnke DUSSELDORF, GERMANY

O 2118 16:00
Menarche is not associated with MS onset or disease activity in a prospective cohort of CIS women
ORAL SESSION: NEUROREHABILITATION
14:45-16:15 | HALL M4
CHAIRPERSONS:
Tiina Rekand, BERGEN, NORWAY
Dafin Muresanu, CLUJ-NAPOKA, ROMANIA

O 2119 14:45 Mechanisms of motor plasticity after stroke
A. Guggisberg, P. Nico1, A. Schnider1 I GENEVA, SWITZERLAND

O 2120 15:00 Risk assessment within 4 days after whiplash injury identifies long-term painful and non-painful neurologic disability: a twelve-year prospective study
M.K. Rasmussen1, T.S. Jensen1, H. Kasch1,1 AARHUS, 2VYBORG, DENMARK

O 2121 15:15 Vascular encephalopathy impairs behavioural compensation following acute unilateral vestibulopathy
A. Zwergal1, F. Schöberl1, M. Patzig1, R. Forbrig1, T. Brandt1, M. Dieterich1 I MUNICH, GERMANY

O 2122 15:30 Transcranial direct current stimulation combined with constraint induced movement therapy facilitates motor function in chronic stroke patients
K. Figlewski1, J.U. Blicher1, J.F. Nielsen2, K. Severinsen1, H. Andersen1 I AARHUS, HAMMEL, DENMARK

O 2123 15:45 Effects of action observation therapy on rehabilitation of motor deficits of the dominant right upper limb in patients with MS: an exploratory study with functional MRI
S. Fumagalli1, M.A. Rocca1, P. Preziosa2, R. Gatti1, R. Messina1, F.G. Martinelli Boneschi1, M. Comola1, G. Comi1, M. Filippi1 I MILAN, ITALY

O 2124 16:00 Whole-hand electrical stimulation in stroke patients in the subacute stage
K. Schwenker1, M. Christova2, B. Wutzl1, C. Florea1, H. Bartsch1, A.B. Kunz1, E. Gallasch2, E. Trinka1, F. Gerstenbrand1, S. Golaszewski1,1 SALZBURG, 2GRAZ, VIENNA, AUSTRIA

ORAL SESSION: AGEING AND DEMENTIA
16:45-18:15 | HALL C
CHAIRPERSONS:
Gunhild Waldemar, COPENHAGEN, DENMARK
Sten Fredrikson, STOCKHOLM, SWEDEN

O 2201 16:45 Roadmap to the biomarker-based diagnosis of Alzheimer’s disease
G. Frisoni1, C. Jack2, B. Winblad3, F.T. Geneva Biomarker Roadmap Task Force1 I GENEVA, SWITZERLAND, 2ROCHESTER, MINNESOTA, USA, 3HUDDINGE, SWEDEN

O 2202 17:00 Cognitive and neuroanatomical features of amyloid positivity in primary progressive aphasia (PPA)
M. Santos1, N. Ayakta1, A. Lazaris1, Z. Miller1, E.G. Spinelli1, M.L. Mandelli1, H. Hubbard1, H. Rosen1, W. Jagust2, B.L. Miller2, L. Grinberg2, W.W. Seeley1, G. Rabinovici1, M.L. Gorno-Tempini1 I SAN FRANCISCO, USA

O 2203 17:15 In vivo correlates of pathological diagnosis in primary progressive aphasia
E.G. Spinelli1, M.L. Mandelli2, M. Santos3, G. Vinceti3, C. Watson4, F. Agosta1, B.L. Miller2, W.W. Seeley4, M. Filippi1, M.L. Gorno-Tempini2 I MILAN, ITALY, SAN FRANCISCO, USA, MODENA, ITALY

O 2204 17:30 Higher intake of fats and carbohydrates is associated with smaller cortical thickness, whereas higher intake of vitamins is associated with larger cortical thickness
S. Staubo1, J. Aakre2, J. Syrjanen2, M. Mielke2, P. Vemuri2, Y. Geda3, W. Kremers3, M. Machulda4, D. Knopman5, R. Petersen5, C. Jack1, R. Roberts1 I HRADEC KRÁLOVE, CZECH REPUBLIC, 2ROCHESTER, MINNESOTA, USA, 3SCOTTSDALE, ARIZONA, USA

O 2205 17:45 Skin nerve α-synuclein deposits as new biomarkers for dementia with Lewy bodies
V. Donadio1, A. Incensi1, S. Capellari1, G. Rizzo1, R. Pantieri1, M. Stanzani-Maserati1, G. Devigili2, R. Eleopra2, F. Montini1, A. Baruzzi1, R. Liguori1 I BOLOGNA, UDINE, ITALY

O 2206 18:00 Retinal examination in Alzheimer’s disease
U.A. Kayabasi1, R.C. Sergott2 I ISTANBUL, TURKEY, PHILADELPHIA, USA

COPENHAGEN, DENMARK, 28 – 31 MAY, 2016
104
**ORAL SESSION: HEADACHE AND PAIN**  
**16:45-18:15 | HALL M4**  
CHAIRPERSONS:  
Dimos Mitsikistas, ATHENS, GREECE (TBC)  
Rigmor Jensen, GLOSTRUP, DENMARK

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>O 2207</td>
<td>Neurophysiological evaluation of pain processing in progressive supranuclear palsy</td>
<td>C. Tassorelli, M. Avenali, R. de Icco, M. Berlangieri, E. Berra, R. Zangaglia, C. Pacchetti, G. Sandrini</td>
<td>I PAVIA, ITALY</td>
</tr>
<tr>
<td>O 2209</td>
<td>Variability of clinical features in attacks of migraine with aura</td>
<td>J. M. Hansen, P. J. Goadsby, A. Charles</td>
<td>I COPENHAGEN, DENMARK</td>
</tr>
<tr>
<td>O 2210</td>
<td>Sensory migraine aura is not associated with structural grey matter abnormalities</td>
<td>A. Hougaard, F. M. Amin, N. B. Arngrim, M. Vlachou, V. A. Larsen, H. Larsson, M. Ashina</td>
<td>I COPENHAGEN, DENMARK</td>
</tr>
<tr>
<td>O 2211</td>
<td>Randomised, double-blind, phase 2 study and 52-week interim results of an open-label extension to evaluate AMG334 for the prevention of episodic migraine</td>
<td>H. Sun, D. Dodick, P. J. Goadsby, S. Silberman, U. Reuter, M. Ashina, J. Saper, R. Cady, F. Zhang, M.-L. Trotman, J. Dietrich, R. Lenz</td>
<td>I THOUSAND OAKS, 2LONDON, UK, 3PHILADELPHIA, USA, 4BERLIN, GERMANY, 5COPENHAGEN, DENMARK, 6ANN ARBOR, 8SPRINGFIELD, USA</td>
</tr>
<tr>
<td>O 2212</td>
<td>Cost-effectiveness and feasibility of telemedicine for primary headache</td>
<td>K. I. Mueller, K. B. Alstadhaug, S. I. Bekkelund</td>
<td>I TRONDØ, 2BODØ, NORWAY</td>
</tr>
</tbody>
</table>

**ORAL SESSION: NEUROIMAGING AND NEUROIMMUNOLOGY**  
**16:45-18:15 | HALL B5.M2**  
CHAIRPERSONS:  
Gitte Moos Knudsen, COPENHAGEN, DENMARK  
Nils Erik Gilhus, BERGEN, NORWAY

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>O 2213</td>
<td>Magnetic resonance diffusion tensor imaging for evaluation of diabetic polyneuropathy</td>
<td>M. Vaezegamose, M. Pham, S. Ringgaard, H. Tanki, N. Ejskjaer, P. Poulsen, H. Andersen</td>
<td>I AARHUS C, DENMARK, 2HEIDELBERG, GERMANY, 3ODEN, DENMARK</td>
</tr>
<tr>
<td>O 2214</td>
<td>The role of functional MRI in the diagnosis and prognosis of patients with severe chronic disorders of consciousness</td>
<td>B. Wutz, C. Florea, M. Seidl, A. B. Kunz, K. Schwenker, N. Rardone, E. Trinka, F. Gerstenbrand, S. Golaszewski</td>
<td>I SALZBURG, VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>O 2217</td>
<td>Evaluation by brain MRI of white matter perivenular lesions in inflammatory microangiopathic ischemia and in demyelinating multiple sclerosis lesions</td>
<td>L. Massacesi</td>
<td>I FLORENCE, ITALY</td>
</tr>
<tr>
<td>O 2218</td>
<td>Novel findings in 13 patients with autoimmune encephalitis and antibodies to the GABAA receptor</td>
<td>M. Spatola, M. Petit-Pedrol, M. Rosenfeld, F. Graus, J. Dalmay</td>
<td>I BARCELONA, SPAIN, 2PHILADELPHIA, USA</td>
</tr>
</tbody>
</table>
**ORAL SESSION: CRITICAL CARE**

16:45-18:15 | HALL B4.M1

**CHAIRPERSONS:**
Erich Schmutzhard, INNSBRUCK, AUSTRIA
Ljiljana Beslac-Bumbasirevic, BELGRADE, SERBIA

---

**O 2219**
16:45
Comparison of different practices of therapeutic coma in status epilepticus management
V. Alvarez¹, J.W. Lee², M.B. Westover², F.W. Drislane²,
J. Novy³, M. Faouzi³, N. Marchi³, B.A. Dworetzky¹,
A. Rossetti³ ¹SION, SWITZERLAND, ²BOSTON, USA, ³LAUSANNE, SWITZERLAND

---

**O 2220**
17:00
Brain death determination in Germany: updated guidelines and the necessity to have uniform criteria
S. Brandt ¹BERLIN, GERMANY

---

**O 2221**
17:15
Status epilepticus in the intensive care unit: incidence and outcome in Australia and New Zealand from 2000 to 2013
A. Hay¹, R. Bellomo¹, D. Pilcher¹, G. Jackson¹,
K.-M. Kaukonen², M. Bailey¹ ¹MELBOURNE, AUSTRALIA, ²HELSINKI, FINLAND

---

**O 2222**
17:30
Head computed tomographic measurement as an early predictor of poor outcome after cardiac arrest
M. Moseby Knappe¹, T. Pellis², I. Dragancea³, H. Friberg¹,
J. Horn¹, M.A. Kuiper⁴, N. Nielsen¹, A. Roncarati⁵,
T. Cronberg¹ ¹LUND, SWEDEN, ²PORDENONE, ITALY, ³AMSTERDAM, THE NETHERLANDS, ⁴LEEUWARDEN, THE NETHERLANDS

---

**O 2223**
17:45
Quantitative EEG in phase-2 trial of SAGE-547: lessons learned for international phase3, randomised, controlled trial for super-refractory status epilepticus (the STATUS trial)
M. Ouir¹, E. Rosenthal³, F. Postma¹, H. Colquhoun¹ ¹CAMBRIDGE, ²BOSTON, USA

---

**O 2224**
18:00
Intravenous epoprostenol for treatment-refractory reversible cerebral vasconstriction syndrome (RCVS)
A.L. Thydén¹, A. Abdul-Alzahra Muhamad³, A. Jacobsen³,
D. Kondziella² ¹KØBENHAVN V, ²COPENHAGEN, DENMARK

---

**ORAL SESSION: MOVEMENT DISORDERS 2**

16:45-18:15 | HALL M5

**CHAIRPERSONS:**
Elena Moro, GRENOBLE, FRANCE
Bernhard Uitdehaag, MAARSSEN, THE NETHERLANDS (TBC)

---

**O 2225**
16:45
Identification of a ponto-cerebello-thalamo-cortical circuit in orthostatic tremor during lying and standing
A. Zwergal, F. Schöberl, K. Feil, G. Xiong, K. Jahn, T. Brandt,
M. Strupp, M. Dieterich ¹MUNICH, GERMANY

---

**O 2226**
17:00
Structural and functional brain network alterations in psychogenic dystonia
F. Agosta¹, E. Sarasso¹, A. Tomic², S. Basaia³, M. Svetel²,
G. Mandic-Stojmenovic³, M. Copetti³, V.S. Kostic³, M. Filippi¹ ¹MILAN, ITALY, ²BELGRADE, SERBIA, ³SAN GIOVANNI ROTONDO, ITALY

---

**O 2227**
17:15
Structural organisation of the brain connectome in patients with psychogenic dystonia
S. Basaia¹, F. Agosta¹, A. Tomic², E. Sarasso³, M. Svetel²,
S. Galantucci³, V.S. Kostic³, M. Filippi¹ ¹MILAN, ITALY, ²BELGRADE, SERBIA

---

**O 2228**
17:30
Relationship between freezing and pedunculopontine nucleus’ size in Parkinson’s disease: semi quantitative analysis based on MRI with modified FGATIR sequence
S. Chen, M. Tir, P. Monet, J.-M. Constans, O. Godefroy,
M. Lefranc, P. Krystkowiak ¹AMIENS, FRANCE

---

**O 2229**
17:45
An ongoing phase-2, open-label, study of WTX101 in Wilson disease patients – early observations
A. Czlonkowska¹, K.H. Weiss², A. Ala³, F. Askari², D. Nicholl³,
M. Schils³ ¹WARSAW, POLAND, ²HEIDELBERG, GERMANY,
³GUILDFORD, UK, ⁴ANN ARBOR, USA, ⁵BIRMINGHAM, UK, ⁶NEW HAVEN, USA

---

**O 2230**
18:00
Phosphorilated alpha-synuclein cutaneous deposits and cardiac autonomic involvement in α-Synucleinopathies
M.P. Giannoccaro, V. Donadio, A. Incensi, E. Cason, R. Liguori
¹BOLOGNA, ITALY
POSTER SESSION
AGEING AND DEMENTIA 3
12:30-13:15 | SCREEN A2
CHAIRPERSONS:
Sandro Sorbi, FLORENCE, ITALY

P 21001 Incidence of dementia in patients suffering from depression and bipolar disorder
E. Giyazitdinova, B. Muinjonov, G. Rakhimbaeva, Y. Musaeva, F. Shermukhamedova | TASHKENT, UZBEKISTAN

P 21002 The use of benzodiazepines in the REMIND cohort: a cross-sectional study in elderly people with cognitive complaints
G. Grande, I. Tramacere, S. Pomati, C. Mariani, G. Filippini | MILAN, ITALY

P 21003 Assessing genetic risk factors for Alzheimer’s disease in a Hungarian cohort
Z. Grosz, R. Bencsik, V. Reményi, D. Csaban, B. Szatmari, M. J. Molnár | BUDAPEST, HUNGARY

P 21004 Abstract cancelled

P 21005 Clinical features of adult-onset neuronal intranuclear inclusions disease
Y. Harigaya1, Y. Nakano2, H. Hatsuta2, M. Sato1, K. Mizushima1, S. Murayama2 | MAEBASHI, ITABASHI, JAPAN

P 21006 Data-driven differential diagnostics of neurodegenerative diseases
A. Tolonen1, H. Rhodius-Meester3, M. Bruun4, M. Baroni5, J. Koikkalainen1, F. Barkhof3, B. Tijms3, M. Baroni5, J. Lötjönen1 | TAMPERE, KUOPIO, FINLAND, AMSTERDAM, THE NETHERLANDS, COPENHAGEN, DENMARK, PERUGIA, ITALY, LONDON, UK

P 21007 Improved fitness after aerobic exercise in patients with mild Alzheimer’s disease
N. Sobol1, S.G. Hasselbalch2, C.H. Dal1, P. Hagh3, K. Hoffmann1, K.S. Frederiksen1, A. Vogel1, V. Siersma1, G. Waldemar1, N. Beyer1 | COPENHAGEN, KOENIGSFELD, DENMARK

P 21008 EEG study
A. Horváth1, G. Barcs, A. Szucs, A. Kamondi | BUDAPEST, HUNGARY

P 21009 Functional and structural brain alterations in two independent samples of patients with posterior cortical atrophy
F. Imperiale1, F. Agosta1, E. Canu1, G. Mandic-Stojmenovic2, G. Magnani1, T. Stojkovic3, F. Caso1, E. Stefanova2, G. Comi3, V.S. Kostic3, A. Falini1, M. Filippi1 | MILAN, ITALY, BELGRADE, SERBIA

P 21010 Two times assessments on tap test for diagnosis of idiopathic normal pressure hydrocephalus
M. Ishikawa | KYOTO, JAPAN

P 21011 Regional differences in opioid use in elderly patients with dementia: a nationwide study
C.E. -A. Jensen-Dahm5, J.K. Zakarias1, C. Gasse6, G. Waldemar1 | COPENHAGEN, AARHUS, DENMARK

P 21012 Abstract cancelled

P 21013 A robot as a caregiver? Expectations of patients with early dementia stages, caregivers and medical staff
A. Korchut1, S. Szklener1, K. Rejdak1, C. Abdelnour Ruiz2, N. Tantinyá3, J. Hernández3, J. Ribes3 | LUBLIN, MADRID, BARCELONA, SPAIN

POSTER SESSIONS
CEREBROVASCULAR DISEASES 6
12:30-13:15 | SCREEN G4
CHAIRPERSON:
Didier Leys, LILLE, FRANCE

P 21014 Masked Mastoiditis’ leading to sagittal sinus thrombosis and 6th nerve palsy in an 8-year-old girl- a case report
M. Hiro, C. Ramesh | WATFORD, UK

P 21015 Syncope and transient ischemic attack due to severe orthostatic hypotension after carotid endarterectomy: a case report
C. Hirel, A. Le Roux, A. Girbovan, F. Pico | VERSAILLES, FRANCE

P 21016 Endovascular treatment of a patient with multiple, symptomatic, unruptured intracranial aneurysms of anterior and posterior cerebral circulation: a case report
I. Hustić, T. Breitenfeld, V. Kalousek, B. Culo, V. Supanc, M. Roje Bedekovic, V. Vargel Solter, V. Basic Kes | ZAGREB, CROATIA
P 21017 CRP as a predictor of the size of ischemic brain lesions among diabetic patients
D. Imamovic, E. Suljic, N. Subasic, A. Nakicevic, A. Mehicevic | SARAJEVO, BOSNIA AND HERZEGOVINA

P 21018 Does the proportion of single-chain rtPA influence the risk of epileptic seizures in patients treated by thrombolytic therapy for cerebral ischemia?
C. Jacquet1, D. Leys2, I. Sibon3, J.-L. Mas3, T. Moulin4, M. Giroud5, R. Bordet1, D. Vivien3, "BORDEAUX, PARIS, 4BESANÇON, 5DIJON, 6CAEN, FRANCE"


P 21020 CBV-ASPECTS score as a predictor of final infarct core in acute ischemic stroke

P 21021 Giant cell arteritis with eye involvement - clinical and color doppler imaging of orbital vessels features
D.C. Jianu, S.N. Jianu, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21022 Clinical and ultrasonographic features in anterior ischemic optic neuropathies
D.C. Jianu, S.N. Jianu, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21023 Clinical and neuroimaging features in emissary vein thrombosis
D.C. Jianu, S.N. Jianu, D. Matcau, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21024 Indirect carotid-cavernous fistula of low-flow type: Color Doppler imaging of retrobulbar vessels feature
D.C. Jianu, S.N. Jianu, F. Dan, L. Petrica | TIMISOARA, ROMANIA

P 21025 Cryptogenic stroke in atrial fibrillation: The Nordic Atrial Fibrillation and Stroke Study (NOR-FIB)

P 21026 Cardioembolic stroke long-term outcome in Latvia
K. Jurjans, E. Miglane, B. Lurina, A. Millers, O. Kalejs, Z. Priedei | RIGA, LATVIA

P 21027 Cardioembolic stroke prevention and mortality for elderly patients in Latvia
K. Jurjans, E. Miglane, B. Lurina, O. Kalejs, A. Millers, Z. Priedei | RIGA, LATVIA

P 21028 Eagle syndrome with bilateral internal carotid artery dissection
K. Krbot, C. Gaebel, J.M. Valdueza | BAD SEGEBERG, GERMANY

P 21029 Abstract cancelled

P 21030 Elaboration of new prognostic model for ultraearly predicting of spontaneous hemorrhagic transformation of cerebral infarct in patients with acute ischemic supratentorial stroke
O. Kozyolkin, A. Kuznietsov | ZAPOROZHYE, UKRAINE

P 21031 New multivariate prognostic model for predicting early lethal outcome after acute ischemic supratentorial stroke
O. Kozyolkin, A. Kuznietsov | ZAPOROZHYE, UKRAINE

P 21032 More severe cerebral white matter changes are associated with elevated blood pressure in acute ischemic stroke – preliminary results
M. Kwarciany, D. Gasecki, K. Kowalczy, T. Nowicki, E. Szurowska, K. Narkiewicz, B. Karaszewski | GDANSK, POLAND

P 21033 Prevalence of high on-treatment platelet reactivity to acetylsalicylic acid used in the prevention of stroke in patients with chronic renal failure
B. Labuz-Roszak, M. Horyniecki, B. Lacka-Gazdzik, M. Snit, B. Mazur, K. Pierzchala | ZABRZE, POLAND

P 21034 Capsular warning syndrome: blood pressure matters
F. Ladeira, S. Calado, M. Viana-Baptista | LISBON, PORTUGAL

P 21035 Buddy wire technique: a simple technique for treatment tortuous cervical ICA during CAS
S.-W. Lee1, S.-G. Baik2, Y. Kim3, G.-S. Song4 | YANGSAN-SI, "YANGSAN, KOREA, REPUBLIC OF"
**P 21036** Urgent stent-assisted angioplasty for severe intracranial atherosclerosis in patients with transient ischemic attack or minor stroke  
T. H. Lee, S.M. Sung, S.W. Lee | BUSAN, KOREA, REPUBLIC OF

**P 21037** Validation of the French version of the Stroke Specific Quality of Life scale (SS-QOL)  
N. Legris, A. Daumas, H. Devilliers, B. Daubail, B. Lucas, M. Giroud, Y. Béjot | DIJON, FRANCE

**P 21038** Cerebral venous thrombosis: retrospective analysis of cases from tertiary hospitals in Hong Kong  
T.C. Li, Y.F. Cheung, W.C. Fong | HKSAR, CHINA

**P 21039** Different strokes in younger folks: defining the causes of stroke in people under 45 years  
A. Lockhart, R. O’connor, I. Noone, N. Tubridy, S. O’riordan, C. Mc Guigan | DUBLIN, IRELAND

**P 21040** Determinants of adherence to oral anticoagulants in patients with atrial fibrillation and stroke  

**P 21041** Intracerebral hemorrhage in an adult with Down syndrome and MoyaMoya disease  
J.P. Marto, C. Borbinha, S. Calado, M. Viana-Baptista | LISBON, PORTUGAL

**P 21042** Auditory evoked potentials in patients with posterior circulation stroke and vertebral artery hypoplasia  
B. Zivadinovic, J. Stamenovic, B. Bisevac | NICE, SERBIA

**P 21043** Long lasting neuropsychological deficits in patients with Transient Global Amnesia (TGA)  

**P 21044** Could ambulatory blood pressure monitoring be a routine investigation for patients with mild cognitive impairment?  
M. Hamdy | CAIRO, EGYPT

**P 21045** Mortality and functional disability of post-stroke delirium  
Z. Dostovic, E. Dostovic, D. Smajlovic, O.C. Ibrahimagic, E. Becirovic | TUZLA, BOSNIA AND HERZEGOVINA

**P 21046** Incidental vs. intentional memory in patients with Parkinson’s disease (PD)  

**P 21047** Scopolamine disrupts place navigation in rats and humans  
J. Laczó, H. Markavá, V. Lobellová, I. Gazova, M. Pařízková, J. Cerman, M. Windisch, J. Hart, A. Stuchlík | BRNO, PRAGUE, CZECH REPUBLIC; LONDON, UK; ST. RADEGUND/GRAZ, AUSTRIA

**P 21048** Short Montreal Cognitive Assessment (s-MOCA): diagnostic accuracy study  
A.J. Larner | LIVERPOOL, UK

**P 21049** Young-onset cognitive decline: not always variant Creutzfeldt-Jakob disease  
J. Williamson, A.J. Larner | LIVERPOOL, UK

**P 21050** Abstract cancelled

**P 21051** Fatigue defined in the context of CNS thermoregulation  
R. Mills, C. Young | PRESTON, LIVERPOOL, UK
POSTER SESSIONS

SUNDAY, 29 MAY
12:30 - 13:15

POSTER SESSION
EPILEPSY 4
12:30-13:15 | SCREEN B2
CHAIRPERSONS:
Leone Ridsdale, LONDON, UK

P 21056  Ictal whistling: a manifestation of frontal discharge
J. El Helou, S. Abbas, S. Koussa | BEIRUT, LEBANON

P 21057  West Syndrome in Latvia (2004-2014)
L. Liepiņa | RIGA, LATVIA

P 21058  Abstract cancelled

P 21059  Double therapy in partial epilepsy: lamotrigine and levetiracetam
Z. Luciano-García, V. Hernando-Requejo, N. Huertas-González | MADRID, SPAIN

P 21060  Abstract cancelled

P 21061  Olfactory auras in patients with temporal lobe epilepsy
R. Manso Calderón | SALAMANCA, SPAIN

P 21062  Emotional affective disorders in elderly patients with post-stroke epilepsy
A. Druzhinin, V. Mikhailov, M. Kissin | SANKT-PETERSBURG, RUSSIAN FEDERATION

P 21063  Neurophysiological features of the pathogenesis of epilepsy in the elderly
V. Mikhailov, A. Druzhinin, A.L. Gorelyk | SANKT-PETERSBURG, RUSSIAN FEDERATION

P 21064  Online epilepsy counseling in Croatia: what do the users want to know?
M. Milosevic, L. Friedrich, I. Bielen, S. Tomasović | ZAGREB, CROATIA

P 21065  Nocebo in epilepsy: meta-analysis of placebo-controlled clinical trials
P. Zis, F. Shafiq, D. Mitsikostas | SHEFFIELD, UK, ATHENS, GREECE

---

P 21052  High prevalence of cognitive impairment in Slovenian patients with diabetes mellitus type 2 (DM2)
L. Mumelj, M. Rakusa, M. Cokolic, A. Zavratnik, M. Rakusa | MARIBOR, SLOVENIA

P 21053  Relation of hypertension and depression-executive dysfunction syndrom in hypertensive stroke patients
L. Mumladze, N. Lobjanidze, N. Akiashvili | TBILISI, GEORGIA

P 21054  The assessment of cognitive and mood disturbances in patients with Parkinson’s disease without dementia

P 21055  Deep phenotyping of Frontotemporal Dementia (FTD) and FTD-MND in Ireland (A clinic-based cohort longitudinal study)
T.A. Omer, S. Hutchinson, C. Doherty, O. Hardiman | DUBLIN, IRELAND

---

P 21056  Ictal whistling: a manifestation of frontal discharge
J. El Helou, S. Abbas, S. Koussa | BEIRUT, LEBANON

P 21057  West Syndrome in Latvia (2004-2014)
L. Liepiņa | RIGA, LATVIA

P 21058  Abstract cancelled

P 21059  Double therapy in partial epilepsy: lamotrigine and levetiracetam
Z. Luciano-García, V. Hernando-Requejo, N. Huertas-González | MADRID, SPAIN

P 21060  Abstract cancelled

P 21061  Olfactory auras in patients with temporal lobe epilepsy
R. Manso Calderón | SALAMANCA, SPAIN

P 21062  Emotional affective disorders in elderly patients with post-stroke epilepsy
A. Druzhinin, V. Mikhailov, M. Kissin | SANKT-PETERSBURG, RUSSIAN FEDERATION

P 21063  Neurophysiological features of the pathogenesis of epilepsy in the elderly
V. Mikhailov, A. Druzhinin, A.L. Gorelyk | SANKT-PETERSBURG, RUSSIAN FEDERATION

P 21064  Online epilepsy counseling in Croatia: what do the users want to know?
M. Milosevic, L. Friedrich, I. Bielen, S. Tomasović | ZAGREB, CROATIA

P 21065  Nocebo in epilepsy: meta-analysis of placebo-controlled clinical trials
P. Zis, F. Shafiq, D. Mitsikostas | SHEFFIELD, UK, ATHENS, GREECE
P 21066  Focal epilepsy with occipital calcifications as a late presentation of a silent coeliac disease: clinical, radiological and electroencephalographic findings of two patients

P 21067  First real-life experience with Perampanel in primary generalized epilepsies
J. Montoya, A. Arciniegas, J. Escriba, B. Hoyo  I XATIVA, SPAIN

P 21068  I am not alone: epilepsy self-management education and support in groups
L. Ridsdale, S. Philpott, A.-M. Krooupa, M. Morgan  I LONDON, UK

P 21069  Recurrent state of confusion during presentation of HaNDL syndrome: report of two cases and review of the literature
T. Bourinaris, T. Kalantzakou, G. Xiromerisiou, K. Katsiordanis, P. Petrou, X. Fitsioris, G. Deretzi  I THESSALONIKI, GREECE

P 21070  Interim analysis from the long-term study of the real-life use of onabotulinumtoxinA for the symptomatic treatment of chronic migraine (REPOSE Study)
F. Ahmed1, J. Pascual3, H. Geevarghese2, S. Brown2  I 1ELLOUGHTON, 2MARLOW, BUCKINGHAMSHIRE, UK, 3SAN SEBASTIAN, SPAIN

P 21071  A rare case of bilateral cluster headache - initially left sided cluster headache changing to a right sided cluster headache and subsequently to bilateral cluster headache
A. Buture, R. Nimeri, M. Hussain, F. Ahmed  I HULL, UK

P 21072  Pain paroxysms with coronal radiation: proposal of a new variant of epicrania fugax
J. Casas1, M.L. Cuadrado1, M. Ruiz Piñero2, E. Martinez2, Á. Gutiérrez-Viedma2, C. Ordás-Bandera2, A.L. Guerrero2  I 1MADRID, 2VALLADOLID, MOSTOLES, SPAIN

P 21073  A novel ATP1A2 mutation in a familial hemiplegic migraine with cognitive impairment
C. Chagot1, S. Frisman1, F. Riant2, E. Tournier-Lasserve2, L. Tyvaert1  I 1NANCY, 2PARIS, FRANCE

P 21074  Abstract cancelled

P 21075  Internal jugular vein thrombosis in a patient with cranial venolymphatic malformation and ocular migraine
A. Ciobotaru, A.C. Mergeani, G. Rusu, F. Antochi, B. Dorobat, C. Cocilu, A. Dimitriade, O. Bajenaru  I BUCHAREST, ROMANIA

P 21076  Headache as isolate symptom in a case of extensive cerebral veins thrombosis
I.-H. Cioreanu1, M.R. Măceanu1, C. Baetu2, M.G. Giurea Neacsu3  I 1BRASOV, 2BUCHAREST, ROMANIA

P 21077  Case report of nummular headache attributed to Langerhans cells histiocytosis. Is there evidence of a peripheral mechanism?
B. Colombo1, G. Magnani1, S. Guerrieri2, V. Martinelli2, G. Comi1  I 1MILAN, 2ALME, ITALY

P 21078  Validating the English version of the Comprehensive Headache-related Quality of Life Questionnaire (CHQQ): first results
E.Csepany, K. Haslum, M. Magyar, T. Gyure, C. Ertsey  I BUDAPEST, HUNGARY

P 21079  Post-dural puncture headache and other complications following intrathecal chemotherapy administration
P. de la Riva1, N. Andrés1, N. Gonzalo2, M. Tainta-Cuezva1, M.A. Urtasun1, J.F. Marti-Massó1  I 1SAN SEBASTIAN, SPAIN, 2RANKWEIL, GERMANY

P 21080  Migraneous aura phenomenon is not subtended by microstructural changes in visual brain areas: a diffusion tensor tract-based spatial statistic (TBSS) study
A. de Mase, A. Russo, F. Conte, L. Marcuccio, D. Corbo, G. Caiazzo, A. Giordano, R. Conforti, F. Esposito, G. Tedeschi, A. Tessitore  I NAPLES, ITALY

P 21081  “Neural-Focusing”: a hybrid supportive therapy in the treatment of chronic cluster migraine: a case report
G. Dore1, M. D’Onofrio2  I 1ITTIRI, 2SASSARI, ITALY

P 21082  Headache related behaviours in population groups at high risk in Slovenia
M. Zaletel, L. Zadravec-Zaletel, J. Pretnar-Oblak, L. Zaletel-Kragelj  I LJUBLJANA, SLOVENIA
POSTER SESSIONS

SUNDAY, 29 MAY
12:30 - 13:15

POSTER SESSION
MOTOR NEURONE DISEASES 1
12:30-13:15 | SCREEN C2
CHAIRPERSON:
Vincenzo Donadio, BOLOGNA, ITALY

P 21083  Riboflavin transporter neuronopathy (RTN) is a rare but treatable adult onset motor neuron disease that may mimic ALS: report of two cases
C. Benoit1, T. Lenglet1, C. Acquaviva2, A. Veauville Merlin1, F. Salachas1, M.D.M. Amador1, Y. Nadjar1
1 PARIS, FRANCE

C. Benoit1, T. Lenglet1, C. Acquaviva2, A. Veauville Merlin1, F. Salachas1, M.D.M. Amador1, Y. Nadjar1
1 PARIS, FRANCE

P 21084  Cognitive and behavioral disorders in patients with familial and sporadic amyotrophic lateral sclerosis: clinical, genetic and radiological features
E. Bersano, F. de Marchi, I. Viganò, M.F. Sarnelli, L. Corrado, F. Palermo, V. Solara, S. D’alfonso, R. Cantello, L. Mazzini
NOVARA, ITALY

P 21085  Amyotrophic Lateral Sclerosis and oxidative stress: a double-blind trial after dietary curcumin supplement
C. Bisordi, M. Rossi, E. Caldareazzo lenco, M. Fabbrini, F. Agricola, L. Chico, A. Lo Gerfo, G. Siciliano
PISA, ITALY

P 21086  Abstract cancelled

P 21087  Acute onset Hirayama disease with extensive myelopathy on spinal cord MRI in flexed posture, illustrating a mechanical pathophysiology
M. Brems1, B. Willekens2, J. Baets3, J. van Goethem3
1 MECHELEN, BELGIUM

P 21088  Investigating resilience in caregivers of patients with Amyotrophic Lateral Sclerosis
T. Burke1, M. Elamin2, M. Galvin2, L. Gallagher2, O. Hardiman2, N. Pender1
1 DUBLIN, IRELAND

P 21089  Do hypermetabolic Amyotrophic Lateral Sclerosis (ALS) patients have different clinical and survivorship patterns as compared to non-hypermetabolic patients?
P. Jesus, B. Marin, P. Fayemendy, M. Nicol, P.-M. Preux, P. Couratier, J.-C. Desport
IMOGES, FRANCE

P 21090  Obsessive Compulsive Disorder as the initial presentation of Motor Neuron Disease/Frontotemporal Dementia: a case report.
F. de Marchi, E. Bersano, M.F. Sarnelli, I. Viganò, V. Solara, R. Cantello, L. Mazzini
NOVARA, ITALY

P 21091  Magnetic resonance measures of subcortical and cortical gray matter in amyotrophic lateral sclerosis
BARI, ITALY

P 21092  Serum Adiponectin alterations in Amyotrophic Lateral Sclerosis and frontotemporal dementia
A. Doretti, P. Bossolasco, R. Cancellò, C. Morelli, V. Silani, L. Cova
MILAN, ITALY

P 21093  Permutation entropy helps to distinguish EMG curve in axonal polyneuropathy
O. Dostal1, O. Vyšata1, P. Kunc1, M. Valis1, A. Procházka1, J. Kuchynka1
1 HRADEC KRÁLOVE, PRAGUE, CZECH REPUBLIC

P 21094  Targeting SOD1 with Morpholino for Amyotrophic Lateral Sclerosis treatment
I. Faravelli, C. Simone, F. Rizzo, G. Ulzi, A. Ramirez, M. Bucchia, A. Bordoni, N. Bresolin, G.P. Comi, S. Corti, M. Nizzardo
MILAN, ITALY

P 21095  TDP-43 is cytoplasmically mislocalised and associated with impaired stress responses and survival of primary neurons from symptomatic amyotrophic lateral sclerosis (ALS) mice
OXFORD, UK

P 21096  Abstract cancelled

P 21097  Is head tremor a sub-group of essential tremor?
B. Emmanuelle, T. Witjas, R. Carron, J. Regis, J.-P. Azulay, E. Guedj, M. Vaugayeau
Marseille, FRANCE

P 21098  Phenomenology and therapeutic strategies in a series of patients with chorea-acanthocytosis
MADRID, SAN SEBASTIAN, SPAIN
P 21099  Amphetamine-induced dyskinesias

P 21100  Switch of double-blind opicapone, entacapone or placebo to open-label opicapone: efficacy results of the 1-year extension of study BIPARK I
J. Ferreira1, A. Lees2, E. Tolosa3, W. Poewe4, M. Banach5, A. Santos2, N. Lopes3, J.F. Roeh3, P. Soares-Da-Silva6 1LISBON, 2CORONADO (S. ROMÃO E S. MAMEDE), PORTUGAL, 3LONDON, UK, 4BARCELONA, SPAIN, 5INNSBRUCK, AUSTRIA, 6CRACOW, POLAND

P 21101  Parkinsonism due to GPI-DBS for cervical dystonia
D. Flisar, M. Trost, N. Zupancic Kriznar, M. Kramberger Gregoric, B. Meglic, Z. Pirtosek  I LJUBLJANA, SLOVENIA

P 21102  Accelerometric assessment of movements in Parkinson's disease fluctuators

P 21103  Pathological features of iPSC-derived midbrain dopaminergic neurons of familial Parkinson’s disease
E. Frattini, G. Monzio Compagnoni, S. Salani, N. Bresolin, G.P. Comi, S. Corti, A. Di Fronzo  I MILAN, ITALY

P 21104  Cortical thinning associated with mild cognitive impairment in Parkinson’s disease
S. Galantucci1, F. Agosta1, T. Stojkovic1, I. Petrović1, E. Stefanova1, E. Canu1, M. Copetti1, V.S. Kostić1, M. Filipi1 1MILAN, 2SAN GIOVANNI ROTONDO, ITALY, 3BELGRADE, SERBIA

P 21105  Functional connectome organisation is altered in PD patients with mild cognitive impairment
S. Galantucci1, F. Agosta1, T. Stojkovic1, S. Basaia1, I. Stankovic2, E. Stefanova2, V.S. Kostic2, M. Filippi1 1MILAN, 2BELGRADE, SERBIA

P 21106  Features of speech in neurodegenerative diseases revealed by cepstral analysis
I. Goursky, S. Likhachev, T. Charnukha, Y. Rushkevich  IMINSK, BELARUS

P 21107  Volumetric and DTI study of the Corpus Callosum in pure Hereditary Spastic Paraplegia
F.J. Navas-Sánchez1, Y. Alemán Gómez1, J.A. Guzmán de Villoria1, L. Lillo1, I. Catalina1, J.L. Muñoz Blanco1, M. J. Sobrido2, M. Desco2, F.J. Grandas Pérez3  I MADRID, 2SANTIAGO DE COMPOSTELA, SPAIN

P 21108  Turkish version Quality Of Life In Essential Tremor Questionnaire (Quest): Validity And Reliability study
S. Guler, F. N. Turan I ADRIANOPLE, TURKEY

P 21109  Four-year longitudinal index stability data from the STRATIFY-2 study
D. Campagnolo, P.-R. Ho, R. Patel, I. Chang, M. Subramanyam, H. Koendgen, G. Kuesters, N. Campbell  I CAMBRIDGE, USA

P 21110  Modelling Uhthoff’s phenomenon: warmer outdoor temperatures might not be enough for causing a decay in cognitive functionality in Multiple Sclerosis patients
J.M. Cañete-Valdeón  I SEVILLE, SPAIN

P 21111  Characterisation of microvesicles release and gene expression profile in monocytes of patients with relapsing-remitting multiple sclerosis: preliminary results of a longitudinal study
T. Carandini, A. Finardi, L. Garzetti, L. Moiola, G. Comi, V. Martinelli, R. Furlan  I MILAN, ITALY

P 21112  The interplay of communicative and cognitive impairment in multiple sclerosis: look behind the door, not through the keyhole
A. Carotenuto1, G. Orefice1, I. Cerillo1, V. Giannino1, M. Rasulo1, G. Arcara1, V. Bambini1, R. Iodice1 1NAPLES, 2PAVIA, ITALY

P 21113  Growth Hormone/IGF-I function in CIS patients is not associated MS conversion in Interferon beta-1b therapy.
R. Lanzillo, A. Carotenuto, C. Di Somma, M. Quarantelli, M. Moccia, A. Cianflone, A. Marsili, G. Puorro, G. Sasso, C. Pivonello, C.V. Russo, A. Colao, V. Brescia Morra  I NAPLES, ITALY

P 21114  Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and glatiramer acetate in multiple sclerosis patients
A. Chan1, G. Cutter2, R. Fox3, A. Zhang4, J. Xiao4, J. Lewin4, M. Edwards4, J. Marantz4 1BOCHUM, GERMANY, 2BIRMINGHAM, ALABAMA, 3CLEVELAND, OHIO, 4CAMBRIDGE, MASSACHUSETTS, USA
P 21115 Adherence to subcutaneous interferon beta-1a in patients participating in the RebiSTAR® patient service program: interim analysis of the non-interventional study RebiSTART
A. Chan1, J. Faiss2, S. Schmidt3, A.-K. Eser4, T. Wagner5, E. Schel5, I.-K. Penner6
1BERNE, SWITZERLAND, 2TEUPITZ, 3BONN, 4DEGGENDORF, 5DARMSTADT, 6DÜSSELDORF, GERMANY

P 21116 Relationship between 25-hydroxyvitamine D levels and Multiple Sclerosis disability
J.R. Chaudhri, S. Alladi, K. Mridula, B. Balaraju, V.S. Bandaru
1HYDERABAD, INDIA

P 21117 Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) β-1a–controlled studies
F. Lublin1, D. Arnold2, A. Bar-or3, G. Comi4, H.-P. Hartung5, S. Hauser5, K. Selmaj6, A. Traboulsee6, P. Chin7, P. Fontoura9, H. Garren9, G. Klingelschmitt8, D. Masterman3, L. Kappos9
1NEW YORK, 2SAN FRANCISCO, 3SOUTH SAN FRANCISCO, USA, 4MONTREAL, CANADA, 5MILAN, ITALY, 6DÜSSELDORF, GERMANY, 7LODZ, POLAND, 8VANCOUVER, CANADA, 9BASEL, SWITZERLAND

P 21118 Hospital admissions due to infections in a cohort of multiple sclerosis patients
A. Costa, A. Silva-Pinto, R. Serrão, A. Sarmento, M.J. Sá, P. Abreu
1PORTO, PORTUGAL

P 21119 Real life experience with Tecfidera treatment in relapsing remitting multiple sclerosis
1LONDON, UK

P 21120 Combined use of kappa free light chain index and isoelectrofocusing of cerebrospinal fluid in diagnosing Multiple Sclerosis: performances and costs
I. Crespi, M.G. Sulas, R. Mora, P. Naldi, D. Vecchia, C. Comi, R. Cantello, G. Bellomo
1NOVARA, ITALY

P 21121 Pharmacokinetic and safety study of GNbAC1, a humanised monoclonal antibody for multiple sclerosis
H. Porchet, A. Lang, F. Curtin
1GENEVA, SWITZERLAND

P 21122 Comparison of azathioprine and of beta interferon efficacy on measures of brain damage evaluated by MRI in relapsing-remitting multiple sclerosis.
L. Massacesi1, M. Grammatica1, L. Vuolo1, A. Banlaro2, M.D. Benedetti2, L. La Mantia3, C. Milanese4, A.M. Repice5, A. Solari6, G. Tedeschi7, G. Filippini8
1FLORENCE, 2VERONA, 3MILAN, ITALY

P 21123 CSF and serum levels of interleukin 8 and its correlation with other CSF markers
Z. Matejcikova, J. Mares, V. Slađkova, T. Syrcinova
1OLOMOUC, CZECH REPUBLIC

P 21124 Using a multidimensional unfolding approach to assess patient preferences for disease modifying therapies in multiple sclerosis
1SALAMANCA, 2ALICANTE, 3MADRID, 4OVIEDO, SPAIN

P 21125 Abstract cancelled

P 21126 Persistent herpetic infection and multiple sclerosis activity. Is there an association?
V. Megeryan, Z. Goncharova
1ROSTOV-ON-DON, RUSSIAN FEDERATION

P 21127 Fingolimod every-other-day in Multiple Sclerosis patients who presented severe adverse events during conventional Fingolimod treatment
1MILAN, 2GALLARATE, 3LEGNANO, 4CATANIA, ITALY, 5LUGANO, SWITZERLAND

P 21128 A Phase III, open-label study to evaluate the effect of ocrelizumab on immune responses in patients with relapsing MS
L. Millar, C. Li, H. Bennett, H. Garren
1BASEL, SWITZERLAND
P 21129  The 10-year economic burden for multiple sclerosis treatment
M. Moccia, R. Palladino, R. Lanzillo, M. Triassi, V. Brescia Morra | NAPLES, ITALY

P 21130  Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis
M. Moccia, R. Palladino, A. Carotenuto, C.V. Russo, M. Triassi, R. Lanzillo, V. Brescia Morra | NAPLES, ITALY

P 21131  Full recovery of retinal periphlebitis in a multiple sclerosis patient after Natalizumab
M. Molina Sanchez, M.B. Gorroño-Echebarria, M.H. Torregrosa Martinez, P. Hernandez Navarro, L. Ayuso Peralta | MADRID, SPAIN

P 21132  Safety and tolerability of cladribine tablets added to IFN-beta therapy in patients with active relapsing multiple sclerosis: final results from the ONWARD study (amended protocol)
X. Montalban1, B. Cohen2, T. Leist3, H. Moses4, C. Hicking5, F. Dangond5 | 1BARCELONA, SPAIN, 2CHICAGO, 3PHILADELPHIA, 4NASHVILLE, 5BILLERICA, USA, 6DARMSTADT, GERMANY

P 21133  Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS)
X. Montalban1, D. Arnold2, A. Bar-or3, J. de Seza4, G. Giovannoni5, B. Hemmer6, K. Rammohan7, N. Maieron8, P. Chin9, P. Fontoura10, H. Garren11, D. Masterman12, A. Sauter13, J. Wolinsky14 | 1BARCELONA, SPAIN, 2CHICAGO, 3CHICAGO, 4PHILADELPHIA, 5NASHVILLE, 6BILLERICA, USA, 7CHICAGO, 8BASEL, SWITZERLAND

P 21134  Pulmonary eosinophilia associated to Natalizumab treatment
A. Moreira Villanueva, E. Munteis Oliva, M. Dominguez Alvarez, A. Zabalza de Torres, E. Curto Sánchez, J. Roquer González | BARCELONA, SPAIN

P 21135  Long-term clinical outcome of multiple sclerosis patients with initial spinal cord involvement
B.I. Tiftikcioglu, I. Ilguzi, Y. Gorlu, U. Sener, F. Tokucoglu | IZMIR, TURKEY

P 21136  Epidemiology of familial cases of multiple sclerosis in Tomsk region, Russian Federation

P 21137  Confirmed progressive multifocal leucoencephalopathy associated to Natalizumab treatment despite negative CSF and clinical findings
C. Tiu, C. Gavan, L. Tatau, A. Marinescu, O. Bajenu | BUCHAREST, ROMANIA

P 21138  Repetitive transcranial magnetic stimulation in the treatment of multiple sclerosis
V. Todorov1, V. Stoyanova1, S. Ivanova2, D. Bogdanova2, G. Radevski3, D. Georgiev4, K. Kmetova4, E. Milushev5, I. Milanov6 | 1SOFIA, 2SOFIA, 3SOFIA, 4SOFIA, 5SOFIA, 6SOFIA, BULGARIA

P 21139  MRI parameters as predictors of long-term disease outcome over 8 years in RRMS patients
D. Jeffery1, D. Piani Meier2, D. Tomic3, D. Häring3, T. Vollmer2 | 1MOORESVILLE, NC, 2DENVER, CO, USA, 3BASEL, SWITZERLAND

P 21140  Fingolimod effects on PASAT scores in RRMS and relation of patient characteristics to PASAT scores
D. Langdon1, I.-K. Penner2, P. Calabrese3, G. Cutter4, D. Häring5, F. Dahlke6, D. Tomic7, L. Kappos8 | 1DRESDEN, GERMANY, 2DRESDEN, GERMANY, 3DRESDEN, GERMANY, 4BIRMINGHAM, ALABAMA, USA

P 21141  Morphological peculiarities of peripheral nervous system in multiple sclerosis
O. Markovska, A. Shapkin, O. Tovzhynska, N. Nekrasova | KHARKIV, UKRAINE

P 21142  4 years PANGAEA: long-term data on effectiveness and safety from patients on natalizumab switching to fingolimod in real world
T. Ziemssen1, H. Albrecht2, J. Haas3, L. Klotz4, M. Lang5, C. Lassec6, S. Schmidt7, B. Tackenberg8, C. Cornelissen9 | 1DRESDEN, 2MUNICH, 3BERLIN, 4MÜNSTER, 5ULM, 6KASSEL, 7BONN, 8MARBURG, 9NUREMBERG, GERMANY

POSTER SESSION MS AND RELATED DISORDERS 8
12:30-13:15 | SCREEN F3
CHAIRPERSON:
Tjaef Ziemssen, DRESDEN, GERMANY

P 21135  Long-term clinical outcome of multiple sclerosis patients with initial spinal cord involvement
B.I. Tiftikcioglu, I. Ilgezi, Y. Zorlu, U. Sener, F. Tokucoglu | IZMIR, TURKEY

P 21136  Epidemiology of familial cases of multiple sclerosis in Tomsk region, Russian Federation

P 21137  Confirmed progressive multifocal leucoencephalopathy associated to Natalizumab treatment despite negative CSF and clinical findings
C. Tiu, C. Gavan, L. Tatau, A. Marinescu, O. Bajenu | BUCHAREST, ROMANIA

P 21138  Repetitive transcranial magnetic stimulation in the treatment of multiple sclerosis
V. Todorov1, V. Stoyanova1, S. Ivanova2, D. Bogdanova2, G. Radevski3, D. Georgiev4, K. Kmetova4, E. Milushev5, I. Milanov6 | 1SOFIA, 2SOFIA, 3SOFIA, 4SOFIA, 5SOFIA, 6SOFIA, BULGARIA

P 21139  MRI parameters as predictors of long-term disease outcome over 8 years in RRMS patients
D. Jeffery1, D. Piani Meier2, D. Tomic3, D. Häring3, T. Vollmer2 | 1MOORESVILLE, NC, 2DENVER, CO, USA, 3BASEL, SWITZERLAND

P 21140  Fingolimod effects on PASAT scores in RRMS and relation of patient characteristics to PASAT scores
D. Langdon1, I.-K. Penner2, P. Calabrese3, G. Cutter4, D. Häring5, F. Dahlke6, D. Tomic7, L. Kappos8 | 1DRESDEN, GERMANY, 2DRESDEN, GERMANY, 3DRESDEN, GERMANY, 4BIRMINGHAM, ALABAMA, USA

P 21141  Morphological peculiarities of peripheral nervous system in multiple sclerosis
O. Markovska, A. Shapkin, O. Tovzhynska, N. Nekrasova | KHARKIV, UKRAINE

P 21142  4 years PANGAEA: long-term data on effectiveness and safety from patients on natalizumab switching to fingolimod in real world
T. Ziemssen1, H. Albrecht2, J. Haas3, L. Klotz4, M. Lang5, C. Lassec6, S. Schmidt7, B. Tackenberg8, C. Cornelissen9 | 1DRESDEN, 2MUNICH, 3BERLIN, 4MÜNSTER, 5ULM, 6KASSEL, 7BONN, 8MARBURG, 9NUREMBERG, GERMANY
P 21143 4 years safety of fingolimod in real world: PANGAEA, a non-interventional study of safety, effectiveness and pharmacoeconomic data for fingolimod patients in daily clinical practice. T. Ziemssen1, H. Albrecht2, J. Haas3, L. Klotz4, M. Lang5, C. Lassek6, S. Schmidt7, B. Tackenberg8, C. Cornelissen9. 1DRESDEN, 2MUNICH, 3BERLIN, 4MÜNSTER, 5ULM, 6KASSEL, 7BONN, 8MARBURG, 9NUREMBERG, GERMANY

P 21144 4 years PANGAEA: A 5-year non-interventional study of safety, effectiveness and pharmacoeconomic data for fingolimod patients in daily clinical practice – effectiveness update. T. Ziemssen1, H. Albrecht2, J. Haas3, L. Klotz4, M. Lang5, C. Lassek6, S. Schmidt7, B. Tackenberg8, C. Cornelissen9. 1DRESDEN, 2MUNICH, 3BERLIN, 4MÜNSTER, 5ULM, 6KASSEL, 7BONN, 8MARBURG, 9NUREMBERG, GERMANY

P 21145 PANGAEA 2.0: State of the art multiple sclerosis patient management in daily clinical practice. A 3-year observational study of patients receiving fingolimod. T. Ziemssen1, R. Kern1, C. Cornelissen2. 1DRESDEN, 2NUREMBERG, GERMANY

P 21146 COPAXONE® Active Registry – Documentation of efficacy, tolerability and quality of life in outpatients with relapsing remitting multiple sclerosis (RRMS) treated with glatiramer acetate. U. Faude1, T. Ziemssen7. 1BERLIN, 2DRESDEN, GERMANY

P 21147 Multicenter open-label non-interventional study (NIS) assessing the alteration of activity in ambulatory patients with relapsing forms of multiple sclerosis (RRMS) under treatment with Glatiramer acetate. A. Müller-Schubert1, T. Ziemssen2, H. Reichmann1, R. Kern2, D. Fendj1. 1BERLIN, 2DRESDEN, GERMANY

POSTER SESSION MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 3
12:30-13:15 | SCREEN B4

Chairperson: Edina Varga, SZEGET, HUNGARY

P 21148 Statin induced autoimmune necrotizing myopathy. T. Kalantzakou, G. Xiromerisiou, A. Tichalas, T. Bourinaris, O. Sinani, J. Rudolf, G. Deretzi. TESSALONIKI, GREECE

P 21149 Immunological subtypes of myasthenia gravis among Ukrainian population (pilot study). O. Kalbus. DNIPROPETROVSK, UKRAINE

P 21150 Epidemiology of myasthenia gravis in the Dnipropetrovsk region, Ukraine. O. Kalbus. DNIPROPETROVSK, UKRAINE

P 21151 Anxiety and depression among myasthenia gravis patients. O. Kalbus. DNIPROPETROVSK, UKRAINE

P 21152 B-cell activating factor is elevated in serum of patients with myasthenia gravis. S.-Y. Kang. JEJU, KOREA, REPUBLIC OF.

P 21153 Remudy, Japanese national registry for neuromuscular diseases. E. Kimura1, H. Nakamura1, S. Mitsuhashi1, M. Morin-Yoshimura1, M. Takahashi1, P. Takeuchi1, S. Wus1, Y. Zheng1, T. Matsumura1, H. Komaki1, I. Nishino1, M. Kawai1, H. Dawkins2, C. Bérard3, H. Loeschmuller4, S. Takeda5. 1KODAIRA, 2SUIIRA, 3HASUDA, 4JAPAN, 5BEIJING, 6DONGYING, CHINA, 7PERTH, 8MARSEILLES, FRANCE, 9NEWCASTLE UPON TYNE, UK


P 21155 Paraneoplastic neuromuscular syndromes and ion channels antibodies. D. Labunskiy. SANTA ROSA, USA

P 21156 Usefulness of MRI in cases of hyperCKemia. P. Marti1, N. Muelas1, J. Diaz-Manera2, J. Vilchez2. 1VALENCIA, 2BARCELONA, SPAIN

P 21157 TRPV2 inhibition therapy can be effective for cardiomyopathy of muscular dystrophy. T. Matsumura1, M. Matsui1, Y. Iwata2, M. Asakura2, T. Saito1, H. Fujimura1, S. Sakoda1. 1TOYONAKA, 2SUIIRA, JAPAN

P 21158 Acute steroid-induced respiratory myopathy secondary to intravenous methylprednisolone for multiple sclerosis relapse. N. McNicholas, E. McKone, C. McGuigan. DUBLIN, IRELAND

P 21160  The prevalence of dementia in Sidi M’Hamed, a district of Algiers city
S. Belarbi, M.I. Kediha, F. Mostefaoui, S. Abroukk, M. Tazir
ALGIERS, ALGERIA

P 21161  Neurological service use around pregnancy
D. Bereczki Jr., A. Ajtay, F. Oberfrank, I. Vastagh
BUDAPEST, HUNGARY

P 21162  Trends in incidence of TIA and ischemic strokes: comparing data from two community-based studies
R. Felgueiras, R. Magalhães, M.C. Silva, M. Correia
PORTO, PORTUGAL

MURCIA, SPAIN

P 21164  Use of neuroimaging in patients presenting with seizure: concordance between guidelines and clinical practice.
MURCIA, SPAIN

P 21165  Anatomical variations circle Willis, aneurisms correlation, and relationship with subarachnoid haemorrhage
E. Harizi1, A. Rroji2
DURRES, TIRANA, ALBANIA

P 21166  Epidemiology of brain and spinal tumours in a sample eight years from a tertiary hospital in Guanajuato, Mexico
M. Maldonado-Vega, F. Farias Serratos, M.A. Guerrero-Ramos, A. Tabares
LEÓN, MEXICO

P 21167  Descriptive analysis of ambulatory neurological care demand in Salamanca, Spain
R. Manso Calderón
SALAMANCA, SPAIN

P 21168  Peripheral Nervous System involvement in spinocerebellar ataxia type 3 - clinical and neurophysiological evaluation
COIMBRA, PORTUGAL

P 21169  Joubert’s syndrome: clinical and radiological findings in 14 patients
L. Ali Pacha1, S. Assami1, S. Nouioua1, T. Benhassine1, E.M. Valente2, M. Tazir1
ALGIERS, ALGERIA, ROME, ITALY

P 21170  Gene-specific DNA methylation is related to drug treatment in Alzheimer’s disease patients
M. Altuna1, I. Rubio1, A. Labarga2, R. Larumbe llundain2, M. Zelaya3, J. Ruiz-Sánchez de Gordoa3, M. Roldán3, C. Echavarri3, M. Mendioroz3
PAMPLONA, ALGASUA, SPAIN

P 21171  Infantile neuroaxonal dystrophy in two female Albanian siblings
A. Babameto Laku, Z. Ylli, D. Ylli, M. Rakacoli, J. Kruja
TIRANA, ALBANIA

P 21172  Differential diagnosis of hyperintense corticospinal tract lesions, detected in adult patients with spastic paraplegia
BUDAPEST, HUNGARY

P 21173  LRRK2, MAPT and HTRA2 mutations in the pedigree of familial neurodegenerative parkinsonism with cognitive deterioration spanning five generations in a genetically isolated population of south-eastern Moravia, Czech Republic
T. Bartonikova, R. Vodicka, K. Mensikova, R. Vrtel, M. Godava, P. Kanovsky, P. Otruba, M. Kaiserova, M. Vaštík, L. Mikulicova
OLOMOUC, CZECH REPUBLIC

P 21174  A post-translational modification in histone is a novel marker for nociceptive activation in primary sensory neurons
S. Beattie, J.V. Torres-Perez, I. Nagy
LONDON, UK

P 21175  Next generation sequencing of SORCS3 in multiple sclerosis patients and controls from the isolated Faroe Islands
S. Binzer1, E. Stenager2, M. Binzer3, J. Hillert3, K. Imrell3
ODENSE, SØNDERBORG, STOCKHOLM, SWEDEN
POSTER SESSIONS

SUNDAY, 29 MAY
12:30 – 13:15

P 21176  Hereditary Spastic Paraplegia: clinical and mutational spectrum in the unexplored Greek population
M. Breza1, G. Koutsis1, D. Lynch2, G. Karadima1, A. Polymeris1, R. Pons1, A. Tucci2, F.M. Santorelli3, A. Tessa1, H. Houlden2, M. Panas1 I ATHENS, GREECE, 1LONDON, UK, 2PISA, ITALY

P 21177  Orthotopic liver transplantation in an MNGIE patients as a successful measure to correct biochemical imbalance
C. Casali I ROME, ITALY

P 21178  Characterisation of a Leber’s hereditary optic neuropathy family with multiple affecteds and two primary LHON mutations m.11778G>A and m.14484T>C
C. Catarino1, U. Ahting1, K. Peters2, C. Wilhelm1, K. Hörtnagel2, S. Biskup2, B. Livionius-Freifrau von Eyb1, T. Meitinger1, T. Klopstock1 I MUNICH, TÜBINGEN, GERMANY

P 21179  Cerebellar and motor pathways changes in diffusion tensor imaging and tractography in cerebrotendinous xanthomatosisis can be partially reversed by treatment with chenodeoxycholic acid
C. Catarino1, C. Vollmar1, C. Kupper1, C. Gallenmüller1, S. Lechner1, K. Hörtnagel2, C. Wilhelm1, S. Biskup2, T. Klopstock1 I MUNICH, TÜBINGEN, GERMANY

P 21180  GNE myopathy in Roma patients homozygous for the p.I618T founder mutation
T. Chamova1, M. Gospodinova1, V. Guergueltcheva1, S. Krause3, S. Cirak1, A. Kaprelyan2, L. Angelova2, V. Mihaylova1, S. Bichev1, D. Chandler6, E. Naydenov1, M. Grudkova1, P. Djukmedzhiev1, D. Bogdanova1, K. Kmeteka1, T. Voit8, O. Pogoryelova1, H. Lochmuller9, H. Goebel9, M. Bahlo7, L. Kalaydjieva1, I. Tournev1 I SOFIA, VARNA, BULGARIA, 1MUNICH, 2COLOGNE, 3BERLIN, GERMANY, 4PERTH, 5PARIS, FRANCE, 6PERTH, 7PARKVILLE, AUSTRALIA, 8PARIS, FRANCE, 9NEWCASTLE, UK

P 21181  A case of late-onset Pompe disease diagnosed by Whole Exome Sequencing despite inconclusive initial muscle biopsy and biochemical studies
D. Katzanä1, H. Latsoudis1, E. Vogiatzi1, A. Plaitakis1, I. Zaganas1 I HERAKLION, CRETE, GREECE

P 21182  Refractory status epilepticus caused by anti-NMDAR encephalitis: a case report
T. Al-Harbi, S. Abdulmanaa1 I DAMMAM, SAUDI ARABIA

P 21183  Circulating anti-CD64 antibodies and clinical outcome in multiple sclerosis patients
P. Annunziata, G. Masi, C. Cioni1 I SIENNA, ITALY

P 21184  Diagnostic and clinical significance of antigen-specific anti-Helicobacter pylori antibodies in patients with multiple sclerosis

P 21185  Autoimmune storm
S. Aslan, C.E. Bekircan-Kurt, A.T. Kurne, S. Erdem-Özdamar I ANKARA, TURKEY

P 21186  Association between neuromyelitis optica spectrum disorders and Behçet’s disease in 2 Moroccan patients
A. Bennis, Z. Attar, F. Dany, M.A. Rafai, B. El Moutawakil, H. El Otmani, I. Slassi I CASABLANCA, MOROCCO

P 21187  The role of serotonin in regulating interactions of the immune and nervous system in multiple sclerosis
A. Boyko, M. Melnikov, M. Pashenkov I MOSCOW, RUSSIAN FEDERATION

P 21188  GNE myopathy in Roma patients homozygous for the p.I618T founder mutation
T. Chamova1, M. Gospodinova1, V. Guergueltcheva1, S. Krause3, S. Cirak1, A. Kaprelyan2, L. Angelova2, V. Mihaylova1, S. Bichev1, D. Chandler6, E. Naydenov1, M. Grudkova1, P. Djukmedzhiev1, D. Bogdanova1, K. Kmeteka1, T. Voit8, O. Pogoryelova1, H. Lochmuller9, H. Goebel9, M. Bahlo7, L. Kalaydjieva1, I. Tournev1 I SOFIA, VARNA, BULGARIA, 1MUNICH, 2COLOGNE, 3BERLIN, GERMANY, 4PERTH, 5PARIS, FRANCE, 6PERTH, 7PARKVILLE, AUSTRALIA, 8PARIS, FRANCE, 9NEWCASTLE, UK

P 21189  Paraplegia following lumbar puncture: a rare complication of spinal dural arteriovenous fistula
A. Čakar, H. I. Akçay, T. Gunduz, M. Kürtüncu I ISTANBUL, TURKEY

P 21190  Adhesion molecule dynamics after Natalizumab withdrawal in T - lymphocytes subpopulations
A. Cobo1, A. Figueras2, L. Bau2, E. Matas3, M.A. Mañe3, L. Romero Pinel2, S. Martinez Yelamos2 I LYONS, FRANCE, 1BARCELONA, 2TARRAGONA, SPAIN

A. Cobo1, A. Figueras2, L. Bau2, E. Matas3, M.A. Mañe3, L. Romero Pinel2, S. Martinez Yelamos2 I LYONS, FRANCE, 1BARCELONA, 2TARRAGONA, SPAIN

C. Casali I ROME, ITALY

P 21183  Circulating anti-CD64 antibodies and clinical outcome in multiple sclerosis patients
P. Annunziata, G. Masi, C. Cioni1 I SIENNA, ITALY

P 21184  Diagnostic and clinical significance of antigen-specific anti-Helicobacter pylori antibodies in patients with multiple sclerosis

P 21185  Autoimmune storm
S. Aslan, C.E. Bekircan-Kurt, A.T. Kurne, S. Erdem-Özdamar I ANKARA, TURKEY

P 21186  Association between neuromyelitis optica spectrum disorders and Behçet’s disease in 2 Moroccan patients
A. Bennis, Z. Attar, F. Dany, M.A. Rafai, B. El Moutawakil, H. El Otmani, I. Slassi I CASABLANCA, MOROCCO

P 21187  The role of serotonin in regulating interactions of the immune and nervous system in multiple sclerosis
A. Boyko, M. Melnikov, M. Pashenkov I MOSCOW, RUSSIAN FEDERATION

P 21188  Paraplegia following lumbar puncture: a rare complication of spinal dural arteriovenous fistula
A. Čakar, H. I. Akçay, T. Gunduz, M. Kürtüncu I ISTANBUL, TURKEY

P 21190  A rare case of longitudinally extensive transverse myelitis - never disregard tuberculosis
C. Coclitu1, A.C. Mergeani1, O. Rusu1, A. Ciobotaru2, T. Parvu2, O. Bajenaru1, F. Antochi1 I BUCHAREST, ROMANIA
P 21191 Spastic paraparesis as the initial manifestation of Sjögren’s syndrome  
F. Correia1, C. Cunha2, L.M. Afonso3, R. Alves4  
1PORTO, 2MATOSINHOS, PORTUGAL

P 21192 Maternal CASPR2 antibodies in neurodevelopmental disorders: findings in human cohorts and in a rodent maternal transfer model.  
E.P. Coutinho5, L. Jacobson5, D. Menassa6,1, J. Domingos5, T. Moloney5, M. Benros3, M. Pederson3, B. Lang4, P.J. Harrison5, P.B. Mortensen3, D. Bannerman5, T. Moloney5, B. Nørgaard-Pedersen5, A. Vincent6  
1OXFORD, UK, 2COPENHAGEN, 3AARHUS, DENMARK

P 21193 Microvesicles as a possible biomarker for microglia activation in vivo during phases of disease activity in Multiple Sclerosis.  
T. Croese, G. Dalla Costa, M. Pisa, V. Martinelli, G. Comi, R. Furlan  
MILAN, ITALY

P 21194 Hepatocellular carcinoma and anti-N-methyl-D-aspartate receptor encephalitis  
C. Cunha, M. Baptista, F. Correia, S. França  
PORTO, PORTUGAL

P 21195 Peripheral regulatory T / Th17 cells contributes to Moya Moya disease  
Y. Xu, X. Cao, L. Weng, D. Guan  
NANJING, CHINA

P 21196 Causes of sporadic cerebellar ataxia with sensory neuronopathy  
P. Zis, P. Sarigiannis, D.G. Rao, M. Hadjivassiliou  
SHEFFIELD, UK

P 21197 Functional rearrangement of language areas in an adult patient with a left frontal lobe Glioblastoma  
PORTUGAL

P 21198 Abstract cancelled

P 21199 Abstract cancelled

P 21190 Ma2-associated paraneoplastic limbic encephalitis in a patient with adeno-carcinoma of the lung  
A. Grisold1, R. Höftberger1, B. Giometto2, E. Aufff1, T. Sycha3  
1VIENNA, AUSTRIA, 2PADUA, ITALY

P 21191 Tanycytic ependymoma of the brain stem - presentation of a rare cystic disease variant and review of literature  
F. Ippen, R. Pfannl, R. Rojas, A. Mahadevan, E. Kasper  
BOSTON, USA

P 21192 Periophthalal dissociation in meningial carcinomatosis – a rare presentation of Ewing Sarcoma  
A. Lazaroue1, I.-R. Carcalici, C. Roman Filip2  
1SIBIU, ROMANIA

P 21193 Tongue myokymia as an unusual symptom of a meningioma of the craniospinal junction  
D. Leupold, O.C. Kim, C. Brugnolato, T. Hundsberger  
ST. GALLEN, SWITZERLAND

P 21194 Primary central nervous system lymphoma: a chameleon case  
M. Lopes1, C. Santos1, V. Mesquita2, L. Regadas2, J. Coutinho3  
1SANTA MARIA DA FEIRA, 2PORTO, PORTUGAL

P 21195 Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme  
M. Lopes1, B. Carvalho2, P. Linhares2, R. Vaz3  
1SANTA MARIA DA FEIRA, 2PORTO, PORTUGAL

P 21196 Incomplete cavernous sinus syndrome as unusual presentation of metastatic prostate adenocarcinoma  
M. Machio Castello, M. Oses, A. Jaimes, D.A. Escobar Montataixe, B. Pfang, A. Martinez Pueyo, R. Saez Pinel, J. Villacampa Aubá, M.A. Garcia-Torres, I. Zambride Capdepón  
MADRID, SPAIN

P 21197 Incidence of brain tumours in the Maltese Islands: a population based study  
M. Mallia1, R. Galea2, M.-A. Mifsud1, M. Gruppetta1, M.-A. Zammit1  
1BIRKIRKARA, 2MSIDA, MALTA

P 21198 Trouseau’s quest - Ischemic stroke and solid cancer: a retrospective 10 year case-control study  
C. Marques-Matos, A. Costa, G. Moreira, E. Azevedo, M. Carvalho  
PORTO, PORTUGAL

P 21199 Atypical neurologic presentation of diffuse large B-cell lymphoma  
J.P. Marto, F. Ladeira, C. Borbinha, T. Lampreia, M. Viana-Baptista  
LISBON, PORTUGAL
POSTER SESSION
NEURO-OPHTHALMOLOGY/ NEUROTOLOGY 1
12:30-13:15 | SCREEN H1
CHAIRPERSON:
Katharina Feil, MUNICH, GERMANY

P 21210 Features of contrast sensitivity in Parkinson’s disease and its changes during motor fluctuations
O. Alenicova, S. Likhachev, I. Goursky | MINSK, BELARUS

P 21211 Optic neuropathy in pernicious anaemia
J. Alves, M.J. Silva, C. Fraga | PENAFIEL, PORTUGAL

P 21212 Abstract cancelled

P 21213 Interhemispheric asymmetry and its role in higher-order vestibular function
Q. Arshad, A. Bronstein | LONDON, UK

P 21214 Association of multiple sclerosis and sudden deafness
S. Atula, S. Sinkkonen, R. Saat, T. Sairanen, T. Atula | HELSINKI, FINLAND

P 21215 Acute bilateral mydriasis associated with anti-GQ1b antibodies
A. Barros, S. Dias, S. Vaz, R. Relvas | LISBON, PORTUGAL

P 21216 Brainstem decompression and unilateral cerebellar tonsil resection in patients with Chiari malformation: prospective examination of clinical outcome and cerebellar, vestibular, and oculomotor function
N. Böttcher, K. Feil, M.L. Strupp, A. Peraud | MUNICH, GERMANY

P 21217 Vestibular function in patients with Niemann-Pick type C disease
T. Bremon1, S. Krafczyk1, S. Bardins1, E. Mengel2, J. Reineke2, M. Strupp1 | MUNICH, MAINZ, GERMANY

P 21218 Oculomotor findings and their correlation with clinical abnormalities in Gaucher disease type3
T. Bremon1, R. Schifffmann3, M. Patterson4, N. Belmatoug5, S. Bardins1, V. Malinova6, E. Mengel2, J. Reineke2, M. Strupp1 | MUNICH, MAINZ, GERMANY, DALLAS, ROCHESTER, USA, CLICHY, FRANCE, PRAGUE, CZECH REPUBLIC

P 21219 Acetazolamide in vestibular migraine prophylaxis: a retrospective study
N. Celebisoy, F. Gokcay, C. Bilgen, T. Kirazli, H. Karapolat, T. Kose | IZMIR, TURKEY

P 21220 Eye movements at an early stage of essential tremor
N. Celebisoy, M. Çelebisoy, A. Süzen Ekinci, E. Akyuz, A. Acarer | IZMIR, TURKEY

POSTER SESSION
NEUROREHABILITATION 2
12:30-13:15 | SCREEN G2
CHAIRPERSON:
Michaela Bisciglia, BRUSSELS, BELGIUM

P 21221 What’s behind cerebellar dizziness?
K. Feil, A. Schindler, S. Krafczyk, A. Zwergal, F. Schöberl, M. Strupp | MUNICH, GERMANY

P 21222 Functional evaluation of stroke patients undergoing early physiotherapy in the Neurointensive care unit

P 21223 Activities of daily living with FampyraLR
J. Jansa | LJUBLJANA, SLOVENIA

P 21224 Study on clinical therapeutic effect of acupuncture on post-stroke depression
Y. Kim, C. F. Teo | SKUDAI, JOHOR, MALAYSIA

P 21225 Comparing the efficacy of different types of repetitive navigated transcranial magnetic stimulation in treatment of pharmacoresistant spasticity in patients with multiple sclerosis: 20Hz rTMS, iTBS or placebo
I. Korzhova, A. Poydasheva, A. Chervyakov, M. Zakharova | MOSCOW, RUSSIAN FEDERATION

P 21226 Abstract cancelled

P 21227 New possible marker of severity of vascular remodeling of the patients in early recovery period after cerebral ischemic hemispheric stroke
S. Medvedkova, O.A. Kozyolkin | ZAPORIZHYA, UKRAINE

P 21228 Action observation training modifies brain grey matter structure in healthy adult individuals

P 21229 NeuroMuscular Electrical Stimulation (NMES) in stroke to improve activity: a systematic review
M.G.H. Kristensen, H. Busk, T. Wienecke | MILAN, ITALY
12:30 - 13:15

**POSTER SESSIONS**

**SUNDAY, 29 MAY**

**POSTER SESSION NEUROTOXICOLOGY/OCURRENTIAL NEUROLOGY**

**12:30 - 13:15 | SCREEN G1**

**CHAIRPERSON:**
Maurizio Leone, SAN GIOVANNI ROTONDO, ITALY

---

**P 21230**

Early web-based tele-rehabilitation in stroke patients: a randomized controlled pilot study


---

**P 21231**

FMRI-navigated rTMS original protocol for disorders of consciousness treatment


---

**P 21232**

Cursive eye-writing with eye on line device (EOL) is feasible in subjects with ALS: a pilot study


---

**P 21233**

Life quality scores of the patients in early recovery period after cerebral ischemic hemispheric stroke

S. Medvedkova, O.A. Kozyalina ZAPORIZHYA, UKRAINE

---

**P 21234**

The Yin and Yang of pharmacological therapy in brain protection and recovery

D. Muresanu, A. Guekht CLUJ, ROMANIA, MOSCOW, RUSSIAN FEDERATION

---

**P 21235**

Silver intoxication induced polyneuropathy: a case report


---

**P 21236**

The struggle in establishing the diagnosis of delayed postanoxic encephalopathy

R.S. Badea, I.C. Cernat, A. Craciunoiu BUCHAREST, ROMANIA

---

**P 21237**

Reversible encephalopathy induced by high dose Trimethoprim-Sulfamethoxazole

H. Ben Abdeljalil PORRENTRUY, SWITZERLAND

---

**P 21238**

A case of cerebral manganism

A. Topkan, S. Bilen, E. Eruyar, Y.S. Karadag, N. Oztekin, F. Ak ANKARA, TURKEY

---

**P 21239**

Atrophy of the corpus callosum and bilateral reversible putamen lesions: an atypical case of Marchiafava-Bignami disease

J. Castelo, C. Santos SANTA MARIA DA FEIRA, PORTUGAL

---

**P 21240**

Metronidazole encephalopathy

N. Segura, V. Delgado, E. Sánchez LA LÍNEA DE LA CONCEPCIÓN, SPAIN

---

**P 21241**

Hyperammonemic encephalopathy induced by sodium valproate

L. Ortega, N. Segura, V. Delgado LA LÍNEA DE LA CONCEPCIÓN, SPAIN

---

**P 21242**

Low back pain disorders as an occupational disease – development methodology


---

**P 21243**

Marchiafava-Bignami disease mimicking left middle cerebral artery stroke

D. Fitas, A. Stocker, R. Lobato VIANA DO CASTELO, PORTUGAL

---

**P 21244**

A case of severe toxic encephalopathy secondary to methanol poisoning

P. Hernandez Navarro, M. Molina Sanchez, M.H. Torregrosa Martinez, M.Á. García Soldevilla MADRID, SPAIN

---

**P 21245**

Delayed leukoencephalopathy after acute carbon monoxide intoxication

P.L. Martínez Ulloa, A. Escobar Villalba, P. Pérez Torre, E. Monreal Laguillo, C. Estévez Fraga, C. Anciones, J. Buisán Catevilla, I. Corral Corral MADRID, SPAIN

---

**P 21246**

Copper deficiency, a not so uncommon cause of posterior cord syndrome

A. Poujois, C. Dussaule, S. Janny, P. Chaine, F. Woimant, N. Djebrani-Oussedik PARIS, LE KREMLIN-BICÊTRE, Clichy, FRANCE

---

**P 21247**

Chorea as a result of chronic carbon monoxide intoxication: a case report

C. Thomsen, A.S. Bisgård, M. Lindelof HERLEV, DENMARK
## POSTER SESSION
### PERIPHERAL NERVE DISORDERS 3
**12:30-13:15** | SCREEN D2

**CHAIRPERSON:**
Frouke Nijhuis, NIJMEGEN, THE NETHERLANDS

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 21248</td>
<td>Pyridoxine (Vitamin B6) toxicity related neuropathy: a case series</td>
<td>J.-P. Nicolò, A. Malhotra, A.R. Carne, D.S. Ayyappan</td>
</tr>
<tr>
<td>P 21249</td>
<td>Treatments options in HINT1 neuropathy</td>
<td>J. Nikodinović Glumac, V. Milic Rasic, V. Brankovic, J. Mladenovic, S. Todorović</td>
</tr>
<tr>
<td>P 21250</td>
<td>A patient homozygous for MFN2 mutation c.2119C&gt;T developed both severe CMT2A and lipomatosis</td>
<td>K. Ørstavik, M. Rasmussen, B. Karime, H. Vindenes, T. Fagerheim, M. van Gheluë, C. Jonsrud, O. Røsby</td>
</tr>
<tr>
<td>P 21252</td>
<td>Familial amyloid polyneuropathy with Ser97Tyr transhydroretin mutation: two new cases</td>
<td>M. I. Pedraza, A. L. Guerrero, N. Fernández, J. J. Telleria, M. Ruiz Piñero, L. Golán</td>
</tr>
<tr>
<td>P 21254</td>
<td>The livedoid vasculopathy, a rare cause at multiplex polyneuropathy in men</td>
<td>V. R. Petre, I. Buraga, C. Baetu, A. M. Enachi, V. Lungu, M. Aamarandei</td>
</tr>
<tr>
<td>P 21255</td>
<td>Can neurological examination predict pathophysiology of peripheral neuropathy?</td>
<td>G. Omejec, T. Zgur, S. Podnar</td>
</tr>
<tr>
<td>P 21256</td>
<td>Pathophysiology of peripheral nerve damage in familial amyloidotic polyneuropathy (FAP)</td>
<td>S. Podnar, S. Sarafonov, I. Tournev, G. Omejec, J. Zidar</td>
</tr>
<tr>
<td>P 21257</td>
<td>Prevalence and risk factors for carpal tunnel syndrome in meat processing industry</td>
<td>M. Rico, S. Cattani, C. Signorelli</td>
</tr>
</tbody>
</table>

## POSTER SESSION
### SLEEP DISORDERS 2
**12:30-13:15** | SCREEN E1

**CHAIRPERSON:**
Ulf Kallweit, Bern, Switzerland

<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 21261</td>
<td>Quantified motor activity in REM sleep compared in REM sleep behaviour disorder, parkinson’s disease, multiple system atrophy and narcolepsy with and without hypocretin deficiency</td>
<td>R. Frandsen, P. J. Jennum</td>
</tr>
<tr>
<td>P 21262</td>
<td>Vitamin D deficiency in narcolepsy with cataplexy</td>
<td>H. Hidalgo, X. Messmer, C. Bassetti, U. Kallweit</td>
</tr>
<tr>
<td>P 21263</td>
<td>Effects of theta burst stimulation over dorsolateral prefrontal cortex on vigilance and executive functions after sleep deprivation</td>
<td>T. Llic, Z. Sundric, N. Komatina</td>
</tr>
<tr>
<td>P 21264</td>
<td>Pitolisant as alternative therapeutic option for narcolepsy: results from the German compassionate use program 2015/16</td>
<td>H. Hidalgo Pareja, G. Mayer, P. Young, U. Kallweit</td>
</tr>
<tr>
<td>P 21265</td>
<td>Restless legs syndrome risk gene BTBD9 knockdown alters expression of ferritin and dopamine receptor genes in zebrafish</td>
<td>M.-K. Kim</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

SUNDAY, 29 MAY
12:30 - 13:15

P 21266  Periodic limb movements during sleep are more severe in narcolepsy with cataplexy than in narcolepsy without cataplexy
J. Krpesova, K. Sonka, M.V. Ibarburu, M.P. Kovalska, M.D. Kemlink, M.I. Prihodova | PRAGUE, CZECH REPUBLIC

P 21267  Restless leg syndrome in patients with epilepsy under levetiracetam monotherapy
G. Kutlu1, F. Genç2, Y. Unal1, D. Aslan Öztürk1, A. Erdal2, Y. Gömçeli3 | MUGLA, ANTALYA, TURKEY

P 21268  The use of melatonin for the treatment of REM sleep behavior disorder in Parkinson's disease
E. Lyashenko, O. Levin, M. Poluektov | MOSCOW, RUSSIAN FEDERATION

P 21269  Abstract cancelled

P 21270  Abstract cancelled

P 21271  Obstructive sleep apnoea and sensomotor polyneuropathy
M. Mihalj, Z. Đogaš, L. Lušić, M. Titlić | SPLIT, CROATIA

P 21272  Restless legs syndrome/Willis-Ekbom disease in patients with Parkinson's disease
M. Minar, R. Tosecka, P. Valkovic | BRATISLAVA, SLOVAKIA

P 21273  Abstract cancelled

P 21274  The effect of sleep and wakefulness disorders on cognitive function in patients with Parkinson's disease (PwPD)
M. A. Nikiting, I. A. Zhukova, V. M. Aflirova, N. G. Zhukova, N. G. Brazovskaya, O. P. Izbaldina, J. S. Mironova, M. A. Titova, A. V. Latypova, S. E. Sukhanov | TOMSK, RUSSIAN FEDERATION

POSTER SESSION

AGEING AND DEMENTIA 4
13:30-14:15 | SCREEN A2

CHAIRPERSON:
Jonathan Schott, LONDON, UK

P 22001  Predeterminative role of early choroid plexus ageing on presenil neuronal atrophy in an animal model: a preliminary histopathological study
N. Aydin1, D. Kotan2, M. D. Aydin3, G. Ozdemir4, P. Keles4, A. Kanat4, C. Yolás3, C. Gundogdu3 | ISTANBUL, SAKARYA, ERZURUM, RIZE, TURKEY

P 22002  Lille apathy rating scale and MDS-UPDRS for screening apathy in Parkinson’s disease
N. Kovacs, R. Weintraut, A. Makkos, M. Kovács, J. Janszky, K. Karádi | PECS, HUNGARY

P 22003  Associations between hypoperfusion in cerebral cortical segments and cognitive impairment in dementia with Lewy Bodies
Y. Kujuro, K. Ohto, T. Toguchi, Y. Shinohara | TOKYO, JAPAN

P 22004  Abstract cancelled

P 22005  Abstract cancelled

P 22006  Frequency and risk factors for aberrant motor behaviour in Alzheimer’s disease and vascular dementia
R. Manso Calderón1, P. Cacabelos Pérez2, M. D. Sevillano García2, M. E. Herrera Prieto2, R. González-Sarmiento1 | SALAMANCA, SANTIAGO DE COMPOSTELA, LEÓN, SPAIN

P 22007  Involvement of kv3.1 in 7-ketocholesterol-, 24(S)-hydroxycholesterol- and tetracosanoic acid-induced lipotoxicity on murine oligodendrocytes 158N: impact on cytosolic potassium level
B. Maryem1, Z. Amira2, M. Soini2, N. Thomas3, B. Rym1, E. A. Mohamed1, L. Gerard3 | TUNIS, MONASTIR, TUNISIA, DIJON, FRANCE

P 22008  Quantitative EEG in Alzheimer’s disease, MCI before and after standardized tests on fatigue
A. Medvedeva | MOSCOW, RUSSIAN FEDERATION

P 22009  Influence of APOE status on subjective spatial navigation complaints and real space performance
I. Mokrisova1, J. Laczó1, M. Pařízková2, M. Vyhňálek2, K. Sheardova1, V. Kaplan2, V. Matoska2, R. Andel2, J. Hort3 | BRNO, PRAGUE, CZECH REPUBLIC, TAMPA, FLORIDA, USA

P 22010  Severe spatial navigation impairment in Lewy body dementia and its structural underpinnings
Z. Nedelska1, J. Laczó1, M. Uller2, M. Vyhňálek2, K. Vlček1, J. Hort3 | PRAGUE, BRNO, CZECH REPUBLIC
POSTER SESSIONS

CEREBROVASCULAR DISEASES 8
13:30-14:15 | SCREEN G4
CHAIRPERSON:
Volker Dietz, ZURICH, SWITZERLAND

P 22011 Psychotropic polypharmacy in patients with dementia
A. Nørgaard\(^1\), C. Jensen-Dahm\(^1\), C. Gasse\(^2\), G. Waldemar\(^1\)
\(^1\)COPENHAGEN, \(^2\)AARHUS, DENMARK

P 22012 Driving performance in the frontotemporal dementia spectrum
I. Berati\(^1\), C. Keros\(^2\), D. Kontaxopoulou\(^1\), S. Fragkiadaki\(^1\),
N. Andronas\(^1\), D. Pavlou\(^1\), M. Stamelou\(^1\), A. Bonakis\(^1\),
L. Stefanis\(^1\), G. Yannis\(^1\), S.G. Papageorgiou\(^1\)
\(^1\)ATHENS, \(^2\)PIRAEUS, GREECE

P 22013 Abstract cancelled

POSTER SESSIONS

CEREBROVASCULAR DISEASES 9
13:30-14:15 | SCREEN G3
CHAIRPERSON:
Uta Meyding-Lamadé, FRANKFURT AM MAIN, GERMANY

P 22021 Prognostic role of absolute lymphocyte count in acute spontaneous cerebellar hemorrhage
A. Son, K. Kondratyuk
\(^1\)ODESSA, UKRAINE

P 22023 Prognostic value of total white blood cell count in acute spontaneous cerebellar hemorrhage: early-term outcome
A. Son, K. Kondratyuk
\(^1\)ODESSA, UKRAINE

P 22024 Diagnostic challenge of a dural arteriovenous fistula – case presentation
Å. Kornfeld, G. Gyori, M. Bokor
\(^1\)BUDAPEST, HUNGARY

P 22025 Efficiency of the «Stroke risk assessment» to identify individuals at high risk of stroke
S. Kotov, E. Sandu, E. Isakova, A. Kotov
\(^1\)MOSCOW, RUSSIAN FEDERATION

P 22027 Abstract cancelled

POSTER SESSIONS

CEREBROVASCULAR DISEASES 10
13:30-14:15 | SCREEN G5
CHAIRPERSON:
Peter R. Brinjikji, KANSAS CITY, USA

P 22051 Global and regional cerebral blood flow in patients with hypertension and ischemic stroke
M. Riaz\(^1\), M. Sadeghipour\(^1\), M. Mooshian\(^1\), M. Mashin\(^1\),
F. Sobh\(^1\), M. Mohammadi\(^1\)
\(^1\)KARAJ, IRAN, ISLAMIC REPUBLIC

P 22052 Association of systolic blood pressure and left ventricular hypertrophy in patients with atrial fibrillation
M. Sadeh\(^1\), L. Shahab\(^2\), M. Dehghan\(^1\)
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22053 Isosorbid dinitrate infusion therapy in the treatment of acute ischaemic stroke
M. Ahmad\(^1\), M. Jafari-Zare\(^1\)
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22054 Oxygenation of the brain and outcomes of patients with subarachnoid hemorrhage
M. Jafari\(^1\), M. Jafari-Zare\(^1\)
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22055 Hyperglycemia and high risk of death after the acute phase of ischemic stroke
M. Mooshian, M. Riaz, M. Riahi
\(^1\)KARAJ, IRAN, ISLAMIC REPUBLIC

P 22056 A novel association of domain-specific items in the stroke impact scale with the functional outcome of patients with acute ischemic stroke
M. Reza\(^1\), M. Zakeri\(^1\), M. Zakeri\(^2\), M. Zakeri\(^3\)
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22057 Association between the presence of stroke and depression in patients with ischemic stroke
M. Jafari\(^1\), M. Jafari-Zare\(^1\)
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22058 Effect of a multi-disciplinary approach in improving the quality of care in patients with acute ischemic stroke
M. Riaz, M. Reza, M. Jafari-Zare, M. Jafari
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22059 The role of a multi-disciplinary approach in the management of acute ischemic stroke
M. Riaz, M. Jafari-Zare, M. Jafari
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC

P 22060 The role of a multi-disciplinary approach in improving the quality of care in patients with acute ischemic stroke
M. Riaz, M. Jafari-Zare, M. Jafari
\(^1\)Tehran, IRAN, ISLAMIC REPUBLIC
P 22031  Common carotid artery dissection in a young patient with hyperhomocysteinemia and hyperuricemia
A.C. Mergeani, A. Dimitriade, B. Dorobat, O. Rusu, A. Ciobotaru, C. Cocolu, T. Parvu, O.A. Bajenaru, F. Antoci
BUCHAREST, ROMANIA

P 22032  The Brunei Epidemiological Study in Stroke and Multiple Sclerosis (BEST) - a Door-to-door survey
HAMBURG, GERMANY, NEGARA, BRUNEI DARUSSALAM

P 22033  To teach to treat - to treat to teach - setting up the Brunei Neuroscience Stroke and Rehabilitation Centre 12,000km away by the help of telemedicine
FRANKFURT AM MAIN, GERMANY, JERUDONG, BRUNEI DARUSSALAM

P 22034  Correlation of risk factors and hemodynamic changes using Transcranian-Doppler and Echocardiography in patients with high grade symptomatic internal carotid stenosis
M. Militaru, A.G. Militaru, D. Lighezan, S. Iurciuc, M. Simu
TIMISOARA, ROMANIA

P 22035  Combinations of cardiovascular risk factors in elderly patients with silent brain infarctions in Ukraine
T.S. Mishchenko, I.M. Nikishkova, V.M. Mishchenko, O. Kvitok
KHARKIV, UKRAINE

P 22036  Abstract cancelled

P 22037  Repetitive intracerebral lobar hematomas in a patient with hidden adrenal pheochromocytoma
E. Monreal, P. Pérez Torre, A. Escobar-Villalba, P. Martínez-Ulloa, R. Vera, J. Masjuan, A. Cruz
MADRID, SPAIN

P 22038  Symptomatic cerebral capillary telangiectasias: report of three cases and literature review
A. Monteiro, C. Lopes, D. Fitas, H. Costa, M. Pinto
ALMADA, PORTUGAL

P 22039  Myelin repair correlates with CARASIL-associated neurological deficits
B. Muinjonov, E. Giyazitdinova
TASHKENT, UZBEKISTAN

P 22040  First application of intravenous thrombolytic therapy in Republic of Kosovo
B. Myftiu, I. Jasufi
PRISHTINA, KOSOVO

P 22041  Orolingual angioedema during thrombolysis for cerebral ischemia
F. Myslimi, D. Leys
TIRANA, ALBANIA, LILLE, FRANCE

P 22042  Protein S deficiency and ischemic stroke in young patients
I. Zekja, I. Alimehmeti, D. Dobi, A. Kuqo, S. Xhaxho, M. Rakacoli, J. Kruja
TIRANA, ALBANIA, MAASTRICHT, THE NETHERLANDS

P 22043  Status epilepticus in intensive care unit: frequency, management and outcome impact: a retrospective study
C. Munteanu, S. Grappa
CHISINAU, MOLDOVA

P 22044  EEGraphic status epilepticus might not be associated with poor neurological prognosis in cooled cardiac arrest survivors
J. Nørregaard, M. Engsig, M. Lindeløf
HERLEV, COPENHAGEN, DENMARK

P 22045  Resting fMRI connectivity between hippocampal sub-region and extra-temporal area in patients of mesial temporal lobe epilepsy
H.-M. Park, J. Yang, Y.-D. Son, S.-I. Hwang
INCHEON, KOREA, REPUBLIC OF

P 22046  Epilepsy in multiple sclerosis
V. R. Petre, I. Buraga, C. Baetu, A. M. Enachi, V. Lungu, M. Amaranandei
BUCHAREST, ROMANIA

P 22047  Effect of UGT1A4 and UGT2B7 polymorphism on lamotrigine metabolism during pregnancy
V. Petrenaite, I. Öhman, L. Ekström, L. Bertilsson, D. Saebye, T. Tomson, A. Sabers
COPENHAGEN, DENMARK, STOCKHOLM, SWEDEN

P 22048  CT perfusion (CTP) findings in stroke-mimics of epileptic origin
S. Quintas, R. López Ruiz, M. de Toledo, M.T. Carreras, A. Gago-Veiga, J. Vivancos
MADRID, SPAIN

P 22049  Seven years of Status Epilepticus in a central hospital
I. Rosário Marques, F. Antunes, C. Fernandes, M.D. Grunho
ALMADA, PORTUGAL
**P 22050** Mesial temporal sclerosis in children
I. Rosário Marques, M.D. Grunho, J.P. Monteiro, M.J. Fonseca II ALMADA, PORTUGAL

**P 22051** Disparity in onset of Lafora disease within the same family and detection at early stages of the disease

**P 22052** Compared to total sleep deprivation with epileptic patients, the partial sleep deprivation is more efficient diagnostic method
D. Sahovic, A. Alajbegovic, J. Djelilovic-Vranic, A. Kucora I SARAJEVO, BOSNIA AND HERZEGOVINA

**P 22053** Tonic-clonic seizures triggering recurrent Tako-tsubo stress cardiomiopathy: a case report and literature review
L. Saraceno, M. Toffetti, G. Bosco, G. Meola I MILAN, ITALY

**P 22054** Quantitative MRI assessment of the differences in lateralization of language-related brain activation in patients with temporal lobe epilepsy
A. Umarov, A.V. Prokhorova, G. Rakhibbaeva, N. Tuychibaeva I TASHKENT, UZBEKISTAN

**P 22055** Seizure semiology in patients with bilateral temporal lobe epilepsy in Uzbekistan
A. Umarov, A.V. Prokhorova, N. Tuychibaeva I TASHKENT, UZBEKISTAN

**POSTER SESSION**
**HEADACHE AND PAIN 4**
**13:30-14:15 | SCREEN C1**

**P 22056** Reduction of aquaporin-4 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension
K. Doppler1, M. Schütz2, C. Sommer2 I WÜRZBURG, GERMANY

**P 22057** Efficacy of biofeedback treatment for migraine and tension type headaches
L. Friedrich1, I. Zobic1, M. Milosevic1, J. Kocak1, A. Soldo Karuga2, T. Pucic2, K. Bacic Baronica1 I ZAGREB, CROATIA

**P 22058** OnabotulinumtoxinA is an effective therapy for nummular headache: experience in a series of 17 cases
B. García, M. Ruiz Piñero, A. Juanatey, M. Pedraza, E. Martínez, J. Barón, L. López-Mesonera, A.L. Guerrero i VALLADOLID, SPAIN

**P 22059** Searching for symptomatic hypnic headache: ambulatory blood pressure monitoring in a series of 25 patients

**P 22060** Tension-type headache over-diagnosis in the emergency department setting
D. García Azorin, M. Farid-Zahran Osuna, J.A. Abelaira Freire, T. Liana Sanchez, G. Ortega Suero, F.J. Martín Sánchez, J. Porta Etessam I MADRID, SPAIN

**P 22061** Episodic migraine and calcitonin gene-related peptide. Effect of treatment with topiramate or zonisamide on peptide plasma levels
D.A. García-Estévez1, S. Silvarrey-Rodriguez1, M. Pardo Parrado1, T. Sogo Lopez1, A. Garcia Pellitero2, L. Bouzas Lago2, J.A. Bravo-Ricoy2, P. Alonso Alonso2 I OURENSE, LUGO, SPAIN

**P 22062** New daily persistent headache (NDPH) with thunderclap headache (TH) onset (NDPH-TH): possible causal role of reversible cerebral vasoconstrictive syndrome (RCVS)
I. Garza, S. Berini, A. Bubolz, C. Robertson I ROCHESTER, USA

**P 20063** Multidisciplinary integrated headache treatment program: results and identification of factors that influence treatment response
V. Golovacheva, V. Parfenov, G. Tabeeva, V. Osipova, D. Pushkarev, A. Andruschenko I MOSCOW, RUSSIAN FEDERATION

**P 22064** Biofeedback training method for patients with lower back pain
I. Goursky, S. Likhachev, V. Vashchylin I MINSK, BELARUS

**P 22065** An investigation of the relationship between the eNOS gene polymorphism and diagnosed migraine
S. Güler, H. Gurkan, H. Tozkir, F.N. Turan, Y. Çelik I ADRIANOPLE, TURKEY

**P 22066** Pituitary adenylate cyclase-activating polypeptide-38 induced migraine attacks in patients with and without familial aggregation of migraine

**P 22067** Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients
**POSTER SESSIONS**

**SUNDAY, 29 MAY**

**13:30 - 14:15**

**POSTER SESSION**

**MOTOR NEURO DISEASES 2**

**13:30-14:15 | SCREEN C2**

**CHAIRPERSONS:**

David Oliver, ROCHESTER, UK

---

**P 22068**

Premonitory and non-headache symptoms induced by CGRP- and PACAP38 in migraine patients

S. Guo, A.L.H. Vollesen, J. Olesen, M. Ashina  I  COPENHAGEN, DENMARK

**P 22069**

Quantitative sensory testing in classical trigeminal neuralgia – a blinded study in patients with and without concomitant persistent pain

S. Younis  I  GLOSTRUP, DENMARK

---

**POSTER SESSION**

**MOVEMENT DISORDERS 5**

**13:30-14:15 | SCREEN E4**

**CHAIRPERSON:**

Lisa Klingelhöfer, DRESDEN, GERMANY

---

**P 22077**

An anterior epidural cyst mimicking Hirayama disease

D. Fitas1, M.D.C. Branco2, F. Silveira2, P. Soares Pinto1, R. Lobato1  I  VIANA DO CASTELO, VILA REAL, PORTO, PORTUGAL

**P 22078**

The patient journey to a national ALS clinic: delayed diagnosis and economic cost

M. Galvin, P. Ryan, M. Heverin, C. Madden, S. Maguire, A. Vajda, O. Hardiman  I  DUBLIN, IRELAND

---

**P 22079**

Brain sodium MRI depicts upper motor neuron involvement in amyotrophic Lateral Sclerosis (ALS)


---

**P 22080**

Evoked potentials in patients with amyotrophic lateral sclerosis

V. Hieb, Y. Rushkevich, G. Zabrodzets, S.A. Likhachev  I  MINSK, BELARUS

**P 22081**

An autopsy case of familial ALS-dementia with R487H VCP gene mutation

K. Inoue1, H. Fujimura1, K. Tayaoka1, M. Hiranob, S. Maekura2, Y. Nakamura2, S. Sakado2  I  TOYOAKA, SAKAI, JAPAN

**P 22082**

CSF level of chromogranin A in amyotrophic lateral sclerosis

M. Kaiserova1, P. Otruba1, K. Mensikova1, Z. Grambalova1, H. Prikrylova-Vranova1, J. Mares1, D. Stejskal1, P. Kanovsky1  I  OLOMOUC, PROSTEJOV, CZECH REPUBLIC

---

**P 22070**

Unusual case of progressive hemiparesis

A. Félix, A. Andre, H. Nzwalo  I  FARO, PORTUGAL

**P 22071**

Man in the barrel with drop neck: an unexpected presentation of motor neuron disease

A. Félix, A. Andre, H. Nzwalo  I  FARO, PORTUGAL

**P 22072**

Theory of mind in early clinical stages of amyotrophic lateral sclerosis

C. Femiano1, F. Troisi1, G. Santangelo2, M. Siciliano2, T. Ferrantino1, G. Piccirillo1, P.F. Esposito1, M.P.A. Tessitore1, M.P.G. Tedeschi1  I  NAPLES, CASERTA, SALERNO, ITALY

**P 22073**

Proposition for a routine-designed standardised EMG setting in early diagnosis of Amyotrophic Lateral Sclerosis (ALS)

M. Ferrara, M.M. Zarrrelli, M.F.P. Apollo, M. Leone  I  SAN GIOVANNI ROTONDO (FG), ITALY

**P 22074**

Structural brain MRI abnormalities in Kennedy’s disease

P.M. Ferrari1, F. Agosta1, G. Querin2, N. Riva1, C. Bertalini2, E. Da Re2, M. Copetti3, G. Comi3, A. Falini3, G. Soraru4, M. Filippo1  I  MILAN, SAN GIOVANNI ROTONDO, ITALY

**P 22075**

An ASAH1variant causing an adult spinal muscular atrophy phenotype without myoclonic epilepsy: a clinical, genetic and biochemical study

M. Filosto1, M. Aureli2, D. Schiumarini2, M. Valsecchi2, B. Castellotti2, A. Todeschini3, S. Rota3, F. Rinaldi3, C. Gellera2, A. Padovani4, M. Filocco5  I  BRESCE, MILAN, GENOA, ITALY

**P 22076**

Onset manifestations of spinal and bulbar muscular atrophy (Kennedy disease)

J. Finsterer1, G. Soraru2  I  VIENNA, AUSTRIA, PADUA, ITALY

---

**P 22078**

Onset manifestations of spinal and bulbar muscular atrophy (Kennedy disease)

J. Finsterer1, G. Soraru2  I  VIENNA, AUSTRIA, PADUA, ITALY

---

**P 22083**

Restless Legs Syndrome (RLS) and insomnia frequency in patients with psoriasis

S. Guver, A. Tekatas, A. Ozer, 8. Sar Kaplan, Y. Doğru  I  ADRIANOPLE, TURKEY

**P 22084**

Myoclonus dystonia: a novel epsilon-sarcoglycan gene mutation with variable clinical presentation in a large Turkish pedigree

M. Gutekkin1, C. Ganos2, N.E. Mengacci2, M. Mirza1  I  KAYSERI, LONDON, UK

**P 22085**

Motor disorder in Huntington’s disease may begin like tic disorder: atypical clinical presentation in a large Turkish pedigree

M. Gutekkin, F.F. Erdoğlan, F. Yetkin, R. Baydemir, M. Mirza  I  KAYSERI, TURKEY
POSTER SESSIONS

SUNDAY, 29 MAY
13:30 - 14:15

**P 22086** Conversion of advanced Parkinson’s disease patients to IPX066, modified-release levodopa-carbidopa (NUMIENT™), from other levodopa-carbidopa formulations
S. Gupta, R. Rubens, N. Rustay, S. Khanna, S. Kell | HAYWARD, USA

**P 22087** Efficacy of IPX066, modified-release levodopa-carbidopa (NUMIENT™) in patients with advanced Parkinson’s disease: responder analyses
S. Gupta, S. Khanna, N. Rustay, R. Rubens, S. Kell | HAYWARD, USA

**P 22088** Cognitive performance fluctuations in Parkinson’s disease: a case report
O. Györfi, E. Rigó, M. Bokor | BUDBAPEST, HUNGARY

**P 22089** The study of the therapeutic effect of transcranial magnetic stimulation in patients with hand’s dystonia
V. Hiep, S. A. Likhachev, G. Zabrodzets, T. Charnukha | MINSK, BELARUS

**P 22090** Abstract cancelled

**P 22091** Abstract cancelled

**P 22092** Validation of the Portuguese version of the 39-item Parkinson’s disease questionnaire
J. Jesus Ribeiro, E. Vieira, P. Ferreira, C. Januário, A. Freire-Gonçalves | COIMBRA, PORTUGAL

**P 22093** Autonomic dysfunctions and sleep disturbances identify Parkinson's disease patients at risk for developing dementia
A. Jurcau, A. Simion | ORADEA, ROMANIA

**P 22094** Clusterin CSF levels in differential diagnosis of neurodegenerative disorders
P. Kanovsky1, H. Prikyrylova Vranova1, M. Kaiserova1, D. Stejskal1, K. Mensikova1, J. Mares1, E. Henykova1, M. Strnad1 | OLOMOUC, PROSTEJOV, CZECH REPUBLIC

**P 22095** First comparison of continuous movement data (Hauser-diary versus Parkinson’s KinetiGraph) in patients with Parkinson’s disease
L. Klingelhofer1, A. Rizos2, M. Horne3, A. Sauerber1, S. McGregor3, R. de Micco2, L. Perkins3, H. Reichmann1, K. R. Choudhuri2 | DRESDEN, GERMANY, LONDON, UK, MELBOURNE, AUSTRALIA

**P 22096** Myeloid microvesicles and risk of multiple sclerosis in patients with clinically isolated syndromes.

**P 22097** A multi-centre audit to describe the burden of bladder dysfunction in multiple sclerosis
A. Davis, B. Turner, M. Ramadhan, C. Albor, K. Schmierer, G. Giovannoni | LONDON, UK

**P 22098** Effect of cladribine tablets on brain atrophy rates in patients with relapsing–remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study
N. de Stefano1, A. Giorgio1, M. Battaglini1, G. Giovannoni1, C. Hicking1, F. Dangond2, M. P. Sormani2 | SIENNA, GENOA, ITALY

**P 22099** Treatment-naïve patients with active relapsing–remitting multiple sclerosis at baseline demonstrate continued disability improvement over 5 years with alemtuzumab: CARE-MSI extension study
R. Arroyo Gonzalez1, D. Dive2, E. Havrda2, S. Hunter2, D. H. Margolin3, K. Thangavelu4, O. Fernández5 | MADRID, SPAIN, LIEGE, BELGIUM, PRAGUE, CZECH REPUBLIC, FRANKLIN, USA, CAMBRIDGE, USA, MALAGA, SPAIN

**P 22100** Pregnancy-related estrogen receptor-alpha expression in lymphocyte subsets of women with multiple sclerosis
G. Di Liberto, G. Salemi, P. Ragonese, M. Lo Pizzo, S. Realmi, D. Di Liberto, F. Dieli | PALERMO, ITALY

**P 22101** Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis: a cross-sectional multicentre study
S. Dias1, A. Gouveia2, T. Santos3, H. Rocha4, C. Rosado Coelho5, L. Ruano6, O. Galego6, M. Diogo6, D. Seixas6, M. J. Sá7, S. Batista2, LISBON, COIMBRA, VILA NOVA DE GAIA, PORTO, SETÚBAL, SANTA MARIA DA FEIRA, PORTUGAL

**P 22102** Visuospatial skills are more severely impaired in secondary than primary progressive multiple sclerosis
S. Dias1, A. Gouveia2, T. Santos3, H. Rocha4, C. Rosado Coelho5, L. Ruano6, O. Galego6, M. Diogo6, D. Seixas6, M. J. Sá7, S. Batista2, LISBON, COIMBRA, VILA NOVA DE GAIA, PORTO, SETÚBAL, SANTA MARIA DA FEIRA, PORTUGAL

**POSTER SESSION MS AND RELATED DISORDERS 9**
13:30-14:15 | SCREEN F1

**CHAIRPERSONS:**
Nicola De Stefano, SIENNA, ITALY

**P 22096** Myeloid microvesicles and risk of multiple sclerosis in patients with clinically isolated syndromes.

**P 22097** A multi-centre audit to describe the burden of bladder dysfunction in multiple sclerosis
A. Davis, B. Turner, M. Ramadhan, C. Albor, K. Schmierer, G. Giovannoni | LONDON, UK

**P 22098** Effect of cladribine tablets on brain atrophy rates in patients with relapsing–remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study
N. de Stefano1, A. Giorgio1, M. Battaglini1, G. Giovannoni1, C. Hicking1, F. Dangond2, M. P. Sormani2 | SIENNA, GENOA, ITALY

**P 22099** Treatment-naïve patients with active relapsing–remitting multiple sclerosis at baseline demonstrate continued disability improvement over 5 years with alemtuzumab: CARE-MSI extension study
R. Arroyo Gonzalez1, D. Dive2, E. Havrda2, S. Hunter2, D. H. Margolin3, K. Thangavelu4, O. Fernández5 | MADRID, SPAIN, LIEGE, BELGIUM, PRAGUE, CZECH REPUBLIC, FRANKLIN, USA, CAMBRIDGE, USA, MALAGA, SPAIN

**P 22100** Pregnancy-related estrogen receptor-alpha expression in lymphocyte subsets of women with multiple sclerosis
G. Di Liberto, G. Salemi, P. Ragonese, M. Lo Pizzo, S. Realmi, D. Di Liberto, F. Dieli | PALERMO, ITALY

**P 22101** Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis: a cross-sectional multicentre study
S. Dias1, A. Gouveia2, T. Santos3, H. Rocha4, C. Rosado Coelho5, L. Ruano6, O. Galego6, M. Diogo6, D. Seixas6, M. J. Sá7, S. Batista2 | LISBON, COIMBRA, VILA NOVA DE GAIA, PORTO, SETÚBAL, SANTA MARIA DA FEIRA, PORTUGAL

**P 22102** Visuospatial skills are more severely impaired in secondary than primary progressive multiple sclerosis
S. Dias1, A. Gouveia2, T. Santos3, H. Rocha4, C. Rosado Coelho5, L. Ruano6, O. Galego6, M. Diogo6, D. Seixas6, M. J. Sá7, S. Batista2 | LISBON, COIMBRA, VILA NOVA DE GAIA, PORTO, SETÚBAL, SANTA MARIA DA FEIRA, PORTUGAL
P 22103  Descriptive study and prognosis analysis of longitudinally extensive transverse myelitis
E.D. Diaz Pertuz  I PAMPLONA, SPAIN

P 22104  Epilepsy and multiple sclerosis
J. Djelilovic-Vranic, M. Tirc-Campara, A. Alajbegovic, E. Djacic  I SARAJEVO, BOSNIA AND HERZEGOVINA

P 22105  Familial multiple sclerosis: clinical features and course
O. Ekmekci, A.N. Yuceyar  I IZMIR - BORNOVA, TURKEY

P 22106  Familial mediterranean fever and multiple sclerosis
O. Ekmekci, A.N. Yuceyar  I IZMIR - BORNOVA, TURKEY

P 22107  Clinical efficacy of fingolimod and identification of predictors of relapses in an Italian cohort of multiple sclerosis patients

P 22108  Investigation of the role of sphingosine pathway genes on response to fingolimod in a cohort of relapsing remitting multiple sclerosis patients

P 22109  Percutaneous balloon compression for trigeminal neuralgia in patients with multiple sclerosis
A. Moreira Villanueva, E. Munteis Oliva, A. Zabalza de Torres, P. de Ceballos Cerrajeria, G. Villalba Martinez, J. Roquer González  I BARCELONA, SPAIN

P 22110  Urinary disorders screening in multiple sclerosis patients. An undervalued problem
T. Muñoz Ruiz, V. Fernandez Sanchez, P. Sanchez Lazano, V. Reyes Garrido, P. Urbaneja Romero, M. Guerrero, A. Leon Martin, A. Gallardo Tur, Ó. Fernández  I MÁLAGA, OVIÉDO, SPAIN

P 22111  Familial multiple sclerosis: characteristics in algerian cohort
L. Nessah, S. Daoudi  I TIZI-OUZOU, ALGERIA

P 22112  Low-dose Rituximab therapy for neuromyelitis optica spectrum disorders

P 22113  Decreased soluble IFNß receptor (sIFNAR2) in multiple sclerosis patients: a potential serum diagnostic biomarker

P 22114  Multiple sclerosis relapse-related costs of oral disease-modifying therapies in denmark: an economic analysis comparing delayed-release dimethyl fumarate, fingolimod, and teriflunomide
P. O’malley, A. Lee, K. O’day, M. Friedman  I ZUG, SWITZERLAND, PALM HARBOR, USA

P 22115  Efficacy, tolerability and safety of teriflunomide in multiple sclerosis in a real-world clinical setting

P 22116  Switching from first and second line therapy to novel oral MS treatments

P 22117  Atypical presentation of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a case report with spinal cord involvement
M. Padroni, C. Calanca, V. Rispoli, V. Tugnoli, E. Baldi, E. Fainardi, E. Granieri, M. Pugliatti, L. Caniatti  I FERRARA, ITALY

P 22118  Prevalence of depression and fatigue in the 11-year follow-up from the BENEFIT study
P 22119  Incorporating the TEMSO SIENA analysis improves correlation of brain atrophy and disability progression  
M. Pia Sormani1, E.-W. Radue2, T. Sprenger3, L. Gaetano2, N. Mueller-Lenke2, J. Wuerfel1, K. Thangavelu4, S. Cavalier4, L. Kappos2  I 1GENOA, ITALY, 2BASEL, SWITZERLAND, 3WIESBADEN, GERMANY, 4CAMBRIDGE, USA

P 22120  Functional and structural MRI predictors of disability worsening in multiple sclerosis: a 4-year follow-up study  
F. Pirro1, M.A. Rocca1, P. Valsasina1, E. Pagani1, A. Meani1, M. Copetti2, F.G. Martinelli Boneschi1, M. Rodegher1, G. Comi1, A. Falini1, M. Filippi1  I MILAN, ITALY

P 22121  Multimodal evoked potentials predict NEDA evolution in patients starting first-line treatment for multiple sclerosis  
M. Pisa, M. Bianco, S. Guerrieri, G. Di Maggio, M. Romeo, L. Moiola, V. Martinelli, G. Comi, L. Leocani  I MILAN, ITALY

P 22122  Myasthenia gravis induced by ipilimumab in a patient with advanced melanoma  
V. Montes, S. Sousa, R. Guerreiro, C. Carmona, F. Pita  I CASCAIS, PORTUGAL

P 22123  Pseudometabolic phenotype in patients with ANOS mutations  
O. Musumeci1, M. Savarese2, G. Di Fruscio2, C. Rodolico1, E. Barca1, V. Nigro2, A. Toscano1  I 1MESSINA, 2NAPLES, ITALY

P 22124  Late-onset Pompe disease in Iran: a clinical and genetic report  
F. Nazari, S. Nafissi, Y. Nilipour, F. Sinaie  I TEHRAN, ISLAMIC REPUBLIC OF

P 22125  Myofascial trigger points creation in mice  
N. Ortiz1, R. Margalef1, M. Sisquella1, M. Bosque1, C. Romeu1, O. Mayoral2, S. Monterde1, M. Priego1, J. Tomas1, M.M. Santafe1  I 1REUS, 2TOLEDO, SPAIN

P 22126  Neutral lipid storage with myopathy: role of micro RNA and muscle imaging  
V. Pegoraro1, C. Angelini, E. Pinzan, E. Tasca1  I VENICE, ITALY

P 22127  Abstract cancelled

P 22128  Clusters of cognitive impairment among different forms of myotonic dystrophies  

P 22129  Progressive Merosin deficiency associated with Lama2 new mutation in a patient deviating from the classical clinical and morphological phenotypes  

P 22130  Evolution of inflammatory and degenerative pathological profiles in inclusion body myositis  
M. Pinto1, R. Taipa2, M. Pires2  I LISBON, PORTO, PORTUGAL

P 22131  Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy: case series and magnetic resonance imaging findings  

P 22132  Anti-musk antibody negative myasthenic crisis patients managed with Rituximab: report of two cases  
P. Ranganathan  I CHENNAI, INDIA

P 22133  Myasthenia gravis associated with scleroderma: the first case in Greece and systematic review of the literature  
P. Zis, P. Kokotis, P. Sfikakis  I ATHENS, GREECE

P 22134  Association between ambient temperature and stroke hospitalisations in Minsk, Belarus  
O. Mukalova, A. Mukalau, A. Pyko  I MINSK, BELARUS

P 22135  First epidemiologic study of Wilson’s disease in France  
**POSTER SESSIONS**

**SUNDAY, 29 MAY**  
13:30 - 14:15 | SCREEN F4

**Chairperson:** Karolina Dziezyc, WARSAW, POLAND

**POSTER SESSION**
**NEUROGENETICS 2**  
13:30-14:15 | SCREEN F4

**P 22137** Prevalence of ischemic stroke phenotypes according to ASCOD classification in a Romanian cohort of patients  
E. Terecoasa, R. Radu, N. Grecu, S. Gheorghievici, C. Tiu  
BUCHAREST, ROMANIA

**P 22138** Pregnancies before or after multiple sclerosis onset modify disease course, relapse rate and severity in women affected by multiple sclerosis: a cohort study  
P. Ragonese, S. Realmuto, G. Vazzoler, P. Aridon, E. Portera, A. Bianchi, G. Savetttieri, G. Salemi  
PALERMO, ITALY

**P 22139** Gender effect on non-motor symptoms in Parkinson’s disease: are men more at risk for most of them?  
BARI, CATANZARO, MESSINA, SALERNO, ITALY

**P 22140** Enhanced CJD surveillance in the older population  
B. Waddell, G. Logan, S. Pal, G. Holloway, S. Shenkin, M. Head, C. Smith, A. Molesworth  
EDINBURGH, UK

**P 22141** Organizational model of ischemic stroke management in Northern Lombardy  
MILAN, COMO, SONDRIO, VARESE, BUSTO ARSIZIO, LEGNANO, LECCO HOSPITAL, GALLARATE, ITALY

**P 22142** Evaluation of pre-hospital and in-hospital times in ischemic stroke management in Northern Lombardy  
MILAN, COMO, SONDRIO, VARESE, BUSTO ARSIZIO, LEGNANO, LECCO, GALLARATE, ITALY

**P 22143** Analysis of SPAST patients in the UK cohort reveals high rate of psychiatric comorbidities  
V. Chelban, A. Tucci, H. Houlden  
LONDON, UK

**P 22144** Functional outcomes in hereditary spastic paraplegia: a prospective cohort study  
N. Christiaen, N. Dupré, J.-D. Brisson, Z. Gan-or, K. Boycott, O. Suchowersky, G. Rouleau, G. Yoon  
QUEBEC CITY, MONTREAL, OTTAWA, EDMONTON, TORONTO, CANADA

**P 22145** Heterozygous mutation of HTRA1 gene in an Italian family with cerebral ischemic small vessel disease  
L. Di Donato, S. Bianchi, G.N. Gallus, A. Cerese, A. Federico, M.T. Dotti  
SIENNA, ITALY

**P 22146** Late-onset Krabbe disease in an adult metabolic disorders consultation  
J. Durães, J. Tomás, M. Tábuas-Pereira, C. Caseiro, L. Lacerda, M.C. Macário  
COIMBRA, PORTO, PORTUGAL

**P 22147** Clinical presentation and molecular genetic testing in spinocerebellar ataxia type 17  
J. Durães, J. Tomás, I. Santana, J.M.G. Lemos, M.C. Macário  
COIMBRA, PORTUGAL

**P 22148** Screening for SLC25A46 mutations in familial and sporadic ataxic patients  
S. Effthymiou, C. Bettencourt, H. Houlden  
LONDON, UK

**P 22149** New mutation in the ABCD1 gene associated with X-linked adrenoleukodystrophy  
MURCIA, SPAIN

**P 22150** Double troubles in families with ALS/FTD related to C9orf72 repeat expansion: causal or causal?  
BOLOGNA, IMOLA, ITALY

**P 22151** A next-generation sequencing study in Italian multiple sclerosis multiplex families: looking for rare susceptibility variants  
MILAN, NOVARA, ITALY

**P 22152** A novel TTBK2 de novo mutation in a Danish family with early childhood onset spinocerebellar ataxia type II (SCA11)  
COPENHAGEN, DENMARK, NOARRE, THE NETHERLANDS
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 22153</td>
<td>Fragile X-associated tremor/ataxia syndrome in two female patients</td>
<td>L. Hvizdsova, M. Kaiserova, M. Vecerkova, K. Mensikova, P. Kanovsky</td>
<td>I. OLOMOUC, CZECH REPUBLIC</td>
</tr>
<tr>
<td>P 22154</td>
<td>Next generation sequencing in the diagnosis of neurodegenerative diseases: Russian experience</td>
<td>N. Abramycheva, E. Fedotova, S. Klyushnikov, S. Illarioshkin</td>
<td>I. MOSCOW, RUSSIAN FEDERATION</td>
</tr>
<tr>
<td>P 22155</td>
<td>Variability in the clinical course of congenital myasthenic syndrome type la</td>
<td>K. Kostreva1, T. Chamova1, V. Guergelcheva1, V.M. Mihaylova2, S. Cheminkova2, I. Tournev1</td>
<td>I. SOFIA, BULGARIA, I. ZURICH, SWITZERLAND</td>
</tr>
<tr>
<td>P 22157</td>
<td>PET study in dementia with Lewy bodies patients with and without REM sleep behavior disorder</td>
<td>L. Ferini Strambi, L. Iaccarino, S. Marelli, S. Iannaccone, G. Magnani, D. Perani</td>
<td>I. MILAN, ITALY</td>
</tr>
<tr>
<td>P 22158</td>
<td>Neural network of predictive motor timing in the context of gender differences</td>
<td>P. Filip, M. Baroš</td>
<td>I. BRNO, CZECH REPUBLIC</td>
</tr>
<tr>
<td>P 22159</td>
<td>FMRI findings in the final stage of Creutzfeldt-Jakob-disease</td>
<td>C. Florea1, S.M. Golaszewski1, A.F. Unterrainer1, M. Kronbichler1, M. Seidl1, R. Nardone1, S. Weis1, F. Gerstenbrand1, E. Trinka1</td>
<td>I. SALZBURG, I. LINZ, I. VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>P 22160</td>
<td>Prevalence of venous sinus stenosis in Pseudotumor cerebi (PTC) using digital subtraction angiography (DSA)</td>
<td>M. Hamsdy</td>
<td>I. CAIRO, EGYPT</td>
</tr>
<tr>
<td>P 22161</td>
<td>Asymmetric cortical and basal ganglia MRI alterations on FLAIR and DWI in a patient with Creutzfeldt-Jackob disease (CJD) carrying a V210I mutation</td>
<td>D. Ippolito, L. Lavorgna, R. Docimo, M.P.M. Cirillo, G. Tedeschi, S. Bonavita</td>
<td>I. NAPLES, ITALY</td>
</tr>
<tr>
<td>P 22162</td>
<td>Squeeze and Trace: evaluation of a novel functional magnetic resonance imaging motor-paradigm developed for stroke patients with impaired hand motor function</td>
<td>L.V. Knudsen1, P. Jensen1, C. Thomsen1, A.O. Boandrup2, P.M. Fisher1, L.H. Pinborg1</td>
<td>I. COPENHAGEN, I. ROSKILDE, DENMARK</td>
</tr>
<tr>
<td>P 22163</td>
<td>Time course of multiple sclerosis lesions visualized with MRI: insight into focal pathology</td>
<td>P. Maggi1, F. Zellini2, A. Banario3, A. Passeri4, L. Massacesi1</td>
<td>I. BRUSSELS, BELGIUM, I. FLORENCE, ITALY</td>
</tr>
<tr>
<td>P 22164</td>
<td>Resting state functional connectivity in olfactory network in de novo Parkinson’s disease</td>
<td>S. Marino, L. Bonanno, F. Caminiti, S. de Salvo, F. Corallo, V. Lo Buono, P. Bramanti, G. Di Lorenzo</td>
<td>I. MILAN, ITALY</td>
</tr>
<tr>
<td>P 22165</td>
<td>CSF biomarkers to detect cognitive decline in IMI PharmaCog WPS / European ADNI: a multicenter study</td>
<td>M. Marizzoni1, C. Ferrari1, S. Galluzzi1, E. Rolandi1, P.J. Visser4, L. Parnetti2, F. Nobile2, M. Didic2, D. Bartrés-Fas2, U. Fiedler3, P. Schonkecht4, P. Payoux5, A. Beltramello5, A. Soricelli6, M. Tsolaki6, P.M. Rossini6, G.L. Forloni1, R. Bordet11, O. Blin5, G. Frisoni6</td>
<td>I. BRESCE, PERUGIA, GENOA, VERONA, NAPLES, ROME, MILAN, ITALY, AMSTERDAM, THE NETHERLANDS, MARSEILLES, TOULOUSE, LILLE, FRANCE, BARCELONA, SPAIN, LEIPZIG, GERMANY, THESSALONIKI, GREECE, GENEVA, SWITZERLAND, BRESCIA, MILAN, ITALY</td>
</tr>
<tr>
<td>P 22166</td>
<td>Brain magnetic resonance imaging in cerebrotendinous xanthomatosis: a single-centre experience</td>
<td>A. Mignani, L. Monti, P. Galluzzi, N. de Stefano, A. Federico, M.T. Dotti</td>
<td>I. SIENNA, ITALY</td>
</tr>
<tr>
<td>P 22167</td>
<td>Clinical application of diffusion tensor imaging in pathology of the spinal cord</td>
<td>M. Moldovanu, O. Gavriliuc</td>
<td>I. CHISINAU, MOLDOVA</td>
</tr>
<tr>
<td>P 22168</td>
<td>Quantitative sparing of cortical metabolism in combination with striatal hypermetabolism on cerebral FDG PET scanning in voltage gated potassium channel mediated limbic encephalitis</td>
<td>P. Moloney, R. Boylan, M. Elamin, S. O’riordan, K. Ronan, C. McGuigan</td>
<td>I. DUBLIN, IRELAND</td>
</tr>
</tbody>
</table>

**SUNDAY, 29 MAY**

13:30 - 14:15

POSTER SESSIONS

NEUROIMAGING 2

13:30-14:15 | SCREEN A3

**Chairperson:** Luigi Ferini Strambi, MILAN, ITALY
SUNDAY, 29 MAY
13:30 - 14:15

POSTER SESSIONS

POSTER SESSION
NEUROIMMUNOLOGY 2
13:30-14:15 | SCREEN H2
CHAIRPERSON:
Maarten Titulaer, ROTTERDAM, THE NETHERLANDS

P 22170 Preliminary analysis of chemical exchange saturation transfer (CEST) images and z-spectrum of different metabolism models
Y. Yang, R. Wu 1, 2 1XIAMEN, 2SHANTOU, CHINA

P 22171 Study of chemical exchange saturation transfer MRI on brain metastases at 1.5 Tesla
Y. Yang, R. Wu 1, 2 1XIAMEN, 2SHANTOU, CHINA

P 22172 Study of chemical exchange saturation transfer MRI on cerebral infarction at 1.5 Tesla
Y. Yang, R. Wu 1, 2 1XIAMEN, 2SHANTOU, CHINA

P 22173 Clinical characteristics, immunological accompaniments and treatment outcomes of autoimmune aerebellar ataxia
V. Damato, G. Silvestri, A. Evoli, R. Iorio 1, 2 ROME, ITALY

P 22174 Long-term neuropsychological outcome of anti-NMDA receptor encephalitis in children
M. de Bruin, F. Aarsen, A. Sonderen van, C. Catsman-De-Berrevoets, R. Neuteboom, M. Schreurs, P.A. Sillevis Smitt 1, 2 ROTTERDAM, 1THE HAGUE, 2THE NETHERLANDS

P 22175 Tolerability of the intravenous immunoglobulin octagam® 10% in neurologic indications: a subgroup analysis of a non-interventional study in Germany
A. Debes, S. Tascou 1, 2 LANGENFELD, GERMANY

P 22176 Therapeutic plasma exchange in patients with neurological diseases: experience of the neurological department, Mohammed VI University Hospital of Marrakech
H. Elmouden, N. Adali, N. Kissani 1, MARRAKECH, MOROCCO

P 22177 Overlapping demyelinating syndrome in an anti-NMDA encephalitis case
L. Fontao, I. Alves 1, C. Santos 1 1SANTA MARIA DA FEIRA, 2PENAFIEL, PORTUGAL

P 22178 Comparison of antibody assays in anti-NMDAR encephalitis
M. Gastaldi 1, A. Thouin 2, E. P. Coutinho 2, L. Jacobson 2, S. Irani 2, A. C. Vincent 1 1PAVIA, ITALY, 2NEWCASTLE, 3OXFORD, UK

P 22179 Rare comorbidity of multiple sclerosis and HIV infection in a patient. New drugs and new possibilities
C. Skarlis, M. Gontika, S. Katsavos, M. Anagnostouli 1, 2 ATHENS, GREECE

P 22180 NMDA autoimmune encephalitis triggered by a herpes simplex virus encephalitis: a case report

P 22181 Autoimmune encephalitis at the neurological intensive care unit: etiologies, reasons for admission and survival

P 22182 The possible role of sirtuin 1 in migraine pathogenesis
C. Irkec, D. Yaziçoğlu Cezyar, T. Altiparmak, R. Tural, N. Altan 1, ANKARA, TURKEY

P 22183 CXCL10 and CXCL13 chemokines in relapsing-remitting and primary progressive multiple sclerosis
P. Iwanowski, L. Kramer, M. Wójcicka, E. Kaufman, R. Kaźmierski, J. Losy 1, POZNAN, POLAND

P 22184 Abstract cancelled

P 22185 MOG positive seronegative NMO presenting with absence F-wave in an electrophysiological study
S. Nahrin, N. Kajtazi, J. Saeedi 1, RIYADH, SAUDI ARABIA

P 22186 Peripheral regulatory T-/Th17-cells contributes to Moya-Maya disease
Y. Xu, X. Cao, L. Weng 1, NANJING, CHINA

POSTER SESSION
NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC DISEASES 2
13:30-14:15 | SCREEN B3
CHAIRPERSON:
Peter D. Berlit, ESSEN, GERMANY

P 22187 Association of parenchymal and vascular damage (mixed pattern) in neuroBehcet's disease: a case series study
H. El Otmani, K. Obondzo, T. Benhaim, M. A. Rafai, B. El Moutawakil, I. SLASSI 1, CASABLANCA, MOROCCO
COPENHAGEN, DENMARK, 28 – 31 MAY, 2016

POSTER SESSIONS

SUNDAY, 29 MAY
13:30 – 14:15

POSTER SESSION
NEURO-OPTHALMOLOGY/ NEURO-OTOLOGY 2
13:30-14:15 | SCREEN H1
CHAIRPERSON:
Dominik Straumann, ZURICH, SWITZERLAND

P 22188 Prognostic factors and long-term follow-up of 20 cases of Neuro-Behçet disease: a retrospective study
B. Houria  I ALGIERS, ALGERIA

P 22189 A case of posterior reversible encephalopathy syndrome (PRES) in a patient with paraganglioma
L. Huachan  I OUTRAM, SINGAPORE

P 22190 Moya-Moya syndrome in a patient with Takayasu’s arteritis
K.D. Jo, W. Jang, M.K. Lee  I GANGNEUNG, KOREA, REPUBLIC OF

P 22191 Impact of white matter lesions on processing speed deficits in systemic lupus erythematosus patients
M. Pawlak1, A. Kalinowska-Lyszczarz, M. Forycka1, M. Wilkosc2, Z. Serafin3, K. Pawlak-Buś1, P. Leszczyński1, E. Wiesiek-Szewczyk3, R. Kazmierski1, W. Kozubski1  POZNAN, POLAND

P 22192 Abstract cancelled

P 22193 Tacrolimus-induced posterior reversible encephalopathy
G. Koc1, S. Bek2  I 1ANKARA, 2ADANA, TURKEY

P 22194 Hypoparathyroidism with severe brain calcinosis presenting as non-convulsive status epilepticus

P 22195 Autoimmune meningoencephalitis with two possible etiologic factors: HCV infection and anti-NMDA receptor antibodies
R. Loureiro, M.V. Dias, J. Becho, M. Santos, F. Carrilho, P. Costa, C. Fidalgo, F. Roxo, A. Palos  I SANTARÉM, PORTUGAL

P 22196 Acquired hepatocerebral degeneration and hepatic encephalopathy: an overlapping case

P 22197 Palinopsia: a strange visual phenomenon
S. Fernandez, N. Fabregat, A. Donaire  I BARCELONA, SPAIN

P 22198 The association between multiple sclerosis and uveitis
T. Godegaard Olsen1, J. Frederiksen2  I 1THISTED, 2GLOSTRUP, DENMARK

P 22199 Blurred vision in MS: is it always optic neuritis?
J. Gauci, C. Chircop, N. Vella  I MSIDA, MALTA

P 22200 Upbeat nystagmus due to B1 deficiency: a case report
M.J. Ibanez, E. Pappa, B. Gaynard, D. Psimaras  I PARIS, FRANCE

P 22201 Isolated vertigo in emergency room
B. Kim  I SEOUL, KOREA, REPUBLIC OF

P 22202 Isolated vertigo with posterior circulation infarction
B. Kim  I SEOUL, KOREA, REPUBLIC OF

P 22203 Benign paroxysmal positional vertigo: 20-year experience in treating 1195 patients with canalith repositioning procedure
N. Chatzakis1, D. Kotzamani1, A. Karatzanis1, S. Velegrakis2, E. Prokopakis 1 HERAKLION CRETE, GREECE, 2ERLANGEN, GERMANY

P 22204 Neuro-phthalomological and clinical findings in Wolfram syndrome: indications of mitochondrial dysfunction
C. La Morga1, M. Carbonelli2, L. Caporalii, F. Sadun2, C. Tononi1, R. Lodi1, M.L. Valentino1, P. Barboni1, R. Liguori2, V. Carelli1  I BOLOGNA, ITALY

P 22205 Saccade kinematics in myotonic syndromes
E. Livitzis, G. Papadimas, I. Potiri, I. Evdokimidis, E. Kararizou, E. Anagnostou  I ATHENS, GREECE

P 22206 Relationship between retinal nerve fiber layer and vitamin D levels in patients with multiple sclerosis
POSTER SESSIONS

SUNDAY, 29 MAY
13:30 - 14:15
SCREEN D2

P 22207 Status of the extracranial segments of the vertebral arteries in the vestibular dysfunction caused by the neurovascular conflict
H. Lushchyk, I. Maryenko, S.A. Likhachev, A. Antonenko, D. Naumenko | MINSK, BELARUS

P 22208 Gradenigo's syndrome caused by odontogenic infection: an unusual aetiology
M. Machio Castello, M. Oses, L. Olivia Garcia, R. Riguél Bobillo, M. Ruggiero Garcia, M.T. Montajo Villasanta, J. Villacampa Aubá, M.A. García Torres, I. Zamarbide Capdeñón | MADRID, SPAIN

POSTER SESSION
PERIPHERAL NERVE DISORDERS 4
13:30-14:15 | SCREEN D2
CHAIRPERSON:
Davide Pareyson, MILAN, ITALY

P 22209 Utility of sensory nerve conduction and summed Z-scores in polyneuropathy
T. Sand1, K.B. Nilsen2, M. Engstrom1, R. Michler1, T. Wader1, K. Todnem1 | TRONDHEIM, OSLO, NORWAY

P 22210 Sjögren’s syndrome presenting as subacute sensory ataxic neuropathy and sensorineural hearing loss

P 22211 Sensory ganglionopathy associated with gluten sensitivity: a case report
J. Sequeira, S. Dias, J. Morgado, C.M.C. Capela, A. Calado, R.M.G. Pedroso | LISBON, PORTUGAL

P 22212 Rituximab in the treatment of anti-myelin-associated glycoprotein (anti-MAG) neuropathy resistant to conventional immune therapies: a 15-year experience
S. Simonetti | GENOA, ITALY

P 22213 Interest of anti-ganglioside antibodies for the diagnosis of neuropathies of unknown aetiology: a series of 47 patients

P 22214 An unusual cause of transient diplopia
K. Szőke, Z. Aranyi, G. Bozsik, D. Bereczki | BUDAPEST, HUNGARY

P 22215 Acute polyneuropathy secondary to thiamine deficiency: one year of follow-up
H. Tibar, W. Regragui, E. Ait Ben Haddou, A. Benomar, M. Yahyaoui | RABAT, MOROCCO

P 22216 Abstract cancelled

P 22217 Lewis-Sumner syndrome (L-SS), a rare variant of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
M.H. Torregrosa Martinez, M. Molina Sánchez, P. Hernández Novarro, L.A. Lazano Garcia-Caro | MADRID, SPAIN

P 22218 Motor unit number estimation in acute inflammatory demyelinating polyneuropathy
M. Vaeggemose, A. Fuglsang-Frederiksen, H. Andersen, B. Isak, T. Harbo, H. Tankisi | AARHUS, DENMARK

P 22219 Can a mobile phone be used to test vibration sensation?
H. van Den Tooren1, E. McKee2, D. McKee | MANCHESTER, EDINBURGH, UK

P 22220 Chronic demyelinating polyneuropathy – clinical-immunological correlation

P 22221 Self-reported questionnaires for patients with suspected neuropathies in outpatient settings
N. Yavorska, V. Smilevska | LVIV, UKRAINE
CASE-BASED FACILITATED WORKSHOP 4: MANAGEMENT OF MULTIPLE SCLEROSIS
08:30 - 10:00 | HALL B4. M2

CHAIRPERSON:
Aksel Siva, ISTANBUL, TURKEY

Management of MS attacks
Aksel Siva, ISTANBUL, TURKEY

Symptomatic management
Oscar Fernandez, MALAGA, SPAIN

Long-term management
Michel Clanet, TOULOUSE, FRANCE

Management of pediatric MS
Alexey Boyko, MOSCOW, RUSSIA

In this case-based facilitated workshop different aspects of multiple sclerosis management will be discussed through pre-prepared real-life four clinical case scenarios.

• The first case will address management of MS attacks and will include issues such as the differential of pseudo-attacks, how to work up a patient prior to attack treatment and attack treatment protocols, including steroid non-responders.

• The second case will cover symptomatic management in an MS patient who had developed some neurologic deficits as a part of her MS.

• The third case is on long-term management, when to start a DMD, which one to start and some of the safety issues as well as when to consider that a patient is a responder or non-responder, and when to switch?

• In the fourth case scenario a paediatric patient with MS will be presented and available options in the management of paediatric MS will be reviewed.

In the first part of the workshop each of the cases will be discussed by one of the four groups together with one of the faculty members who will act as a facilitator and then in the second part each case will be discussed by all participants.

HANDS-ON COURSE 4: NEUROPHYSIOLOGY III – NON-INVASIVE BRAIN STIMULATION
08:30 - 10:00 | HALL B5. M1

CHAIRPERSON:
Letizia Leocani, ROME, ITALY

Single transcranial magnetic stimulation (TMS)
Josep Classen, LEIPZIG, GERMANY

Repetitive TMS and transcranial direct current stimulation (rTMS and tDCS)
Letizia Leocani, ROME, ITALY

The practical course on magnetic and direct current stimulation will provide an opportunity for learning of the basic principles, standards of use, and potential applications of TMS and tDCS in clinical neurophysiology and neurology. Participants will have learned how to determine motor threshold, how to record motor evoked potentials, how to determine central motor latency, conduct silent period, and paired-pulse TMS studies, and how to safely apply repetitive TMS and tDCS. Participants will also learn how to interpret findings of TMS studies.

This course is supported by NATUS MEDICAL Inc. and Neuroelectrics SL

INTERACTIVE SESSION 3: MDS-ES/EAN: PAROXYSMAL AND ACUTE MOVEMENT DISORDERS
08:30 - 10:00 | HALL B

CHAIRPERSON:
Timothy Lynch, DUBLIN, IRELAND

Movement disorders in the intensive care unit
Timothy Lynch, DUBLIN, IRELAND

Paroxysmal dyskinesia or epilepsy?
Laurent Vercueil, GRENOBLE, FRANCE

Psychogenic movement disorders
Kailash Bhatia, LONDON, UK

Participants are encouraged to actively engage with immediate feedback to support learning via the congress App EAN 2016.
FOCUSED WORKSHOP 13: SLEEP AND COGNITION
08:30 - 10:00 | HALL C

CHAIRPERSON:
Pierre Maquet, LIEGE, BELGIUM

Sleep and cognition
Pierre Maquet, LIEGE, BELGIUM

Sleep and emotion
Virginie Sterpenich, GENEVA, SWITZERLAND

Sleep and dementia
Sebastiaan Overeem, NIJMEGEN, THE NETHERLANDS

Target Audience: Basic scientists, clinical academicians, (practitioners), students/residents/trainees

Scientific Content: The workshop covers three different topics illustrating the importance of sleep in clinical neurology. Pierre MAQUET presents the mechanisms by sleep and wakefulness mutually interact, and which constrain patients performance and recovery. Professor Schwartz explores the structural and anatomical links between emotional processing and neurological diseases such as narcolepsy. Professor Overeem reviews the mechanisms sleep, and lack of sleep, are involved in brain amyloid clearance and accumulation, respectively.

FOCUSED WORKSHOP 14: GUT MICROBIOTA, IMMUNOLOGY AND NEUROLOGICAL DISEASES
08:30 - 10:00 | HALL M1

CHAIRPERSON:
Gurumoorthy Krishnamoorthy, MARTINSRIED, GERMANY

Microbiota and the gut-brain axis
Patricia Lepage, JOUY-EN-JOSAS, FRANCE

Microbiota and CNS autoimmunity
(multiple sclerosis)
Gurumoorthy Krishnamoorthy, MARTINSRIED, GERMANY

Gut microbiome: a key regulator of neurodevelopment and behaviour
John F. Cryan, CORK, IRELAND

Target Audience: Basic scientists, clinical academicians, students/residents/trainees

Scientific Content: The human intestinal microbiota, composed of approximately 100,000 billion microorganisms, can be considered as an organ within another, which co-evolved with its host to achieve a symbiotic relationship leading to physiological homeostasis. Dysbiosis of the intestinal microbiota (changes in bacterial composition) has been associated with local dysfunctions of the gastrointestinal tract, such as inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS), but also, at distance, in obesity and metabolic diseases. The possible involvement of the ‘microbiota-gut-brain’ axis in the development of such disorders, will be further discussed, as well as the role of gut microbiome in central nervous system immune mediated, neurodevelopmental and behavioural disorders.

FOCUSED WORKSHOP 15: EXOME SEQUENCING GOES BEDSIDE: NEW GENES IN NEUROLOGICAL DISORDERS
08:30 - 10:00 | HALL M3

CHAIRPERSON:
Matthis Synofzik, TUBINGEN, GERMANY

Cerebellar ataxias: exome sequencing unravels novel genes, false friends and clinical hints for bedside
Matthis Synofzik, TUBINGEN, GERMANY

Atypical parkinsonian syndromes: rapidly expanding genetic disease spectrum, yet distinct clinical and imaging signatures
Henry Houlden, LONDON, UK

Motor neuron disease and spastic paraplegias: large-scale exome sequencing reveals common pathogenetic hubs
Rebecca Schüle, TUBINGEN, GERMANY

Target Audience: Basic scientists, clinical academicians, practitioners, students/residents/trainees

Scientific Content: Next generation genomics like whole exome sequencing (WES) has led to a quantum leap in clinical neurology and neurogenetics, providing unprecedented options to diagnose previously unsolved patients, to define the genetic basis of many rare and complex neurological disorders, and to gain first insights into underlying molecular pathways. Given this success, WES is now moving from academic research settings to clinical routine, and from few well-selected families to many individual patients with less unique phenotypes. This development is evidenced by the fact that the „Clinical Exome“ has now become readily available, allowing to use standardized WES with high coverage, quick turn-around times, clear reports requiring no genetic expert knowledge, at relatively low cost ( <1500€). This focussed workshop will
1. give an overview on the methodology of WES, its strengths and its pitfalls
2. provide an overview on novel genes and associated molecular pathways in three exemplary neurodegenerative disease groups where WES has allowed to identify several new genes within only few years: degenerative ataxias, parkinsonian syndromes, and motor neuron diseases
3. outline and discuss the power and the limitations of using WES „at the bedside“, i.e. in the daily practice of busy clinical routine with only one patient or family at a time and sometimes without additional expert knowledge for interpreting the particular WES variants at hand.

**FOCUSED WORKSHOP 16: SYNDROMES OF CENTRAL VISUAL AND VESTIBULAR DISORDERS**

**08:30 - 10:00 | HALL M4**

**CHAIRPERSON:**
Christopher Kennard, OXFORD, UK

**Cortical visual disorders and neglect**
Christopher Kennard, OXFORD, UK

**Peripheral vestibular disorders with essential bedside testing**
Barry Seemungal, LONDON, UK

**Central vestibular disorders (from brainstem to cortex)**
Thomas Brandt, MUNICH, GERMANY

**Target Audience:** Clinical academicians, practitioners, students/residents/trainees

**Scientific Content:** Actual knowledge of syndromes and diagnostic procedures of peripheral vestibular and the different central visual and vestibular disorders depending on the lesion site

**FOCUSED WORKSHOP 17: ALS AND FTD: TWO CONVERGING DISEASES?**

**08:30 - 10:00 | HALL M5**

**CHAIRPERSON:**
Vincenzo Silani, MILAN, ITALY

**Neuropathology of FTD and ALS – comparing the patterns of propagation**
Johannes Brettschneider, PHILADELPHIA, USA

**Assessment of neuropsychology in ALS and FTD**
Thomas Bak, EDINBURGH, UK

**ALS and FTD: genetics and phenotypes**
Vincenzo Silani, MILAN, ITALY

**Target Audience:** Basic Scientists, clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

**Scientific Content:** ALS and FTD are since 2016 a single disease: the neuropathology first provided proof and genetics largely confirmed and contributed in defining the convergence. The clinical implications are so relevant both in the subgrouping of the patients and in the design of clinical trials that further clarifications are highly needed for a more accurate definition of the cognitive and motor involvement of both diseases.

**FOCUSED WORKSHOP 17: ALS AND FTD: TWO CONVERGING DISEASES?**

**08:30 - 10:00 | HALL M5**

**CHAIRPERSON:**
Vincenzo Silani, MILAN, ITALY

**Neuropathology of FTD and ALS – comparing the patterns of propagation**
Johannes Brettschneider, PHILADELPHIA, USA

**Assessment of neuropsychology in ALS and FTD**
Thomas Bak, EDINBURGH, UK

**ALS and FTD: genetics and phenotypes**
Vincenzo Silani, MILAN, ITALY

**Target Audience:** Basic Scientists, clinical academicians, practitioners, students/residents/trainees, non-physician health professionals

**Scientific Content:** ALS and FTD are since 2016 a single disease: the neuropathology first provided proof and genetics largely confirmed and contributed in defining the convergence. The clinical implications are so relevant both in the subgrouping of the patients and in the design of clinical trials that further clarifications are highly needed for a more accurate definition of the cognitive and motor involvement of both diseases.
MONDAY, 30 MAY
8:30 - 14:30

SPECIAL SESSION 6: ILAE-CEA/EAN: HOT TOPICS IN EPILEPSY
08:30 - 10:00 | HALL M0

CHAIRPERSON:
Hermann Stefan, ERLANGEN, GERMANY
Reetta Kälviäinen, KUOPIO, FINLAND

Recent advances in structural brain imaging in epilepsies
Reetta Kälviäinen, KUOPIO, FINLAND

EEG and MEG monitoring in epilepsy
Sándor Beniczky, DIANALUND, DENMARK

Epilepsy and gender
Gerhard Luef, INNSBRUCK, AUSTRIA

Seizures and epilepsy in the aging population
Hermann Stefan, ERLANGEN, GERMANY

PLENARY SYMPOSIUM 2: NEUROIMAGING OF DEMENTIA
10:30 - 12:30 | HALL A

CHAIRPERSON:
Reinhold Schmidt, GRAZ, AUSTRIA
Massimo Filippi, MILAN, ITALY

Imaging of cerebral small vessel disease
Reinhold Schmidt, GRAZ, AUSTRIA

Imaging of Alzheimer’s disease
Philip Scheltens, AMSTERDAM, THE NETHERLANDS

Imaging of frontotemporal dementia
Massimo Filippi, MILAN, ITALY

Monitoring treatment response in dementia trials
Nick Fox, LONDON, UK

HOW TO IMPROVE YOUR CHANCES...
ABSTRACT, POSTER AND PRESENTATION TIPS FOR SUCCESS AT INTERNATIONAL MEETINGS
13:00 - 14:30 | HALL B4. M2

CHAIRPERSON:
Hannah Cock, LONDON UK

How to Prepare & Submit your abstract
Hannah Cock, LONDON, UK

Preparing your poster or slides
Aksel Sirv, ISTANBUL, TURKEY

Delivering your poster or oral presentation
Claudia Sommer, WÜRZBURG, GERMANY (TBC)

Target Audience: Neurologists at any level who are relatively inexperienced in submitting work for presentation at international congresses, or experienced in their native country, but may be less competitive/successful on an international stage.

Educational objective: Practical advice on every step from abstract preparation to delivering your poster or oral platform presentation will be provided by experts from the Education and Program committees of the EAN, with ample opportunity to ask questions and seek advice.

CASE-BASED FACILITATED WORKSHOP 5: CARE OF THE PERSON WITH ALS
14:45 - 16:15 | HALL B4. M2

CHAIRPERSON:
David Oliver, CANTERBURY, UK

Telling the diagnosis and initial care
Marianne de Visser, AMSTERDAM, THE NETHERLANDS

Interventions – gastrostomy and ventilation – and the palliative care needs of ALS patients and their families
Johanna Anneser, MUNICH, GERMANY

Care at the end of life
David Oliver, CANTERBURY, UK

Assisted suicide and euthanasia in ALS - experience across Europe
Markus Weber, ST. GALLEN, SWITZERLAND
The care of the person with ALS and their family is complex and involves the careful assessment and management of all aspects of care – physical, psycho-social and spiritual. This workshop considers the pathway of care from the telling of the diagnosis and initial management of symptoms and other issues, the complex decisions for patients and families with interventions, in particular gastrostomy and non-invasive ventilation, and the care as the condition deteriorates and the patient approaches end of life, including when a patient considers assisted dying.

Learning objectives: The workshop will aim to allow participants to look at the issues of caring for a person with ALS, particularly as the end of life approaches.

At the end of the workshop participants will be able to
• Describe the importance of good care in the initial stages following diagnosis and the importance of the telling of the diagnosis
• Discuss the use of gastrostomy and ventilator support in the care of a person with ALS
• Discuss the changes in the use of gastrostomy and ventilator support as the end of life approaches
• Show awareness of the recognition of the end of life phase in ALS and the support that may be provide for patients and families
• Show awareness of the issues of hastened death – by assisted suicide or euthanasia for people with ALS

SPECIAL SESSION 11: HISTORY OF NEUROLOGY
14:45 - 16:15 | HALL M0

CHAIRPERSON:
Mads Ravnborg, COPENHAGEN, DENMARK

A short introduction to the history of Scandinavian neurology: from the sagas to the Nobel prizes
Ragnar Stien, OSLO, NORWAY

Nicolaus Steno, Discourse on the Anatomy of the Brain, Paris 1665, with a new programme for brain research
Troels Kardel, COPENHAGEN, DENMARK

Functional mapping of the human brain using regional cerebral blood flow techniques – the early development
Lars Friberg, FREDRIKSBERG, DENMARK

The regional CBF changes during migraine attacks
Jes Olesen, COPENHAGEN, DENMARK

SYMPOSIUM 5: NEW PERSPECTIVES IN THE TREATMENT OF NEUROMUSCULAR DISEASES: THERAPIES ON THE HORIZON
14:45 - 16:15 | HALL B

CHAIRPERSONS:
Eduardo Nobile-Orazio, MILAN, ITALY
John Vissing, COPENHAGEN, DENMARK

Amyotrophic lateral sclerosis: still far from an effective therapy?
Vincenzo Silani, MILAN, ITALY

Myasthenia gravis: new therapies for new antibodies?
Nils-Erik Gilhus, BERGEN, NORWAY

Immune mediated neuropathies: monoclonal antibodies and what else?
Eduardo Nobile-Orazio, MILAN, ITALY

Genetic treatment in muscular dystrophies: hope or reality?
Francesco Muntoni, LONDON, UK

Scientific content: A number of novel therapies have been proposed in the recent years in different neuromuscular disease raising some expectations especially for diseases where current therapies are unsatisfactory. We will approach in this Symposium the new therapeutic approach and the new possible perspective in some neuromuscular disease. We decided to address two diseases in whom effective therapies are available although they are not always satisfactory leading to the continuous search or more effective and safer therapies, such as myasthenia gravis and CIDP, and two diseases where the consistent advances in the comprehension of their pathogenesis has not yet led to effective therapies such as muscular dystrophies and motor neuron diseases.
SYMPOSIUM 6: ESO/EAN: ACUTE STROKE: NEW OPPORTUNITIES AND CHALLENGES FOR NEUROLOGISTS

14:45 - 16:45 | HALL A

CHAIRPERSONS:
Danilo Toni, ROME, ITALY
Christina Kruuse, COPENHAGEN, DENMARK

Intracranial large vessel occlusions: how to recognise them as fast as possible
Patrik Michel, LAUSANNE, SWITZERLAND

Anterior and posterior circulation: mind the differences
Daniel Strbian, ESPOO, FINLAND

Pathway of acute stroke: how to reduce the 'pit-stops' of acute stroke
Danilo Toni, ROME, ITALY

Who should treat acute large vessel occlusions: neurologists, radiologists or neuro-interventionists?
Christine Kremer, MALMÖ, SWEDEN

Scientific content: Acute stroke is an emergency that general neurologists face regularly. Regarding its treatment, recanalisation strategies, including the administration of intravenous (IV) recombinant tissue-type plasminogen activator (rt-PA) and intra-arterial approaches, aim to establish revascularisation by rescuing cells in the penumbra prior to any irreversible injury. Endovascular techniques have shown greater benefit up to 8 h after stroke onset in the proximal anterior circulation in addition to best medical therapy (IVT up to 4.5 h in most patients), compared to intravenous rt-PA alone. However, several issues remain concerning their use in posterior circulation, the applicability of RCT trials on anterior circulation for basilar occlusion. Moreover, it needs to be discussed who should perform these techniques: certified neurologists, interventional radiologists or radiologists.

EHF/EAN TOPICAL SYMPOSIUM: CGRP ANTIBODIES: A NEW CLASS OF MIGRAINE-SPECIFIC PREVENTIVE MEDICATION

14:45 - 16:45 | HALL M5

CHAIRPERSONS:
Messoud Ashina, FREDRIKSBERG, DENMARK
Dimos Mitsikostas, ATHENS, GREECE

Current treatment for migraine: efficacy and safety outcomes
Julio Pascual, SANTANDER, SPAIN

The role of CGRP in migraine: from molecule to man
Messoud Ashina, FREDRIKSBERG, DENMARK

CGRP antibodies in treatment of migraine: efficacy and mechanism of action
Peter Goadsby, LONDON, UK

Can acute and preventive migraine medication pass the blood brain barrier?
Gitte Moos Knudsen, COPENHAGEN, DENMARK

Target Audience: Basic scientists, clinical academicians, practitioners, students/residents/trainees

Scientific content: Calcitonin gene related peptide (CGRP), a peptide present in sensory trigeminal fibres, induces dilatation of extracerebral arteries. CGRP plays a key role in migraine pathophysiology. In migraine patients, intravenous infusion of CGRP causes a migraine attack. Randomized controlled trails (RCT) have demonstrated that CGRP monoclonal antibodies may prevent migraine attacks. This session will review the role of CGRP in migraine, the results of RCT in migraine sufferers and discuss possible site of action of CGRP antibodies in migraine.

Supported by an unrestricted educational grant from Novartis
TEACHING COURSE 13: DIAGNOSTIC AND THERAPEUTICAL APPROACH TO MUSCLE SYNDROMES – LEVEL 1
14:45 - 18:15 | HALL C

CHAIRPERSON:
Corrado Angelini, VENICE, ITALY

Dysphagia: differential diagnosis and treatment
Bruno Eymard, PARIS, FRANCE

How to diagnose proximal muscle weakness
Corrado Angelini, VENICE, ITALY

How to diagnose distal muscle weakness
Bjarne Udd, TAMPERE, FINLAND

How to diagnose muscle weakness in children
Francesco Muntoni, LONDON, UK

This teaching course is directed to diagnose muscle and end-plate disorders by clinical patterns such as proximal or distal weakness, muscle MRI imaging, EMG studies and a series of laboratory investigations such as serum CK and antibody screening, muscle biopsy study such as biochemistry, muscle histopathology, immunohistochemistry, electron microscopy and new molecular techniques on DNA and RNA, i.e. next generation sequencing analysis. At the end of the presentations, physicians and neurologists attending to the teaching course will receive a full-immersion and up-to-date access to current diagnosis and possible treatments in neuromuscular disorders, including both muscular dystrophies and myositis, acquired muscle disorders and metabolic disorders or myasthenic disorders.

TEACHING COURSE 14: PAIN IN CENTRAL NEUROLOGICAL CONDITIONS – LEVEL 2
14:45 - 18:15 | HALL M1

CHAIRPERSON:
Nadine Attal, BOULOGNE-BILLANCOURT, FRANCE

Pain in stroke
Troels S. Jensen, ARHUS, DENMARK

Pain in spinal cord injury patients
Maija Haanpää, HELSINKI, FINLAND

Pain in multiple sclerosis
Giorgio Cruccu, ROME, ITALY

Pain in syringomyelia
Nadine Attal, BOULOGNE-BILLANCOURT, FRANCE

Pain is common in central neurological conditions including stroke, multiple sclerosis or spinal cord injury. Although neuropathic pain is usually the most troublesome, many of these patients also suffer from nociceptive or visceral pain, that can also impair quality of life and complexifies the therapeutic management.

Educational objectives:
• learn about epidemiology and risk factors for neuropathic pain associated with stroke, multiple sclerosis and spinal cord injury.
• understand the mechanisms of pain related to these neurological conditions
• know the therapeutic management of pain particularly neuropathic pain including drug and non pharmacological treatment, and the current therapeutic recommendations.

TEACHING COURSE 15: CLINICAL PRESENTATIONS OF METABOLIC DISORDERS – LEVEL 2
14:45 - 18:15 | HALL M2

CHAIRPERSON:
Davide Pareyson, MILAN, ITALY

Metabolic disorders presenting with dementia or psychosis
Oliver Bonnot, NANTES, FRANCE

Metabolic disorders presenting with movement disorders
Antonio Federico, SIENA, ITALY

Metabolic disorders presenting with ataxia or spastic paraplegia
Jean-Marc Burgunder, BERN, SWITZERLAND

Metabolic disorders presenting with peripheral neuropathies
Davide Pareyson, MILAN, ITALY

Genetic metabolic disorders of the central and peripheral nervous system are important for several reasons. Although rare if considered individually, they are overall frequent. Early diagnosis is fundamental to provide correct therapy (as some of them are treatable), proper genetic counselling and to avoid misdiagnosis with the more common disorders they often mimic. Four specialists in the field will discuss metabolic diseases presenting with different clinical pictures. Olivier Bonnot, Antonio Federico, Jean-Marc Burgunder and Davide Pareyson will discuss heritable metabolic disorders characterized by psychosis/dementia, movement disorders, ataxia/spasticity, and peripheral neuropathy, respectively. They will review the diagnostic algorithms, the most relevant diagnostic challenges as well as the clinical and instrumental key elements for a correct diagnosis.
TEACHING COURSE 16: INTERVENTIONS IN NEUROCITICAL CARE – LEVEL 2

**14:45 - 18:15 | HALL M3**

**CHAIRPERSON:**
Christina Panea, BUCHAREST, ROMANIA

- **Fluid and electrolyte management**
  Christina Panea, BUCHAREST, ROMANIA

- **Analgesia, sedation and relaxation**
  Ronny Beer, INNSBRUCK, AUSTRIA

- **Nutrition in the Neuro ICU**
  Murat Arsava, ANKARA, TURKEY

- **Emerging new roles for neurologists in the treatment of patients with subarachnoid haemorrhage and traumatic brain injury**
  Erich Schmutzhard, INNSBRUCK, AUSTRIA

In neurocritical care it becomes more and more accepted that a wide variety of seemingly non-neurological interventions may interact with a stressed or even failing brain, thereby preventing progression of failure and reversing functional impairment. Therefore, a broad critical care medicine basis is the prerequisite for the best possible management of neurocritical care patients. Christina Panea details the aspects of fluid and electrolyte management, any mismanagement in this respect may add to neurological deterioration, even permanent damage of brain tissue, e.g. brain edema, pontine myelinolysis aso. The same applies to best balanced nutrition, avoiding malnutrition, refeeding syndrome and over-nutrition in NICU patients, discussed by Murat Arsava. Similarly, the delicate measures in NICU patients, so essential for keeping the intracranial equilibrium and homeostasis, namely analgesia, sedation and relaxation are discussed in this course, Ronny Beer will point to all potential pitfalls and how to avoid possible life-threatening mistakes in this ICU-management aspect. Finally, Erich Schmutzhard will address the emerging new roles for neurologists in the treatment of patients with subarachnoid haemorrhage and traumatic brain injury. It is the thorough knowledge of brain metabolism, brain function and malfunction which qualifies the neurologist to be the key person in the emergency-, intensive care- and post intensive care management of these patients.

TEACHING COURSE 17: UPDATE ON EPILEPSY IN CHILDREN – NEW TRENDS IN DIAGNOSIS AND TREATMENT – LEVEL 1

**14:45 - 18:15 | HALL M4**

**CHAIRPERSON:**
Rima Nabbout, PARIS, FRANCE

- **Clinical pearls and pitfalls in the diagnosis of pediatric epilepsy**
  Daniela Pohl, OTTAWA, CANADA

- **New genes – when, why and what to test in children with epilepsy**
  Rima Nabbout, PARIS, FRANCE

- **New antiepileptic drugs – pros and cons in kids**
  Thomas Bast, KEHL-KORK, GERMANY

- **Nonpharmacological treatment approaches: Ketogenic diet and neurostimulation**
  Helen Cross, LONDON, UK

This session is dedicated to childhood epilepsies and will focus on 4 major aspects.

Dr. Pohl will present clinical cases of difficult to diagnose and common pitfalls in the diagnosis of pediatric epilepsies. Her talk will include the new proposals for classification and terminology in epilepsy syndromes. She will emphasize the key role of EEG-video.

Dr. Nabbout will speak about conjoint efforts of clinicians and the spectacular advances of molecular biology tools have allowed the identification of causal genes in childhood epilepsy syndromes as Dravet syndrome or Epilepsy of infancy with migrating focal seizures and the description of new genetic syndromes as for patients with PCDH19 or CDKL5 mutations. This presentation will focus on some monogenic genetic epilepsy syndromes of interest for paediatric neurologists. It aims to discuss the impact of gene discovery on diagnosis, genetic counselling and our future vision of development of new targeted therapies that should aim beyond the treatment of seizures to cure a genetic disease.

Dr. Bast will address the current knowledge of AEDS in childhood epilepsies and will emphasize the level of evidence for the efficacy of these drugs the new AEDs. He will discuss also possible misuse of these drugs.

And Dr. Cross will discuss the use of non pharmacological treatments in childhood epilepsies and will emphasize the level of evidence for the efficacy of these drugs the new AEDs. He will discuss also possible misuse of these drugs.
**ORAL SESSION: CEREBROVASCULAR DISEASES 2**

**16:45-18:30 | HALL A**

**CHAIRPERSONS:**
Franz Fazekas, GRAZ, AUSTRIA
Christina Kruuse, HERLEV, DENMARK

---

**O 3101**
**16:45**
Hemorrhagic strokes in Caribbean
M. Agbetou, R. Dellis, F. Alecu, S. Mecharles, C. Dan, L. Lannuzel, C. Alecu
1POINTE À PITRE, 2POINTE À PITRE, FRANCE

**O 3102**
**17:00**
Brain metabolic alterations in patients with hypertension: a 2D-1H proton magnetic resonance spectroscopy imaging study
Z. Cao, R.H. Wu, B.D. Ye, Z.W. Shen, Y.Y. Xiao
SHANTOU, CHINA

**O 3103**
**17:15**
No evidence for increased brain iron deposition in patients with ischemic white matter disease
GRAZ, AUSTRIA

**O 3104**
**17:30**
The prehospital Aarhus stroke severity scale for prediction of emergent large vessel occlusion: design, validation and comparison with other scales
S. Hastrup, D. Damgaard, S.J. Paaske, G. Andersen
AARHUS, DENMARK

**O 3105**
**17:45**
Vertebrobasilar occlusion stroke: does stent retrievers' thrombectomy modify the outcome?
F. Perren, V. Mendes Pereira
1GENEVA, SWITZERLAND, 2TORONTO, CANADA

**O 3106**
**18:00**
Gender differences in thrombolysed stroke patients
1KØBENHAVN V, 2COPENHAGEN, DENMARK

---

**TOURNAMENT CLINICAL**

**14:45 - 16:15 | HALL B5, M1**

**CHAIRPERSONS:**
Claudio Bassetti, BERN, SWITZERLAND
Marianne Dieterich, MUNICH, GERMANY
Jesper Erdal, COPENHAGEN, DENMARK

---

**T 201**
**14:45**
Low maternal folic acid in women with epilepsy during pregnancy is linked to autistic traits in the child at 3 years of age
BERGEN, NORWAY

**T 202**
**15:00**
Anti-LGI1 mediated autoimmune encephalitis in Denmark: a multicenter retrospective study
1COPENHAGEN, 2AARHUS, 3ODENSE, 4AALBORG, DENMARK

**T 203**
**15:15**
Clinical, biochemical, molecular and histological features of 65 Portuguese patients with genetically confirmed mitochondrial disorders
S. Cruz, R. Taipa, C. Nogueira, C. Pereira, L. Almeida, R. Neiva, T. Geraldes, M. Melo Pires, L. Vilarinho
1AMADORA, 2PORTO, 3ALMADA, PORTUGAL

**T 204**
**15:30**
Imaging nigrostriatal circuitry with 11C-PE2I PET and Neuromelanin-sensitive MR in Parkinson’s disease
1LONDON, 2CAMBRIDGE, UK, 3LUND, SWEDEN

**T 205**
**15:45**
Identification of MS patients at highest risk of cognitive impairment using integrated brain MRI assessment approach
PRAGUE, CZECH REPUBLIC
2GENOA, ITALY, 3MELBOURNE, AUSTRALIA, 4BUFFALO, USA

**T 206**
**16:00**
Complete resection of contrast enhancing tumor volume is associated with improved survival in recurrent glioblastoma – results from the DIRECTOR trial
1ZURICH, SWITZERLAND, 2MUNICH, 3FRANKFURT AM MAIN, 4REGENSBURG, 5DUSSELDORF, 6BONN, 7HOMBURG/SAAAR, 8BOCHUM, GERMANY, 9VIENNA, AUSTRIA, 10HEIDELBERG, GERMANY

---

**TOURNAMENT | ORAL SESSIONS**

**MONDAY, 30 MAY**

**16:45 - 18:30**

---

**COPENHAGEN, DENMARK, 28 – 31 MAY, 2016**
MONDAY, 30 MAY
16:45 - 18:15

ORAL SESSION:
COGNITIVE NEUROLOGY/NEUROPSYCHOLOGY 2
16:45-18:15 | HALL B5. M1
CHAIRPERSONS:
Steen Hasselbalch, COPENHAGEN, DENMARK
Wolfgang Heide, CELLE, GERMANY

O 3108  16:45
Effectiveness of Sphenopalatine Ganglion (SPG) stimulation for cluster headache: 24-month long-term follow-up results from the pathway CH-1 study
R. Jensen, M. Barloese, J.M. Lainez, C. Gaul, J. Schoenen, A. Goodman, A. Caparso, A. May, T. Jürgens I GLOSTRUP, COPENHAGEN, DENMARK; J. LIEGE, BELGIUM; VALENCIA, SPAIN; KOENIGSTEIN, GERMANY

O 3109  17:00
Prevalence of post-stroke cognitive disorders: a meta-analysis
M. Barbay, O. Godefroy, M. Roussel, M. Diouf, S.G. Grecogvasc I AMIENS, FRANCE

O 3110  17:15
Different patterns of gray and white matter damage are associated to PASAT and SDMT performances in relapsing remitting multiple sclerosis patients

O 3111  17:30
Anodal tDCS over left parietal cortex improves apraxic imitation deficits

O 3112  17:45
Personality traits could influence permeability of transcranial direct current stimulation in depressed patients
S.E. Parhizgar, S.M. Rayegani, S. Seyedahmadian, S. Ghafoorfar I TEHRAN, IRAN

O 3113  18:00
Montreal cognitive Assessment in mild cognitive impairment: correlation with cerebral spinal fluid biomarkers and prediction of conversion to dementia

ORAL SESSION:
HEADACHE AND PAIN 2
16:45-18:15 | HALL MS
CHAIRPERSONS:
Jes Olsen, COPENHAGEN, DENMARK
Peter Goadsby, LONDON, UK

O 3114  16:45
Effectiveness of Sphenopalatine Ganglion (SPG) stimulation for cluster headache: 24-month long-term follow-up results from the pathway CH-1 study
R. Jensen, M. Barloese, J.M. Lainez, C. Gaul, J. Schoenen, A. Goodman, A. Caparso, A. May, T. Jürgens I GLOSTRUP, COPENHAGEN, DENMARK; J. LIEGE, BELGIUM; VALENCIA, SPAIN; KOENIGSTEIN, GERMANY

O 3115  17:00
Persistent idiopathic facial pain: a prospective systematic study of clinical characteristics and neuroanatomical findings at 3.0 Tesla MRI
S. Maarbjerg, F. Wolfram, T.B. Heinskou, P. Rochat, A. Gozalov, J. Brennum, J. Olesen, L. Bendtsen I COPENHAGEN, DENMARK

O 3116  17:15
Self-medication with over-the-counter analgesics: a survey of patient characteristics and attitudes about pain medication

O 3117  17:30
Overlooked chronic pain in diabetic patients with cognitive impairment
M. Rakusa, S. Guo, M. Ashina I COPENHAGEN, DENMARK

O 3118  17:45
Tolerability of antiepileptic drugs in migraine and epilepsy: who is at increased risk of adverse events?
M. Romoli, S. Siliquini, I. Corbelli, S. Caproni, C. Bedetti, P. Eusebi, C. Costa, P. Sarchielli, P. Calabresi I PERUGIA, ITALY

O 3119  18:00
PACAP38 dose-response study in migraine patients
A.L.H. Vollesen, S. Guo, M. Ashina I COPENHAGEN, DENMARK
ORAL SESSION: MOVEMENT DISORDERS 3
16:45-18:15 | HALL M0
CHAIRPERSONS:
Pille Taba, TARTU, ESTONIA
Timothy Lynch, DUBLIN, IRELAND

O 3120
16:45
Functional connectivity underpinnings of fatigue in “drug-naïve” patients with Parkinson’s disease
A. Giordano1, M.P.A. Tessitore1, R. de Micco1, P.G. Caiazzo1, A. Russo1, M.P.M. Cirillo1, P.F. Esposito2, M.P.G. Tedeschi1
1NAPLES, 2SALERNO, ITALY

O 3121
17:00
The cerebral structural and functional signatures of impulse control disorder in Parkinson’s disease
F. Imperiale1, F. Agosta1, E. Canu1, V. Spica2, M. Ječmenica Lukić2, M. Copetti3, V.S. Kostic2, M. Filippi1
1MILAN, ITALY, 2BELGRADE, SERBIA, 3SAN GIOVANNI ROTONDO, ITALY

O 3122
17:15
Increased serotonin-to-dopamine transporter ratios in Parkinson’s disease dyskinesias: a longitudinal study
A.-A. Roussakis1, N. Lao-Kaim1, A. Martin Bastida1, N. Valle-Guzman2, Z. Kefalopoulou1, G. Paul1, H. Widner3, M. Politis1, T. Foltynie1, R.A. Barker2, P. Piccini1
1LONDON, 2CAMBRIDGE, UK, 3LUND, SWEDEN

O 3123
17:30
Unilateral MR-guided high intensity focused ultrasound ablation of the cerebellothalamic tract in essential tremor
S. Schreglmann1, S. Haegele-Link2, R. Bauer2, N.A. Wegener1, A. Lebeda3, B. Werner1, E. Martin3, G. Kägi2
1LONDON, UK, 2ST. GALLEN, SWITZERLAND

O 3124
17:45
Relationship between the MDS-UPDRS and quality of life in Parkinson’s disease: a large international multicenter study (the QUALPD study)
M. Škorvánek1, P. Martinez-Martin2, N. Kovacs3, I. Zezula1, M. Rodriguez-Violante1, J.-C. Corvol5, P. Taba6, K. Seppi1, I. Zezula1, M. Rodriguez-Violante1, J.-C. Corvol5, P. Taba6, K. Seppi1, 1KOSICE, SLOVAKIA, 2MADRID, SPAIN, 3PÉCS, HUNGARY, 4MEXICO DF, MEXICO, 5PARIS, FRANCE, 6TARTU, ESTONIA, 7INNSBRUCK, AUSTRIA, 8MOSCOW, RUSSIAN FEDERATION, 9LONDON, UK, 10CHICAGO, USA

O 3125
18:00
A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy
J. Vissing1, R. Barresi2, N. Witting1, M. van Ghelue3, L. Gammelgaard4, L. Bindoff5, V. Straub6, H. Lochmuller6, J. Hudson7, C. M. Wahl8, S. Arnardottir9, K. Dahlbom10, C. Jonsrud3, M. Dunø1
1COPENHAGEN, DENMARK, 2NEWCASTLE UPON TYNE, UK, 3TROMSØ, NORWAY, 4VYBORG, DENMARK, 5BERGEN, NORWAY, 6NEWCASTLE, UK, 7NEWCASTLE UPON THYNE, UK, 8DURACH, GERMANY, 9SOLNA, SWEDEN, 10ÖREBRO, SWEDEN

ORAL SESSION: MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE
16:45-18:15 | HALL B
CHAIRPERSONS:
Antonio Toscano, MESSINA, ITALY
Henning Andersen, AARHUS, DENMARK

O 3126
16:45
Peripheral neuropathy in patients with CPEO associated with single and multiple mtDNA deletions
D. Lehmann1, M.E. Kornhuber1, C. Clajus1, C.L. Alston2, S. Zierz1
1HALLE, GERMANY, 2NEWCASTLE, UK

O 3127
17:00
Targeted next generation sequencing to unravel undiagnosed limb girdle muscular dystrophies
E. Mauri1, F. Magri1, M. Savarese2, G. Di Fruscio2, A. Govoni1, M. Moggio1, R. Brusa1, D. Piga1, D. Ronchi1, R. Del Bo1, F. Fortunato1, V. Nigro2, G.P. Comi1
1MILAN, 2NAPLES, ITALY

O 3128
17:15
Insulin signalling and cytoskeleton abnormalities contribute to insulin resistance in myotonic dystrophies
G. Meola1, L.V. Renna1, S. Iachettini1, B. Fossati1, L. Saraceno1, R. Colombo1, R. Cardani1
1SAN DONATO MIL., 2MILAN, ITALY

O 3129
17:30
Central nervous system abnormalities in late onset Pompe disease (LOPD): evidences from neuropsychological, morphological and functional MRI studies
O. Musumeci1, S. Marino1, F. Granata1, E. Barco1, F. Corallo1, S. de Salvo1, L. Bonanno1, R. Morabito1, M. Longo1, P. Bramanti1, A. Toscano1
1MESSINA, ITALY

O 3130
17:45
A novel clinical tool to classify facioscapulohumeral muscular dystrophy phenotypes
G. Ricci1, L. Ruggiero1, L. Vercelli1, F. Sera1, A. Nikolic1, F. Mele1, M. Govi1, C. Angelini1, G. Antonini1, A. Berardinnelli1, E. Bucc1, M. Cao1, G. D’angelo1, A. Di Muzio1, M. Filosto1, L. Maggi1, M. Moggio1, T. Mongini1, E. Pegoraro1, C. Rodolo1, L. Santoro1, G. Siciliano1, G. Tomelleri1, L. Villa1, R. Tuliper1
1MODENA, 2NAPLES, 3TURIN, ITALY, 4LONDON, UK, 5LIDO VENICE, 6ROME, 7PAVIA, 8PADUA, 9BOSIO PARINI, 10CHIETI, 11BREGA, 12MILAN, 13MESSINA, 14PIZA, 15VERONA, ITALY

O 3131
18:00
A heterozygous 21-bp deletion in CAPN3 causes dominantly inherited limb girdle muscular dystrophy
J. Vissing1, R. Barresi2, N. Witting1, M. van Ghelue3, L. Gammelgaard4, L. Bindoff5, H. Lochmuller6, J. Hudson7, C. M. Wahl8, S. Arnardottir9, K. Dahlbom10, C. Jonsrud3, M. Dunø1
1COPENHAGEN, DENMARK, 2NEWCASTLE UPON TYNE, UK, 3TROMSØ, NORWAY, 4VYBORG, DENMARK, 5BERGEN, NORWAY, 6NEWCASTLE, UK, 7NEWCASTLE UPON THYNE, UK, 8DURACH, GERMANY, 9SOLNA, SWEDEN, 10ÖREBRO, SWEDEN
P 31001 Abstract cancelled

P 31002 Differences in prevalence and treatment of atrial fibrillation in dementia disorders. Data from the Swedish Dementia Registry
D. Religa, L. Bognandi, P. Čermáková, B. Winblad, M. Seyed-Fereshtehnejad, S. Garcia-Ptacek, M.E. Enkstetterl STOCKHOLM, SWEDEN

P 31003 Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

P 31004 High incidence of sporadic Creutzfeldt-Jakob disease in Slovenia in 2015
T. Rus, N. Čakš Jager, M. Popović, M. Blaško Markič, M. Kramberger Gregoric LJUBLJANA, SLOVENIA

P 31005 Clinical variability in Gerstmann-Sträussler-Scheinker syndrome: a retrospective case study
R. Rusina, S. Johanidesová, Z. Rohan, R. Matěj PRAGUE, CZECH REPUBLIC

P 31006 Timed Up and Go Dual Task and 11C-PiB-PET as prognostic indicators of progression in mild cognitive impairment and mild AD
M. Schjonning Nielsen1, A. Hviid Simonsen2, I. Law2, V. Siersma2, S.G. Hasselbalch2, P. Hagh1 ROSKILDE, COPENHAGEN, DENMARK

P 31007 Quantitative electroencephalography (qEEG) as a prognostic marker of progression in mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD)
M. Schjonning Nielsen1, A. Hviid Simonsen2, S.G. Hasselbalch2, P. Hagh1 ROSKILDE, COPENHAGEN, DENMARK

P 31008 Czech Brain Aging Study (CBAS) – National longitudinal cohort study with AD biomarkers. Design and first data about progression rates in 3 year follow-up
K. Sheardova1, M. Vyhnálek2, Z. Nedelska2, J. Laczó2, R. Andel2, R. Marcinia2, D. Hudecek2, B. Dvorakova2, O. Lerch3, J. Hort2 BRNO, CZECH REPUBLIC, TAMPAPA, FLORIDA, USA

P 31009 Combination therapy of cholinesterase inhibitor plus memantine for behavioral and psychological symptoms in Alzheimer’s disease patients
C. Shin GWANG-JU, KOREA, REPUBLIC OF

P 31010 miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia: an exploratory study
S.S. Sørensen, A.-B. Nygaard, T. Christensen HILLERØD, DENMARK

P 31011 Structural brain changes on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)

P 31012 Abstract cancelled

P 31013 Wake-Up Stroke and Thrombolytic Therapy
M. Nevsímalova1, M. Reiser1, L. Štěrba1, J. Sova2, K. Hes2, J. Fiedler1, S. Ostry1 ČESKÉ BUDĚJOVICE - BUDweis, CZECH REPUBLIC, ČESKÉ BUDĚJOVICE, CZECH REPUBLIC

P 31014 A case report of a young patient with acute ischemic stroke and marijuana/ cannabis abuse
N. Neykov, I. Staikov, A. Simeonova SOFIA, BULGARIA

P 31015 Abstract cancelled

P 31016 Primary angiitis of the CNS presenting as migraine-like headache with oculomotor nerve palsy: a case report
Z. U. Nissa, M. Khan, H. Hashim, S. Alrukn DUBAI, UNITED ARAB EMIRATES
<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 31017</td>
<td>Non-dominant posterior variant alien hand syndrome after acute right thalamo-occipital infarction: a case report</td>
<td>F.D. Örken, E. Kivrak, Z. Cengiz, N. Gonderten</td>
<td>ISTANBUL, TURKEY ARAB EMIRATES</td>
</tr>
<tr>
<td>P 31018</td>
<td>Isolated unilateral and bilateral internuclear ophthalmoplegia due to ischemic stroke</td>
<td>P. Oroz, I. Szőcs, G. Varallyay, G. Rudas, D. Bereczki, I. Vastagh</td>
<td>BUDAPEST, HUNGARY</td>
</tr>
<tr>
<td>P 31019</td>
<td>Cognitive and behavioral deficiency after bilateral thalamic infarct due to occlusion of the artery of Percheron</td>
<td>B. Özkara, H. Kaya, S. Mulayim, H. Efendi</td>
<td>KOCAELI, TURKEY</td>
</tr>
<tr>
<td>P 31020</td>
<td>Gamma aminobutyric acid receptor antagonist promotes functional neurological recovery after permanent distal middle cerebral artery occlusion in rats</td>
<td>M. Pace, L. Facchin, A. Adamantidis, P. Machado, D.M. Hermann, C. Bassetti</td>
<td>BERNE, SWITZERLAND, FRANCE, ESSEN, GERMANY</td>
</tr>
<tr>
<td>P 31021</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 31022</td>
<td>Incidence of stroke in young adults admitted to a stroke unit</td>
<td>P. Pérez Torre, F.J. González Gómez, A. Escobar Villaiba, P. Martínez Uloa, E. Monreal Laguillo, A. de Albóniga-Chindurza, A. de Felipe Mimbreira, C. Matute Lozano, R. Vera, A. Cruz Culebras, J. Masjuan</td>
<td>MADRID, SPAIN</td>
</tr>
<tr>
<td>P 31023</td>
<td>Subclavian steal syndrome: a diagnostic challenge: case report</td>
<td>I. Karanfilovic, M. Perovska</td>
<td>SKOPJE, MACEDONIA</td>
</tr>
<tr>
<td>P 31024</td>
<td>Stent retrievers thrombectomy in acute middle cerebral artery occlusion: should it be performed in the elderly?</td>
<td>F. Perren, L. Puke, C. Kremer, V. Mendes Pereira</td>
<td>GENEVA, SWITZERLAND, LUND, SWEDEN, TORONTO, CANADA</td>
</tr>
<tr>
<td>P 31025</td>
<td>TOAST vs. ASCOD: Agreement and comparison between etiologic and phenotypic classification of ischemic stroke in a Romanian cohort of patients</td>
<td>C. Tiu, P. Radu, E. Terecsoasa, V. Tiu, O.A. Bajenaru</td>
<td>BUCHAREST, ROMANIA</td>
</tr>
<tr>
<td>P 31026</td>
<td>Antiphospholipid antibodies negative Sneddon’s syndrome: study of 25 cases with cerebral MRI and angiography</td>
<td>M. Rahman, S. Aidi, M. Maamar, L. Semli, R. Elhassani, M. Jiddane, C. Hicham, M. Benadeljil, M. El Alaoui Faris</td>
<td>RABAT, MARRAKECH, MOROCCO</td>
</tr>
<tr>
<td>P 31027</td>
<td>Emotional and cognitive changes in stroke patients</td>
<td>I. Severyn</td>
<td>KHARKOV, UKRAINE</td>
</tr>
<tr>
<td>P 31028</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 31029</td>
<td>Association of lipoprotein subfractions with arterial stiffness in acute ischemic stroke</td>
<td>P. Šiarnik, Z. Čarnická, K. Klobucnikova, B. Kollár, I. Žitňanová, P. Turcani</td>
<td>BRATISLAVA, SLOVAKIA</td>
</tr>
<tr>
<td>P 31030</td>
<td>Improved post-ischaemic stroke recovery over 1 year with Escalopram for 3 months</td>
<td>A. Jurcau, A. Simion</td>
<td>ORADEA, ROMANIA</td>
</tr>
<tr>
<td>P 31031</td>
<td>Admission glucose levels affect stroke outcome after mechanical thrombectomy</td>
<td>A. Slowik, A. Ferens, A. Golenia, J. Chrzanowska-Wasko, D. Wloch-Kopec, B. Lasocha, P. Brzegowy, T. Popiela</td>
<td>CRACOW, POLAND</td>
</tr>
<tr>
<td>P 31032</td>
<td>Feasibility and safety of thrombolysis triage by mobile off-site teleconsultation with iPad in Hong Kong</td>
<td>Y. Soo, V. Ip, K. Leung, F. Fan, A. Chan, S.H. Ma, V. Mok, L. Wong, T. Leung</td>
<td>HONG KONG, HONG KONG (SAR OF CHINA)</td>
</tr>
<tr>
<td>P 31034</td>
<td>Predictors of functional outcome at 3 months after cardioembolic ischemic stroke</td>
<td>S. Sousa, A. Sousa, G. Nunes, S. Galego, M. Mariano, A. Fior, C. Sousa, A. Paiva Nunes</td>
<td>CASCAIS, LISBON, PORTUGAL</td>
</tr>
</tbody>
</table>
P 31036 Stroke, atrial fibrillation and anticoagulation - fights with the mortar
M.H. Strothjohann, F. Weber | BAD CAMBERG, GERMANY

P 31037 Treatment of atrial fibrillation in dementia patients
A. Subić1, S. García-Ptacek2, P. Čermákův3, M. Gregoric Kramberger1, B. Winblad2, M.E. Erkdoes2 | I BAD CAMBERG, GERMANY, 2STOCKHOLM, SWEDEN

P 31038 Factor affecting functional outcome after endovascular recanalisation in wake-up stroke
S.M. Sung1, T.H. Lee1, S.W. Lee2 | I BUSAN, 2YANGSAN, KOREA, REPUBLIC OF

P 31039 Neurosonology for the diagnosis of stroke in isolated acute vestibular syndromes

P 31040 Emotional and behavioural impairment: think about stroke
L. Tesolin | I TRIESTE, ITALY

P 31041 Thickening of liquids reduces aspiration risk in acute stroke patients
J. Zaborski, A. Czernuszenko | I WARSAW, POLAND

P 31045 Neuropsychological tests for multiple sclerosis: validation of a battery for the Portuguese population
M.J. Sa2, M. Neves1, C. Sousa1, A.M. Passos2, A. Ferreira1 | I PORTO, 2LISBON, PORTUGAL

P 31046 Normalisation of timed neuropsychological tests with the use of dysarthria and upper limbs performance tests
T. Costabile, F. Abate, A. Liguori, F. Paciello, G. de Michele, A. Filli, F. Sacca | I NAPLES, ITALY

P 31047 Montreal Cognitive Assessment (MoCA) in the detection of cognitive dysfunction in multiple sclerosis

P 31048 Assessment of the visuospatial gnosis: using computer method of 3D rotating object recognition
I. Shvetsova, S. Brakk, E. Mozheiko, S. Prokopenko | I KRASNOYARSK, RUSSIAN FEDERATION

P 31049 Dementia rating scale in differentiating multiple system atrophy, progressive supranuclear palsy and dementia with Lewy bodies
S. Skelina, M. Petrova, R. Pavlova, S. Mehrabian, L.D. Traykov | I SOFIA, BULGARIA

P 31050 Pathogenetic aspects of cognitive disorders in type 2 diabetes mellitus
O. Tovazhnynska, I. Bezuglova, N. Nekrasova, O. Markovska | I KHARKIV, UKRAINE

P 31051 The investigation of cognitive impairment in young adults with substance use disorders
T. Unal, D. Aykol Unal | I IZMIR, TURKEY

P 31052 Gray and white matter damage differently correlated with cognition in adult multiple sclerosis patients with different age of disease onset
L. Vacchi1, M.A. Rocca1, B. Colombo1, M. Rodegher1, L. Moiola1, A. Ghezzi2, G. Comi1, A. Falini1, M. Filippi1 | I MILAN, 2GALLARATE, ITALY

P 31053 Abstract cancelled

P 31054 Abstract cancelled

P 31055 Ceramide and neuropsychiatric symptoms in Parkinson's disease with cognitive impairment
Y. Xing | I BEIJING, CHINA
POSTER SESSION
EPILEPSY 6
12:30–13:15 | SCREEN B2
CHAIRPERSON:
Hermann Stefan, ERLangen, GERmany

P 31055 The relation between Ala16Val polymorphism (MnSOD gene) and oxidative stress in epilepsy
1SANTA MARIA, BRAZIL, 2LONDON, UK

P 31056 Neurosarcoidosis, a chameleon for low grade glioma: a case report and literature review
P. Shanmugarajan1, M. Vinjam, D. Warren, E. Wright, P. Chumas, M. Maguire11
1LEEDS, UK

P 31057 Palinopsia as an atypical manifestation of LGI1 antibody-associated limbic encephalitis: a case report
E. Stach1, J. Biberon, B. de Toffol12
1TOURS, FRANCE

P 31058 Visual field defects in epilepsy patients treated with temporal lobe resection
A.T. Steensberg1, A.S. Olsen1, M.H. Litman1, E. Holm1, T. Kjaer2, B. Jespersen1, M. Kolko1, L.H. Pinborg1
1COPENHAGEN, 2ROSKILDE, DENMARK

P 31059 Seizures and epilepsy in the aging population
H. Stefan2
1ERLANGEN, GERMANY

P 31060 Abstract cancelled

P 31061 Analysis of predictive values of historical data in evaluation of patients with first transient loss of consciousness
A. Stojanov1, M. Spasic, Z. Peric, S. Luke1, M. Kolko1, L.H. Pinborg1
1NIS, SERBIA

P 31062 Acute systemic inflammatory response syndrome in status epilepticus
S. Szklenier1, A. Korchut, M. Godek, K. Rejdak1
1LUBLIN, POLAND

P 31063 Forced normalisation: an overlooked entity in epileptic patients
A. Topkan1, S. Bilen1, A.P. Titiz, E. Eruyar, F. Ak1
1ANKARA, TURKEY

P 31064 Abstract cancelled

P 31065 Abstract cancelled

P 31066 Acute ischemic stroke in status epilepticus – underestimated? Results from an 8-year cohort study
C. Traenka1, G.M. de Marchis1, L. Hert, D.J. Seiffge2, A. Polymeris1, N. Peters1, L. Bonati1, S.T. Engelter1, P.A. Lyrer1, S. Ruegg1, R. Sutter1
1BASEL, SWITZERLAND

P 31067 Efficacy of eslicarbazepine acetate versus controlled-release carbamazepine as monotherapy in patients with newly diagnosed partial-onset seizures
E. Trinka1, P. Kowacs2, E. Ben-Menachem3, C.E. Elger4, J. Moreira5, R. Pinto6, F. Ikedo5, A. Pereira5, J.F. Rocha6, P. Soares-Da-Silva1, Á. Guerrero1
1SALZBURG, AUSTRIA, 2CURITIBA, BRAZIL, 3GOTHENBURG, SWEDEN, 4BONN, GERMANY, 5CORONADO, 6PORTO, PORTUGAL

POSTER SESSION
HEADACHE AND PAIN 5
12:30–13:15 | SCREEN C1
CHAIRPERSON:
Panagiotis Zis, SHEFFIELD, UK

P 31068 Onabotulinumtoxin A in chronic migraine beyond first year. Real-life data in 115 patients
I. Aicua-Rapun1, E. Martinez Velasco1, A. Hernando1, M. Ruiz Piñero1, A. Carreres1, E. Porqueres1, S. Herrero1, Á.L. Guerrero Peral1, F. Iglesias1
1BURGOS, 2VALLADOLID, SPAIN

P 31069 Abstract cancelled

P 31070 Communication of results of the employment of onabotulinumtoxin A in chronic migraine
M. Altuna, M. Martin Bujanda, M.C. Navarro1
1PAMPLONA, SPAIN

P 31071 Angiotensin II Type 2 receptor antagonist EMA401 for the treatment of pain in patients with chemotherapy-induced peripheral neuropathy: efficacy and nerve biomarkers in skin biopsies
P. Anand, R. Privitera, Y. Yangou, P. Misra2
1LONDON, UK

P 31072 Primary nasal pain
A. Arbex Bassols1, M. Villa López1, A. Perez Rodriguez1, M. Rosón González2, P. Pire García1, L. Vela Dosojo1, J. Pareja Grande1
1MADRID, SPAIN

P 31073 Reduced medication use with sphenopalatine ganglion (SPG) stimulation for cluster headache: 24-month long-term follow-up results from the Pathway CH-1 study
M. Bartoese1, R. Jensen2, J.M. Lainez3, C. Gaul4, J. Schoenen1, A. Goodman4, A. Caparso3, A. May4, T. Jürgens6
1COPENHAGEN, 2GLOSTRUP, DENMARK, 3VALENCIA, SPAIN, 4KOENIGSTEIN, 5HAMBURG, 6ROSTOCK, GERMANY, 7LIEGE, BELGIUM, 8REDWOOD CITY, USA
### POSTER SESSIONS

#### MONDAY, 30 MAY

**12:30 - 13:15**

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 31074</td>
<td>Women with chronic and episodic migraine exhibit similar widespread pressure pain sensitivity</td>
<td>M. Palacios-Ceña1, J. Baron Sanchez2, L. Florencia4, G. Ferracini1, Á.L. Guerrero Peral1, C. Ordás-Bandera3, C. Fernández-de-Las-Peñas1</td>
<td>MADRID, SPAIN; VALLADOLID, MADRID, SPAIN; MOSTOLES, SPAIN; SÃO PAULO, BRAZIL</td>
</tr>
<tr>
<td>P 31075</td>
<td>Epicrania fugax combining forward and backward paroxysms in the same patient: the first three cases</td>
<td>J. Baron Sanchez1, A. Gutierrez2, M. Ruiz Piñero1, A. Perez2, Á.L. Guerrero Peral1, M.L. Cuadrado2</td>
<td>VALLADOLID, MADRID, SPAIN</td>
</tr>
<tr>
<td>P 31076</td>
<td>Topographical pressure pain sensitivity maps over the head are different in migraine patients compared with health controls</td>
<td>J. Baron Sanchez1, M. Palacios-Ceña2, M. Ruiz Piñero1, M. de Lera1, Á.L. Guerrero Peral1, P. Madeleine1, C. Fernández-de-Las-Peñas1</td>
<td>VALLADOLID, MADRID, SPAIN</td>
</tr>
<tr>
<td>P 31077</td>
<td>Onabotulinumtoxin A in chronic refractory migraine: a pilot study</td>
<td>A. Bartkova, P. Otruba, V. Sladkova, J. Zapletalova, P. Hlustik, P. Kanovsky</td>
<td>OLOMOUC, CZECH REPUBLIC</td>
</tr>
<tr>
<td>P 31078</td>
<td>Thromboelastometry for investigation of coagulation profile in patients with neuroinfectious diseases</td>
<td>E. M. Craemer1, B. Bassa1, F. Idris2, N.A. Rahman2, S. Diah3, H. Muharram3, U. Meyding-Lamade1</td>
<td>FRANKFURT AM MAIN, GERMANY; JALAN TUNGKU, NEGERI SULTAN, BRUNEI DARUSSALAM</td>
</tr>
<tr>
<td>P 31079</td>
<td>Electroencephalographic findings in Mexican patients with and without viral herpetic encephalitis</td>
<td>J.I. Castro Macías, F. Farias Serratos, M. Maldonado-Vega, C.V. Farias Serratos, J.M. Muñoz Barrett</td>
<td>LEÓN, MEXICO</td>
</tr>
<tr>
<td>P 31080</td>
<td>Neurosarcoïdosis presenting as an immune reconstitution syndrome in HIV</td>
<td>P. Holmes</td>
<td>LONDON, UK</td>
</tr>
<tr>
<td>P 31081</td>
<td>The association of brachial neuritis and acute Hepatitis E infection</td>
<td>P. Holmes, V. Williams</td>
<td>LONDON, UK</td>
</tr>
</tbody>
</table>

---

**INFECTION AND AIDS 1**

**12:30-13:15 | SCREEN F3**

**Chairperson:**
Leo Visser, TIEBURG, THE NETHERLANDS

<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 31082</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 31083</td>
<td>Progressive multifocal encephalopathy (PML) causing an isolated cerebellar syndrome</td>
<td>M. Bayat</td>
<td>ARHUS, DENMARK</td>
</tr>
<tr>
<td>P 31084</td>
<td>Isolated intracranial hypertension as the presenting sign of Lyme disease</td>
<td>R. Beyrouti, S. Mostoufizadeh, S. Courtis, E. Cohen</td>
<td>TOURS, FRANCE</td>
</tr>
<tr>
<td>P 31085</td>
<td>A rare cause of facial nerve palsy</td>
<td>M. Carvalho Dias, A.P. Antunes, A.C.G. Fonseca, T. Pinho E Melo</td>
<td>LISBON, PORTUGAL</td>
</tr>
<tr>
<td>P 31087</td>
<td>The effectiveness of acupuncture in cluster headache: the first randomised patient/assessor blinded, controlled sham study</td>
<td>A. Bougeo, N. Spantidias, M. Karavis, M. Fili, E. Anagnostou, L. Grkia, T. Thomaidis, I. Kararizou, I. Evdokimidis</td>
<td>ATHENS, GREECE</td>
</tr>
<tr>
<td>P 31088</td>
<td>The association of brachial neuritis and acute Hepatitis E infection</td>
<td>P. Holmes</td>
<td>LONDON, UK</td>
</tr>
</tbody>
</table>

---

**POSTER SESSIONS**

**COPENHAGEN, DENMARK, 28 – 31 MAY, 2016**

---

**159**
MONDAY, 30 MAY
12:30 - 13:15

**POSTER SESSIONS**

**MOTOR NEURONE DISEASES 3**
12:30-13:15 | SCREEN C2

**CHAIRPERSON:**
Josef Finsterer, VIENNA, AUSTRIA

- **P 31092** Validation of the Lancet Consensus score for the diagnosis of tuberculous meningitis in a population of meningitis in Qatar
  Y.Z.B. Imam, P. Chandra, H. Ahmadullah, M. Almaslamani, A. Alkhad, D. Deleu | DOHA, QATAR

- **P 31093** Validation of Thwaite’s diagnostic score for the diagnosis of tuberculous meningitis in a population of meningitis in Qatar
  Y.Z.B. Imam, H. Ahmadullah, P. Chandra, M. Almaslamani, A. Alkhad, D. Deleu | DOHA, QATAR

- **P 31094** Abstract cancelled

- **P 31095** Breast cancer susceptibility in patients with spinal bulbar muscular atrophy: a case report
  I. Martinelli1, E. Da Re1, G. Querin1, C. Bertolin1, E. Pegoraro1, M. Pennuto1, V. Guerini1, G. Soraru1 | Padua, TRENT, ITALY

- **P 31096** Stratokinetik stability in patients with ALS
  V. Merkurj, Y. Rushkevich, J. Maryenko, S. Likhachev | MINSK, BELARUS

- **P 31097** Comparing the functioning and well-being of people with motor neuron disease, multiple sclerosis and Parkinson’s disease
  D. Morley, L. Kelly, S. Dummett, J. Dawson, R. Fitzpatrick, C. Jenkinson | OXFORD, UK

- **P 31098** The relationship between regional cortical atrophy and cognitive impairment in DM1 patients: a voxel based morphometric study
  B. Muninson, E. Gyiayzidinova | TASHKENT, UZBEKISTAN

- **P 31099** The development of an evidence based guideline on the assessment and management of motor neuron disease/amyotrophic lateral sclerosis
  D. Oliver1, A. Edwards2, C. McDermott3, A. Radunovic4 | 1ROCHESTER, 2LEEDS, 3SHEFFIELD, 4LONDON, UK

- **P 31100** Immunohistochemical study of progranulin in the skin of amyotrophic lateral sclerosis
  S. Ono | KINSHARA, JAPAN

- **P 31101** MicroRNAs as biomarkers of spinal and bulbar ALS
  V. Pegoraro1, E. Tasca1, A. Merico1, E. Pinzani1, C. Angelini1 | 1VENICE, 2PADOA, ITALY

- **P 31102** Intravenous immunoglobulins efficacy in a case of ALS with myasthenic symptoms
  G. Piccirillo, F. Troisi, M.R. Monsurro, F. Habetzwallner, B.M. de Martino, G. Tedeschi | NAPLES, ITALY

- **P 31103** Cortical dysfunction in symptomatic and at risk ALS detected by MEG
  M. Proudfoot1, G. Rohenkohl1, G.L. Colclough1, J. Wu2, P.M. Andersen3, K. Talbot1, M.W. Woolrich1, M. Benatar2, A.C. Nobre3, M.R. Turner4 | OXFORD, UK, 1MIAMI, USA, 2UMEA, SWEDEN

- **P 31104** Spinal and Bulbar Muscular Atrophy (SBMA) outcome measures: is creatinine a new reliable biomarker?
  G. Querini1, E. Da Re1, I. Martinelli1, L. Bello1, C. Bertolin1, D. Pareyson1, E. Pegoraro1, G. Soraru1 | PADUA, MILAN, ITALY

- **P 31105** Neuromyelitis optica spectrum disorder and amyotrophic lateral sclerosis in a 50-year-old male: a case report

- **P 31106** Prognostic value of ALSFRS sub-scores
  J. Rooney, T. Burke, O. Hardiman | DUBLIN, IRELAND

- **P 31107** Complex tremorometry, electro-oculography and neuropsychological assessment of fragile X premutation carriers
  A. Kovacs, Z. Farkas, S. Gulyas, J. Karpati, A. Kamondi | BUDAPEST, HUNGARY

- **P 31108** More frequent presence of non-motor symptoms among Hungarian Parkinson’s disease patients
  M. Kovacs, G. Dei, Z. Aschermann, P. Ac, E. Bosnyak, J. Janszky, A. Makkos, S. Komoly, N. Kovacs | PECS, HUNGARY

- **P 31109** Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations: exploratory OFF- and ON-time responder analyses of pooled phase III studies
  A. Lees1, J. Ferreira2, T. Muller3, F. Stocchi3, C. Oliveira4, A. Santos5, N. Lopes3, J.F. Rocha3, P. Soares-Da-Silva3 | 1LONDON, UK, 3LISBON, 4CORONADO (S. ROMÃO E S. MAMEDE), 5PORTUGAL

POSTER SESSIONS

**MOVEMENT DISORDERS 6**
12:30-13:15 | SCREEN E4

**CHAIRPERSON:**
Antonella Macerollo, LONDON, UK

- **P 31107** Complex tremorometry, electro-oculography and neuropsychological assessment of fragile X premutation carriers
  A. Kovacs, Z. Farkas, S. Gulyas, J. Karpati, A. Kamondi | BUDAPEST, HUNGARY

- **P 31108** More frequent presence of non-motor symptoms among Hungarian Parkinson’s disease patients
  M. Kovacs, G. Dei, Z. Aschermann, P. Ac, E. Bosnyak, J. Janszky, A. Makkos, S. Komoly, N. Kovacs | PECS, HUNGARY

- **P 31109** Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations: exploratory OFF- and ON-time responder analyses of pooled phase III studies
  A. Lees1, J. Ferreira2, T. Muller3, F. Stocchi3, C. Oliveira4, A. Santos5, N. Lopes3, J.F. Rocha3, P. Soares-Da-Silva3 | 1LONDON, UK, 3LISBON, 4CORONADO (S. ROMÃO E S. MAMEDE), 5PORTUGAL

- **P 31110** Prognostic value of ALSFRS sub-scores
  J. Rooney, T. Burke, O. Hardiman | DUBLIN, IRELAND

- **P 31111** Complex tremorometry, electro-oculography and neuropsychological assessment of fragile X premutation carriers
  A. Kovacs, Z. Farkas, S. Gulyas, J. Karpati, A. Kamondi | BUDAPEST, HUNGARY
Opicapone’s onset and stabilisation of treatment effects in Parkinson’s disease patients with motor fluctuations


Neurological manifestations of Wilson disease in Belarus

I. Pliashko, S. Likhachev, Minsk, Belarus

Paroxysmal non-kinesigenic dyskinesia with dysphonia alleviated by carbamazepine

N. Lekken, L. E. Hjermind, J. Vissing, Copenhagen, Denmark

Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations at different stages of symptom progression

N. Lopes1, J. Ferreira2, A. Lees3, W. Poewe4, H. Reichmann5, A. Santos1, C. Oliveira1, J. F. Rocha1, P. Soares-Da-Silva1, Lisbon, Portugal, London, Uk, ‘Innsbruck, Austria, Dresden, Germany

Analysis of impulse control disorders in phase III studies of opicapone in Parkinson’s disease patients with motor fluctuations

N. Lopes1, J. Ferreira2, A. Lees3, T. Müller4, H. Reichmann5, H. Gama1, A. Santos1, C. Oliveira1, J. F. Rocha1, P. Soares-Da-Silva1, Lisbon, Portugal, London, Uk, Berlin, Germany, Dresden, Germany

Effect of vibration on motor performance: a new intervention to improve bradykinesia in Parkinson’s disease?


Myoclonus-dystonia syndrome, obsessive-compulsive disorder and epilepsy: another plus in a dystonia-plus syndrome?


Novel PLA2G6 c.1627C>T homozygous mutation and response to DBS-Gpi

A. D. Magalhães1, L. Guedes1, M.V.S. Coelho1, T. Teodoro1, A.F. Valadas2, H. Carvalho1, B. Cattoni1, J. Ferreira1, Lisbon, Portugal, Setúbal, Portugal

Direct comparisons for botulinum neurotoxins in movement disorders

R. Maggio, S. Lalli, A. Albanese, Milan, Italy

Dopamine receptor genes polymorphisms: a risk factor for developing dyskinesia in Parkinson’s disease

L. Magistrelli1, M. Ferrari2, F. de Marchi3, F. Marino2, G.D. Oggioni1, M. Careccio1, G. Riboldazzi1, G. Bono1, M. Cosentino1, R. Cantello1, C. Comi1, Novara, Varese, Italy

The effect of improved nutritional status on psychiatric features and quality of life in Parkinson’s disease patients

N. Ongun, C. Erdogan, E. Degirmenci, L. S. Bir, Denizli, Turkey

Treatment of OFF episodes in Parkinson’s disease: an evaluation of patient and caregiver insights

E. Pappert1, N. Degruyther2, A. Agro3, San Antonio, USA, Toronto, Canada

Treatment of OFF episodes in Parkinson’s disease: an evaluation of physician practices

E. Pappert1, A. Agro3, N. Degruyther2, San Antonio, USA, Toronto, Canada

Oral sublingual apomorphine film (APL-130277) produces no buccal mucosal irritation: results of a toxicological study

E. Pappert1, B. Dzyngel2, T. Bilbault2, A. Agro3, San Antonio, USA, Toronto, Canada

Late onset atypical Pantothenate-Kinase associated neurodegeneration with homozygous PANK2 mutation in three Sardinian siblings

R. Piredda, E. Sechi, A. L. Rassu, A. Addis, D. Urso, C. Fois, R. Ortu, G. Sechi, Sassari, Italy

Abstract cancelled

Additional gait impairment by the presence of peripheral nerve disease in pediatric patients with hereditary spastic paraplegia

J. Pulido-Valdeolivas1, D. Gómez Andrés2, J.A. Martín-Gonzalo2, J. Rodríguez-Andonaegui2, J. López-López2, S. I. Pasqual Pascual2, E. Rausell2, San Sebastián de los Reyes, Spain

Is there a relationship between non–motor symptoms and main indicators of Parkinson’s disease (stage, form, duration)?

E. Rabatánova, Z. Goncharova, M. Gelpey, Rostov-on-Don, Russian Federation
P 31128  Segawa disease: a clinical study of eight Tunisian patients
A. Riahi, M. Messelmani, I. Bedoui, H. Derbali, M. Mansour, J. Zaouati, R. Mrissa
I TUNIS, TUNISIA

P 31129  Wilson’s disease associated with immotile cilia syndrome: a case report
M. Romoli, N. Tambasco, P. Prontera, E. Nardi, G. Clerici
I PERUGIA, ITALY

P 31130  Abstract cancelled

P 31131  Providing PD treating doctors much better disease status data: our measurement of typing cadence provides great data and enables treating doctors to evaluate changes in disease management. We will show data on actual patients
J. Samzelius
I SAN FRANCISCO, USA

P 31132  Opicapone’s safety in Parkinson’s disease patients with motor fluctuations: results of the 1-year extension of study BIPARK I
A. Santos1, J. Ferreira2, A. Lees3, F. Stocchi4, O. Rascol5, N. Lopes1, H. Gama1, J.F. Rocha1, P. Soares-Da-Silva1
1
cORONADO (S. ROMÁO E S. MAMEDE), 2LISBON, PORTUGAL, 3LONDON, UK, 4ROME, ITALY, 5TOULOUSE, FRANCE

P 31133  Daclizumab HYP efficacy on disease outcome measures using an expanded definition of highly active relapsing–remitting multiple sclerosis: results from SELECT and DECIDE
G. Giovannoni1, T. Ziemssen2, W. Ma3, S. Fam3
1LONDON, UK, 2DRESDEN, GERMANY, 3CAMBRIDGE, USA

P 31134  Liver Transaminase Elevations in the DECIDE study of daclizumab HYP versus intramuscular interferon beta-1a
S. Fam1, P. McCroskery1, W. Ma1, L. Chiodo2, G. Sabatella1
1CAMBRIDGE, 2NORTH CHICAGO, USA

P 31135  Assessment of 2015 neuromyelitis optica criteria in Rouen university hospital
L. Fechtenbaum1, R. Marignier2, R. Lefaucheur1, F. Le Goff1, J. Gueudry1, D. Malteb1, B. Bourre1
1ROUEN, 2LYONS, FRANCE

P 31136  Observational, retrospective study to characterise patients with RRMS and long-term treatment with sc interferon (IFN) beta 1-a
1SARAGOSSA, 2BARCELONA, 3SANTA CRUZ DE TENERIFE, 4VIGO, 5SANTIAGO DE COMPOSTELA, 6MADRID, 7GIPUZKOA, 8VALENCIA, 9LÉRIDA, 10VIZCAYA, 11MALAGA, SPAIN

P 31137  Neural cell adhesion molecules in acute optic neuritis: relation to clinical and paraclinical findings
J.L. Frederiksen1, K. Farooq1, S. Gnanapavan2
1COPENHAGEN, DENMARK, 2LONDON, UK

P 31138  Long-term efficacy of teriflunomide in patients recently diagnosed with relapsing forms of MS
M. Freedman1, G. Comi2, A. Miller4, J. Wolinsky5, J. Oh6, K. Thangavelu6, P. Truffinet7, L. Kappos8
1OTTAWA, 2TORONTO, CANADA, 3MILAN, ITALY, 4NEW YORK, 5HOUSTON, 6CAMBRIDGE, USA, 7CHILLY-MAZARIN, FRANCE, 8BASEL, SWITZERLAND

P 31139  A retrospective analysis of efficacy in McDonald 2010 multiple sclerosis (MS) patients in the ORACLE-MS study
M. Freedman1, T. Leist2, G. Comi6, B.A.C. Cree3, P.K. Coyle4, H.-P. Hartung7, P. Vermersch8, D. Damian5, F. Dangond5
1OTTAWA, CANADA, 2PHILADELPHIA, 3SAN FRANCISCO, 4STONY BROOK, 5BILLERICA, USA, 6MILAN, ITALY, 7DÜSSELDORF, GERMANY, 8LILLE, FRANCE

P 31140  Number needed to treat analysis comparing teriflunomide with injectable and oral disease-modifying therapies in relapsing multiple sclerosis
M.S. Freedman1, A.E. Miller2, K. Thangavelu3, S. Hass3
1OTTAWA, 2NEW YORK, USA, 3CAMBRIDGE, USA

P 31141  INSPIRATION-MRI: standardized acquisition and centralised quantitative reading of MRI scans of RRMS patients in German daily clinical practice
A. Gass1, J. Gregori2, S. Hoffmann3, A. Fuchs4, C. Cornelissen3
1MANNHEIM, 2HEIDELBERG, 3NUREMBERG, GERMANY

P 31142  Quality of life in carers of patients with relapsing–remitting multiple sclerosis: a pilot study
D. Gigineishvili, M. Kareli, A. Tsiskaridze, R. Shakarishvili
I TBILISI, GEORGIA
**P 31143** Brain health: time matters in multiple sclerosis – developmental process and objectives of international consensus policy recommendations  
G. Giovannoni1, H. Butzkueven 4, K. Costello6, S. Dhib-Jalbut 6, J. Hobart2, G. Kobelt8, G. Pepper3, M.P. Sormani9, C. Thalheim10, A. Traboulsee11, T. Vollmer7  
1LONDON, 2PLYMOUTH, 3LEEDS, UK, 4PARKVILLE, AUSTRALIA, 5NEW YORK, 6NEW BRUNSWICK, 7AURORA, USA, 8MULHOUSE, FRANCE, 9GENOA, ITALY, 10BRUSSELS, BELGIUM, 11VANCOUVER, CANADA

**P 31144** Improvements in patient-reported treatment satisfaction with teriflunomide: preliminary results from the European, Latin American, and Canadian cohorts enrolled in the Teri-PRO Phase 4 study  
R. Gold1, C. Laganke2, B. Khatri3, K. Edwards4, S. Cavalier5, S. Brette7, P. Rufi8, P. Coyle6  
1BOCHUM, GERMANY, 2CULLMAN, 3MILWAUKEE, 4LATHAM, 5CAMBRIDGE, USA, 7BOULOGNE-BILLANCOURT, 8CHILLY-MAZARIN, FRANCE

**P 31145** CONFIDENCE: Phase IV study to evaluate medication satisfaction with glatiramer acetate 40mg/ml three-times weekly versus once-daily glatiramer acetate 20mg/ml in patients with RRMS  
A. Grinspan 1, S.K. Gandhi3, G.R. Cutter2, M. Copetti3, D. Kormann1, A. Veneziano 1  
1FRAZER, 2BIRMINGHAM, USA, 3SAN GIOVANNI ROTONDO, 4MILAN, ITALY

**P 31146** Reversibility of Natalizumab effects on peripheral immune cell dynamics in patients with multiple sclerosis (MS)  
T. Playing1, K.K. Muralidharan1, G. Kuesters1, D. Mikel1, K. Evans1, M. Subramanyam1, I. Nestorov1, Y. Chen1, P.-R. Ho1, D. Amarante1, J. de Seze6, R. Fox2, R. Gold4, D. Jeffery3, L. Kappos1, B. Weinstock-Guttman4, H.-P. Hartung1, B. Cree4  
1CAMBRIDGE, 2CLEVELAND, 3MOORESVILLE, 4SAN FRANCISCO, USA, 5STRASBOURG, FRANCE, 6BOCHUM, 7DÜSSELDORF, GERMANY, 8BASEL, SWITZERLAND, 9BARCELONA, SPAIN

**P 31147** Working memory and its relationship with the mood level in patients with multiple sclerosis  
E. Tyburski, A. Potemkowski, A. Sołtys, M. Chęć, A. Samochowiec  
1SZCZECIN, POLAND

**P 31148** Executive dysfunctions differ between secondary progressive and primary progressive MS  
E. Tyburski, A. Potemkowski, A. Sołtys, M. Chęć, A. Samochowiec  
1SZCZECIN, POLAND

**P 31149** Comparison of MRI criteria for the diagnosis of multiple sclerosis: role of cortical lesions  
P. Preziosi1, M.A. Rocca1, S. Mesaroš2, M. Copetti3, A. Rovira4, J. Sastre-Garriga4, J. Drulovic4, A. Droby6, F. Zipp5, M. Calabrese5, M. Filippi1  
1MILAN, 2SAN GIOVANNI ROTONDO, 3VERONA, ITALY, 4BELGRADE, SERBIA, 5BARCELONA, SPAIN, 6MAINZ, GERMANY

**P 31150** Anti-myelin antibodies in demyelinating disorders – a search for disease biomarkers  
K. Prus, E. Belniak, K. Mitosek Szewczyk, K. Rejdak  
1LUBLIN, POLAND

**P 31151** Gait performance gets closer to normalcy after a 15-day course of fampridine in patients with primary progressive multiple sclerosis  
1MADRID, SPAIN

**P 31152** Transcranial sonography of subcortical structures in patients with multiple sclerosis  
P. Pug1, A. Lasek-Bal 1  
1KATOWICE, POLAND

**P 31153** Characterisation of NMO spectrum disorders in an Italian cohort of patients  
1MILAN, ITALY

**P 31154** Clinical spectrum of multiple sclerosis and response to treatment in south Indian population  
B. Rangappan Munirathnam, J. Marimuthu, U.M. Elumalai  
1CHENNAI, INDIA

**P 31155** A case of very late onset neuromyelitis optica spectrum disease  
M. Reis Costa, P. Alves, T. Tedoro, P. Antunes, L. Albuquerque  
1LISBON, PORTUGAL

**P 31156** Whole brain and gray matter atrophy are correlated to long-term disability progression in multiple sclerosis patients  
1MÁLAGA, SPAIN

**P 31157** Interim analysis of the non-interventional study REBIFLECT: adherence to subcutaneous interferon β-1a in patients using RebiSmart®-logged data and their reflection in doctor–patient interviews  
1BAMBERG, 2DRESDEN, 3DÜSSELDORF, 4HAMBURG, 5DARMSTADT, 6ROSTOCK, GERMANY
P 31158 Evidence of favourable changing course of multiple sclerosis in the last 15 years: a real-world clinical study

P 31159 Differentiating neuromyelitis optica from multiple sclerosis after optic neuritis: the axon-myelin index

P 31160 Age at disease onset influences gray matter and white matter damage in adult multiple sclerosis patients
L. Vacchi1, M.A. Rocca1, B. Colombo1, M. Rodegher1, L. Moiola1, A. Ghezzi2, G. Comi1, A. Falini1, M. Filippi1 I MILAN, ITALY

P 31161 Gene HLA DRB1 alleles characterisation of MS patients in Latvian population
L. Vainsteine, G. Gulbe, L. Kovalchka, G. Karelis, J. Eglite, V. Kenina I RIGA, LATVIA

P 31162 Post-lumbar puncture headache: a frequent and unpredictable adverse event in multiple sclerosis work up
D. Vecchio1, P. Naldi1, C. Comi1, V. Ferro1, M. Leone2, R. Cantello1 I NOVARA, SAN GIOVANNI ROTONDO, ITALY

P 31163 Treatment-Naïve patients with highly active relapsing-remitting multiple sclerosis at baseline demonstrate continued clinical improvement with alemtuzumab over 5 years: CARE-MS I extension study
P. Vermersch1, J. Lycke2, V. Limmroth3, B. Singer4, S. Krieger5, D.H. Margolin6, K. Thangavelu6, R. Berkovich7 I LILLE, FRANCE, GOTHENBURG, SWEDEN, COLOGNE, GERMANY, ST LOUIS, NEW YORK, CAMBRIDGE, LOS ANGELES, USA

P 31164 Dutch online survey patient reported outcomes (PROs) in MS: modified Morisky scale correlates with real life medication adherence of daily glatiramer acetate 20mg/ml
K. Zuurbier1, M. Reijis-Scheijgrond1, L.H. Visser2 I HAARLEM, TILBURG, NETHERLANDS

P 31165 Dutch online survey patient reported outcomes (PROs) in MS: modified Morisky scale correlates with real life medication adherence of daily glatiramer acetate 20mg/ml
K. Zuurbier1, M. Reijis-Scheijgrond1, L.H. Visser2 I HAARLEM, TILBURG, NETHERLANDS

P 31166 Visual evoked potentials in the study of the visual system in patients with multiple sclerosis
S. Karpov, I. Vyshlova, I. Azoidis, A. Karpov I STAVROPOL, RUSSIAN FEDERATION

P 31167 Comorbid conditions and medication utilisation among paediatric and adult-onset multiple sclerosis patients in England
M. Wenten, N. Everage, N. Payas, T. Soman I CAMBRIDGE, USA

P 31168 Assessment of treatment satisfaction in multiple sclerosis: a review of the literature
Y. Wu1, S.K. Gandhi 1, J. Hobart4, G. Cutter2, A. Grinspan 3 I FRAZER, BIRMINGHAM, WESTON, USA, PLYMOUTH, UK

P 31169 Adherence to glatiramer acetate 40mg versus oral disease-modifying therapies for multiple sclerosis
R. Halpern1, R. Wolbeck1, C. Blauer-Peterson1, Y. Wu2, S.K. Gandhi2 I EDEN PRAIRIE, FRAZER, USA

P 31170 In patients with RRMS, SC peginterferon beta-1a every 2 weeks demonstrated comparable clinical efficacy to SC interferon beta-1a TIW using a matching-adjusted method
P. Coyle1, S. Shang2, X. You4, C. Castrillo-Viguera5, D. Gasparatto2, B. Werneburg2, D. Fiore I STONY BROOK, CAMBRIDGE, USA

P 31171 Intrathecal chitotriosidase as a prognostic marker in multiple sclerosis

P 31172 Evaluation of patient’s treatment methods using of walking tests during relapse of multiple sclerosis (MS)
G. Zemgulyte, R. Balnyte, K. Petrikonis I KAUNAS, LITHUANIA
POSTER SESSION
MUSCLE AND NEUROMUSCULAR JUNCTION DISEASE 5
12:30-13:15 | SCREEN B4
CHAIRPERSON:
Benedikt Schoser, BERLIN, GERMANY

P 31173
Cardiac safety of multiple doses of bimagrumab (BYM338) in healthy older adults: a randomised, double-blind, phase I study
D. Rooks1, D. Yates1, S. Neelakantham2, J. Buchbjerg3, D. Laurent3, O. Petricoul3, E. Svensson1 1CAMBRIDGE, USA, 2HYDERABAD, INDIA, 3BASEL, SWITZERLAND

P 31174
Homozygosity of the sodium channel myotonia SCN4A gene and intra familial phenotypic variability
M. Schahrazede Linda, M. Samira  I ALGIERS, ALGERIA

P 31175
Abstract cancelled

P 31176
Enzyme replacement therapy with alglucosidase alfa and pregnancy in late-onset Pompe disease
M. Santos, I. Conceicao  I LISBON, PORTUGAL

P 31177
Limb-girdle muscular dystrophy type 2A carrying novel mutations in the human CAPN3 gene (c.559delA)

P 31178
Dantrolene as a possible prophylactic treatment for RYR1-related rhabdomyolysis
R. Scacco1, V. Voermans3, H. Jungbluth1, R. Quinilvan1 1LONDON, UK, 3Nijmegen (GLD), NETHERLANDS

P 31179
Muscle b-enolase deficiency presenting with different kinetic profiles in muscle tissue
R. Wigley1, B. Sacco2, A. Gardiner1, S. Booth1, S. Chatfield1, R. Godfrey1, R. Kirk1, D. Hilton-Jones2, H. Houlden1, R. Quinilvan1 1LONDON, 2OXFORD, UK

P 31180
Chronic inflammatory demyelinating polineuropathy. The RareBOX.org project: where the patient meets himself
E. Schirinzi1, C. Lucchesi1, E. Giorli1, D. Cocito2, E. Nobile-Orzano1, G. Siciliano1, M. Marra1 1PISA, 2TURIN, 3MILAN, 4LECCE, ITALY

---

POSTER SESSION
NEUROGENETICS 3
12:30-13:15 | SCREEN F4
CHAIRPERSON:
David Lynch, LONDON, UK

P 31181
Amifampridine phosphate in patients with Lambert-Eaton myasthenic syndrome (LEMS): a phase 3, multicenter, double-blind, placebo-controlled trial
B. Schoser1, S. Oh5, N. Shcherbakova10, A. Kostera-Pruszczyk11, M. Alsharabati2, M. Dimacone5, J.M. Blanco1, D. Lavrinici6, P. Shieh6, C. Via11, A. Meisel1, T. Brannagan7, P. Shieh6, C. Vial11, K. Sivakumar8, Y. So9 1MUNICH, 2BERLIN, GERMANY, 3BIRMINGHAM, 4BIRMINGHAM, ALABAMA, 5KANSAS CITY, 6LOS ANGELES, 7NEW YORK, 8PHOENIX, 9STANFORD, USA, 10MOSCOW, RUSSIAN FEDERATION, 11WARSAW, POLAND, 12MADRID, SPAIN, 13BELGRADE, SERBIA, 14LYONS, FRANCE, 15PECS, HUNGARY

P 31182
Treating anti-MuSK myasthenia gravis
V. Serban  I PHILADELPHIA, USA

P 31183
Potential role of BAFF and TNFα in the course of myasthenia gravis
E. Sobieszczuk, J. Kubiszewska, M. Lipowska, P. Szczudlik, B. Szyluk, M. Dutkiewicz, A. Kostera-Pruszczyk  I WARSAW, POLAND

P 31184
The number of CTG repeat is correlated with the accumulation of visceral fat in myotonic dystrophy type 1
H. Takada, S. Kon, Y. Oyama, T. Kimura, F. Nagahata  I AOMORI, JAPAN
MONDAY, 30 MAY
12:30 - 13:15

P 31188  Gene delivery to oligodendrocytes re-establishes gap junctions and rescues a hypomyelinating leukodystrophy model
E. Georgiou1, A. Kagiava1, K. Sidropoulou2, J. Richter1, I. Sarigiannidou3, C. Papanoptyotou1, G. von Jonquieres4, C. Christodoulou1, M. Klugmann4, K. Kleopa4 | NICOSIA, CYPRUS, 1HERAKLION, GREECE, 2SYDNEY, AUSTRALIA

P 31189  Abstract cancelled

P 31190  Report of a family with a benign phenotype of SPG11
F. Ladeira, P. Esperança, T. Lampreia | LISBON, PORTUGAL

P 31191  Late-onset cerebellar ataxia: don’t forget SCA 17
A. Randall, A. J. Lamer | LIVERPOOL, UK

P 31192  Exome sequencing reveals double pathology: MFN2 and COL7A1 gene mutations in the same patient
I. Leonardis, A. Maver, B. Peterlin | LJUBLJANA, SLOVENIA

P 31193  Whole exome sequencing reveals novel NOV and DCAF13 mutations in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy
H. Lin | BEIJING, CHINA

P 31194  Novel biallelic missense mutations in CTC1 gene identified in a Chinese family with cereboretinal microangiopathy with calcification and cysts (CRMCC)
H. Lin | BEIJING, CHINA

P 31195  A novel EPM2a mutation affecting only the cytoplasmic isoform of laforin leads to late onset and slow progression of Lafora disease with prominent parkinsonism
D. Lynch, D. Hughes, A. Pittman, H. Houlden | LONDON, UK

P 31196  Further evidence that mutations in AARS2 cause an adult onset leukodystrophy
D. Lynch1, W.J. Zhang1, R. Lakshmanan1, R. Phadke1, I. Davagnanam1, H.A. Hanağası2, A. Bhattacharjee3, H. Wilson1, N.C. Fox1, H. Houlden1 | LONDON, UK, 2ISTANBUL, TURKEY

P 31197  C9ORF72 hexanucleotide repeat expansion in ALS patients from Russia
E. Lysogorskaia, N. Abramycycheva, M. Stepanova, M. Zakharova, S. Illarioshkin | MOSCOW, RUSSIAN FEDERATION

POSTER SESSIONS
NEUROIMMUNOLOGY 3
12:30-13:15 | SCREEN H2
CHAIRPERSON
Frank Leyboldt, HAMBURG, GERMANY

P 31198  Results of a multicentre, non-interventional study (NIS) on the long-term tolerability of octagam® 5% in neurologic indications in Germany
A. Debes, C. Lietz, S. Tascou | LANGENFELD, GERMANY

P 31199  First case of anti SOX-1 (AGNA) paraneoplastic antibodies positive, seronegative, neuromyelitis optica in an elderly woman
M. Turk1, M. Klarendic2, T. Rus3, B. Meglic2, U. Rot2 | NOVO MESTO, 1NOVO MESTO, 2LJUBLJANA, SLOVENIA

P 31200  Faciobrachial dystonic seizures. The importance of thinking about autoimmunity
T. Liaño Sanchez, M.E. García García, B. Parejo Carbonell, B. Abarrategui, I. Garcia Morales | MADRID, SPAIN

P 31201  Borreliosis and associated autoimmunity
I. Lisá, J. Ďurovská, J. Pancák, G. Timarova, Ľ. Lisý | BRATISLAVA, SLOVAKIA

P 31202  Myasthenia gravis: diagnostic and therapeutic aspects in Ukraine
R. Lomako, V. Pashkovskyi | DNIPROPETROVSK, UKRAINE

P 31203  Coexistence of onconeural antibodies anti-Hu and anti-Yo in a patient with small-cell lung carcinoma

P 31204  Response to therapeutic plasma exchange in central nervous system inflammatory diseases: multiple sclerosis and autoimmune encephalitis

P 31205  Aseptic meningitis as a rare manifestation of neuro-Behçet’s disease: long-term follow-up of six patients
A.N. Ozdag Acarli, T. Gunduz, S. Ala, G. Akman Demir, M. Kürttüncü | ISTANBUL, TURKEY

P 31206  Humoral response against myelin associated glycoprotein in Parkinson’s disease reflect oligodendroglial degeneration
E. Papuc, K. Rejdak | LUBLIN, POLAND
<table>
<thead>
<tr>
<th>Poster ID</th>
<th>Title</th>
<th>Authors</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 31207</td>
<td>Sjogren Syndrome presenting as autoimmune non-vasculitic meningoencephalitis (NAIM) and sensory ganglionopathy</td>
<td>J.P.G.N.T. Peres1, A.H. Valverde2</td>
<td>ALCABIDECHE, AMADORA, PORTUGAL</td>
</tr>
<tr>
<td>P 31208</td>
<td>Oxysterols, memory lymphocytes and multiple sclerosis: a peculiar team</td>
<td>A. Clotti1, A. Mathias1, J. Seebach1, D.P. Renaud1, C. Pat1</td>
<td>LAUSANNE, GENEVA, SWITZERLAND</td>
</tr>
<tr>
<td>P 31209</td>
<td>Epidemiological features of paraneoplastic polyneuropathies in cancer patients</td>
<td>Y. Raduta1, V. Raduta1, V.V. Ponomarev1, V. Sushko2</td>
<td>BREST, BELARUS</td>
</tr>
<tr>
<td>P 31211</td>
<td>Coexistence of autoimmune diseases and autoantibodies in patients with myasthenia gravis</td>
<td>S. Tamer1, H.N. Gunes2, E. Gökçal1, T. Yeldas1</td>
<td>VAN, ANKARA, TURKEY</td>
</tr>
<tr>
<td>P 31212</td>
<td>Skull chloroma in a patient with myeloid leukemia and pancytopenia</td>
<td>A.C. Mergeani, O. Rusu, C. Cociatu, A. Ciobotaru, T. Parvu, O.A. Bajenaru</td>
<td>BUCHAREST, ROMANIA</td>
</tr>
<tr>
<td>P 31213</td>
<td>Bilateral facial nerve palsy secondary to administration of nab-paclitaxel</td>
<td>D. Naoumis, I. Spanou, M. Antonopoulou, A. Isakidou, N. Kentepozidis, E. Kourmenios</td>
<td>BUCHAREST, ROMANIA</td>
</tr>
<tr>
<td>P 31214</td>
<td>Primary dural involvement of multiple myeloma (MM): description of 2 cases</td>
<td>A. Ołaskoag, L. Martinez-Merino, L. Pulido, A. Gorosquieta, M.C. Viguria, E. Erro</td>
<td>PAMPLONA, SPAIN</td>
</tr>
<tr>
<td>P 31216</td>
<td>Posterior reversible encephalopathy syndrome in pediatric oncology: a four clinical cases</td>
<td>J. Passos, M. Valente, S. Nunes, D. Salgado</td>
<td>LISBON, PORTUGAL</td>
</tr>
<tr>
<td>P 31217</td>
<td>Intramedullary pleomorphic xanthoastrocytoma with anaplastic features: a triple rare entity</td>
<td>C. Rosado Coelho1, J. Pimentel1, P. Pereira2, L. Roque3, J.P. Farias3</td>
<td>SETÚBAL, LISBON, PORTUGAL</td>
</tr>
<tr>
<td>P 31218</td>
<td>Dramatic response and prolonged survival after intensive chemotherapy with autologous stem cell transplantation in a case of lymphomatosis cerebri</td>
<td>L. Royer-Perron, C. Houiller, K. Mokthani, D. Leclercq, S. Choquet, A. Alentorn, A. Duran-Pena, K. Hoang-Xuan, A. Gonzalez-Aguilar</td>
<td>PARIS, FRANCE</td>
</tr>
<tr>
<td>P 31219</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P 31221</td>
<td>Headache in renal cell carcinoma: a possible paraneoplastic symptom?</td>
<td>S. Thissen</td>
<td>HEERLEN, NETHERLANDS</td>
</tr>
<tr>
<td>P 31223</td>
<td>Basal ganglia germinoma in adult: a case report</td>
<td>C. Vialatte de Pémille, K. Mokhtari, F. Bielle, C. Alapetite, A. Ibdaï</td>
<td>PARIS, FRANCE</td>
</tr>
<tr>
<td>P 31224</td>
<td>Frontal parafalcine meningioma presenting as parkinsonism</td>
<td>S. Vijayarangam Shanmugam, P. Hart, S. Stapleton, S. Omer</td>
<td>LONDON, UK</td>
</tr>
<tr>
<td>P 31225</td>
<td>Abstract cancelled</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**POSTER SESSION**

**NEURO-OPTHALMOLOGY/NEURO-OTOLOGY 3**

**12:30-13:15 | SCREEN H1**

**CHAIRPERSON:**
Eleftherios Papathanasiou, NICOSIA, CYPRUS

**P 31226** Assessing rotation and acting forces in vestibular patients during walking and balance tasks with combined motion capture and accelerometers

J. Decker, C. Pradhan, T. Brandt, K. Jahn, R. Schniepp
MUNICH, BAD AIBLING, GERMANY

**P 31227** Ophthalmologic presentation of CADASIL

J. Martins, J. Serino, V. Carvalho, C. Cunha, J. Martins
MATOSINHOS, PORTUGAL

**P 31228** Regional patterns of brain gray and white matter abnormalities in patients with hereditary optic neuropathies: dominant optic atrophy vs. leber hereditary optic neuropathy

MILAN, ITALY

**P 31229** Disconjugate horizontal eye movements in spinocerebellar ataxia type 3 (SCA3)

COIMBRA, PORTUGAL

**P 31230** Improvement of visual field with medicinal herbs in normal tension glaucoma: a small open pilot study

T. Okabe
TOKYO, JAPAN

**P 31231** Why and when to refer patients for vestibular evoked myogenic potentials: a critical review

E. Papathanasiou, D. Straumann
NICOSIA, CYPRUS, ZURICH, SWITZERLAND

**P 31232** Isolated opsoclonus: a case series

E. Papp, A. Alentorn, M. J. Ibanez, A. I. Grinev, G. Breton, B. Gaymard, D. Psimaros
PARIS, FRANCE

**P 31233** Isolated unilateral ptosis due to neurovascular conflict

G. Piccirillo, F. Trojsi, R. Conforti, G. Tedeschi
NAPLES, ITALY

**P 31234** Sensitive assessment of acute optic neuritis by a new digital flicker test

G. Pihl-Jensen, S. Trauzettel-Klosinski, J. L. Frederiksen
GLOSTRUP, DENMARK, TÜBINGEN, GERMANY

**P 31235** No gender difference on optic coherence tomography in acute optic neuritis

G. Pihl-Jensen, J. L. Frederiksen
GLOSTRUP, DENMARK

**P 31236** Susac’s syndrome - a multidisciplinary approach

M. Reis Costa, T. Teodoro, L. P. P. A. de Abreu, P. Alves, L. Albuquerque, P. Antunes
LISBON, PORTUGAL

**POSTER SESSION**

**NEUROREHABILITATION 3**

**12:30-13:15 | SCREEN G2**

**CHAIRPERSON:**
Stefan Goliszewski, SALZBURG, AUSTRIA

**P 31237** Computer use aspects in patients with motor disabilities

S. Bostantjopoulou, M. Plotnick, G. Zeilig, A. Gottlieb, R. Kizony, S. Chlomissiou, A. Nichogiannopoulos, Z. Katsarou
THESSALONIKI, ATHENS, GREECE, TEL AVIV, ISRAEL

**P 31238** Towards a new way for upper limb rehabilitation: a promising combined approach

R. S. Calabrà, A. Naro, M. Russo, A. Cacciola, A. Leo, D. Milardi, P. Bramanti
MESSINA, ITALY

**P 31239** Functional validation of an iPad delivered prism adaptation procedure in healthy young adults

A. S. Champod, G. Haidar, G. Eskes
WOLFVILLE, HALIFAX, CANADA

**P 31240** Abstract cancelled

**P 31241** Outcome prediction of consciousness disorders in the acute stage based on a complementary motor behavioural tool

K. Diserens
LAUSANNE, SWITZERLAND

**P 31242** Understanding of typed text by patients after stroke and healthy volunteers: does typography matter?

R. Gizatullin, L. Akhmadeeva, L. Nurtdinova, B. Veytsman
UFA, RUSSIAN FEDERATION, FAIRFAX, USA

**P 31243** Long-term coma-state and the bedrest-syndrome

SALZBURG, VIENNA, AUSTRIA

**P 31244** The locked-in-plus-syndrome

SALZBURG, VIENNA, AUSTRIA
POSTER SESSIONS

MONDAY, 30 MAY
12:30 - 13:15
SCREEN G1

**POSTER SESSION**
**NEUROTRAUMATOLOGY**
12:30 - 13:15 | SCREEN G1
CHAIRPERSON:
Edvard Ehler, PARDUBICE, CZECH REPUBLIC

**P 31245** The impact of proper handling of ARAT zero scores on the heterogeneity of data in rehabilitation studies
A. Guekht1, E. Doppler2, J.C. Vester3, D. Muresanu4
1MOSCOW, RUSSIAN FEDERATION
2UNTERACH, AUSTRIA
3MUNICH, GERMANY
4CLUJ, ROMANIA

**P 31246** Effects of early intervention of swallowing therapy on recovery from dysphagia following stroke
M.H. Harirchian1, J. Bakhtiyari1, P. Sarraf1, N. Nakhostin-Ansari1, A. Tafakhori1, J. Logemann3, S. Faghihzadeh2
1TEHRAN, IRAN
2ZANJAN, ISLAMIC REPUBLIC OF
3EVANSTON, USA

**P 31247** SPAsticity in PractiCE (SPACE) – an international, observational study of botulinum toxin type A in spasticity
J. Harriss1, J. Wissel2, O. Simon3, K. Sternberg3, N. Roche4, C. Cantú-Brito5, S. Khatkova6, P. Säterö7
1LONDON, UK
2BERLIN, GERMANY
3FRANKFURT AM MAIN, GERMANY
4GARCHES, FRANCE
5MEXICO CITY, MEXICO
6MOSCOW, RUSSIAN FEDERATION
7GOTHENBURG, SWEDEN

**P 31248** Neurophysiological aspects of combined craniofacial trauma
S. Karpov, K. Gandylyan, K. Karakov, I. Azoidis, E. Eisseeva
STAVROPOL, RUSSIAN FEDERATION

**P 31249** Characteristics of the neuropsychiatric status of patients in the acute phase of combined trauma (CT)
S. Karpov, E. Nazarova, I. Azoidis, A. Apaguni
STAVROPOL, RUSSIAN FEDERATION

**P 31250** Duration and clinical course of post-concussion syndrome in Albania (PCS)
E. Basha, T. Qalliu, B. Zilami, J. Kruja
TIRANA, ALBANIA

**P 31251** Abstract cancelled

**P 31252** What are the clinical manifestations of a disabling atlantoaxial subluxation? A descriptive study
H. Huhmar, L. Soinne
HELSINKI, FINLAND

**P 31253** The clinical presentation of atlantoaxial subluxation in light of three cases undergoing stabilising surgery
H. Huhmar1, V. Leinonen2, L. Soinne3
1HELSINKI, 2KUOPIO, FINLAND

**P 31254** Can occipitoatlantal subluxation cause a spasmodic dysphonia? A case study
H. Huhmar, L. Soinne
HELSINKI, FINLAND

**P 31255** Formation of vertebral artery syndrome in the late period of cervical spine injury
M. Suleymanova, E. Karpova, E. Omelchenko, S. Karpov, I. Azoidis
STAVROPOL, RUSSIAN FEDERATION

**P 31256** FAQ of traumatic brain injury patients: do I really have a chance for a full recovery after TBI?
A. Korchut, S. Szklenr, M. Majewski, K. Rejdak, T. Trojanowski
LUBLIN, POLAND

**P 31257** Indicators of melatonin and brain-specific proteins in patients with mild consequences of traumatic brain injury
V. Korshnyak, O. Korshnyak
KHARKIV, UKRAINE

**P 31258** The characteristics of an acute craniocerebral injury, which was caused by explosive wave, in participants of military operations in Eastern Ukraine
V. Korshnyak, V.I. Sukhorukov, Y. Bovt
KHARKIV, UKRAINE

**P 31259** Secondary brain ischemia in the postoperative period in patients with traumatic acute subdural hematomas
J. Kuzibaev
TASHKENT, UZBEKISTAN

**P 31260** KPT-350, a selective inhibitor of nuclear export (SINE) compound, reduces primary and secondary injury in core-impact and peri-impact TBI lesions
S. Tamir1, N. Tajiri2, S. Acosta2, Y. Landesman1, M. Lee3, S. Shacham1, C. Borlongan2, C. Drolen
1NEWTON, 2TAMPA, USA

**P 31261** Diagnosis and monitoring with Brainstem Auditory Evoked Potentials (BAEP) in patients with brain concussion
D. Tsakova, K. Genov, A. Shmarov, L.D. Traykov
SOFIA, BULGARIA
P 31262  Nerve ultrasound findings in a patient with Charcot-Marie-Tooth (CMT) disease type 4C
A. Felbecker, R. Stark, D. Leupold, T. Hundsberger I ST. GALLEN, SWITZERLAND

P 31263  Parsonage-Turner syndrome or herpes zoster neuritis?
D. Gabriel, P. Salgado, M.N. Cardoso, C. Ramos, A.P. Correia, G. Lopes I PORTO, PORTUGAL

P 31264  IgM MGUS anti-MAG neuropathy can rarely expresses as distal motor neuropathy
G. Galassi, M. Tondelli, A. Ariatti, P. Nichelli, F. Valzania I MODENA, ITALY

P 31265  The clinical, electrophysiological and morphological peculiarities of atypical chronic inflammatory demyelinating polyneuropathies
E. Gavriliuc I CHISINAU, MOLDOVA

P 31266  CIDP – intravenous immunoglobulin or corticosteroids?
M.G. Giurea Neacsu1, B. Ioan2, M. Burago3, C. Baetu4, I.-H. Ciorceanu5, A.M. Ghitoiu6, A.M. Enachi7 1BUCHAREST, 2BRASOV, 3ROMANIA, 4TURIN, 5Rome, 6GENOA, 7ROMA

P 31267  Recurrent facial edema: two new cases of Melkersson-Rosenthal Syndrome
B. Palazon, S. Atienza, J.J. Hernandez I MURCIA, SPAIN

P 31268  Neuronal ganglia as a cause of peripheral nerve lesion – clinical and neurosonographic findings
T. Hundsberger I ST. GALLEN, SWITZERLAND

P 31269  Abstract cancelled

P 31270  High dose intravenous immunoglobulin is effective in painful diabetic polyneuropathy resistant to conventional treatments. Results of a double blind, randomised, placebo-controlled, multicenter trial
S. Jann1, R. Fazio2, D. Cocito3, A. Toscano4, A. Schenone4, G.A. Marfia5, G. Antonini5, L. de Toni6, Franceschina6, D. Velardo1, M. Grandis1, A. Mazzetti1, G. Mataluni1, E. Peci1 I 1MILAN, 2TURIN, 3MESSINA, 4GENOA, 5ROME, 6LECCO, ITALY

P 31271  Abstract cancelled

P 31272  Subjective symptoms of Carpal Tunnel Syndrome correlate more with psychological factors than electrophysiological severity
F. Khan1, R. Pauli2, K.S. Sandhya3, A. Majeeed4, A. Radhakrishnan5 I THRISSUR, 6COCHIN, 7THRUVANANTHAPURAM, 8INDIA

P 31273  The anodal action potential for the assessment of sensory nerve excitability
J. Leote1, P. Pereira2, J. Valls-Sole1 I BARCELONA, SPAIN, 2LISBON, PORTUGAL

P 31274  Abstract cancelled

P 31275  A high-density polysomnographic picture of a case of NREM parasomnia
N. Amato1, M. Manconi1, O. David2, S. Miano1, F. Zellini1, M. Abbafati1, L. Ratti1 I LUGANO, SWITZERLAND, 2GRENOBLE, FRANCE

P 31276  Sleep-wake functions in advanced Parkinson’s disease: frequency, associations and evolution after deep brain stimulation

P 31277  Health-related quality of life in patients with narcolepsy type 1 and type 2

P 31278  Altered distribution of nocturnal eye movements in narcolepsy type 1
J.A.E. Christensen, L. Kempfner, H. Leonthin, M.H. Hansen, M. Nikolic, P.J. Jennum I GLOSTRUP, DENMARK

P 31279  Seizure frequency during recent year but not month correlates with quality of sleep, depression, anxiety and quality of life in epilepsy
A. Darabyan, L. Ghahramanyan, T. Stepanyan, N. Yeghiazaryan, S. Khachatryan I YEREVAN, ARMENIA

P 31280  Poor quality of sleep is associated with lower quality of life scores in patients with epilepsy compared to healthy controls
A. Darabyan1, H. Amroyan1, L. Ghahramanyan1, A. Karamyan2, S. Khachatryan1 I YEREVAN, ARMENIA, 2SALZBURG, AUSTRIA

P 31281  Prolonged bed rest and hypoxic exposure affect breathing stability and sleep macrostructure
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 31282</td>
<td>Clinico-biological characteristics in restless legs syndrome in a population of hemodialysis patients - Role of vitamin C deficiency</td>
<td>L. Dolenc Groselj1, S. Morrison1, D. Mirnik1, S. Korsic1, O. Eiken2, I. Mekjavic1</td>
<td>Ljubljana, Slovenia, Stockholm, Sweden</td>
</tr>
<tr>
<td>P 31283</td>
<td>Sleep disturbance in patients with Huntington’s Disease - polysomnography characteristics</td>
<td>J. El Helou, E. Sarkis, E. Khneisser, H. Azar, D. Chelala</td>
<td>Beirut, Lebanon</td>
</tr>
<tr>
<td>P 31284</td>
<td>Automatic and visual scorings of REM sleep without atonia for the diagnosis of idiopathic REM sleep behavior disorder</td>
<td>R. Ferri1, M. Zucconi2, A. Galbiati2, F. Rinaldi3, L. Ferini Strambi2</td>
<td>Troina, Milan, Brescia, Italy</td>
</tr>
<tr>
<td>P 31285</td>
<td>Evaluation of worry and rumination in insomnia patients</td>
<td>S. Marelli, M. Linares, A. Galbiati, G.E. Lombardi, V. Castronovo, L. Ferini Strambi</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>P 31286</td>
<td>Clinical and polysomnographic differences between idiopathic and symptomatic REM sleep behavior disorder</td>
<td>S. Marelli, A. Galbiati, F. Colli, M. Zucconi, A. Oldani, L. Ferini Strambi</td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>P 31287</td>
<td>Is dream enactment or motor activity the pathological finding in REM sleep behaviour disorder? Correlation to changes in the brain quantified with diffusion tensor imaging</td>
<td>R. Frandsen1, P.J. Jemnnum2</td>
<td>Glostrup, Glostrup - Copenhagen, Denmark</td>
</tr>
<tr>
<td>P 32001</td>
<td>Laterality of the breath holding index assessment</td>
<td>A. Tomek, B. Urbanová, H. Magerová, H. Marková, J. Paulasová Schwabová, P. Jansky, I. Makrisova, J. Laczo, M. Vyhnanek, J. Hort</td>
<td>Prague, Czech Republic</td>
</tr>
<tr>
<td>P 32002</td>
<td>Heterogeneity of dementia associated with Parkinson’s disease</td>
<td>N. Trofimova1, I. Preobragenskaya2</td>
<td>Pereslavl, Moscow, Russian Federation</td>
</tr>
<tr>
<td>P 32003</td>
<td>The relationship with silent lacunar infarctions in basal ganglia and clinical features in Alzheimer’s disease</td>
<td>Y. Uchiyama, M. Iwata, H. Hashida, K. Kitagawa</td>
<td>Tokyo, Japan</td>
</tr>
<tr>
<td>P 32004</td>
<td>The effect of physical exercise on cerebral blood flow in Alzheimer’s disease</td>
<td>L.A. van der Kleij, E.T. Petersen, H.R. Siebner, J. Hendriks1, K. Frederiksen2, N. Sobol3, S.G. Hasselbalch4, E. Garde5</td>
<td>Utrecht, Netherlands, Copenhagen, Denmark</td>
</tr>
<tr>
<td>P 32005</td>
<td>Comparing longitudinal behaviour changes in the primary progressive aphasias</td>
<td>T. van Langenhove, C. Leyton, O. Piguet, J.R. Hodges</td>
<td>Sydney, Australia</td>
</tr>
<tr>
<td>P 32006</td>
<td>Insulin-like growth factors in spinal fluids from patients with and without Alzheimer’s dementia</td>
<td>A.S. Vintner, H. Gottrup, J. Frystyk, H. Andersen</td>
<td>Aarhus, Denmark</td>
</tr>
<tr>
<td>P 32007</td>
<td>Objective monitoring of dysarthria in FTD-MND: a case series</td>
<td>M. Poole, A. Brodtmann, D. Darby, A. Vogel</td>
<td>Melbourne, Australia</td>
</tr>
<tr>
<td>P 32008</td>
<td>Development of a specialised tool for the assessment of testamentary capacity (TC) in patients with dementia</td>
<td>P. Voskou, I. Beratis, A. Economou, A. Douzenis, S.G. Papageorgiou</td>
<td>Athens, Greece</td>
</tr>
<tr>
<td>P 32009</td>
<td>A sporadic case of early-onset Alzheimer’s disease with spastic paraparesis, cognitive impairment and cerebral white matter lesions due to a PSEN1 mutation</td>
<td>B. Wilke, M.T. van Den Bossche, S. Engelborghs, C. van Broeckhoven, P. Crau</td>
<td>Edegem, Antwerp, Belgium</td>
</tr>
</tbody>
</table>
**MONDAY, 30 MAY**

**13:30 - 14:15**

**POSTER SESSION**

**CEREBROVASCULAR DISEASES 12**

13:30-14:15 | SCREEN G4

**CHAIRPERSON:**

Valeria Caso, PERUGIA, ITALY

---

**P 32010** Plasma ceramides and neuropsychiatric symptoms of Alzheimer’s disease

Y. Xing | BEIJING, CHINA

**P 32011** Regional differences in antipsychotic drug use in elderly patients with dementia: a nationwide study

J.K. Zakarias1, C. Jensen-Dahm1, C. Gasse2, A. Nørgaard3, L. Stevnsborg4, T. Moos5, G. Waldemar1 | 1COPENHAGEN, 2AARHUS, 3AALBORG, DENMARK

---

**P 32012** Sex differences in the care, and outcomes of transient ischemic attack in Tashkent

S. Rakhimberdiyev, Y. Musaeva, G. Rakhimaeva | TASHKENT, UZBEKISTAN

**P 32013** RISCLON – Risk of recurrent stroke in CLOpidogrel non-responders

C.L. Rath, T. Wienecke | ROSKILDE, DENMARK

**P 32014** Ultrascanographic evaluation of a series of patients with Takayasu’s arteritis in a tertiary center

M. Reis Costa, P. Viana, V. Oliveira | LISBON, PORTUGAL

**P 32015** Cognitive impairment in cerebral small vessel disease

A. Riahi, I. Bedoui, H. Derbali, M. Messelmani, M. Mansour, J. Zaouali, R. Mrissa | TUNIS, TUNISIA

**P 32016** Implication of Caudate nucleus lacunar infarcts in post-stroke depression

A. Riahi, H. Derbali, I. Bedoui, M. Messelmani, M. Mansour, J. Zaouali, R. Mrissa | TUNIS, TUNISIA

**P 32017** Reversible cerebral vasoconstriction syndrome diagnosis with perfusion MRI

P. Ripellino, E. Prodi, A. Cianfoni, C.W. Cereda | LUGANO, SWITZERLAND

**P 32018** Cardioembolic stroke caused by cardiac metastatic melanoma – a case report

M. Rosón González1, L. Castillo1, M. Villa1, M.E. Novillo1, A. Perez2, P. Pire3, A. Arbe4, A. Mendez5, P. Bandres6, L. Vela7 | 1ALCORCÓN, SPAIN, 2MADRID, SPAIN

**P 32019** Reccurent in-stent stenosis of cervico-cerebral arteries

O. Rusu, C. Coclitu, T. Parvu, A. Ciobotaru, A.C. Mergeani, B. Dorobat, O. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

---

**P 32020** Cerebral reperfusion syndrome–complication of carotid artery endarterectomy: a case report

O. Rusu, C. Coclitu, A. Ciobotaru, T. Parvu, A.C. Mergeani, M.T. Vasile, B. Dorobat, F. Antochi | BUCHAREST, ROMANIA

**P 32021** Abstract cancelled

**P 32022** Abstract cancelled

**P 32023** Prevalence of post-stroke spasticity in Poland and its impact on activities of daily living and quality of life in one-year follow-up

M. Schinwelski, E. Sitek, J. Slawek | GDANSK, POLAND

**P 32024** The impact of seasonal changes on cerebrovascular diseases: a retrospective study in Northern Cyprus

S. Ertuğrul Mut, F. Selcuk, S. Usar Incırlı | NİCOSIA, TURKEY

**P 32025** Leukocyte subtype counts in the acute phase of ischemic stroke as biomarker for haemorrhagic complications and outcome

A. Semerano, D. Strambo, G. Comi, L. Roveri, M. Bacigaluppi | MILAN, ITALY

---

**POSTER SESSION**

**CEREBROVASCULAR DISEASES 13**

13:30-14:15 | SCREEN G3

**CHAIRPERSON:**

Catarina Fonseca, LISBON, PORTUGAL

---

**P 32026** Risk factors for hemorrhagic transformation in patients with acute posterior circulation territory infarction

B.S. Demirtas, L. Öcek, B. Tiftikcioğlu, O. Oztekin, Y. Zorlu | İZMIR, TURKEY

**P 32027** Positive trend in door-to-needle time and stroke outcome after implementation and data analysis of Romanian stroke thrombolysis registry

C. Tiu, V. Tiu, E. Terceasa, A. Neacsu, O.A. Bajenaru | BUCHAREST, ROMANIA

**P 32028** Unusual aetiologies of cerebral venous sinus thrombosis

G. Tondo, A. Naldi, R. Cantello | NOVARA, ITALY

**P 32029** Headache – a common symptom in acute cerebrovascular disease

I.A. Torop, L. Sabre, R. Vibo, J. Kõrv | TARTU, ESTONIA
### POSTER SESSIONS

#### MONDAY, 30 MAY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairperson</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:15</td>
<td>EPILEPSY 7</td>
<td>Eugen Trinka (TBC)</td>
<td>SCREEN B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SALZBURG, AUSTRIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LAUSANNE, SWITZERLAND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GENELA, GERMANY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>LONDON, UK</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Utrecht, NETHERLANDS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sofia, BULGARIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Milan, ITALY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Zagreb, CROATIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Brussels, BELGIUM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bucharest, ROMANIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dublin, IRELAND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Budapest, HUNGARY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Madrid, SPAIN</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Moscow, RUSSIAN FEDERATION</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Istanbul, TURKEY</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>VILNIUS, LITHUANIA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Kuopio, FINLAND</td>
</tr>
</tbody>
</table>

#### POSTER SESSIONS

<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P 32030</td>
<td>The studying of lipid metabolism and endothielium dysfunction in young patients with spondylogenic vertebrobasilar insufficiency (SVBI)</td>
<td>N. Nekrasova, O. Tovazhnyanska, O. Markovska (KHARKIV, UKRAINE)</td>
</tr>
<tr>
<td>P 32031</td>
<td>Neuropsychological disorders in isolated cerebellar infarctions</td>
<td>O. Mialovitska, G. Trepet (KIEV, UKRAINE)</td>
</tr>
<tr>
<td>P 32033</td>
<td>Imaging presentation of intracerebral hemorrhage in an East European community (Grodno, Belarus)</td>
<td>S. Tismanova, I. Shaporov, N. Filina, S. Kulesh (GRODNO, BELARUS)</td>
</tr>
<tr>
<td>P 32034</td>
<td>Abstract cancelled</td>
<td></td>
</tr>
<tr>
<td>P 32035</td>
<td>Ratio between carotid artery stiffness and blood flow - a new ultrasound index of ischemic leukoaraiosis</td>
<td>M. Turk (LJUBLJANA, SLOVENIA), M. Zaletel (NOVO MESTO, SLOVENIA)</td>
</tr>
<tr>
<td>P 32036</td>
<td>Abstract cancelled</td>
<td></td>
</tr>
<tr>
<td>P 32037</td>
<td>MoCA vs. MMSE in post-stroke patients</td>
<td>S. Xhaxho, J. Xhaxho, J. Hankolari, B. Xhaxho, J. Kruja (TIRANA, ALBANIA)</td>
</tr>
<tr>
<td>P 32038</td>
<td>Time of the day and the onset of stroke</td>
<td>S. Xhaxho, J. Xhaxho, R. Sanxhaku, B. Xhaxho, J. Kruja (TIRANA, ALBANIA)</td>
</tr>
<tr>
<td>P 32039</td>
<td>DSA study of supratentorial venous sinus in cases with non-venous system disease</td>
<td>L. Yin, D. Li, C. Ma (DALIAN, CHINA)</td>
</tr>
<tr>
<td>P 32042</td>
<td>Young people with epilepsy have an increased risk of eating disorder symptoms and poor quality diet</td>
<td>E. Kolstad, M.H. Bjerk, N.E. Gilhus, J. Clenches-Aas, G. Veiby, M.I. Lossius (BERGEN, OSLO, TAERUM, NORWAY)</td>
</tr>
<tr>
<td>P 32043</td>
<td>Abstract cancelled</td>
<td></td>
</tr>
<tr>
<td>P 32044</td>
<td>The prospective role of orexin-a levels in epileptic seizure</td>
<td>H.I. Ciriklar, D. Kocam, M. Yucel, M. Ceylan, G. Gurol, O.F. Bayraktutan, I.H. Ciftcil, S. Karayi, E. Zeruzum, TURKEY</td>
</tr>
<tr>
<td>P 32045</td>
<td>Gene expression for Schwannoma-derived growth factor using microarrays method in epilepsy (of the temporal lobes, frontal and generalised)</td>
<td>M. Grabek Gawloowicz, L. Katula, A. Petniak, J. Karwat, P. Gil-Kulik, J. Kocky (LUBLIN, POLAND)</td>
</tr>
</tbody>
</table>

COPENHAGEN, DENMARK, 28 – 31 MAY, 2016

173
P 32047 Serum MMP-9 and TIMP-1 level increases after generalised tonic-clonic seizures
A. Cudna, A. Jopowicz, P. Mierzejewski, I. Kurkowska-Jastrzebska | WARSAW, POLAND

P 32048 Interictal heart rate in patients with epilepsy
I. Manka-Gaca, B. Labuz-Roszak, K. Pierzchala, A. Machowska-Majchrzak, Z. Kalarus, B. Sredniawa | ZABRZE, POLAND

P 32049 EEG and ECG changes in patients with epilepsy

P 32050 The level of apoptotic cells and antiepileptic drug (AEDs) pharmacotherapy in epilepsy patients

P 32051 Expression of circulating miR-132 in mesial temporal lobe epilepsy: a preliminary study

P 32052 Rasmussen’s encephalitis: other „movements” besides epilepsy
L. Leitão1, J. Peres1, S. Reimão2, R. Peralta2, J. Pimentel2 | 1AMADORA, 2LISBON, PORTUGAL

P 32053 Eslicarbazepine acetate: update of post-marketing safety data
M. Vieira, H. Gama, J. Graça, R. Costa, R. Sousa, P. Soares-Da-Silva | CORONADO, PORTUGAL

P 32054 Abstract cancelled

P 32055 Depression prevalence and severity among headache patients compared to the general population in Albania
I. Alimehmeti1, M. Rakacollı2, S. Grabova2, E. Kurmaku2, P. Jahja3, E. Rrakli2, J. Kruja2 | 1TIRANA, ALBANIA

P 32056 Possible risk factors for migraine and tension type headache
E.R. Lebedeva1, N.R. Kobzeva1, D.V. Gilev1, J. Olesen2 | 1YEKATERINBURG, RUSSIAN FEDERATION, 2COPENHAGEN, DENMARK

P 32057 Idiopathic intracranial hypertension clinically manifested as bilateral sixth nerve palsy, combined with the enlargement of superior ophthalmic veins: a case report
J.E. Lee1, Y.B. Kim1, I.U. Kang1, D.W. Bae1, K.S. Kim2 | SEOUL, KOREA, REPUBLIC OF

P 32058 Case study of repetitive transcranial magnetic stimulation of the motor cortex for thalamic pain
H. Lin | BEIJING, CHINA

P 32059 Gender differences in the lifestyle of cluster headache patients: results from the Danish cluster headache survey
N. Lund, M. Barloese, A.S. Petersen, A.H. Snoer, R. Jensen | COPENHAGEN, DENMARK

P 32060 Marked diagnostic delay in cluster headache – An analysis of the clinical features: results from the Danish cluster headache survey
N. Lund, M. Barloese, A.S. Petersen, A.H. Snoer, R. Jensen | COPENHAGEN, DENMARK

P 32061 Experimental provocation of “ice-cream headache” by ice cubes and ice water
S. Mages, O. Hensel, T. Kraya, S. Zierz | HALLE, GERMANY

P 32062 An atypical migraine: the key role of perfusion imaging
S. Magno1, M. Ghosn2, F. Baronnet Chauvet2, S. Deltour2, M. Ollivier1, C. Rosso3, Y. Samson2 | 1PARIS/MILAN, 2PARIS, FRANCE

P 32063 Headache in Hungarian neurology outpatient services
M. Magyar, E. Csepany, T. Gyüre, A. Ajtay, D. Bercziki, F. Oberfrank, C. Ertsey | BUDAPEST, HUNGARY

P 32064 Clinico-demographic features of trigeminal autonomic cephalias: an experience from a tertiary care center
Y. Malik, S. Siddiqi, J. Inshasi, M. Altashi, A. Almadani | DUBAI, UNITED ARAB EMIRATES

P 32065 Primary headache data series from a tertiary care hospital: a review of 12 years
Y. Malik, P. Sarathchandran, J. Dar, S. Siddiqi, A. Almadani | DUBAI, UNITED ARAB EMIRATES

P 32066 Follow-up study of 12-18 years on subtypes of headache in a population of children below 6 years old: preliminary results
F. Marchese, P. Marchese, V. Raieli, D. Puma, G. La Franca, F. Vanadia | PALERMO, ITALY
POSTER SESSION
HEADACHE AND PAIN 7
13:30–14:15 | SCREEN C4
CHAIRPERSON:
Jes Olesen, GLOSTRUP, DENMARK

P 32067  No pain perception abnormalities in allodinic patients between attacks
L. Marcuccio, A. Russo, F. Conte, A. Giordano, A. Tessitore, G. Tedeschi | NAPLES, ITALY

P 32068  Cluster headache in Czech patients
J. Markova1, A. Bartkova2, R. Kotas3, J. Mastik4, I. Niedermayerova1 | PRAGUE, 1LOMOUC, 2PLZEN, 3BRNO, CZECH REPUBLIC

P 32069  DT-MRI reveals widespread white matter abnormalities in migraine patients compared to healthy controls

P 32070  Pituitary apoplexy: a challenging and emergent diagnosis
R. Martins, P. Pita Lobo | PALERMO, ITALY

P 32071  Ice cream headache in students and family history of headache: a cross-sectional questionnaire-based study
T. Mehl, A. Zierz, T. Kraya, S. Zierz | HALLE, GERMANY

P 32072  Capabilities of electromyography in the dysfunction temporomandibular joint
N. Safonova, V. Mikhailov, J. Kotsiubinskaya, I. Ashnokova, T. Lopushanskaya | SAINT-PETERSBURG, RUSSIAN FEDERATION

P 32073  Tension type headache – an osteopathic treatment
D. Mikó, M. Jachacz-Lopata, W. Likus, G. Bajor | KATOWICE, POLAND

P 32074  Cervicogenic headache as a symptom of poor posture
M. Jachacz-Lopata, D. Mikó, W. Likus, G. Bajor | KATOWICE, POLAND

P 32075  Telemedicine in diagnosis and management of non-acute headaches: an open-labeled noninferiority randomised controlled study
K.I. Mueller1, K.B. Alstadhaug2, S.I. Bekkelund1 | TROMSØ, 1BODØ, NORWAY

P 32076  Modulatory effect of nitroglycerin on the L-kynurenine hydrolase and kynurenine 3-monooxygenase expression in the rat cervical spinal cord

P 32077  Occipital seizure with persistent homonymous hemianopia with T2 hypointensity on MRI in non-ketotic hyperglycemia
Z.U. Nissa, S. Siddiqi, S. Abdool | DUBAI, UNITED ARAB EMIRATES

P 32078  Clinical factors associated with migraine chronification
A. Novo, J. Jesus Ribeiro, L. Sousa, S. Batista | COIMBRA, PORTUGAL

P 32079  Towards a pragmatic migraine model for drug testing: Cilostazol and Isosorbide-5-mononitrate provocation in healthy subjects
E. K. Hansen, J. Olesen | GLOSTRUP, DENMARK

P 32080  The role of mental and behavioural disorders in the primary headaches management determination
G. Osmanova, A. Musayev | BAKU, AZERBAIJAN

P 32081  Headache in multiple sclerosis
M. Ozturk, M. Ozden, S. Topaloglu Tuac, F. Basoglu, A. Soysal, S. Baybas | ISTANBUL, TURKEY

POSTER SESSION
INFECTION AND AIDS 2
13:30–14:15 | SCREEN F3
CHAIRPERSON:
Johann Sellner, SALZBURG, AUSTRIA

P 32082  Genetic variants influencing susceptibility to pneumococcal meningitis identified by an exome array analysis
A. Kloek1, B. Ferwerda1, J. van Setten1, A. van der Ende1, M. Valls Seron1, M. Brouwer1, D. van de Beek1 | AMSTERDAM, 1UTRECHT, NETHERLANDS

P 32083  Nonidiopathic hypertrophic pachymeningitis

P 32084  Activation of dormant infections in the acute period of experimental hemorrhagic stroke (EHS)
O. Makarenko | KIEV, UKRAINE

P 32085  A difficult diagnosis: Tuberculosis with CNS and peritoneal involvement in an immunocompetent patient

P 32086  Meningitis caused by streptococcus suis
P 32087  Herpes simplex 1 encephalitis due to reactivation by cutaneous herpes zoster in an immunocompetent adult
M. Oses, B. Pfang, M. Machio, M.A. Garcia-Torres, A. Herranz, R. Fernández-Robles, I. Zamarbide I MADRID, SPAIN

P 32088  Atypical ramsay hunt syndrome with oculomotor palsy
M. Oses, M. Machio, L. Olivié, R. Rigual, B. Sobrino, M. Ruggiero García, M.A. García-Torres, I. Zamarbide I MADRID, SPAIN

P 32089  Diagnostic approach to acute encephalitis in adults in a spanish tertiary hospital over a three-year period (2013-2015)
J. Perez Lucas, E. Miñano Guillamón, E.M. Alba Suarez, P. López Ruiz I MADRID, SPAIN

P 32090  MRI findings in tick-borne encephalitis
A. Pichler, H. Rock, F. Fazekas I GRAZ, AUSTRIA

P 32091  Recurrence of herpes simplex encephalitis after 16 years
A.L. Rassu, R. Piredda, A. Addis, E. Sechi, C. Fois, W. Boadu, E. Nako, G. Sechi I SASSARI, ITALY

P 32092  Anti-NMDAR encephalitis after herpetic encephalitis in an adult patient
P. Salgado, I. Moreira, L. Albuquerque, A. Martins Silva I PORTO, PORTUGAL

P 32093  HIV-PML: remember to test
R. Samoes1, S. Rackstraw1, M. Marta2 I PORTO, PORTUGAL, "LONDON, UK

P 32094  SOD1: phenotypic variability, incidence and penetrance in a north-west tuscan cohort of patients
M. Rossi, C. Bisordi, E. Caldorazzo Ienco, M. Fabbrini, L. Chico, C. Carlesi, A. Lo Gerfo, A. Fogli, G. Siciliano I PISA, ITALY

P 32095  Outcome measures and natural history study in spinal and bulbar muscular atrophy (SBMA)
A. Sagnelli1, I. Tramacere1, A. Castaldo1, M. Montesano1, V. Sciolli1, C. Gellera1, E. Vitelli2, F. Taroni1, C. Mariotti1, D. Pareyson1 I MILAN, LODI, ITALY

P 32096  Absence of wide-spread mis-splicing in the pre-clinical phase of a native promoter driven TDP-43 mouse model of ALS

P 32097  Participation of protein kinase C in neurite inhibitory effect in plasma of patients with spinal muscular atrophy type II
M. Sokolova, V. Penniyaynen, S. Lobzin I SAINT-PETERSBURG, RUSSIAN FEDERATION

P 32098  Matching genetic and clinical information – a new spastin mutation causing HSP4 and a new non-pathogenic epsilon sarcoglycan mutation in one patient
R. Stark, A. Felbeck I ST. GALLEN, SWITZERLAND

P 32099  Occurrence of multiple ALS-associated mutations in Italian patients
N. Ticozzi, C. Tiloca, V. Pensato, D. Calini, B. Castellotti, A. Ratti, C. Gellera, V. Silani I MILAN, ITALY

P 32100  Care preferences in amyotrophic lateral sclerosis (ALS) patients and carers using a discrete choice experiment
S. Maguire, K. Tobin, O. Hardiman, C. Normand, M. Galvin I DUBLIN, IRELAND

P 32101  Longitudinal analysis of a discrete choice experiment of preferences for care of amyotrophic lateral sclerosis patients and their carers
K. Tobin, S. Maguire, C. Normand, O. Hardiman, M. Galvin I DUBLIN, IRELAND

P 32102  Whole-brain microstructural abnormalities in amyotrophic lateral sclerosis (ALS): High-Angular Resolution Diffusion Imaging (HARDI) study in bulbar-onset versus spinal-onset ALS
F. Troisi1, G. Caiazzo1, C. Femiano2, F. Di Nardo1, M. Fratello2, G. Santangelo2, M. Siciliano1, G. Piccirillo2, M.R. Monsurro1, M. Cirillo1, A. Tessitore1, F. Esposito1, G. Tedeschi1 I NAPLES, "CASERTA, ITALY

P 32103  Abstract cancelled

P 32104  Phenotype comparison between young- and elderly-onset motor neuron disease patients
F. Verde, N. Ticozzi, C. Morelli, S. Messina, A. Doretti, B. Paolotti, C. Tiloca, L. Maderna, V. Silani I MILAN, ITALY

P 32105  Severe MRI-visible Virchow-Robin spaces in amyotrophic lateral sclerosis: clue to the pathogenesis?
A. Voong I VERONA, ITALY
POSTER SESSION
MOVEMENT DISORDERS 8
13:30-14:15 | SCREEN E4
CHAIRPERSON:
Evzen Ruzicka, PRAG, CZECH REPUBLICK

P 32106  Independent validation of the quality of life in essential tremor questionnaire (QUEST)
A. Makkos, M. Kovács, J. Janszky, N. Kovacs | PÉCS, HUNGARY

P 32107  Gastrostomy and parkinsonism: a retrospective study of indication and outcomes
C. Marois, M.D.M. Amador, C. Payan, L. Lacomblez, V. Mesnage, D. Grabli | PARIS, FRANCE

P 32108  Patient satisfaction with botulinum toxin for the treatment of cervical dystonia – a survey among patients in Spain
M.J. Martí Domenech, M.J. Catalán | BARCELONA, MADRID, SPAIN

P 32109  Abstract cancelled

P 32110  Abstract cancelled

P 32111  Intrusive thoughts as non-motor off symptoms of Parkinson’s disease: a case report
S. Medic, D. Kuljic Obradovic | BELGRADE, SERBIA

P 32112  Hereditary atypical parkinsonism with novel mutation of the VPS35 and FBXO7 genes

P 32113  Delayed improvement after spinal tap test in normal pressure hydrocephalus – evidence from a serial gait analysis experiment

P 32114  Evaluation of symptomatic efficacy and safety of RASAGILINE (Azilect®) in Parkinson’s disease patients with wearing-off/end-of-dose akinesia using wearing-off-questionnaire-32 (WOQ-32) in daily routine
U. Faude, D. Fendji, B. Mollenhauer | BERLIN, KASSEL, GERMANY

P 32115  Comparison of posterior striatal cholinergic interneurones in progressive supranuclear palsy, Alzheimer’s disease and Lewy body dementia
B. Muinjonov, E. Gyiayditinova, G. Rakhimbayeva | TASHKENT, UZBEKISTAN

P 32116  Comparison of prognostic factors in progressive supranuclear palsy and frontotemporal dementia (Uzbeki trial)
B. Muinjonov, E. Gyiayditinova, G. Rakhimbayeva | TASHKENT, UZBEKISTAN

P 32117  Prevalence, clinical features and MRI correlation of poststroke movement disorders
L. Mumladze, N. Lobjanidze, N. Akashvili | TBILISI, GEORGIA

P 32118  The features and frequency of motor and non-motor symptoms in patient with Parkinson’s disease in Siberian region, Russia
M. A. Nikitina, I. A. Zhukova, V. M. Alfirova, N. G. Zhukova, O. P. Izboldina, J. S. Mironova, M. A. Titova, A. V. Latypova, N. G. Brazovskaya, S. E. Sukhanov | TOMSK, RUSSIAN FEDERATION

POSTER SESSION
MOVEMENT DISORDERS 9
13:30-14:15 | SCREEN E3
CHAIRPERSON:
Anna Sauerbier, LONDON, UK

P 32119  Comparative cross-sectional survey of Parkinson’s non-motor symptoms in UK white Caucasian and Malaysian Chinese patients

P 32120  The applause sign in frontotemporal lobar degeneration and related conditions

P 32121  Abstract cancelled

P 32122  Demography and clinical profile among Parkinson Disease patients in Egypt: data of 374 cases
H. Shehata, N. Shalaby, A. Abdelalim, A. Elmazny | CAIRO, EGYPT
**MONDAY, 30 MAY**

**13:30-14:15**

**POSTER SESSIONS**

**MS AND RELATED DISORDERS 14**

**13:30-14:15 | SCREEN F1**

**Chairperson:**

Nicholas Gutowski, Exeter, UK

---

**P 32123** Differences in MDS-UPDRS scores based on Hoehn and Yahr stage and disease duration: results of a large international multicenter study of 3206 patients (the QUALPD study)

M. Škorvánek¹, P. Martinez-Martín², N. Kovacs³, I. Zezula¹, M. Rodriguez-Violante¹, J.-C. Corvol⁴, P. Tabo⁴, K. Seppi⁴, O. Levin⁸, A. Schrag⁸, T. Foltynie⁶, V. Han¹, C. Goetz¹⁰

¹KOSICE, SLOVAKIA, ²MADRID, SPAIN, ³PECS, HUNGARY, ⁴MEXICO DF, MEXICO, ⁵PARIS, FRANCE, ⁶TARTU, ESTONIA, ⁷INNSBRUCK, AUSTRIA, ⁸MOSCOW, RUSSIAN FEDERATION, ⁹LONDON, UK, ¹⁰CHICAGO, USA

---

**P 32124** Multiple system atrophy (MSA) phenotype associated with frontotemporal lobar degeneration (FTLD)-TDP pathology

A.L. Sousa, R. Taipa, M. Melo Pires, M. Magalhães

PORTO, PORTUGAL

---

**P 32125** MicroRNA in CSF and plasma as diagnostic biomarkers in Parkinson’s disease and multiple system atrophy

C. Starhof, A.-M. Hejl, N. Heegaard, K. Winge

COPENHAGEN, DENMARK

---

**P 32126** Adherence to pharmacotherapy in Parkinson’s disease patients who take 3 and more daily doses of dopaminergic medication

I. Straka¹, M. Škorvánek², P. Valkovic¹

¹BRATISLAVA, ²KOSICE, SLOVAKIA

---

**P 32127** Determinants of disability and quality of life in mild to moderate Parkinson’s disease

N. Subasic, E. Suljic, D. Imamovic, S. Hajric, Z. Ajanovic, A. Mehicic

SARAJEVO, BOSNIA AND HERZEGOVINA

---

**P 32128** Abstract cancelled

---

**P 32129** Objective olfactory testing and self-assessment of olfactory function in patients with Parkinson’s disease

M. Titova, O. Izhboldina, J.S. Mironova, I.A. Zhukova, N. Zhukova, M. Nikitova, V. Alifirova

TOMSK, RUSSIAN FEDERATION

---

**P 32130** Abstract cancelled

---

**P 32131** Prospective study of disease progression in atypical form of pantothenate-kinase-associated neurodegeneration (PKAN)

A. Tomić, I. Petrović, M. Svetel, V. Dobricic, N. Dragasevic Miskovic, V. Kostić

BELGRADE, SERBIA
Efficacy and safety outcomes in Vitamin D supplement users in Fingolimod FREEDOMS trials
1TURKU, FINLAND, 2BASEL, SWITZERLAND, 3EAST HANOVER, USA

Abstract cancelled

The healthcare utilisation and cost of prolonged-release fampridine without disease-modifying therapies in patients with multiple sclerosis throughout Germany during 2011–2013
M.-Y. Huang, C. Prosser, P. Landsman-Blumberg, J. Haas, S. Braun, E. Gleissner, T. Ziemssen
1PALM HARBOR, USA, 2HANOVER, 3HISMANING, 4DRESDEN, GERMANY

Optical coherence tomography reflectance as a novel biomarker of retinal axonal damage in a preclinical model of multiple sclerosis
S.-C. Huang, V. Castoldi, R. Santangelo, S. Marenna, S. Maestroni, L. Chaabane, G. Zerbini, P. Rama, G. Comi, L. Leocani
1MILAN, ITALY

Treatment-naive patients with active relapsing-remitting multiple sclerosis demonstrate improved quality of life over 5 years with alemtuzumab related to disability improvement: CARE-MS I extension study
R.M. Hupperts, P. Vermersch, D.H. Margolin, K. Thangavelu, R. Arroyo Gonzalez
1SITTARD, NETHERLANDS, 2LILLE, FRANCE, 3CAMBRIDGE, USA

Can the motor disability level related to multiple sclerosis be measured from the French health insurance database?
J. Roux, O. Grimaud, E. Leray
1RENNES, FRANCE

Rebound of multiple sclerosis activity during pregnancy after fingolimid withdrawal
A. Ruq, N. Solà Valls, M. Sepulveda, Y. Blanco, S. Llufriu, A. Saiz
1BARCELONA, SPAIN

Tracing premotor–motor connectivity during the phase of motor preparation in MS patients
1CAGLIARI, 2NAPLES, ITALY, 3COPENHAGEN, DENMARK, 4GRENOBLE, FRANCE

Relation between gender and depression in multiple sclerosis patients
S. Sabanagic-Hajric, E. Suljic, N. Subasic
1SARAJEVO, BOSNIA AND HERZEGOVINA

Reasons for subcutaneous interferon beta-1a three times a week discontinuation among patients with multiple sclerosis: a real-world retrospective cohort study
M. Sabidó-Espin, R. Munschauer
1DARMSTADT, GERMANY, 2ROCKLAND, USA

The brief international cognitive assessment for multiple sclerosis (BICAMS) for the evaluation of the EDSS cerebral functional score
F. Socca, T. Costabile, A.M. Barbarulo, A. Carotenuto, S. Casertano, R. Lanzillo, M. Moccia, C. Pane, F. Rossi, C.V. Russo, E. Signoriello, G. Lus, V. Brescia Morra
1NAPLES, ITALY

Balo’s concentric sclerosis with a benign course
J. Sanchez Ortuño, A. Sanz Monllor, N. Garcia Lax, J.A. Motos Garcia, M. Palao Rico, M.L. Martinez Navarro
1MURCIA, SPAIN

The long-term impact of natalizumab on multiple sclerosis: to continue or to stop?
F. Sangalli, L. Moiola, M. Radaelli, L. Ferre, F. Esposito, B. Colombo, V. Martinelli, G. Comi
1MILAN, ITALY

Acute disseminated encephalomyelitis: a 14 years review
1MURCIA, SPAIN

Uncommon side effects of glatiramer acetate
1MURCIA, SPAIN

Treatment-naive patients with active relapsing-remitting multiple sclerosis at baseline demonstrate slowing of brain volume loss with alemtuzumab: 5-year outcomes from the CARE-MS I extension study
1ZURICH, SWITZERLAND, 2BARCELONA, SPAIN, 3LONDON, UK, 4MONTREAL, 5VANCOUVER, CANADA, 6CAMBRIDGE, USA, 7MILAN, ITALY

Effect of lipoic acid on oxidative stress in multiple sclerosis patients: a double blind randomised clinical trial
F. Seifar, M. Khalili, A. Azimi
1TABRIZ, 2TEHRAN, IRAN, ISLAMIC REPUBLIC OF
P32157 Serum exosomal microRNA profiling reveals new biomarkers of MS
I. Selmaj, M. Namiecsinska, M. Cichalewska, K. Selmaj, M. Mycko I LODZ, POLAND

P32158 Cerebrospinal fluid neurofilament light chain protein correlates with magnetic resonance imaging markers of inflammation in patients with a first demyelinating episode

P32159 Novel GYG1 mutation causing late-onset polyglucosan body myopathy with nemaline rods
G. Tasca 1, F. Fattori 1, M. Monforte 1, C. Hedberg-Oldfors 2, M. Sabatelli 1, B. Udd 1, E. Bertini 1, E. Ricci 1, A. Oldfors 2 I 1ROME, ITALY, 2GOTHENBURG, SWEDEN

P32160 Myopathy following the treatment of mesalazine: a case report
A. Çetiz, H. Akgün, S. Tasdemir, O. Oz, U.H. Ulas, S. Demirkaya I ANKARA, TURKEY

P32161 Abstract cancelled

P32162 Rigid spine syndrome: a rare subtype of muscular dystrophy: a case report
A. Çetiz, U.H. Ulas, O. Oz, M. Yücel, S. Demirkaya I ANKARA, TURKEY

P32163 Screening of Pompe disease in South Hungary
E.T. Varga, L. Vécei I SZEGED, HUNGARY

P32164 Stiff Person Syndrome: a female case report with focal onset and multiple limb involvement
S. Var, A. Barros, A. Calado, J. Sequeira, D. Melancia, A. Fernandes I LISBON, PORTUGAL

P32165 Congenital myasthenic syndromes - our experience

P32166 Motor weakness and functional disability in patients with myasthenia gravis: a population based study
L. Vinge, J. Jakobsen, H. Andersen I AARHUS, DENMARK

P32167 Myotonic dystrophy type 2 significantly affects quality of life
M. Vujnic 1, S.Z. Peric 2, T. Paunovic 2, J. Pesovic 2, M. Perić 2, D. Lavrnic 2, D. Savic-Pavicnović 2, V. Rakovec Stojanovic 2 I 1BANJA LUKA, 2BELGRADE, SERBIA

P32168 Perifascicular distribution of glycogen in juvenile dermatomyositis
S. Xirou, G. Papadimas I ATHENS, GREECE

P32169 Demographic, clinical, and electrophysiologic features in patients with myasthenia gravis: case series study
M. Yücel 1, O. Oz 2, S. Tasdemir 2, H. Akgün 3, Ü.H. Ulas 3, S. Demirkaya 3 I 1ISTANBUL, 2ANKARA, TURKEY

P32170 Hormonal response to bimagrumab: a randomised, placebo-controlled study in healthy older men and women
M. Zakaria 1, A. He 1, Y. Li 1, P. Pinot 2, O. Petricoul 2, D. Laurent 3, D. Roos 1, R. Roubenoff 2 I CAMBRIDGE, USA, 4BASEL, SWITZERLAND

P32171 Immune-mediated necrotising myopathy – serious adverse effect of statin treatment
E. Zuponic, U. Rot, M. Meznaric, B. Karitnik I LJUBLJANA, SLOVENIA

P32172 Abstract cancelled

P32173 Hereditary coproporphyria due to a new mutation in the CPOX gene
Progressive neuronal degeneration in a patient with photosensitivity: a case of Xeroderma Pigmentosum of group A
M.A. Obadia, P. Reach, B. Law, B. Rohaut, J. Lamoril, M. Catala | PARIS, FRANCE

Are mutations in the GJB1 gene risk factor for multiple sclerosis?
B. Peterlin, T. Hojs Fabjan, M. Menih, G. Rudolf, A. Peterlin | LJUBLJANA, MARIBOR, SLOVENIA

Six generations of Frontotemporal Dementia linked to chromosome 3 (FTD-3): demographics of the Danish CHMP2B family

The role of ApoE gene polymorphism and vascular risk factors in the susceptibility to early and late Alzheimer’s disease in an Iranian population
S. Samadzadeh, R. Abofzaei, A. Shakeri, T. Sabokbar | TEHRAN, ISLAMIC REPUBLIC OF IRAN

New mutation in hereditary spastic paraplegia in Murcia
I. Sanchez Ortuño, A. Sanz Monllor, N. García Lax, J.A. Motos Garcia, M. Palao Rico, J.A. Iniesta Valera | MURCIA, SPAIN

Late-onset Alexander disease: a novel mutation
D. Sangalli, A. Ciammola, C. Morelli, A. Moroni, I. Ceccherini, F. Girotti, V. Silani | MILAN, GENOA, ITALY

Ataxia-neuropathy with cognitive decline due to a novel mutation in MTCOII, a subunit of mitochondrial complex IV
J. Schäfer, S. Jackson | DRESDEN, GERMANY

Diagnostic accuracy of laboratory tests and muscle biopsy in patients with genetically confirmed mitochondrial disease
S. Schreglmann, P. Johannsen, L. Hoffelner, V.M. Mihaylova, M. Auers, G. Kagi, A. Schaller, H. Jung | LONDON, ZURICH, ST. GALLEN, BERN, SWITZERLAND

Phenotypic features of GDAP1 mutations in Tunisian Charcot-Marie-Tooth patients
I. Kacem, A. Gargouri Berrechid, Y. Sidiham, A. Nasri, M. Ben Djebara, É. Leguern, R. Gouder | TUNIS, TUNISIA, PARIS, FRANCE

Expression changes of genes associated with apoptosis and survival processes in Parkinson’s disease

mtDNA alterations and autism associated nuclear gene variants in the background of autism spectrum disorder
N. A. Varq, K. Pentélényi, P. Balicza, V. Reményi, V. Hárásfalvi, R. Bencsis, A. Illés, C. Prekop, M.J. Molnar | BUDAPEST, HUNGARY

A comprehensive assessment of cervical cord lesions in patients with multiple sclerosis on T1-MPRAGE at 3T: relationship with cordatrophy and disability
M.A. Rocca, P. Valsasina, P. Preziosa, M. Aboulwafa, M. Horsfield, G. Comi, A. Falini, M. Filippetti | MILAN, ITALY, LEICESTER, UK

Superficial siderozis: a case report
F.D. Örken, E. Timer, S. Mumcu, M. Korkmaz, Z. Tanriverdi, B. Aydin Islamoglu | ISTANBUL, TURKEY

A case of spontaneous bilateral dissecting aneurysms of the internal carotid arteries
T. Parvu, C.I. Coclitu, O. Rusu, A. Ciobotaru, A.C. Mergeani, O. Bajenaru, F. Antochi | BUCHAREST, ROMANIA

Correlation between brain MRI and anosognosia
E. Pinzan, C. Angelini, F. Bevilacqua, E. Tsuchiya, S. Baldanzi, G. Siciliano, V. Pegoraro | VENICE, LIDO VENICE, PISA, ITALY

Patterns of regional gray matter and white matter atrophy progression contributing to clinical deterioration in MS: a 5-year tensor-based morphometry study
P. Preziosa, M.A. Rocca, E. Pagani, S. Mesaros, J. Drulovic, M. Filippetti | MILAN, ITALY, BELGRADE, SERBIA

Asymmetric reversible restricted diffusion in hyperammonemic encephalopathy: a case report
N. Randhawa, J. Chew, J. Shewchuk, H. Nygaard | VANCOUVER, CANADA

Altered corticostral connectivity in Parkinson’s disease is related to cognitive impairment
L. Rektorova, L. Anderkova, M. Barton | BRNO, CZECH REPUBLIC

Cerebral aneurysm causing a rare condition: superficial siderosis of the central nervous system
I. Sanchez Ortuño, A. Sanz Monllor, N. García Lax, J.A. Motos Garcia, M. Palao Rico, M.L. Martinez Navarro | MURCIA, SPAIN
POSTER SESSIONS
MONDAY, 30 MAY
13:30 - 14:15

P 32193  Imaging of nuclear Overhauser enhancement in human brain tumor at 3 Tesla

P 32194  Transcranial sonography of the insula: digitised image analysis of fusion images with magnetic resonance
D. Skoloudik1, P. Bartova1, J. Maskova2, P. Dusek2, J. Blahuta3, K. Langova3, U. Walter3, R. Herzig3  I OSTRAVA, 1PRAGUE, 2OLOMOUC, 3HRADEC KRÁLOVÉ, CZECH REPUBLIC, 4ROSTOCK, GERMANY

P 32195  A semi-automatic method for multiple sclerosis lesion segmentation on dual-echo magnetic resonance images: application in a multicenter context
L. Storelli1, E. Pagani1, M. A. Rocca1, P. Preziosa1, A. Gallo2, G. Tedeschi2, N. de Stefano2, H. Vrenken4, D. Thomas5, L. Mancini5, C. Enzinger6, F. Fazekas6, M. Filippi1  I 1MILAN, 2NAPLES, 3SIENNA, ITALY, 4AMSTERDAM, NETHERLANDS, 5LONDON, UK, 6GRAZ, AUSTRIA

P 32196  Optic neuritis imaging: changes in size and signal of the optic nerve over time in multiple sclerosis patients
M. Tradi1, A. Abanou2, L. Hughes3  I LEVALLOIS-PERRET, PARIS, FRANCE, 2READING, UK

P 32199  Therapeutic target of memory b-cells depletion helps to tailor administration frequency of Rituximab in neuromyelitis optica spectrum disorders patients.
G. Romero1, J. Bas2, M. Cohen1, M. Ticchioni1, J. Pelletier2, B. Audoin1, C. Lebrun-Frenay1  I NICE, MARSEILLES, FRANCE

P 32200  In-vitro catecholamines mimics stroke induced inhibition of neutrophil extracellular traps formation
J. Ruhnau, L. Blümke, C. Lange, A. Dressel, A. Vogelgesang  I GREFSWALD, GERMANY

P 32201  Are CSF protein levels and plasma neutrophil/lymphocyte ratio associated with prognosis of Guillain-Barré syndrome?
S. Sahin, N. Çınar, S. Karsidag  I ISTANBUL, TURKEY

P 32202  New biomarkers in the diagnosis of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
M. Sialitski, V. Ponomarev, H. Ivanchyk  I MINSK, BELARUS

P 32203  European AIDS clinical society screening questions don’t predict nor exclude HIV-associated neurocognitive disorders: a NAMACO study (Neurocognitive Assessment of the Metabolic and Aging Cohort)

P 32204  Paraneoplastic ataxia associated to anti CV2 antibodies in an alcoholic patient: a diagnostic challenge
T. Kalantzakou, O. Sinani, G. Xiromerisiou, V. Paraskevopoulou, K. Katsiaridaris, T. Bourinaris, A. Tychalas, E. Koutlas, G. Deretzi  I THESSALONIKI, GREECE

P 32205  Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up

P 32206  Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis and neuropsychiatric autoimmune encephalopathy
M. Suzuki, H. Kato, T. Ohashi  I CHIBA, JAPAN

P 32207  Limbic Encephalitis Associated with Sjögrens Syndrome: report of three cases
R. Turkoglu, S. Ozyurt, E. Tuzun  I ISTANBUL, TURKEY

P 32208  Presumed tuberculous meningitis relapsing after steroid reduction: a case of AMPA receptor antibody-associated encephalitis
H. van Den Tooren, M. Maskery, C. Kobylecki, N. Rathod, S. Srinivapura, D. McKee  I MANCHESTER, UK
**P 32209** Therapeutic challenges of stiff person syndrome: a case report
E.T. Varga1, T. Györgyi Md2, L. Vécsei1 I 1SZEGED, 2BUDAPEST, HUNGARY

**P 32210** Abstract cancelled

**P 32211** Characterising the impact of teriflunomide on the CD4+ T-cell repertoire of patients with relapsing-remitting MS in the Teri-DYNAMIC study
H. Wiendl1, C.C. Gross1, M. Lindner1, M. Eschborn1, L. Weisser1, A. Posevitz-Fejfar1, A. Schulte-Mecklenbeck1, B. van Wijmeersch2, S. Brette3, T.J. Turner5, A. Jagerschmidt4, A. Bar-or6, R. Hupperts7, L. Klotz1 I 1MÜNSTER, GERMANY, 2HASSELT, BELGIUM, 3BOULOGNE-BILLANCOURT, 4CHILLY-MAZARIN, FRANCE, 5CAMBRIDGE, USA, 6MONTREAL, CANADA, 7MAASTRICHT, NETHERLANDS

**POSTER SESSION**
**NEUROLOGICAL MANIFESTATIONS OF SYSTEMIC DISEASES 3**
**13:30-14:15 | SCREEN B3**
**CHAIRPERSON:** Eduardo Nobile-Orazio, MILAN, ITALY

**P 32212** Rapidly progressive dementia and orofacial dyskinesia: neurosyphilis and “Candy Sign”?
J.P. Marto, C. Borbinha, T. Lampreia, L. Alves, M. Viana-Baptista I LISBON, PORTUGAL

**P 32213** Health-related quality of life of nursing student’s with or without premenstrual syndrome
A. Ozkan1, G. Tannverdi1, Y. Ozenli1, C. Bakar1, H.I. Ozisk Karaman1 I CANAKKALE, 2ADANA, TURKEY

**P 32214** The importance of thermal threshold testing in detecting of small fiber neuropathy in Type 1 diabetes mellitus
V. Potockova, R. Mazanec, A. Tomek I PRAGUE, CZECH REPUBLIC

**P 32215** Ophthalmoparesis and temporal arteritis: double trouble
I. Rosario Marques1, F. Antunes1, M.D. Grunho, A. Ribeiro I ALMADA, PORTUGAL

**P 32216** Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) with extensive neurologic involvement and neutrophilia
E. Sechi, A. Addis, R. Piredda, A. L. Rassu, C. Fois, L. Batzu, G. Sechi I SASSARI, ITALY

**P 32217** Isolated central nervous system vasculitis caused by Whipple’s disease
D. Sisak1, C. Hornyák1, I. Balogh1, A. Muter1, A. Iljicsov1, G. Várallyay1, I. Zsigmondi1, P. Lakatos1, L. Sipos1, E. Turányi1, D. Berezckii1, T. Kovács1 I 1BUDAPEST, 2DEBRECEN, HUNGARY, 3BERLIN, GERMANY

**P 32218** Rare case of deep cerebral hemorrhage and atrial fibrillation in a patient with Fabry’s disease
E.A. Solomon, D. Anghel, A. Gitman, M. Marian I BUCHAREST, ROMANIA

**P 32219** ANCA positive vasculitis disguised as a recurrent stroke due to vertebral artery dissection
A. Toth, G. Rudas, E. Kiss, D. Berezcki, I. Sipos I BUDAPEST, HUNGARY

**P 32220** The neurologist and the gastroenterologist – inpatient neurological consultation in the gastroenterology and hepatology department
P. Viana, P. Santos, L. Guedes, A.I. Verdelho, J.G.D.B.C. Pimentel, J.M.M.C. Ferro I LISBON, PORTUGAL

**P 32221** Ataxia as a presentation feature of Neurosarcoid
S. Vijayarangan Shanmugam, A. Al-Memar I LONDON, UK

**POSTER SESSION**
**NEUROLOGY AND ARTS; HISTORY OF NEUROLOGY; ETHICS IN NEUROLOGY; EDUCATION IN NEUROLOGY;**
**13:30-14:15 | ROOM: E2**
**CHAIRPERSON:** Jan Kuks, GRONINGEN, THE NETHERLANDS

**P 32222** Hazardous effects of nonnatural life on visual pathways: a biophysical experimental study
A. Aydin1, A. Aydin1, N. Gursan2 I ISTANBUL, 2ERZURUM, 3SAKARYA, TURKEY

**P 32223** Abstract cancelled

**P 32224** Neurology: an introductory course for neurology residents

**P 32225** The neuro-ethics of the logical speech and the ethics of reality in the psychoneuroanalytical model
G. Dore1, M. D’onofrio2 I ITTIRI, 2SASSARI, ITALY
MONDAY, 30 MAY

13:30 - 14:15

**POSTER SESSIONS**

**NEURO-OPHTHALMOLOGY/ NEUROTOLGY 4**

13:30-14:15 | SCREEN H1

**CHAIRPERSON:**
Christopher Kennard, OXFORD, UK

P 32237  Bilateral optic disc swelling: not always papilledema: a case report
J. Perez Lucas, M. Baez, M. Fernandez-Fournier Ferna | MADRID, SPAIN

P 32238  Anterior ischemic optic neuropathy and hematological malignancy: a systematic review of case-reports and case-series
F. Rodrigues, D. Sousa, G. Duarte, F. Campos, F. Pinto | LISBON, PORTUGAL

P 32239  Visual system involvement in cerebrotendinous xanthomatosis: the role of dentate nucleus on eye movement control
F. Rosini1, E. Pretegiani2, A. Mignarri1, G. Tumminelli1, A. Federico1, L. Optican2, M.T. Dotti1, A. Rufa1 | SIENNA, ITALY, *BETHESDA, USA

P 32240  Situational factors of fear of falling in vertigo and balance disorders
C. Schlick, R. Schniepp, K. Jahn | MUNICH, GERMANY

P 32241  Abstract cancelled

P 32242  Development of an algorithm for the differential diagnosis of oculomotor abnormalities
M. Strupp1, S.A. Kolb2 | MUNICH, GERMANY, *ALLSCHWIL, SWITZERLAND

P 32243  The benefit of optical coherence tomography and visual evoked potentials in optic neuritis: a pilot study
T. Svrčinová, J. Mares, V. Sládкова, M. Šín, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

P 32244  Tolosa-Hunt syndrome: the recurrence is not always on the same side
H. Tifar, W. Regragui, E. Ait Ben Haddou, A. Benomar, M. Yahyaoui | RABAT, MOROCCO

P 32245  The role of the cerebellum in the antisaccade performance: insights from Spinocerebellar Ataxia Type 2 (SCA2) and Late Onset Cerebellar Ataxia (LOCA)
G. Tumminelli1, F. Rosini1, P. Piu1, E. Pretegiani1, A. Federico1, A. Rufa1 | SIENNA, ITALY, *BETHESDA, USA

---

**P 32226**  Neurological training for fellows in Germany – from a chief physician’s point of view
C. Franke1, H. Hellriegel2, A.-S. Biesalski3, R. Kiefer4 | BERLIN,
KIEL, WUPPERTAL, ROTENBURG, GERMANY

**P 32227**  Mozart’s plausible neurological disorders
C. Gardner-Thorpe | EXETER, UK

**P 32228**  Mapping the clinical translation of successful and unsuccessful neurological drugs
A. Hakala, J. Kimmelman | MONTREAL, CANADA

**P 32229**  Quality of stroke patient information – a systematic review
A.C. Kruetzelmann1, S. Koepke2, A.C. Rahn1, G. Thomalla1, C. Heesen1 | HAMBURG, LÜBECK, GERMANY

**P 32230**  Possible descriptions of stroke and some other neurological disorders with sudden onset in Greek mythology and in the Bible and their presentation in art
M. Klarendic, B. Podlipnik | LJUBLJANA, SLOVENIA

**P 32231**  Neural trophic and Determinant Structures in CNS pathology. Alexey Speransky and Georgy Kryzhanovsky – Contribution to theoretical basis of modern neurology
D. Labunskiy | SANTA ROSA CA, USA

**P 32232**  Patient and student attitudes to clinical demonstrations – is it time we stopped ‘protecting’ our patients?
J. Mistry, F. Schon, H. Cock | LONDON, UK

**P 32233**  Knowledge gap about neurology in Uganda lags behind children with learning disabilities in education
J. Nakibirango | KAMPALA, UGANDA

**P 32234**  Do we agree on the content of the screening neurological exam?
E. Ruzicka, P. Marusic | PRAGUE, CZECH REPUBLIC

**P 32235**  Oliver Sacks, “Awakenings” to neurology? A 2015 survey among french neurologists
H. Doudoux, L. Vercueil | GRENOBLE, FRANCE

**P 32236**  William Warrington (1869-1919): GBS before G, B, and S?
B. Ziso, A. Larner | LIVERPOOL, UK

---

**P 32237**  Bilateral optic disc swelling: not always papilledema: a case report
J. Perez Lucas, M. Baez, M. Fernandez-Fournier Ferna | MADRID, SPAIN

**P 32238**  Anterior ischemic optic neuropathy and hematological malignancy: a systematic review of case-reports and case-series
F. Rodrigues, D. Sousa, G. Duarte, F. Campos, F. Pinto | LISBON, PORTUGAL

**P 32239**  Visual system involvement in cerebrotendinous xanthomatosis: the role of dentate nucleus on eye movement control
F. Rosini1, E. Pretegiani2, A. Mignarri1, G. Tumminelli1, A. Federico1, L. Optican2, M.T. Dotti1, A. Rufa1 | SIENNA, ITALY, *BETHESDA, USA

**P 32240**  Situational factors of fear of falling in vertigo and balance disorders
C. Schlick, R. Schniepp, K. Jahn | MUNICH, GERMANY

**P 32241**  Abstract cancelled

**P 32242**  Development of an algorithm for the differential diagnosis of oculomotor abnormalities
M. Strupp1, S.A. Kolb2 | MUNICH, GERMANY, *ALLSCHWIL, SWITZERLAND

**P 32243**  The benefit of optical coherence tomography and visual evoked potentials in optic neuritis: a pilot study
T. Svrčinová, J. Mares, V. Sládкова, M. Šín, P. Kanovsky | OLOMOUC, CZECH REPUBLIC

**P 32244**  Tolosa-Hunt syndrome: the recurrence is not always on the same side
H. Tifar, W. Regragui, E. Ait Ben Haddou, A. Benomar, M. Yahyaoui | RABAT, MOROCCO

**P 32245**  The role of the cerebellum in the antisaccade performance: insights from Spinocerebellar Ataxia Type 2 (SCA2) and Late Onset Cerebellar Ataxia (LOCA)
G. Tumminelli1, F. Rosini1, P. Piu1, E. Pretegiani1, A. Federico1, A. Rufa1 | SIENNA, ITALY, *BETHESDA, USA
P 32246  Stochastic resonance in the vestibular system
M. Wuehr, J. Boerner, J. Decker, C. Pradhan, R. Schniepp I MUNICH, GERMANY

P 32247  Dopamine preserves visual motion perception despite noise interference of human V5/MT
N. Yousif, R. Fu, B. Abou-El-Ela-Bourquin, V. Bhrugubanda, S. Schultz, B.M. Seemungal I LONDON, UK

POSTER SESSION
PERIPHERAL NERVE DISORDERS 6
13:30-14:15 | SCREEN D2
CHAIRPERSON:
Nazha Birouk, RABAT, MOROCCO

P 32248  Chronic inflammatory demyelinating polyneuropathy - still a challenging diagnosis
D. Leupold, L. Schlig, A. Felbecker, D. Ziegglansberger, B. Tettenborn, T. Hundsberger I ST. GALLEN, SWITZERLAND

P 32249  Abstract cancelled

P 32250  Abstract cancelled

P 32251  Trauma and Guillain–Barré syndrome
C. Machado, J.N. Alves, A.F. Santos, J. Pinho, R.J.P. Maré, C. Ferreira I BRAGA, PORTUGAL

P 32252  Subcutaneous versus intravenous immunoglobulin in drug-naive patients with chronic inflammatory demyelinating polyneuropathy (CIDP) – a randomised, single-blind, cross-over trial
L.H. Markvardsen, S.H. Sindrup, I. Christiansen, J. Jakobsen, H. Andersen I AARHUS, ODENSE, COPENHAGEN, DENMARK

P 32253  Aerobic capacity and muscle strength are improved following aerobic and resistance exercise in patients treated with subcutaneous immunoglobulin for CIDP
L.H. Markvardsen, K. Overgaard, K. Heje, S.H. Sindrup, I. Christiansen, J. Vissing, H. Andersen I AARHUS, ODENSE, COPENHAGEN, DENMARK

P 32254  Nerve lesions can be detected by diffusion tensor imaging in patients with CIDP treated with subcutaneous immunoglobulin
L.H. Markvardsen, M. Vaeggemose, H. Andersen I AARHUS, DENMARK

P 32255  The de-novo mutation p.R190W in the MORC2 gene cause severe axonal Charcot–Marie–Tooth disease in Czech a patient
R. Mazanec1, P. Lassuthová1, M. Šafka-Brožková1, M. Krůtová1, S. Zuchner2, M. Gonzales2, V. Potockova1, P. Seeman1 I PRAGUE, CZECH REPUBLIC, MIAMI, USA

P 32256  Genetic epidemiology analysis of Cx32 gene mutations in Hungary
G.M. Milley1, A. Gaś1, E. Varga2, Z. Grosz1, Z. Aranyi1, J. Boczán2, B. Kalman1, M.J. Molnár1 I BUDAPEST, SZEGET, DEBRECEN, PECS, HUNGARY

P 32257  An axonal membrane excitability gradient could contribute to the length-dependent susceptibility to neuropathy
M. Moldovan1, R. Arnold2, M. Rosberg1, S. Alvarez1, R. Morris1, C. Krarup1 I COPENHAGEN, DENMARK, SYDNEY, AUSTRALIA

P 32258  Uncommon cluster of Guillain–Barré cases in northern Portugal – an outbreak?
S. Moreira, C. Santos, P. Grebe, J. Rofiz I SANTA MARIA DA FEIRA, PORTUGAL

P 32259  Late onset transthyretin familial amyloid polyneuropathy in Valencia, a non-endemic area
N. Muelas Gomez1, T. Sevilla1, M. Frasquet Carrera1, R. Sivera1, F. Mayordomo1, M.M. Cano Teuler1, R. Sánchez-Roy1, M.A. García-Quesada1, M. Garcés-Sánchez2, P. Martí Martinez1, I. Azorín1, C. Gomis1, L. Bataller1, J.F. Vázquez Costa1, M.R. Vilchez1, J.J. Vilchez1 I VALENCIA, GANDIA, ELCHE, SPAIN
Die Nervenheilkunde ist eine der bekanntesten Fort- und Weiterbildungsumschriften für Neurologen, Psychiater und Nervenärzte. Da bei psychischen Störungen Hausärzte fast immer die ersten Ansprechpartner sind und die Weichenstellung für eine kompetente fachärztliche Behandlung in ihren Händen liegt, wendet sich die Nervenheilkunde zugleich an Primärärzte.


* Unsere Abonnements sind Medien-Abonnements (Print + Digital), die Preise sind unverbindlich empfohlene Preise. Innerhalb Deutschlands inkl. der gesetzlich gültigen MwSt., im Ausland zzgl. der gesetzlich gültigen MwSt. | Deutschland und Europa inkl. Versandkosten | Versandkosten „Übersee“ auf Anfrage

Jährliche Bezugspreise*
Institute: € 340,–
Privatpersonen: € 192,–
Studierende: € 96,–
Einzelheft: € 32,–

Bestellen Sie jetzt!
Schattauer GmbH | Aboservice
Heuriedweg 19a | 88131 Lindau
Tel.: 01805 012562
E-Mail: aboservice@schattauer.de

www.nervenheilkunde-online.de
SYMPOSIUM 7: UNDERSTANDING FUNCTIONAL CONNECTIVITY USING MRI
08:00 - 10:00 | HALL M1

CHAIRPERSONS:
Massimo Filippi, MILAN, ITALY
Ludwig Kappos, BASEL, SWITZERLAND

Brain functional connectivity assessed using MRI: the basis
Bharat B. Biswal, NEWARK, USA

Clinical applications in MS
Maria A. Rocca, MILAN, ITALY

Implications for clinical trial design and monitoring of drug efficacy
Till Sprenger, WIESBADEN, GERMANY

Scientific content: Functional connectivity is a useful research tool, and reliable analysis and methods have been developed. New disease insights are emerging in a variety of neurologic and psychiatric disorders, including multiple sclerosis. Though the acquisition and analysis methods are still evolving, meaningful data are emerging on the potential application of fMRI in trial design and monitoring treatment efficacy.

SYMPOSIUM 8: NEW DIAGNOSTIC DEVELOPMENTS IN EPILEPSY
08:00 - 10:00 | HALL M2

CHAIRPERSONS:
Paul Boon, GHENT, BELGIUM
Eric Taubøll, OSLO, NORWAY

Definitions and classification of seizures
Jukka Peltola, TAMPERE, FINLAND

Neurophysiological assessment of epilepsies
Paul Boon, GHENT, BELGIUM

3D multimodal imaging for epilepsy surgery
John Duncan, LONDON, UK

Genetic screening
Jose Serratosa, MADRID, SPAIN

Scientific content: This symposium will provide recent information on diagnostic definitions and techniques in epilepsy patients. The recently changed definition of epilepsy will be extensively explained, followed by state-of-the-art lectures on EEG, structural and functional imaging and genetic diagnostic procedures. The target audience is general neurologist who seek to expand their knowledge on up-to-date diagnostic procedures for epilepsy in daily practice.

SYMPOSIUM 9: UNTANGLING INFLAMMATORY AND DEGENERATIVE ASPECTS OF MULTIPLE SCLEROSIS
08:00 - 10:00 | HALL M3

CHAIRPERSONS:
Martin Kerschensteiner, MUNICH, GERMANY
Xavier Montalban, VALL D’HEBRON, SPAIN

Insights from MS pathology
Wolfgang Brück, GÖTTINGEN, GERMANY

Insights from experimental models
Martin Kerschensteiner, MUNICH, GERMANY

Insights from clinical imaging
Paul Matthews, LONDON, UK

Insights from therapeutic trials
Xavier Montalban, VALL D’HEBRON, SPAIN

Scientific content: In this symposium we want to highlight how inflammation and neurodegeneration contribute to the common neuroinflammatory disease multiple sclerosis (MS). In particular, we want to explore how inflammatory and degenerative disease mechanisms drive disease progression, how their inter-relation changes as the disease advances and how they can be best targeted therapeutically. For this purpose, we will summarize recent insights from the histopathological analysis of MS tissue, the in vivo analysis of experimental disease models, the advanced multi-modal imaging of MS patients and therapeutic trials in relapsing-remitting and progressive MS.

HANDS-ON COURSE 5: NERVE AND MUSCLE IMAGING FOR CLINICIANS
08:00 - 10:00 | HALL B5.M1

CHAIRPERSON:
Einar Wilder-Smith, SINGAPORE, SINGAPORE

Ultrasound in nerve entrapments
Einar Wilder-Smith, SINGAPORE, SINGAPORE

Ultrasound as a diagnostic tool to classify polyneuropathies
Leo Visser, TILBURG, THE NETHERLANDS

MRI imaging in myopathies
Bjarne Udd, TAMPERE, FINLAND
This course aims to introduce clinicians to understanding the role Nerve Ultrasound imaging plays in the diagnosis of entrapment neuropathies and polyneuropathies. Focus will be on the sonographic patterns (specific distribution of nerve enlargement) in different entrapments and polyneuropathies. A special focus will be how ultrasound can help to determine whether a polyneuropathy is demyelinating or axonal.

MRI imaging in myopathies will provide basic insight into typical patterns of muscle involvement in the different muscle diseases and address when to request muscle MRI to accelerate the diagnostic process, and optimize site for muscle biopsy.

This course is supported by Cadwell Industries, Inc.

CASE-BASED FACILITATED WORKSHOP 6: NEUROPSYCHOLOGICAL TESTING IN DEMENTIA FOR NON-NEUROPSYCHOLOGISTS
08:30 - 10:00 | HALL B4.M2

CHAIRPERSON
Ana Verdelho, LISBON, PORTUGAL

Global measures of cognition
Ana Verdelho, LISBON, PORTUGAL

Neuropsychological evaluation in demented patients
Florence Pasquier, LILLE, FRANCE

How non-psychiatrists can do a “psychiatric” bed-side evaluation
Elizabeta Mukaetova-Ladinska, NEWCASTLE UPON TYNE, UK

With the progressive ageing of population cognitive decline and dementia is becoming one of the most frequent challenges of health and neurological care. Recent advances lead to several ancillary investigations available to clarify the etiology of cognitive decline. Correct diagnosis and correct use of those investigations depends on the initial clinical diagnosis.

This case-based facilitated workshop is designed to improve the skills to make a cognitive evaluation more precise in the first approach to the patient. Three experts of the field will approach, in a very practical way, not only the neuropsychological procedures but also how to deal with the interview of a patient with cognitive decline.
SPECIAL SESSION 9:
SHARED DECISION MAKING IN NEUROLOGY
08:30 - 10:00 | HALL M5

CHAIRPERSON:
Christoph Heesen, HAMBURG, GERMANY

SDM as the concept for medicine of the 21st century – chances and challenges
Norbert Donner-Banzhoff, MARBURG, GERMANY

SDM in multiple sclerosis treatment decision making
Christoph Heesen, HAMBURG, GERMANY

SDM in Parkinson treatment choices
Frouke Nijhuis, NIJMEGEN, THE NETHERLANDS

SDM in stroke acute care and secondary prevention
Christopher McKevitt, LONDON, UK

Scientific content: Patient involvement in medical decision making is increasingly recognized especially in ageing societies with more chronic diseases with partially effective treatments. SDM is a concept based on exchange of information on different levels between a patient and a healthcare provider based on different competencies of both. As a prerequisite SDM needs evidence-based patient information for which defining a decision to be made and listing all options with their possible benefits and risks is necessary. Based on a SDM approach even a scientifically clear superior option might not the right one for a given patient. Therefore, SDM realizes individualized, preference sensitive medicine. While many medical decisions lack substantial controlled study evidence on one hand and a relevant number of patients might explicitly refrain from getting involved in medical decisions on the other there are a number of paradigmatic decisional issues in clinical neurology which could possibly be improved by structured SDM approaches. Examples are: early treatment of multiple sclerosis, anticoagulation in stroke, escalation and deescalation of antiepileptic drugs, deep brain stimulation for Parkinson’s disease but also everyday issues as PRT for radicular syndromes or medical treatment for tension type headache. While SDM study data show increased knowledge and enhanced self-efficacy, some data indicate also increased effectivity of health-care resources use. However, improved health outcomes have seldom been shown up to now.

Three aims will be pursued:
1. to give an overview of the current theoretical and methodological concepts in SDM such as the concept of complex interventions and evidence-based patient information, different study designs, interventions and outcomes.
2. to summarise the development stage in neurology focusing multiple sclerosis, Parkinson’s disease and stroke.
3. to develop a working group SDM in neurology with an educational but also research need and exchange agenda.

SPECIAL SESSION 10:
EAN RESIDENT AND RESEARCH FELLOW SECTION (RRFS): PROSPECTS FOR NEUROLOGISTS IN TRAINING IN THREE CORNERS OF EUROPE
08:30 - 10:00 | HALL B5.M2

CHAIRPERSON:
Peter Balicza, BUDAPEST, HUNGARY

Prospects for young neurologists in the Nordic countries
Daniel Kondziella, COPENHAGEN, DENMARK

Neurology education in Western Europe
Elena Moro, GRENOBLE, FRANCE

Neurology education in Central and Eastern Europe
Ildiko Szőcs, BUDAPEST, HUNGARY

Scientific content: The special session intends to shed light on strengths and weaknesses of neurology education in different parts of Europe, and identify common strategies to improve. Speakers will focus on neurology education from medical school through residency to consultant neurologist, and highlight the positions, opportunities, career prospects for neurologists in training, as well as drivers for mobility in their area.
PLENARY SYMPOSIUM 3: HIGHLIGHTS AND LATE BREAKING NEWS
10:30 - 12:30 | HALL M1

CHAIRPERSON:
Mads Ravnborg, COPENHAGEN, DENMARK

Faculty:
Steen Hasselbalch, COPENHAGEN, DENMARK
Finn Sellebjerg, COPENHAGEN, DENMARK
Arne Lindgren, LUND, SWEDEN
Erik Taubøll, OSLO, NORWAY

After the presentation of the Congress Highlights the winners of the Tournament Prizes will be announced and receive their certificates.
Closing words by Günther Deuschl, EAN President

TEACHING COURSE 18: LIFE AFTER STROKE – LEVEL 2
13:00 - 16:30 | HALL B1

CHAIRPERSON:
Natan Bornstein, TEL-AVIV, ISRAEL

Women issues
Valeria Caso, PERUGIA, ITALY

Motor deficits – their consequences and rehabilitation
Natan Bornstein, TEL-AVIV, ISRAEL

Cognitive and higher cortical disorders – how to help?
Dafin Muresanu, CLUJ-NAPOCA, ROMANIA

Pharmacological and non-pharmacological support beyond secondary prevention
Anna Członkowska, WARSAW, POLAND

Recent advances in acute stroke management and prevention have allowed to reduce the burden of stroke and reduce the incidence. Nevertheless, a vast majority of patients still require special attention and management due to their disability and specific issues like gender. This teaching course will focus on specific issues in the female patients like pregnancy and future administration of oral contraceptives and also hormone replacement therapy. Motor rehabilitation is crucial for reducing disability rates, although recently there is a lot of discussion due to the arrival of new RCTs questioning the intensity of rehabilitation and when to start.

Cognitive and higher cortical disorders are often underestimated in post-stroke patients, especially in those who otherwise recover in terms of motor function. Their assessment, screening and treatment is crucial for full recovery of patients. Recent data also show that patients may benefit from additional pharmacological and non-pharmacological support in rehabilitation. Because of many controversies on this topic an overview will be presented.

TEACHING COURSE 19: CHALLENGES IN NEWLY DIAGNOSED EPILEPSY – LEVEL 1
13:00 - 16:30 | HALL B2

CHAIRPERSON:
Antonio Gil-Nagel, MADRID, SPAIN

What is enough for the diagnosis for epilepsy?
Heather Angus-Leppan, LONDON, UK

How to estimate the prognosis and risks of newly diagnosed epilepsy?
Torbjörn Tomson, STOCKHOLM, SWEDEN

How to choose the first-line drug?
Antonio Gil-Nagel, MADRID, SPAIN

What to do, when the patient does not accept the diagnosis?
Bettina Schmitz, BERLIN, GERMANY

Patients with newly diagnosed epilepsy are entitled to a diagnosis, prognosis and management that are specific and precise. This TC updates knowledge of adequate diagnosis of epilepsies and epileptic syndromes and discusses about the prognoses and risks. The aim is also to give an overview of current treatment options and the decision-making process in selecting the optimal initial treatment for each patient. As in any other medical condition, acceptance of diagnosis is the first step in the therapeutic process. We will cover those challenging situations, when the patient needs the treatment, but is not able to accept the diagnosis or therapy.
The increasing use of MRI of the CNS by clinicians and researchers has raised the amount of incidental neuroimaging findings. The prevalence of incidental brain findings is higher when high resolution MRI sequences are used and, as expected, the chance of revealing pathologic findings is higher in old age individuals. The proportion of subjects who actually have neurological symptoms referable to apparently incidental brain findings is low. Many of the detected abnormalities are nonspecific in aetiology and are classified as unidentified bright objects. Vascular white matter hyperintensities, silent brain infarcts, inflammatory lesions, tumors and structural or vascular abnormalities are often identified incidentally. The course will offer practical skills to be applied in the interpretation of incidental neuroimaging findings, understanding their pathophysiology, and deciding whether further investigations and possible treatment are necessary.
EAN considers the production of neurological guidelines a major commitment, as this is a primary tool to improve clinical practice in neurology. This level 1 teaching course is the first within an EAN Congress and will overview the problems and challenges of developing guidelines. It is aimed both at clinicians who want to critically evaluate and use guidelines and at EAN members and specialist trainees who want to develop guidelines within the umbrella of our 31 Scientific Panels. A specific attention will be paid to the knowledge of the GRADE system (Grading of Recommendations, Assessment, Development and Evaluation) which aims to provide a homogeneous and transparent approach to the entire process of guideline creation.
NMDPD 2016
11th International Congress on Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders
Ljubljana, Slovenia | October 6-9, 2016
Submit Your Abstract
Abstract Submission Deadline: May 10, 2016
Early Registration Deadline: June 21, 2016
COMPANY SPONSORED PROGRAMME
We wish to express our gratitude to the following companies, who, through their generosity, have helped to make this congress possible.

PREMIUM SPONSOR

Roche  NOVARTIS PHARMACEUTICALS  SANOFI GENZYME

MAJOR SPONSOR

Bial  MERCK  TEVA Neuroscience

SPONSOR

ACTELION  ALEXION  BAYER  Bial Elsai  Biogen  Boston Scientific  Britannia Pharmaceuticals Ltd  CYNAPSUS  SCHWABE  From Nature. For Health.  Lilly  EVER PHARMA  octapharma®  Shire  Zambon  Medtronic Further, Together

CONTRIBUTOR

ABBVIE  NATUS neurology
### EXHIBITORS

**2016**

<table>
<thead>
<tr>
<th>NAME/TITLE</th>
<th>BOOTH NUMBER</th>
<th>NAME/TITLE</th>
<th>BOOTH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie Inc.</td>
<td>D16</td>
<td>EVER Pharma</td>
<td>C42</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals Ltd</td>
<td>B20</td>
<td>EXCEMED – Excellence in Medical Education</td>
<td>D33</td>
</tr>
<tr>
<td>Aequus Research</td>
<td>D34</td>
<td>F. Hoffmann-La Roche Ltd</td>
<td>A20</td>
</tr>
<tr>
<td>Alexion Pharmaceuticals, Inc.</td>
<td>D10</td>
<td>icometrix</td>
<td>C16</td>
</tr>
<tr>
<td>Allergan ApS</td>
<td>C18</td>
<td>Interacoustics</td>
<td>A48</td>
</tr>
<tr>
<td>American Academy of Neurology</td>
<td>D22</td>
<td>International Niemann-Pick Disease Alliance (INPDA)</td>
<td>D41</td>
</tr>
<tr>
<td>Autonomic Technologies GmbH</td>
<td>D43</td>
<td>International Parkinson and Movement</td>
<td></td>
</tr>
<tr>
<td>Bayer</td>
<td>C20</td>
<td>Disorder Society</td>
<td>C15</td>
</tr>
<tr>
<td>Bial &amp; Eisai Cooperation</td>
<td>D14</td>
<td>Karger Publishers</td>
<td>C35</td>
</tr>
<tr>
<td>Biogen</td>
<td>C01</td>
<td>Lifelines iEEG</td>
<td>B30</td>
</tr>
<tr>
<td>BioMarin Europe Ltd.</td>
<td>C03</td>
<td>MedDay pharmaceuticals</td>
<td>C44</td>
</tr>
<tr>
<td>Boston Scientific</td>
<td>C10</td>
<td>Medtronic Inc.</td>
<td>C12</td>
</tr>
<tr>
<td>Britannia Pharmaceuticals</td>
<td>C17</td>
<td>Merck</td>
<td>B10</td>
</tr>
<tr>
<td>BMJ</td>
<td>C32</td>
<td>Natus Europe GmbH</td>
<td>B38</td>
</tr>
<tr>
<td>Cadwell Industries, Inc.</td>
<td>C13</td>
<td>Netherlands Society of Neurology</td>
<td>D42</td>
</tr>
<tr>
<td>CeGaT GmbH</td>
<td>A46</td>
<td>Neuroelectrics</td>
<td>D32</td>
</tr>
<tr>
<td>Charité – Universitätsmedizin Berlin</td>
<td>C14</td>
<td>Neurionx</td>
<td>D44</td>
</tr>
<tr>
<td>CorTechs Labs</td>
<td>D40</td>
<td>Novartis Pharma AG</td>
<td>A01</td>
</tr>
<tr>
<td>DEYMED Diagnostic s.r.o.</td>
<td>C40</td>
<td>Octapharma AG</td>
<td>A40</td>
</tr>
<tr>
<td>Dystonia Europe</td>
<td>C30</td>
<td>*RRFS - Residents and research fellows section of the European Academy of</td>
<td></td>
</tr>
<tr>
<td>European Academy of Neurology Registration Area</td>
<td>EAN Booth</td>
<td>Neurology*</td>
<td>EAN Booth</td>
</tr>
<tr>
<td>ebrain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECNP</td>
<td>C31</td>
<td>Otometrics</td>
<td>D47</td>
</tr>
<tr>
<td>ECTRIMS</td>
<td>C36</td>
<td>Sanofi Genzyme</td>
<td>A10</td>
</tr>
<tr>
<td>Electrical Geodesics, Inc.</td>
<td>D30</td>
<td>Shire International GmbH</td>
<td>D20</td>
</tr>
<tr>
<td>Epilog</td>
<td>D26</td>
<td>Teva Pharmaceuticals Europe BV</td>
<td>A30</td>
</tr>
<tr>
<td>ESNCH (European Society of Neurosonology and Cerebral Hemodynamics)</td>
<td>C37</td>
<td>The Brain Prize</td>
<td>D28</td>
</tr>
<tr>
<td>European Brain Council</td>
<td>D46</td>
<td>The Lancet</td>
<td>B32</td>
</tr>
<tr>
<td>EFNA (European Federation of Neurological Associations)</td>
<td>D01</td>
<td>Turkish Neurological Society</td>
<td>D45</td>
</tr>
<tr>
<td>European Medical Journal</td>
<td>C33</td>
<td>Wisepress Ltd.</td>
<td>E01</td>
</tr>
<tr>
<td>European Pain Federation EFIC</td>
<td>C34</td>
<td>Wiley</td>
<td>A50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wolters Kluwer</td>
<td>D24</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zambon SpA</td>
<td>C08</td>
</tr>
</tbody>
</table>
Join us in Copenhagen to learn more about treating Parkinson's Disease!

**From OFF to ON – New approaches to the treatment of OFF episodes in Parkinson’s Disease**

Saturday, May 28th 2016  
1:00pm - 2:30pm | Hall M0

Chair – C Warren Olanow, MD

Levodopa Induced OFF Episodes – The Problem  
*Fabrizio Stocchi, MD*

Current Approaches to the Treatment of OFF Episodes  
*Anthony Schapira, MD*

Rescue Therapies - What’s in the Pipeline  
*C Warren Olanow, MD*

Panel Discussion

*Symposium Sponsored by Cynapsus Therapeutics Inc.*
97 % of dementia patients develop BPSD*

Dr. Willmar Schwabe Satellite Symposium:
»EGB 761® in Dementia«

Learn more about the prevalence, clinical importance and treatment of BPSD!
SATURDAY, 28 MAY

13:00 - 14:30

DR. WILLMAR SCHWABE

13:00 - 14:30 | HALL M1

EGb 761® in Dementia – from pre-clinic to clinic*

CHAIRPERSON:
Amos D. Korczyn, TEL AVIV, ISRAEL

"Neurotransmitters and EGb761 in cognitive dysfunction – recent findings"
Jan Kehr, UPPSALA, SWEDEN

"BPSD : prevalence, clinical importance and treatment options"
Armin von Gunten, LAUSANNE, SWITZERLAND

EXCEMED

13:00 - 14:30 | HALL B

Current and future treatments for MS

CHAIRPERSON:
Giancarlo Comi, MILAN, ITALY
Mark Freedman, OTTAWA, CANADA
Per Soelberg Sørensen, COPENHAGEN, DENMARK

Immunology of MS: classical theories and new insights
Tjalf Ziemssen, DRESDEN, GERMANY

From immunology to treatment: current and future therapeutic strategies
Alexandre Prat, MONTREAL, CANADA

From treatments to side effects: preventing and managing risks
Celia Oreja-Guevara, MADRID, SPAIN

Concluding remarks
Giancarlo Comi, MILAN, ITALY
Mark Freedman, OTTAWA, CANADA
Per Soelberg Sørensen, COPENHAGEN, DENMARK

CYNAPSUS

13:00 - 14:30 | HALL M0

From OFF to ON – New approaches to the treatment of OFF episodes in Parkinson’s disease

CHAIRPERSON:
C. Warren Olanow, NEW YORK, NY, USA

Levodopa-induced OFF episodes – the problem
Fabrizio Stocchi, ROME, ITALY

Current approaches to the treatment of OFF episodes
Anthony Schapira, LONDON, UNITED KINGDOM

Rescue therapies – what’s in the pipeline
C. Warren Olanow, NEW YORK, NY, USA
2nd Congress of European Academy of Neurology

BRAIN HEALTH:
Translating Scientific Evidence Into Clinical Practice in MS

Chair: Professor Per Soelberg Sørensen, MD, PhD, Denmark

Join us at the Sanofi Genzyme Satellite Symposium
Sunday, May 29th, 13.00 - 14.30hrs
Bella Center, Hall B
What’s New in the Management of Motor Symptoms and Motor Complications in PD?

Find out at the Zambon Satellite Symposium Sunday May 29 13.00–14.30 Hall C

Zambon is proud to invite you to meet our Experts, and discover more about the innovative treatment, safinamide. At this symposium you will learn exactly how this new therapy can prolong the efficacy window of levodopa in Parkinson’s disease, providing a balanced control of motor symptoms and motor complications.
SATELLITE SYMPOSIUM

Innovations in diagnosis and monitoring of inherited ataxias: a spotlight on NP-C
Chaired by Mathieu Anheim (Strasbourg, France)

Satellite Symposium at the 2nd Congress of the European Academy of Neurology (EAN)
Supported by an educational grant provided by Actelion Pharmaceuticals Ltd

Plan of the Bella Center Copenhagen
Ground Floor

Actelion Symposium (Hall M0)
Actelion Booth (Stand B20)
“I’ve just buttoned my own shirt. People say, ‘Is that all?’. I say, ‘to me it’s not all, but it is a great victory.’”
SANOFI GENZYMEx
13:00 - 14:30 | HALL B
Brain Health: Translating Scientific Evidence into Clinical Practice in MS

CHAIRPERSON:
Per Soelberg Sørensen, COPENHAGEN, DENMARK
---------------------------------------------------------------
Welcome and Opening
Per Soelberg Sørensen, COPENHAGEN, DENMARK

Brain volume loss in MS: underlying pathophysiology
Heinz Wiendl, MÜNSTER, GERMANY

Lost in Translation? Brain Atrophy from Clinical Studies to Clinical Practice
Andreas Lysandropoulos, BRUSSELS BELGIUM

The Role of Brain Atrophy in Decision-making for Early Treatment
Andrew Chan, BERN, SWITZERLAND

Q & A
Per Soelberg Sørensen, COPENHAGEN, DENMARK

ZAMBON
13:00 - 14:30 | HALL C
What’s New in the Management of Motor Symptoms & Motor Complications in PD?

CHAIRPERSON:
Bas Bloem, NIJMEGEN, THE NETHERLANDS
Per Odin, BREMERHAVEN, GERMANY
---------------------------------------------------------------
Levodopa: The Mainstay for Managing Motor Symptoms
Per Odin, BREMERHAVEN, GERMANY

How to manage PD progression?
Paolo Barone, SALERNO, ITALY

Introducing Safinamid: A New Therapeutic Options to Address Motor Symptoms & Motor Complications in PD
Werner Poewe, INNSBRUCK, AUSTRIA

Panel discussion

ACTELION
13:00 - 14:30 | HALL M0
Innovations in diagnosis and monitoring of inherited ataxias: a spotlight on NP-C

CHAIRPERSON:
Mathieu Anheim, STRASBOURG, FRANCE
---------------------------------------------------------------
Niemann-Pick disease Type C: blink and you’ll miss it!
John Ealing, MANCHESTER, UK

An algorithm for ataxia: paving the way for differential diagnosis of rare neurological disorders
Mathieu Anheim, STRASBOURG, FRANCE

Detecting NP-C patients in clinical practice: successful screening approaches in patients with unexplained ataxia
Matthias Synofzik, TÜBINGEN, GERMANY

Monitoring movement disorders in the modern world
Elin Haf Davies, LONDON, UK

Question & Answers
All

Summary and close
Mathieu Anheim, STRASBOURG, FRANCE

SHIRE
13:00 - 14:30 | HALL M5
THE RARE AND UNDETECTED – Lysosomal storage diseases in neurology

CHAIRPERSON:
Arndt Rolfs, ROSTOCK, GERMANY
---------------------------------------------------------------
Caring for rare neurologic diseases in the EU – challenges and prospects
Arndt Rolfs, ROSTOCK, GERMANY

Parkinson and Gaucher disease – linking the rare and the undetected
TBC

Stroke and fabry disease – common manifestation of a rare disease
Ricardo Reisin, BUENOS AIRES, ARGENTINA

Mucopolysaccharidosis – implications of the blood-brain barrier for treating a rare neurodegenerative disease
Maurizio Scarpa, WIESBADEN, GERMANY

Neuroimaging in diagnosing rare neurologic diseases
Christian Enzinger, INNSBRUCK, AUSTRIA
Disease activity in MS
The B-cell connection

Visit the Roche Booth
Exploring the Interaction between Amyloid and Tau in Alzheimer’s Disease: Implications for Diagnosis, Disease Progression, and Management

Sunday, 29 May 2016: 18.30-20.00

Bella Center, Copenhagen: Hall C

This Satellite Symposium is being held in conjunction with the 2nd Congress of the European Academy of Neurology 2016.

Agenda

18.30-18.45 Introductory Remarks
John Hardy, UK (Chair)

18.45-19.05 Amyloid and Tau Interactions: How Does Current Knowledge Affect Treatment Targets in AD?
Bengt Winblad, Sweden

19.05-19.15 Q&A

19.15-19.35 Amyloid and Tau Imaging: What Can They Tell Us, Independently and Together?
Mark Mintun, USA

19.35-19.55 Panel Discussion
All

19.55-20.00 Closing Remarks
John Hardy, UK

Learning Objectives:

At the end of this session, participants will be able to:

- Discuss hypothetical models of the relationship between amyloid and tau
- Understand potential roles of amyloid and tau imaging in diagnosis and management
- Recognize how recent knowledge and developments may influence future drug development

John Hardy, PhD
Professor of Neuroscience, Institute of Neurology, University College London, London, UK

Mark Mintun, MD
President and Chief Medical Officer, Avid Radiopharmaceuticals, A wholly owned subsidiary of Eli Lilly, Philadelphia PA, USA

Bengt Winblad, MD, PhD
Professor, Director, Karolinska Institutet, Center for Alzheimer Research, Stockholm, Sweden

Light refreshments provided
A Satellite Symposium at the 2nd Congress of the European Academy of Neurology 2016

The Role of Complement in Neurological Disorders

Bella Center Copenhagen | Hall M1
Copenhagen, Denmark
Sunday, 29 May | 18:30 – 20:00
A light reception will be provided at 18:15

Overview:
Complement plays a role in several neurological disorders, including NMO, MG, and neuropathies. Join us to learn about the complement cascade, its role in tissue damage, and the heterogeneity of patients across complement-mediated neurological disorders. Our faculty panel will conclude with a live question-and-answer session.

No CME/CNE credits are associated with this program.

Agenda:

18:30 – 18:40
Welcome and Introductions
Saiju Jacob, MBBS, MD, DPhil, FRCP (Lon)

18:40 – 19:00
Complement in Neurological Disorders
Saiju Jacob, MBBS, MD, DPhil, FRCP (Lon)
Edgbaston, Birmingham, United Kingdom

19:00 – 19:20
Role of Complement in Myasthenia Gravis
James F. Howard, Jr, MD
Chapel Hill, North Carolina, USA

19:20 – 19:40
Complement in Neuromyelitis Optica Spectrum Disorder
Dean M. Wingerchuk, MD, MSc, FRCP(C)
Scottsdale, Arizona, USA

19:40 – 19:55
Question-and-Answer Session Panel

20:00
Meeting Adjournment
Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders – we call this **Progress In Mind**

All over the world psychiatric and neurological disorders are a growing burden, not only for individuals but for families and societies as well.

An estimated 700 million people worldwide are living with these disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences.

Lundbeck is a specialized pharmaceutical company focused on depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease. For more than 70 years, we have been at the forefront of research within neuroscience and our development and distribution of pioneering treatments continues to make a difference to patients worldwide.

We are recognized for having helped hundreds of millions of people living with psychiatric and neurological disorders. However, there is still a massive need for further help.

Therefore, in the early stage research and development pipeline we are exploring different drug modalities and effects, of both small molecules and antibodies.
SUNDAY, 29 MAY
18:00 - 20:00

ROCHE
18:30 - 20:00 | HALL B
New insights in MS: How are approaches to MS management changing?

CHAIRPERSON:
Per Soelberg Sørensen, COPENHAGEN, DENMARK

Setting sights on optimised MS patient care
Per Soelberg Sørensen, COPENHAGEN, DENMARK

Exploring the impact of the MS disease burden
Eva Havrdová, PRAGUE, CZECH REPUBLIC

Connecting disease activity and progression in MS
Patrick Vermersch, LILLE, FRANCE

Striving for balance in MS clinical practice
Giancarlo Comi, MILAN, ITALY
Tjalf Ziemssen, DRESDEN, GERMANY

The time to act: optimising patient care
Gavin Giovannoni, LONDON, UK

Panel discussion
All faculty and Per Soelberg Sørensen

Meeting close

ELI LILLY
18:30 - 20:00 | HALL C
Exploring the interaction between Amyloid and Tau in Alzheimer’s disease: implications for diagnosis, disease progression, and management

CHAIRPERSON:
John Hardy, LONDON, UK

Introductory Remarks
John Hardy, LONDON, UK

Amyloid and Tau Interactions: How does current knowledge affect treatment targets in AD?
Bengt Winblad, STOCKHOLM, SWEDEN

Q&A

Amyloid and Tau imaging: what can they tell us, independently and together?
Mark Mintun, PHILADELPHIA, PA, USA

Panel discussion
All

Closing remarks
John Hardy, LONDON, UK

ALEXION
18:30 - 20:00 | HALL M1
The role of complement in neurological disorders

CHAIRPERSON:
Saiju Jacobs, BIRMINGHAM, UK

Welcome and Introductions
Saiju Jacobs, BIRMINGHAM, UK

Complement in Neurological Disorders
Saiju Jacobs, BIRMINGHAM, UK

Role of complement in myasthenia gravis
James F. Howard, CHAPEL HILL, NC, USA

Complement in neuromyelitis optica spectrum disorder
Dean M. Wingerchuk, SCOTTSDALE, AZ, USA

Question-and-answer session
Panel

Meeting Adjournment
Your invitation to the

Novartis sponsored satellite symposium at the 2nd EAN Congress 2016

The real MS

Monday, 30 May 2016, 13:00–14:30
Hall B, Bella Center Copenhagen, Denmark
TALES OF THE UNEXPECTED: ELEMENTARY CLUES TO DIAGNOSING MUSCULAR DISEASES

MONDAY 30 MAY 2016, 13:00–14:30
HALL M1, BELLA CENTRE, COPENHAGEN

Satellite symposium at the 2nd EAN Congress
Copenhagen, May 28–31, 2016

SANOFI GENZYME
COPENHAGEN, DENMARK, 28 – 31 MAY, 2016

NOVARTIS
13:00 - 14:30 | HALL B
The real MS: outcomes and evidence in the real-world

CHAIRPERSON:
Maria Trojano, BARI, ITALY

The bigger picture: striving for better long-term outcomes in MS
Tjalf Ziemssen, DRESDEN, GERMANY

Building the evidence: making the most of real-world data
Jan Hillert, STOCKHOLM, SWEDEN

Where can big data take us?: personalised medicine in MS
Sergio Baranzini, SAN FRANCISCO, LA, USA

SANOFI GENZYME
13:00 - 14:30 | HALL M1
Tales of the unexpected: elementary clues to diagnosing muscular diseases

CHAIRPERSON:
John Vissing, COPENHAGEN, DENMARK

Introduction
John Vissing, COPENHAGEN, DENMARK

Excess of glycogen: pinpointing the cause
John Vissing, COPENHAGEN, DENMARK

Myalgia and exertional dyspnoea: tracking down the cause
Tiziana Mongini, TURIN, ITALY

Limb girdle muscle weakness: the road to a correct diagnosis
Nicolai Preisler, COPENHAGEN, DENMARK

Exertional myalgia: the diagnostic hunt
Cornelia Kornblum, BONN, GERMANY

Summary & Closing remarks
John Vissing, COPENHAGEN, DENMARK

EVER NEUROPHARMA
13:00 - 14:30 | HALL A
Integrating acute and rehabilitation treatment strategies in stroke therapy

CHAIRPERSON:
Valeria Caso, PERUGIA, ITALY

Neurorecovery in acute stroke – updates & highlights
Milan Vosko, LINZ, AUSTRIA

Challenges & opportunities in motor recovery after stroke
Andreas Winkler, BAD PIRAWARTH, AUSTRIA

The role of Imaging in Stroke Rehabilitation
Jan Sobesky, COLOGNE, GERMANY

Pharmacological Support in Early Rehabilitation – The CARS (Cerebrolysin and Recovery After Stroke) Trial Results
Dafin Muresanu, CLUJ-NAPOCA, ROMANIA
TEVA
18:30 - 20:00 | HALL C
Multiple Sclerosis – Multiple Solutions – one choice: What’s yours?

CHAIRMAN:
Patrick Vermersch, NEUROLOGIST, LILLE, FRANCE
MODERATOR
Astrid Joosten, SYMPOSIUM HOST, ROTTERDAM, THE NETHERLANDS

Facing challenges together
Patrick Vermersch, NEUROLOGIST, LILLE, FRANCE
Astrid Joosten, SYMPOSIUM HOST, ROTTERDAM, THE NETHERLANDS

Keynote lecture: building a family – a patient’s journey
Kerstin Hellwig, NEUROLOGIST, BOCHUM, GERMANY
Stefan Verlohen, GYNAECOLOGIST, BERLIN, GERMANY

60 seconds | Interactive panel discussion
All

Interfering with the immune system
Markus Kleinewietfeld, IMMUNOLOGIST, DIEPENBEEK, BELGIUM

60 seconds | Interactive panel discussion
All

Closing remarks
Patrick Vermersch, NEUROLOGIST, LILLE, FRANCE

Additional panel members:
Heinz Wiendl, NEUROLOGIST, MÜNSTER, GERMANY

Joop Arends, INFECTIOUS DISEASES PHYSICIAN, UTRECHT, THE NETHERLANDS

Bianca Weinstock-Guttmann, NEUROLOGIST, BUFFALO, NY, USA
1 in 3 Patients will not Respond Adequately to Anti-Epileptic Drugs

VNS Therapy® is an implantable medical device for Drug-Resistant Epilepsy (DRE)

VNS Therapy is an easy to use treatment that controls seizures by sending mild pulses from the generator to the left vagus nerve at regular intervals all day, every day.

Can be safely used as an adjunctive treatment, offering proven therapeutic outcomes.

VNS = Vagus Nerve Stimulation

AspireSR® is CE mark approved and commercial distribution may vary by country.

VNS THERAPY® EUROPCCAN INDICATION FOR USE

VNS Therapy is indicated for use as an adjunctive therapy in reducing the frequency of seizures in patients whose epileptic disorder is dominated by partial seizures (with or without secondary generalization) or generalized seizures that are refractory to seizure medications. The Model 106 AspireSR® Seizure Response System, which is intended for patients who experience seizures that are associated with cardiac rhythms increased known as idio-ventricular tachycardia.

CONTRAINDICATIONS: The VNS Therapy system cannot be used in patients after a bilateral or left cervical sympathectomy. Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy on patients implanted with the VNS Therapy system. Diagnostic ultrasound is not included in this contraindication. Cardiac arrhythmia (Model 106 only) - The Autostim Mode feature should not be used in patients with clinically meaningful arrhythmias or who are using treatments that interfere with normal intrinsic heart rate responses.

WARNINGS: Physicians should inform patients about all potential risks and adverse events discussed in the VNS Therapy Physician Manual. Including information that VNS Therapy may not be a cure for epilepsy. Since seizures may occur unexpectedly, patients should consult with a physician before engaging in unsupervised activities, such as driving, swimming, and bathing, or in strenuous sports that could harm them or others. A malfunction of the VNS Therapy system could cause painful or direct current stimulation, which could result in nerve damage. Removal or replacement of the VNS Therapy system requires an additional surgical procedure. Patients who have pre-existing swallowing, cardiac, or respiratory difficulties (including, but not limited to, obstructive sleep apnea and chronic pulmonary disease) should discuss with their physicians whether VNS Therapy is appropriate for them since there is the possibility that stimulation might worsen their condition. Postoperative bradycardia can occur among patients with certain underlying cardiac arrhythmias. VNS Therapy should be performed, however, special equipment and procedures must be used.

ADVERSE EVENTS: The most commonly reported side effects from stimulation include hoarseness (voice alteration), paresthesia (numbness or tingling in the skin), dyspnea (shortness of breath), sore throat, and increased coughing. The most commonly reported side effect from the implant procedure is infection. The information contained here represents partial excerpts of important prescribing information from the product labeling. Patients should discuss the risks and benefits of VNS Therapy with their healthcare provider. Visit www.VNSTherapy.com for more information

TO DISCOVER HOW VNS THERAPY COULD HELP YOUR DRE PATIENTS, VISIT WWW.VNSTHERAPY.COM

VNS Therapy® is a registered trademark of Cyberonics, Inc.
OVERVIEW OF FORUM PROGRAMMES ORGANISED WITHIN THE EXHIBITION AREA

Additional forum talks reserved after the date of printing will be announced-on site.

SATURDAY, 28 MAY
12:45 - 13:00
MEDTRONIC FORUM TALK
How can visualization become a common language for multidisciplinary DBS teams?
Mathieu Chastellain, MEDTRONIC EUROPE

SUNDAY, 29 MAY
10:00 – 10:30
BOSTON SCIENTIFIC FORUM TALK
Possibilities offered by a DBS Directional System: clinical cases
Manuela Pilleri, VICENZA, ITALY

12:45 – 13:00
MEDTRONIC FORUM TALK
Medtronic DBS and non-motor symptoms
Karen Østergaard (TBC), ARHUS, DENMARK

MONDAY, 30 MAY
10:00 - 10:15
BAYER FORUM TALK
VITAMIN D and MS
Paul Friedemann

12:45 – 13:00
MEDTRONIC FORUM TALK
Long-term clinical experience with Medtronic DBS for Epilepsy
Jukka Peltola, TAMPERE, FINLAND

16:15 – 16:45
BOSTON SCIENTIFIC FORUM TALK
Clinical experience with Vercise PC, directional system
Michael Schüpbach, BERN, SWITZERLAND

TUESDAY, 31 MAY
10:00 – 10:30
BOSTON SCIENTIFIC FORUM TALK
Directional DBS of the subthalamic nucleus: a pilot study – preliminary observations
Martin Reich, WÜRZBURG, GERMANY